• 专利附录
  • 专利说明
  • 权利要求
  • 类似技术
  • 同族专利
  • 引用文献
  • 法律状态
  • 优先权
    • 专利摘要:
    The present invention relates to aminobutanoic acid derivatives represented by general formula (I) and salts thereof, in which the symbols in the formula have the same meanings as described in the specification. Compounds of formula (I) inhibit matrix metalloproteinases, rheumatoid arthritis, osteoarthritis, pathological bone resorption, osteoporosis, periodontal disease, interstitial nephritis, arteriosclerosis, emphysema, Liver cirrhosis, corneal injury, diseases of metastatic infiltration or proliferation of cancer cells, autoimmune diseases (clonal disease, Sjgren's disease, etc.), diseases caused by vascular outflow or infiltration of leukocyte cells, angiogenesis, multiple sclerosis, It is useful for the prophylaxis and / or treatment of aortic aneurysms, endometriosis and the like.
    公开号:KR20010024456A
    申请号:KR1020007003763
    申请日:1998-10-07
    公开日:2001-03-26
    发明作者:간지 다카하시；쯔네유키 수기우라
    申请人:우에노 도시오；오노 야꾸힝 고교 가부시키가이샤；
    IPC主号:
    专利说明:

    Aminobutanoic acid derivatives {AMINOBUTANOIC ACID DERIVATIVES}
    Matrix metalloproteinase (hereinafter abbreviated as MMP) is a neutral metalloproteinase with zinc at its active center (hereinafter abbreviated as Zn 2+ ) and under physiological conditions collagen, laminin, proteoglycan, fibronectin By decomposing elastin, gelatin, etc., it acts on growth and tissue remodeling of joint tissue, bone tissue, connective tissue and the like. To date, more than 10 molecular species with different primary structures have been identified in MMP. Specifically, interstitial collagenase (MMP-1), leukocyte collagenase (MMP-8), gelatinase A (MMP-2), gelatinase B (MMP-9), stromycin 1 (MMP) -3), stromycin 2 (MMP-10), matrilysine (MMP-7), metalloelase (MMP-12), etc. are mentioned.
    As properties common to each of these enzymes,
    (1) having Zn 2+ in the center of activity and requiring calcium ions (Ca 2+ ) for enzyme activity,
    (2) secreted as a latent type enzyme and activated outside the cell,
    (3) having high homology to the amino acid sequence,
    (4) having the ability to degrade various extracellular matrix components present in vivo;
    (5) It is known that activity is inhibited by a tissue metalloproteinase inhibitor (TIMP) which is a common inhibitor.
    Inhibitors of MMPs are thought to be useful for the prevention and / or treatment of various diseases resulting from abnormal secretion and activity of MMPs. Examples of the disease include rheumatism, osteoarthritis, pathological bone resorption, osteoporosis, periodontal disease, interstitial nephritis, arteriosclerosis, emphysema, cirrhosis, corneal injury, metastasis infiltration or proliferation of cancer cells. Diseases, autoimmune diseases (clone disease, Sjgren's disease, etc.), diseases caused by vascular outflow and infiltration of leukocyte cells, angiogenesis, multiple sclerosis, aortic aneurysms, and endometriosis.
    Several compounds with matrix metalloproteinase inhibitory action are known. Especially, it is known that the substrate (Gly-Ile-Ala-Gly or Gly-Leu-Ala-Gly) near the break point of collagen has high affinity with collagenase. Numerous studies have been conducted on substrate analog matrix metalloproteinase inhibitors with chemical modifications that have zinc affinity groups at the cleavage site of the substrate [Inhibitors of matrix metalloproteinases (MMP's), Nigel RA Beeley, Phillip RJ Ansell, Andrew JP Docherty et al Curr. Opin. Ther. Patents., 4,7-16 (1994), Current Drugs Ltd ISSN 0962-2594. However, since these substrate analog inhibitors are peptide analogs, it is expected that there will be various problems. For this reason, it is required to non-peptide these inhibitors, and several kinds have been reported.
    For example, in the examples of the specification of EP 757037, the formula (W)

    It is disclosed that the sulfonyl amino acid derivative represented by this has a matrix metalloproteinase inhibitory effect.
    Examples of the specification of EP 757984 include formula (X).

    It is disclosed that the hydroxamic acid derivative represented by this has a matrix metalloproteinase inhibitory effect.
    In the examples in the specification of WO 9723459, the formula (Y)

    It is disclosed that the aromatakeketo-acid derivative represented by the matrix metal has a inhibitory effect on matrix metalloproteinase.
    In the examples in the specification of WO 9718188, the formula (Z)

    It is disclosed that the hydroxamic acid derivative represented by the matrix has an inhibitory effect on matrix metalloproteinase and TNFα secretion.
    Summary of the Invention
    The present inventors conducted intensive studies to find a compound having an inhibitory action against matrix metalloproteinases such as gelatinase, stromycin or collagenase, and the like, and the formula (I) is a carboxylic acid amino derivative of γ-amino acid. It was found that a novel aminobutanoic acid derivative represented by) achieves the object.
    The present invention provides a process for preparing 1) an aminobutanoic acid derivative represented by formula (I), or a nontoxic salt thereof, 2) a method for preparing an aminobutanoic acid derivative represented by formula (I) and a nontoxic salt thereof, and 3) a chemical formula The present invention relates to a drug containing an aminobutanoic acid derivative represented by (I) and a nontoxic salt thereof as an active ingredient.

    [Wherein, R 1 represents -COOR 10 , -CONHOR 10 , -CONHNHR 10 ,-(CH 2 ) n SR 50 or -Y-PO (OR 51 ) 2 ,
    R 10 is (i) a hydrogen atom, (ii) a C1-8 alkyl group, (iii) a phenyl group, (iv) a C1-8 alkyl group substituted with a phenyl group or a C1-8 alkoxy group, or (v) a phenyl group, benzyl group or C1∼ 8 represents an oxycarbonyl group substituted with an alkyl group,
    n represents an integer of 0 to 3,
    R 50 represents (i) a hydrogen atom, (ii) a C 1-8 alkyl group, (iii) -COR 52 (wherein R 52 represents a C 1-8 alkyl group or a phenyl group), (iv) -SR 53 (in the group, R 53 represents a hydrogen atom, a C1-8 alkyl group or a phenyl group),
    R 51 represents a hydrogen atom, a C1-8 alkyl group or a phenyl group,
    Y represents a single bond, -CH 2 -or -O-,
    R 2 , R 3 , R 4 , R 5 , R 6 , and R 7 are each independently
    1) hydrogen atom,
    2) a C1-8 alkyl group,
    3) a C2-8 alkenyl group,
    4) -OR 11 ,
    5) -SR 11 ,
    6) -NR 12 R 13 ,
    7) -COR 14 ,
    8) Cyc1,
    9) a C1-8 alkyl group substituted with a group selected from -OR 11 , -SR 11 , -NR 12 R 13 , -COR 14 , a guanidino group or Cyc1, or
    10) a group selected from -OR 11 , -SR 11 , -NR 12 R 13 , -COR 14 , guanidino group or Cyc1 represents a substituted C2-8 alkenyl group, or
    R 3 group and R 4 group are integrated, C1-8 alkylene group, R 5 group and R 6 group are integrated, C1-8 alkylene group, R 3 group and R 6 group are integrated, C1-8 alkylene group, R 2 group and R 3 The groups are integrated to form a C2-8 alkylene group, an R 4 group and an R 5 group are integrated to form a C2-8 alkylene group, or an R 6 group and an R 7 group are integrated to represent a C2-8 alkylene group,
    In the group, Cyc1 represents a carbocyclic ring or a heterocyclic ring, and these carbocyclic or heterocycles represent one or more (i) C1-8 alkyl groups, (ii) C1-8 alkoxy groups, (iii) nitro groups, (iv ) Guanidino group, (v) amidino group, (d) halogen atom, (vii) nitrile group, (viii) hydroxyl group, (ix) benzyloxy group, (x) -NR 101 R 102 (R 101 and R 102 each independently represent a hydrogen atom or a C1-8 alkyl group), (xi) -COOR 103 (R 103 represents a hydrogen atom or a C1-8 alkyl group), (xii) trifluoromethyl group, (xiii) trifluoro Phenyl group, (xvi) phenyloxy group, (xvii) phenylsulfonyl group, (xviii) phenyl group or nitrile group, substituted by a romoxyoxy group, (xiv) phenyl group, (xv) C1-8 alkyl group or C1-8 alkoxy group the C1~8 alkyl group, (xix) heterocyclic, or (xx) keto group, (xxi) -CONR 104 R 105 the C1~8 alkoxy group substituted with a (group of, R 104 and R 105 are each independently hydrogen, optionally substituted Atom C 1-8 alkyl group or phenyl group) may be substituted.
    R 11 is
    (i) a hydrogen atom,
    (ii) a C1-8 alkyl group,
    (iii) a Cyc 1 group,
    (iv) -COR 18 groups,
    (v) a C1-8 alkyl group substituted with a group selected from -OR 15 , -SR 15 , -NR 16 R 17 , -COR 18 , guanidino group or Cyc1,
    R 15 represents a hydrogen atom, a C 1-8 alkyl group, Cyc 1, or a C 1-8 alkyl group substituted with a Cyc 1 or C 1-8 alkoxy group,
    R 16 represents a hydrogen atom or a C1-8 alkyl group,
    R 17 represents a hydrogen atom, a C 1-8 alkyl group or —COR 19 (wherein R 19 represents a C 1-8 alkyl group, a C 1-8 alkyl group substituted with Cyc 1 or Cyc 1),
    R 18 is a hydroxyl group, a C 1-8 alkyl group, a C 1-8 alkoxy group, or —NR 20 R 21 (wherein, R 20 and R 21 are each independently substituted with a hydrogen atom, a C 1-8 alkyl group, Cyc 1 or Cyc 1; 8 alkyl group).
    R 12 represents a hydrogen atom, a C1-8 alkyl group, a Cyc1 or a C1-8 alkyl group substituted with Cyc1,
    R 13 represents a hydrogen atom, a C 1-8 alkyl group, a C 1-8 alkyl group substituted with Cyc 1, Cyc 1 or —COR 22 (wherein R 22 represents a C 1-8 alkyl group, a C 1-8 alkyl group substituted with Cyc 1 or CyC 1) Indicates
    R 14 is a hydroxyl group, a C 1-8 alkyl group, a C 1-8 alkoxy group, a C 1-8 alkyl group substituted with Cyc 1, Cyc 1 or —NR 23 R 24 (wherein R 23 and R 24 are each independently (i) a hydrogen atom , (ii) a C1-8 alkyl group, (iii) Cyc1 or (iv) a Cyc1 or a C1-8 alkyl group substituted with a hydroxyl group).
    (1) R 8
    1) hydrogen atom,
    2) a C1-8 alkyl group,
    3) a C1-8 alkoxycarbonyl group,
    4) a C1-8 alkyl group substituted with a group selected from -OR 26 , -SR 26 , -NR 27 R 28 or -COR 29 , or
    5) When CyC2 represents a substituted C1-8 alkoxycarbonyl group,
    R 9 is Represents a group,
    (2) R 8 is Flag or When representing a flag,
    R 9 is
    1) a C1-8 alkyl group,
    2) a C1-8 alkoxy group,
    3) a C1-8 alkoxy group substituted with Cyc2,
    4) a C1-8 alkyl group substituted with a group selected from -OR 26 , -SR 26 , -NR 27 R 28 , -COR 29 or Cyc2, or
    5) Represents a group,
    In the group, Cyc2 represents a carbocyclic ring or a heterocycle, and these carbocyclic rings or heterocycles may include one or more of (i) C1-8 alkyl group, (ii) C1-8 alkoxy group, (iii) nitro group, (iv) Guanidino group, (v) amidino group, (vi) halogen atom, (vii) nitrile group, (viii) hydroxyl group, (ix) benzyloxy group, (x) -NR 201 R 202 (R 201 and R 202 Each independently represents a hydrogen atom or a C1-8 alkyl group), (xi) -COOR 203 (R 203 represents a hydrogen atom or a C1-8 alkyl group), (xii) trifluoromethyl group, (xiii) trifluoro By a methyloxy group, (xiv) phenyl group, (xv) phenyl group substituted by C1-8 alkyl group or C1-8 alkoxy group, (xvi) phenyloxy group, (xvii) phenylsulfonyl group, (xviii) phenyl group or nitrile group A substituted C1-8 alkyl group, (xix) heterocycle or (xx) keto group, (xxi) -CONR 204 R 205 substituted C1-8 alkoxy group (wherein R 204 and R 205 are each independently a hydrogen atom , C 1-8 alkyl group or phenyl group) may be substituted.
    R 26 represents a hydrogen atom, a C 1-8 alkyl group, Cyc 2 or a C 1-8 alkyl group substituted with Cyc 2,
    R 27 represents a hydrogen atom, a C1-8 alkyl group, a Cyc2 or a C1-8 alkyl group substituted with Cyc2,
    R 28 represents a hydrogen atom, a C 1-8 alkyl group, a C 1-8 alkyl group substituted with Cyc 2, Cyc 2 or -COR 30 (R 30 represents a C 1-8 alkyl group, a Cyc 2 or a C 1-8 alkyl group substituted with Cyc 2),
    R 29 represents a hydroxyl group, a C 1-8 alkyl group, a C 1-8 alkyl group substituted with Cyc 2, Cyc 2 or -NR 31 R 32 (R 31 and R 32 are each independently substituted with a hydrogen atom, a C 1-8 alkyl group, Cyc 2 or Cyc 2 C1-8 alkyl group);
    Represents a carbocyclic ring or a heterocyclic ring,
    R 25 represents -EG,
    E is
    1) single bond,
    2) -CONR 33 -,
    3) -NR 33 CO-,
    4) -CO-O-,
    5) -O-CO-,
    6) -NR 33 -CO-NR 34- ,
    7) -CO-CH 2- ,
    8) -CO-,
    9) -O-CO-NR 33- ,
    10) -NR 33 -CO-O-,
    11) -O-CO-O-,
    12) -CS-NR 33 -,
    13) -NR 33 -CS-,
    14) -CS-O-,
    15) -O-CS-,
    16) -NR 33 -CS-R 34- ,
    17) -CS-CH 2- ,
    18) -CS-,
    19) -O-CS-NR 33- ,
    20) -NR 33 -CS-O-,
    21) -O-CS-O-,
    22) -CH 2 -CH 2- ,
    23) -HC = CH-,
    24) -C≡C-
    25) -SO 2 -NR 33 -,
    26) -NR 33 -SO 2- ,
    27) -SO 2 -CH 2- , or
    28) -CH 2 -SO 2- ;
    In the group, R 33 and R 34 each independently represent a hydrogen atom, a C1-8 alkyl group, a C1-8 alkyl group substituted with CyC3 or CyC3,
    Cyc3 represents a carbocyclic ring or a heterocyclic ring, and these carbocyclic rings or heterocycles include one or more (i) C1-8 alkyl groups, (ii) C1-8 alkoxy groups, (iii) nitro groups, (iv) guanies Dino group, (v) amidino group, (vi) halogen atom, (vii) nitrile group, (viii) hydroxyl group, (ix) benzyloxy group, (x) -NR 301 R 302 (R 301 and R 302 are respectively Independently a hydrogen atom or a C1-8 alkyl group), (xi) -COOR 303 (R 303 represents a hydrogen atom or a C1-8 alkyl group), (xii) trifluoromethyl group, (xiii) trifluoromethyljade Or (xiv) a phenyl group, (xv) a phenyl group substituted by a C1-8 alkyl group or a C1-8 alkoxy group, (xvi) a phenyloxy group, (xvii) a phenylsulfonyl group, (xviii) a phenyl group or a nitrile group A C1-8 alkoxy group substituted with a C1-8 alkyl group, (xix) heterocycle or (xx) keto group, (xxi) -CONR 304 R 305 group (wherein R 304 and R 305 are each independently a hydrogen atom, C1 ～ 8 It may even be substituted by a phenyl group or represents an kilgi).
    G is
    1) hydrogen atom,
    2) a C1-8 alkyl group,
    3) Cyc4,
    4) -OR 35 ,
    5) -SR 35 ,
    6) halogen atom,
    7) nitro groups,
    8) nitrile group,
    9) -NR 36 R 37 ,
    10) -COR 38 ,
    11) a C1-8 alkyl group substituted with a group selected from Cyc4, -OR 35 , -SR 35 , a halogen atom, -NR 36 R 37 or -COR 38 ,
    In the group, CyC4 represents a carbocyclic ring or a heterocycle, and these carbocyclic rings or heterocycles may include one or more of (i) C1-8 alkyl group, (ii) C1-8 alkoxy group, (iii) nitro group, (iv ) Guanidino group, (v) amidino group, (vi) halogen atom, (vii) nitrile group, (viii) hydroxyl group, (ix) benzyloxy group, (x) -NR 401 R 402 (R 401 and R 402 each independently represents a hydrogen atom or a C1-8 alkyl group), (xi) -COOR 403 (R 403 represents a hydrogen atom or a C1-8 alkyl group), (xii) trifluoromethyl group, (xiii) trifluoro Phenyl group, (xvi) phenyloxy group, (xvii) phenylsulfonyl group, (xviii) phenyl group or nitrile group, substituted by a romoxyoxy group, (xiv) phenyl group, (xv) C1-8 alkyl group or C1-8 alkoxy group A C 1-8 alkoxy group substituted with a C 1-8 alkyl group, a (xix) heterocycle, a (xx) keto group, or a (xxi) -CONR 404 R 405 group, wherein R 404 and R 405 are each independently Hydrogen atom, C1-8 alkyl group or phenyl group) may be substituted.
    R 35 represents a hydrogen atom, a C 1-8 alkyl group, a C 1-8 alkoxy group, a C 1-8 alkyl group substituted with Cyc 4 or Cyc 4,
    R 36 represents a hydrogen atom, a C 1-8 alkyl group, a C 1-8 alkyl group substituted with Cyc 4 or Cyc 4,
    R 37 represents a hydrogen atom, a C 1-8 alkyl group, a C 1-8 alkyl group substituted with Cyc 4, Cyc 4 or -COR 39 (R 39 represents a C 1-8 alkyl group, a C 1-8 alkyl group substituted with Cyc 4 or Cyc 4),
    R 38 is a hydroxyl group, C 1-8 alkyl group, Cyc 4, a C 1-8 alkyl group substituted with Cyc 4 , -NR 40 R 41 (R 40 and R 41 are each independently a hydrogen atom, a C 1-8 alkyl group, CyC 4 or Cyc 4 substituted) C1-8 alkyl group) or integrally with -EG to represent C1-4 alkylidene,
    p represents an integer of 1 to 5,
    M represents a C1-8 alkylene group,
    J represents a single bond, an oxygen atom, a sulfur atom or -NR 42- (R 42 represents a hydrogen atom or a C1-8 alkyl group),
    Is a single bond or R 2 , R 3 , R 4 , R 5 , R 6 , or R 7 when adjacent two groups which are not bonded to the same carbon are hydrogen, desorption to represent a double bond (wherein R 3 When group and R 4 group are integrated, C1-8 alkylene group, R 5 group and R 6 group are integral, C1-8 alkylene group, R 3 group and R 6 group are integral and represent C1-8 alkylene group. Not)].
    The present invention relates to an aminobutanoic acid derivative, a method for producing the same, and a medicament containing the derivative as an active ingredient.
    More specifically, formula (I)

    The aminobutanoic acid derivatives represented by the formula (all symbols have the same meaning as described later), non-toxic salts thereof, preparation methods thereof, and pharmaceuticals containing them.
    In the present invention, unless otherwise indicated, the isomers include all of them. For example, the alkyl group, the alkoxy group, and the alkylene group include a straight chain and a branched chain. Double bonds in alkenylene groups include those which are mixtures of E, Z and EZ. Moreover, the isomer which arises by presence of an asymmetric carbon atom, such as the case where a branched alkyl group, an alkoxy group, and an alkylene group exists, is also included.
    In the present invention, the C1-8 alkyl group is methyl, ethyl, propyl, butyl, pentyl, hexyl, heptyl, octyl group and isomers thereof.
    The C 1-8 alkoxy group is a methoxy, ethoxy, propoxy, butoxy, pentyloxy, hexyloxy, heptyloxy, octyloxy group and isomers thereof.
    The C1-8 alkyl group substituted with a phenyl group is methyl, ethyl, propyl, butyl, pentyl, hexyl, heptyl, octyl group and isomer thereof substituted by one phenyl group.
    C1-8 alkyl group substituted by C1-8 alkoxy group is methyl substituted by methoxy, ethoxy, propoxy, butoxy, pentyloxy, hexyloxy, heptyloxy, octyloxy group and one isomer group thereof , Ethyl, propyl, butyl, pentyl, hexyl, heptyl, octyl groups and isomers thereof.
    The C1-8 alkyl group substituted with the nitrile group is methyl, ethyl, propyl, butyl, pentyl, hexyl, heptyl, octyl group and isomer thereof substituted by one nitrile group.
    An oxycarbonyl group substituted with a phenyl group is a phenyloxycarbonyl group.
    The oxycarbonyl group substituted with the benzyl group is a benzyloxycarbonyl group.
    The oxycarbonyl group substituted with a C1-8 alkyl group is methyloxycarbonyl, ethyloxycarbonyl, propyloxycarbonyl, butyloxycarbonyl, pentyloxycarbonyl, hexyloxycarbonyl, heptyloxycarbonyl, octyloxycarbonyl group and These isomers.
    C2-8 alkenyl group is vinyl, propenyl, butenyl, pentenyl, hexenyl, heptenyl, octenyl, butadienyl, pentadienyl, hexadienyl, heptadienyl, octadienyl, hexatriene Nil, heptatrienyl, octatrienyl groups and isomers thereof.
    The C1-8 alkylene group is methylene, ethylene, trimethylene, tetramethylene, pentamethylene, hexamethylene, heptamethylene, octamethylene group and isomers thereof.
    C2-8 alkylene groups are ethylene, trimethylene, tetramethylene, pentamethylene, hexamethylene, heptamethylene, octamethylene group and isomers thereof.
    Halogen atom means chlorine, bromine, fluorine or urea atom.
    C1-8 alkoxycarbonyl group is methyloxycarbonyl, ethyloxycarbonyl, propyloxycarbonyl, butyloxycarbonyl, pentyloxycarbonyl, hexyloxycarbonyl, heptyloxycarbonyl, octyloxycarbonyl group and isomers thereof to be.
    The C1-4 alkylidene group is methylidene, ethylidene, propylidene, butylidene and isomers thereof.
    A carbocyclic ring means a C3-15 monocyclic, bicyclic or tricyclic carbon ring. As these rings, for example, cyclopropane, cyclobutane, cyclopentane, cyclohexane, cycloheptane, cyclopentene, cyclohexene, cyclopentadiene, cyclohexadiene, benzene, pentene, indene, naphthalene, azulene, fluorene, Phenanthrene, anthracene, acenaphthylene, biphenylene, perhydropentarene, perhydroindene, perhydronaphthalene, perhydroazulene, perhydrofluorene, perhydrophenanthrene, perhydroanthracene, perhydroacenaph Tylene, perhydrobiphenylene, an adamantyl ring, etc. are mentioned.
    A heterocyclic ring represents the 5-18 membered monocyclic, bicyclic or tricyclic heterocycle containing 1-4 nitrogen atoms, 1-2 oxygen atoms, and / or 1-2 sulfur atoms. 5- to 18-membered monocyclic, bicyclic or tricyclic heterocycles containing 1 to 4 nitrogen atoms, 1 to 2 oxygen atoms and / or 1 to 2 sulfur atoms are 1 to 4 nitrogen atoms, 1 to 1 5- to 18-membered monocyclic, bicyclic or tricyclic heterocyclic aryl containing two oxygen atoms and / or one or two sulfur atoms, or a portion or all thereof saturated.
    Examples of the 5-18 membered monocyclic, bicyclic or tricyclic heterocyclic aryl containing 1 to 4 nitrogen atoms, 1 to 2 oxygen atoms and / or 1 to 2 sulfur atoms include pyrrole, imidazole and tria Sol, tetrazole, pyrazole, pyridine, pyridine, pyrimidine, pyridazine, azepine, diazepine, furan, pyran, oxepin, oxazine, thiophene, thiaine (thiopyran), thiepine, oxazole , Isoxazole, thiazole, isothiazole, oxadiazole, oxazine, oxadiazine, oxazepine, oxadiasepine, thiadiazole, thiazine, thiadiazine, thiazepine, thiadiazine, Indole, isoindole, benzofuran, isobenzofuran, benzothiophene, isobenzothiophene, indazole, quinoline, isoquinoline, phtharazin, naphthyridine, quinoxaline, quinazoline, cinnaline, benzoxazole, benzothia Sol, benzimidazole, carbazole, acridine ring and the like.
    Partially or completely saturated with a 5-18 membered monocyclic or bicyclic heterocycle containing 1 to 4 nitrogen atoms, 1 to 2 oxygen atoms and / or 1 to 2 sulfur atoms, pyrroline, Pyrrolidine, imidazoline, imidazolidine, triazoline, triazolidine, tetrazoline, tetrazolidine, pyrazoline, pyrazolidine, piperidine, piperazine, tetrahydropyridine, tetrahydropyrimidine, Tetrahydropyridazine, dihydrofuran, tetrahydrofuran, dihydropyran, tetrahydropyran, dihydrothiophene, tetrahydrothiophene, dihydrothiaine (dihydrothiapyran), tetrahydrothiaine (tetrahydrothio) Pyran), dihydrooxazole, tetrahydrooxazole, dihydroisoxazole, tetrahydroisoxazole, dihydrothiazole, tetrahydrothiazole, dihydroisothiazole, tetrahydroisothiazole, morpholine, Thiomorpholine, indolin, isoindolin, dihydrobenzofuran, perhydrobenzofuran, dihydroisobenzofuran, perhydroisobenzofuran, dihydrobenzothiophene, perhydrobenzothiophene, dihydroisobenzoti Offen, perhydroisobenzothiophene, dihydroindazole, perhydroindazole, dihydroquinoline, tetrahydroquinoline, perhydroquinoline, dihydroisoquinoline, tetrahydroisoquinoline, perhydroisoquinoline, dihydrophthalazine , Tetrahydrophthazine, perhydrophthazine, dihydronaphthyrizine, tetrahydronaphthyrizine, perhydronaphthyrizine, dihydroquinoxaline, tetrahydroquinoxaline, perhydroquinoxaline, dihydroquinazolin, tetrahydrokinazolin , Perhydroquinazolin, dihydrocinnoline, tetrahydrocinnoline, perhydrocinnoline, dihydrobenzooxazole, perhydrobenzooxazole, dihydroben Thiazole, perhydrobenzothiazole, dihydrobenzoimidazole, perhydrobenzoimidazole, benzoxazepine, benzooxadiasepine, benzothiazepine, benzothiadiazepine, benzoazine, benzodiazepine, indoleoxazepine , Indole tetrahydroxazepine, indole oxadiazepine, indole tetrahydroxydiazepine, indolethiazepine, indoletetrahydrothiadiazepine, indolethiadiazepine, indoletetrahydrothiadiazepine, indolezepine, indoletetra Hydroazepine, indolediazepine, indoletetrahydrodiazepine, benzoprazan, benzothiadiazole, benzotriazole, camphor, imidazothiazole, dihydrocarbazole, tetrahydrocarbazole, perhydrocarbazole, dihi Droacridine, tetrahydroacridine, perhydroacridine, dioxolane, dioxane, dithiolan, dithiane, dioxazine, dithiazin ring, etc. are mentioned.
    [salt]
    In the present invention, all non-toxic salts are included. For example, a general salt, an acid addition salt, a hydrate salt, etc. are mentioned.
    The compound of the present invention represented by the formula (I) is converted into the corresponding salt by a known method. The salt is nontoxic and preferably water soluble. Suitable salts include salts of alkali metals (potassium, sodium, etc.), salts of alkaline earth metals (calcium, magnesium, etc.), ammonium salts, pharmaceutically acceptable organic amines (tetramethylammonium, triethylamine, methylamine, dimethylamine, Salts of cyclopentylamine, benzylamine, phenethylamine, piperidine, monoethanolamine, diethanolamine, tris (hydroxymethyl) amine, lysine, arginine, N-methyl-D-glucamine, etc.) have.
    In the compound of the present invention represented by the general formula (I), the acid addition equivalent is converted into a salt by a known method. Acid addition salts are preferably nontoxic and water soluble. Suitable acid addition salts include inorganic acid salts such as hydrochloride, hydrobromide, sulfate, phosphate, nitrate, or acetates, trifluoroacetates, lactates, tartarates, oxalates, fumarates, maleates, citrates, benzoates, Organic acid salts such as methanesulfonate, ethanesulfonate, benzenesulfonate, toluenesulfonate, isethionate, glucuronate and gluconate.
    In addition, the compound of this invention or its salt represented by general formula (I) can also be converted into a hydrate by a well-known method.
    Among the compounds of the present invention represented by general formula (I), preferred compounds include general formula (I-A)

    (Wherein all symbols have the same meanings as above),
    Formula (I-B)

    (Wherein all symbols have the same meanings as above),
    Formula (I-C)

    (Wherein all symbols have the same meanings as above),
    Formula (I-D)

    (Wherein all symbols have the same meanings as above),
    Formula (I-E)

    (Wherein all symbols have the same meanings as above),
    Formula (I-F)

    (Wherein all symbols have the same meanings as above),
    Formula (I-G)

    (Wherein all symbols have the same meanings as above),
    Formula (I-H)

    (Wherein all symbols have the same meanings as above),
    Formula (I-J)

    (Wherein all symbols have the same meanings as above),
    Formula (I-K)

    (Wherein all symbols have the same meanings as above),
    Formula (I-L)

    (Wherein all symbols have the same meanings as above),
    Formula (I-M)

    (Wherein all symbols have the same meanings as above),
    Formula (I-N)

    (Wherein all symbols have the same meanings as above),
    Formula (I-O)

    (Wherein all symbols have the same meanings as above),
    Formula (I-P)

    (In formula, G <1> represents a methyl group, a halogen atom, a nitro group, a nitrile group, and the other symbol represents the same meaning as the above.),
    Formula (I-Q)

    In the formula, all the symbols represent the same meaning as mentioned above.
    More preferably, the compounds shown in the following Tables 1-105, these nontoxic salts, the compound described in the Example, etc. are mentioned. In the following tables, Phth represents a phthalimide group, Ph represents a phenyl group, MOM represents a methoxymethyl group, EOM represents an ethoxymethyl group, MEM represents a (2-methoxyethoxy) methyl group, and BOM represents a benzyloxymethyl group.


























    [Method for Producing Compound of the Invention]
    The compound of this invention represented by General formula (1) can be manufactured by the method as described in the following method or the Example.
    [1] Of the compounds of the present invention represented by formula (I), a compound wherein R 1 is -COOR 10 , that is, formula (I-1)

    In the formula, all the symbols represent the same meaning as described above, and the compound represented by the following methods (a) to (c) can be produced.
    (a) -COOR 10 groups in the R 1 group do not represent a -COOH group, and any of R 2 , R 3 , R 4 , R 5 , R 6 , R 7 , R 8 and R 9 groups is a -COOH group or Compounds which do not represent containing groups, hydroxyl groups or groups containing them or amino groups or groups containing them, ie formula (I-la)

    (Wherein, R 10-1a denotes an oxy group substituted by a C1~8 alkyl group or a phenyl, benzyl or C1~8 alkyl substituted with C1~8 alkyl group, a phenyl group, a phenyl group, or C1~8 alkoxy, R 2- 1a , R 3-1a , R 4-1a , R 5-1a , R 6-1a , R 7-1a , R 8-1a , R 9-1a are R 2 , R 3 , R 4 , R 5 , The same meaning as R 6 , R 7 , R 8 , and R 9 is provided, except that R 2-1a , R 3-1a , R 4-1a , R 5-1a , R 6-1a , R 7-1a , R Any of the groups 8-1a and R 9-1a do not represent a -COOH group, a hydroxyl group or an amino group or a group containing them, and other symbols represent the same meaning as described above), and the compound represented by the formula (II)

    (Wherein all symbols have the same meanings) and the compound represented by the formula (III)

    It can be manufactured by amidation-reacting the compound represented by (wherein all the symbols show the same meaning as mentioned above).
    Amidation reactions of a compound represented by the formula (II) with a compound represented by the formula (III) are known, for example
    (l) using acid halides,
    (2) using mixed acid anhydrides,
    (3) The method of using a condensing agent, etc. are mentioned.
    In detail, these methods
    (1) A method of using an acid halide is, for example, carboxylic acid in an inert organic solvent (chloroform, methylene chloride, diethyl ether, tetrahydrofuran, etc.) or in a solvent-free acid halide (oxalyl chloride, thionyl chloride, etc.). And an acid halide obtained by reacting at -20 ° C to reflux temperature in the presence of a tertiary amine (pyridine, triethylamine, dimethylaniline, dimethylaminopyridine, etc.), with an amine and an inert organic solvent (chloroform, methylene chloride, diethyl). Ether, tetrahydrofuran, etc.), and is made to react at 0-40 degreeC.
    (2) A method of using a mixed acid anhydride is, for example, carboxylic acid in an inert organic solvent (chloroform, methylene chloride, diethyl ether, tetrahydrofuran, etc.) or as a solvent-free tertiary amine (pyridine, triethylamine, In the presence of dimethylaniline, dimethylaminopyridine, and the like, and reacted with an acid halide (pivaloyl chloride, tosyl chloride, mesyl chloride, etc.) or an acid derivative (such as ethyl chloroformate and isobutyl chloroformate) at 0 to 40 ° C. And the obtained mixed acid anhydride is reacted with an amine at 0-40 degreeC in an inert organic solvent (chloroform, methylene chloride, diethyl ether, tetrahydrofuran, etc.).
    (3) A method of using a condensing agent is, for example, carboxylic acid and amine in tertiary amine (pyridine) in an organic solvent (chloroform, methylene chloride, dimethylformamide, diethyl ether, tetrahydrofuran, etc.) or without solvent. Condensation agent (1,3-dicyclohexylcarbodiimide (DCC), l-ethyl-3- [3- (dimethylamino), with or without triethylamine, dimethylaniline, dimethylaminopyridine and the like ) Propyl] carbodiimide (EDC), 1,1'-carbonyldiimidazole (CDI), 2-chloro-1-methylpyridinium urea and the like), and 1-hydroxybenztriazole (HOBt) It is performed by making it react at 0-40 degreeC, with or without using.
    It is preferable to perform all these reactions (1), (2), and (3) on an anhydrous condition in inert gas (argon, nitrogen, etc.) atmosphere.
    (b) -COOR 10 groups in the R 1 group do not represent a -COOH group, and at least one of R 2 , R 3 , R 4 , R 5 , R 6 , R 7 , R 8, and R 9 groups is a -COOH group Or a compound showing a group containing the same, a hydroxyl group or a group containing the same or an amino group or a group containing the same, that is, the formula (I-1b)

    (Wherein, R 2-1b, R 3-1b, R 4-1b, R 5-1b, R 6-1b, R 7-1b, R 8-1b, R 9-1b is R 2, R 3 each , R 4, R 5, R 6, R 7, R 8, the same meaning as R 9. However, R 2-1b, R 3-1b, R 4-1b, R 5-1b, R 6-1b , At least one of R 7-1b , R 8-1b and R 9-1b groups represents a -COOH group, a hydroxyl group or an amino group or a group containing them, and the other symbols represent the same meaning as described above. In the formula (I-1a), a compound in which a -COOH group, a hydroxyl group, an amino group, or a group containing them is protected, that is, a formula (I-1al)

    Wherein R 2-1a1 , R 3-1a1 , R 4-1a1 , R 5-1a1 , R 6-1a1 , R 7-1a1 , R 8-1a1 , and R 9-1a1 are each R 2 , R 3 , R 4 , R 5 , R 6 , R 7 , R 8 , and R 9 have the same meanings, except that R 2-1a1 , R 3-1a1 , R 4-1a1 , R 5-1a1 , R 6-1a1 At least one of the groups R 7-1a1 , R 8-1a1 , R 9-1a1 is protected -COOH group (e.g., methyl, ethyl, t-butyl and benzyl groups), protected hydroxyl group (e.g. Methoxymethyl group, tetrahydropyranyl group, t-butyldimethylsilyl group, acetyl group, benzyl group, etc.) or protected amino group (e.g., benzyloxycarbonyl group, t-butoxycarbonyl group, trifluoroacetyl group, etc.) or containing them Group, and the other symbols represent the same meanings as mentioned above) by applying the compound represented by alkali hydrolysis, deprotection reaction under acidic conditions, deprotection reaction of silyl group or deprotection reaction by hydrolysis. Can be.
    Deprotection reactions by alkali hydrolysis are well known, for example, alkali metal hydroxides (sodium hydroxide, potassium hydroxide, lithium hydroxide, etc.), alkaline earth metals in organic solvents (methanol, tetrahydrofuran, dioxane, etc.). It is performed at the temperature of 0-40 degreeC using hydroxide (barium hydroxide, calcium hydroxide, etc.), carbonate (sodium carbonate, potassium carbonate, etc.) or its aqueous solution, or a mixture thereof.
    Deprotection reactions under acidic conditions are known, for example, in organic solvents (methylene chloride, chloroform, dioxane, ethyl acetate, anisole, etc.), organic acids (acetic acid, trifluoroacetic acid, methanesulfonic acid, trimethylsilyl iodide, etc.). ), Or an inorganic acid (hydrochloric acid, sulfuric acid) or a mixture thereof (hydrobromic acetic acid, etc.) at a temperature of 0 to 100 ° C.
    Deprotection reaction of a silyl group is well-known, For example, it carries out at the temperature of 0-40 degreeC using tetrabutylammonium fluoride in the organic solvent (tetrahydrofuran, acetonitrile etc.) which can be mixed with water.
    The deprotection reaction by hydrolysis is well known, for example, an inert solvent (eg, tetrahydrofuran, dioxane, diethoxyethane, diethyl ether, etc.), alcohol (eg, methanol, ethanol, etc.), Benzene-based (e.g., benzene, toluene, etc.), ketone-based (e.g., acetone, methyl ethyl ketone, etc.), nitrile-based (e.g., acetonitrile, etc.), amide-based (e.g., dimethylformamide, etc.), water, ethyl acetate, Acetic acid or a mixture of two or more thereof, and the like] in the presence of a hydrogenation catalyst (eg, palladium-carbon, palladium black, palladium, palladium hydroxide, platinum dioxide, nickel, rani-nickel, etc.), and an inorganic acid (eg, In the presence or absence of hydrochloric acid, sulfuric acid, hypochlorous acid, boric acid, tetrafluoroboric acid, etc.) or organic acids (e.g., acetic acid, p-toluenesulfonic acid, oxalic acid, trifluoroacetic acid, formic acid, etc.), at atmospheric pressure or under pressure. Hydrogen atmosphere or ammonium formate Performed in load, the temperature of 0~200 ℃. When using an acid, you may use its salt.
    (c) a compound in which the COOR 10 group in the R 1 group represents a -COOH group, that is, the formula (I-1c)

    (Wherein all symbols have the same meanings as mentioned above), the compound represented by the above formulas (I-la) and (I-1b), namely
    Formula (I-1ab)

    In the formula, all symbols represent the same meanings as described above. The compounds represented by the above formulas can be produced by application to alkali hydrolysis, deprotection under acidic conditions, or deprotection by hydrogenolysis.
    Hydrolysis under these alkaline conditions, deprotection under acidic conditions, and deprotection by hydrogenolysis are well known and are carried out by the above-described method.
    [2] In the compound of the present invention represented by formula (I),
    A compound wherein R 1 is -CONHOR 10 or -CONHNHR 10 , ie, formula (I-2)

    In the formula, R 1-2 represents -CONHOR 10 or -CONHNHR 10 and other symbols represent the same meaning as described above. The compound represented by the following methods (a) and (b) can be produced.
    (a) R 1 represents -CONHOR 10 or -CONHNHR 10 and any of the groups R 2 , R 3 , R 4 , R 5 , R 6 , R 7 , R 8 and R 9 contain -COOH or Compounds which do not represent groups, i.e., formula (I-2a)

    Wherein R 2-2a , R 3-2a , R 4-2a , R 5-2a , R 6-2a , R 7-2a , R 8-2a , and R 9-2a are R 2 and R 3 , respectively. , R 4 , R 5 , R 6 , R 7 , R 8 , and R 9 have the same meanings, except that R 2-2a , R 3-2a , R 4-2a , R 5-2a , R 6-2a And none of the groups R 7-2a , R 8-2a and R 9-2a represent a -COOH group or a group containing them, and other symbols represent the same meaning as described above. In the compound prepared in (I-1), the R 1 group represents a COOH group, and any of R 2 , R 3 , R 4 , R 5 , R 6 , R 7 , R 8, and R 9 groups is a -COOH group or the same. Compounds which do not represent containing groups, ie formula (I-1d)

    (Wherein all symbols have the same meanings) and the compound represented by the formula (IV)
    H 2 N-OR 10 (IV)
    (Wherein R 10 has the same meaning as above) or formula (V)
    H 2 N-NHR 10 (V)
    Wherein the compound represented by (wherein R 10 represents the same meaning as above) is subjected to the amidation reaction and, if necessary, is subsequently subjected to hydrolysis under alkaline conditions and / or deprotection under acidic conditions and / or valence. It can manufacture by applying to the deprotection reaction by calcination.
    This amidation reaction, hydrolysis under alkaline conditions, deprotection under acidic conditions, and deprotection by hydrogenolysis are well known and are carried out by the above-described method.
    (b) R 1 represents -CONHOR 10 or -CONHNHR 10 , and at least one of R 2 , R 3 , R 4 , R 5 , R 6 , R 7 , R 8 and R 9 groups is a -COOH group or A compound representing a group containing it, ie formula (I-2b)

    Wherein R 2-2b , R 3-2b , R 4-2b , R 5-2b , R 6-2b , R 7-2b , R 8-2b , and R 9-2b are R 2 and R 3 , respectively. , R 4 , R 5 , R 6 , R 7 , R 8 , and R 9 have the same meanings, except that R 2-2b , R 3-2b , R 4-2b , R 5-2b , R 6-2b Among the R 7-2b , R 8-2b and R 9-2b groups, at least one group represents a -COOH group or a group containing them, and another symbol represents the same meaning as described above. Compounds of which the —COOH group or groups containing them in I-2a) are each protected, ie
    Formula (I-2a1)

    Wherein R 2-2a1 , R 3-2a1 , R 4-2a1 , R 5-2a1 , R 6-2a1 , R 7-2a1 , R 8-2a1 , and R 9-2a1 are each R 2 , R 3 , R 4 , R 5 , R 6 , R 7 , R 8 , and R 9 have the same meanings, except that R 2-2a1 , R 3-2a1 , R 4-2a1 , R 5-2a1 , R 6-2a1 At least one of R 7-2a1 , R 8-2a1 and R 9-2a1 groups represents a protected -COOH group (eg, methyl group, ethyl group, t-butyl group and benzyl group) or a group containing them, and The symbol can be produced by applying the compound represented by the above meaning) to an alkali hydrolysis, a deprotection reaction under acidic conditions, or a deprotection reaction by hydrogenolysis.
    Although hydrolysis under these alkaline conditions, deprotection under acidic conditions, and deprotection by hydrogenolysis are known, they are carried out by the above-described method.
    [3] In the compound of the present invention represented by formula (I),
    R 1 is — (CH 2 ) n SR 50 , ie formula (I-3)

    In the formula, R 1-3 represents-(CH 2 ) n SR 50 and other symbols represent the same meaning as described above. The compound represented by the following methods (a) and (b) Can be.
    (a) R 1 represents-(CH 2 ) n SR 50 , and any of R 2 , R 3 , R 4 , R 5 , R 6 , R 7 , R 8 and R 9 groups is a -COOH group or Compounds not containing groups, i.e., formula (I-3a)

    (In the formula, R 2-3a , R 3-3a , R 4-3a , R 5-3a , R 6-3a , R 7-3a , R 8-3a , R 9-3a are R 2 and R 3 , respectively. , R 4 , R 5 , R 6 , R 7 , R 8 , and R 9 have the same meanings, except that R 2-3a , R 3-3a , R 4-3a , R 5-3a , R 6-3a And none of the groups R 7-3a , R 8-3a and R 9-3a represent a -COOH group or a group containing them, and the other symbols represent the same meaning as described above. )

    (Wherein X represents a halogen atom, and other symbols represent the same meaning as described above), and the general formula (VII)
    R 501 SK (VII)
    In the formula, R 501 can be produced by reacting a compound represented by a C 1-8 alkyl group, -COR 52 , -SR 531 (wherein R 531 represents a C 1-8 alkyl group or a phenyl group).
    In addition, when R <50> is a compound which shows a hydrogen atom or -SH, it can manufacture by continuing to apply the compound obtained above to a deprotection reaction.
    The reaction is known and is carried out by refluxing in, for example, an organic solvent (acetone, tetrahydrofuran, etc.).
    Deprotection reactions performed subsequently are well known, for example, hydroxides of alkali metals (sodium hydroxide, potassium hydroxide, lithium hydroxide, etc.), alkali earth metal hydroxides in organic solvents (methanol, tetrahydrofuran, dioxane, etc.). (Barium hydroxide, calcium hydroxide, etc.) or carbonate (sodium carbonate, potassium carbonate, etc.) or an aqueous solution thereof, or a mixture thereof, at a temperature of 0 to 40 ° C.
    (b) R 1 represents-(CH 2 ) n SR 50 , and at least one of R 2 , R 3 , R 4 , R 5 , R 6 , R 7 , R 8 and R 9 groups is a -COOH group Or a compound representing a group containing it, ie formula (I-3b)

    (In the formula, R 2-3b , R 3-3b , R 4-3b , R 5-3b , R 6-3b , R 7-3b , R 8-3b , R 9-3b are R 2 and R 3 , respectively. , R 4 , R 5 , R 6 , R 7 , R 8 , and R 9 have the same meanings, except that R 2-3b , R 3-3b , R 4-3b , R 5-3b , R 6-3b Among the R 7-3b , R 8-3b and R 9-3b groups, at least one group represents a -COOH group or a group containing them, and another symbol represents the same meaning as described above. A compound in which the -COOH group or group containing them in I-3a) is respectively protected, that is, formula (I-3a1)

    Wherein R 2-3a1 , R 3-3a1 , R 4-3a1 , R 5-3a1 , R 6-3a1 , R 7-3a1 , R 8-3a1 , R 9-3a1 are each R 2 , R 3 , R 4 , R 5 , R 6 , R 7 , R 8 , and R 9 have the same meanings, except that R 2-3a1 , R 3-3a1 , R 4-3a1 , R 5-3a1 , R 6-3a1 , At least one of R 7-3a1 , R 8-3a1 , R 9-3a1 groups represents a protected -COOH group (eg, methyl group, ethyl group, t-butyl group and benzyl group) or a group containing them, and The symbol can be produced by applying the compound represented by the above meaning) to an alkali hydrolysis, a deprotection reaction under acidic conditions, or a deprotection reaction by hydrogenolysis.
    Hydrolysis under these alkaline conditions, deprotection under acidic conditions, and deprotection by hydrogenolysis are well known and are carried out by the above-described method.
    [4] In the compound of the present invention represented by formula (I), R 1 is
    -Y-PO (OR 51 ) 2 phosphorus, ie formula (I-4)

    In the formula, R 1-4 represents -Y-PO (OR 51 ) 2 and other symbols represent the same meaning as described above. The compound represented by the following methods (a) to (d) may be produced. Can be.
    (a) R 1 represents -Y 1 -PO (OR 51 ) 2 (wherein Y 1 represents -O- and the other symbols represent the same meaning as described above), and R 2 , R 3 , Compounds in which none of the groups R 4 , R 5 , R 6 , R 7 , R 8 and R 9 represent -COOH groups or groups containing them, i.e., formula (I-4a)

    Wherein R 2-4a , R 3-4a , R 4-4a , R 5-4a , R 6-4a , R 7-4a , R 8-4a , R 9-4a are R 2 , R 3 , respectively. , R 4 , R 5 , R 6 , R 7 , R 8 , and R 9 have the same meanings, except that R 2-4a , R 3-4a , R 4-4a , R 5-4a , R 6-4a Any of the groups R 7-4a , R 8-4a and R 9-4a do not represent a -COOH group or a group containing them, and the other symbols represent the same meaning as described above. )

    (Wherein all symbols have the same meanings as defined above) and a compound represented by the formula (IX)

    In the formula, R 511 represents a C1-8 alkyl group, a phenyl group or a known protecting group of phosphoric acid, and the other symbols represent the same meaning as described above. It can manufacture by carrying out a deprotection reaction.
    Said reaction is well-known and is performed by making it react at 0-40 degreeC, for example in an organic solvent (pyridine etc.).
    Moreover, the deprotection reaction of the protecting group of phosphoric acid is well-known, For example, it is performed by making it react at 0-40 degreeC using zinc acetic acid in an organic solvent (pyridine etc.).
    (b) R 1 represents -Yl-PO (OR 5l ) 2 , and at least one of R 2 , R 3 , R 4 , R 5 , R 6 , R 7 , R 8 and R 9 groups is -COOH Compounds representing groups or groups containing them, ie formula (I-4b)

    Wherein R 2-4b , R 3-4b , R 4-4b , R 5-4b , R 6-4b , R 7-4b , R 8-4b , and R 9-4b are each R 2 , R 3 , R 4 , R 5 , R 6 , R 7 , R 8 , and R 9 have the same meanings, except that R 2-4b , R 3-4b , R 4-4b , R 5-4b , R 6-4b Among the R 7-4b , R 8-4b and R 9-4b groups, at least one group represents a -COOH group or a group containing them, and another symbol represents the same meaning as described above. Compounds of which the -COOH group or groups containing them in I-4a) are each protected, i.e., formula (I-4al)

    Wherein R 2-4a1 , R 3-4a1 , R 4-4a1 , R 5-4al , R 6-4al , R 7-4al , R 8-4al , and R 9-4a1 are each R 2 , R 3 , R 4 , R 5 , R 6 , R 7 , R 8 , and R 9 have the same meanings, except that R 2-4a1 , R 3-4a1 , R 4-4a1 , R 5-4al , R 6-4al At least one of R 7-4al , R 8-4al and R 9-4a1 groups represents a protected -COOH group (eg, methyl group, ethyl group, t-butyl group and benzyl group) or a group containing them, and The symbol can be produced by applying the compound represented by the above meaning) to an alkali hydrolysis, a deprotection reaction under acidic conditions, or a deprotection reaction by hydrogenolysis.
    Hydrolysis under these alkaline conditions, deprotection under acidic conditions, and deprotection by hydrogenolysis are well known and are carried out by the above-described method.
    (c) R 1 represents -Y 2 -PO (OR 51 ) 2 (wherein Y 2 represents a single bond or -CH 2- , and the other symbols represent the same meaning as described above), and R 2 A compound in which none of the R 3 , R 4 , R 5 , R 6 , R 7 , R 8 and R 9 groups represents a -COOH group or a group containing the same, ie formula (I-4c)

    Wherein R 2-4c , R 3-4c , R 4-4c , R 5-4c , R 6-4c , R 7-4c , R 8-4c , R 9-4c are R 2 , R 3 , respectively. , R 4 , R 5 , R 6 , R 7 , R 8 , and R 9 have the same meanings, except that R 2-4c , R 3-4c , R 4-4c , R 5-4c , R 6-4c Any one of R 7-4c , R 8-4c and R 9-4c groups does not represent a -COOH group or a group containing them, and other symbols represent the same meanings as described above. )

    (Wherein all symbols have the same meanings as above), and a compound represented by the formula (XI) or (XII)
    (R 511 O) 3 P (XI)
    (R 511 O) 2 POK (XII)
    In the formula, all symbols represent the same meanings as mentioned above, and when the phosphoric acid is protected, it can be manufactured by continuing deprotection reaction.
    Said reaction is well-known and is performed by making it react at 0-120 degreeC, for example in organic solvents (tetrahydrofuran, dimethylformamide, etc.).
    The deprotection reaction of a phosphoric acid group is well-known, and is performed by the method mentioned above. (d) R 1 represents -Y 2 -PO (OR 51 ) 2 , and at least one of R 2 , R 3 , R 4 , R 5 , R 6 , R 7 , R 8, and R 9 groups is- Compounds representing COOH groups or groups containing them, ie formula (I-4d)

    Wherein R 2-4d , R 3-4d , R 4-4d , R 5-4d , R 6-4d , R 7-4d , R 8-4d , R 9-4d are R 2 , R 3 , respectively. , R 4 , R 5 , R 6 , R 7 , R 8 , and R 9 have the same meanings, except that R 2-4d , R 3-4d , R 4-4d , R 5-4d , R 6-4d Among the R 7-4d , R 8-4d and R 9-4d groups, at least one group represents a -COOH group or a group containing them, and another symbol represents the same meaning as described above. I-4c) compounds in which the —COOH group or group containing them are each protected, ie formula (I-4cl)

    Wherein R 2-4cl , R 3-4c1 , R 4-4cl , R 5-4cl , R 6-4c1 , R 7-4cl , R 8-4c1 , and R 9-4c1 are R 2 and R 3 , respectively. , R 4 , R 5 , R 6 , R 7 , R 8 , and R 9 have the same meanings, except that R 2-4cl , R 3-4c1 , R 4-4cl , R 5-4cl , R 6-4c1 At least one of R 7-4cl , R 8-4c1 and R 9-4c1 groups represents a protected -COOH group (eg, methyl group, ethyl group, t-butyl group and benzyl group) or a group containing them, and The symbol can be produced by applying the compound represented by the above meaning) to an alkali hydrolysis, a deprotection reaction under acidic conditions, or a deprotection reaction by hydrogenolysis.
    Hydrolysis under these alkaline conditions, deprotection under acidic conditions, and deprotection by hydrogenolysis are well known and are carried out by the above-described method.
    In the present invention, the deprotection reaction means general deprotection reactions which can be easily understood by those skilled in the art, such as alkali hydrolysis, deprotection reaction under acidic conditions, and deprotection reaction by hydrogenolysis. By using it separately, the target compound of this invention can be manufactured easily.
    As those skilled in the art can easily understand, the protecting group for the carboxyl group may be a methyl group, an ethyl group, a t-butyl group and a benzyl group, and other groups are not particularly limited as long as they can be easily and selectively detached. For example, those described in T. W. Greene, Protective Groups in Organic Synthesis, Wiley, New York, 1991 are used.
    Examples of the protecting group for the hydroxyl group include a methoxymethyl group, tetrahydropyranyl group, t-butyldimethylsilyl group, acetyl group, and benzyl group, but are not particularly limited as long as the group can be easily and selectively detached. For example, those described in T. W. Greene, Protective Groups in Organic Synthesis, Wiley, New York, 1991 are used.
    Examples of the protecting group for the amino group include a benzyloxycarbonyl group, t-butoxycarbonyl group, and trifluoroacetyl group, but any other group is not particularly limited as long as it can be easily and selectively detached. For example, those described in T. W. Greene, Protective Groups in Organic Synthesis, Wiley, New York, 1991 are used.
    Formula (II), Formula (III), Formula (IV), Formula (V), Formula (VI), Formula (VII), Formula (VIII), Formula (IX), Formula (X), Formula (XI) or The compound represented by the formula (XII) is known per se or can be easily prepared by a known method.
    In each reaction in the present specification, the reaction product is a high-performance liquid chromatography, thin layer chromatography, or column chromatography or washing, recrystallization using conventional purification means, such as distillation under atmospheric pressure or reduced pressure, silica gel or magnesium silicate. It can refine | purify by methods, such as these. Purification may be carried out for each reaction or may be carried out after the completion of several reactions.
    Pharmacological activity of the compound of the present invention
    It was demonstrated by the following experiment that the compound of this invention represented by general formula (I) has matrix metalloproteinase inhibitory activity.
    (1) Gelatinase A Inhibitory Activity
    [Experimental method]
    10 mM p-aminophenylmercury acetate (APMA) (5 μl) was added to a solution of assay buffer (40 μl) of purified progelatinase A (5 μl) from human normal skin fibroblast cells (HNDF), The enzyme was activated by preincubation at 37 ° C. for 1 hour.
    Synthetic substrate (MOCAc-Pro-Leu-Gly -A2pr (Dnp) -Ala-Arg-NH 2); or the test compound was not added and the solution of the test compound of (130 μl final concentration 13.5 μM) and various concentration of solution ( 20 μl) were preincubated at 37 ° C. for 5 minutes. The activating enzyme (50 µl / well) prepared above was added thereto and incubated at 37 ° C. for 5 minutes to start the enzyme reaction. Enzyme activity was expressed as an increase in fluorescence intensity [325 nm (Ex) / 393 nm (Em)] per minute. Inhibitory activity is expressed as percent inhibition against enzyme activity when no test compound is added. For example, the compound of Example 71 had an IC 50 value of 0.50 nM.
    (2) collagenase inhibitory activity
    [Experimental method]
    1 mg / ml trypsin (45 μl) was added to a solution of analytical buffer (105 μl) purified from human normal dermal fibroblasts (HNDF) and preincubated for 1 minute at 37 ° C. To activate the enzyme. To the solution, 5 mg / ml soybean trypsin inhibitor (SBTI; 50 μl) was added to inactivate the trypsin. A solution of a synthetic substrate (Ac-Pro-Leu-Gly- [2-mercapto-4-methyl-pentanoyl] -Leu-Gly-OEt) (105 μl; final concentration of 1.33 mM) and various concentrations of the test compound or A solution (20 μl) without adding the test compound was preincubated at 26 ° C. for 5 minutes. The activating enzyme (75 µl / tube, 50 µl) prepared above was added thereto and incubated at 26 ° C. for 10 minutes. The absorbance of 324 nm of 40 points in total was measured for this 10 minutes, and Vmax in 30 points among them was measured. For example, the compound of Example 71 had an IC 50 value of 2.5 μΜ.
    (3) stromycin inhibitory activity
    [Experimental method]
    Nine volumes of human stromycin (yagaisa) were mixed with one volume of 10 mM p-aminophenylmercury acetate (APMA) and activated at 37 ° C. for 20 hours. 10 μl of the test compound dissolved in dimethylsulfoxide in 150 μl of assay buffer (50 mM Tris-HCl, 10 mM CaCl 2 , 0.05% Brij35, 0.02% NaN 3 (pH7.5)) and the synthetic substrate NFF-3 (Mca- 10 μl of 10 mM dimethylsulfoxide solution of Arg-Pro-Lys-Pro-Val-Glu- Nva-Trp-Arg-Lys (DNP) -NH2, Nva: Norvalin, Peptide Research Institute) Was added, an additional 30 μl of analytical buffer was incubated at 37 ° C. for 10 minutes, and then 50 μl of the activated stromal lysine solution was added to initiate the enzyme reaction. Enzyme activity was expressed as an increase in fluorescence intensity [325 nm (Ex) / 393 nm (Em)] per minute. Inhibitory activity is expressed as percent inhibition against enzyme activity when no test compound is added. For example, the compound of Example 71 had an IC 50 value of 26 nM.
    [toxicity]
    The toxicity of the compound of the present invention is very low and can be judged to be sufficiently safe for use as a medicine.
    [Application to Drugs]
    In animals, including humans, especially humans, by inhibiting matrix metalloproteinases such as gelatinase, stromycin or collagenase, rheumatoid arthritis, pathological bone resorption, osteoporosis, periodontal disease, interstitial nephritis , Arteriosclerosis, emphysema, liver cirrhosis, corneal injury, disease of metastasis invasion and proliferation of cancer cells, autoimmune disease (clonal disease, Sjgren's disease, etc.), disease caused by vascular outflow or infiltration of leukocyte cells, angiogenesis, It is useful for the prevention and / or treatment of multiple sclerosis, aortic aneurysms, endometriosis and the like.
    In order to use the compound of the present invention represented by the formula (I), its nontoxic salt, acid addition salt, or hydrate thereof for the above-mentioned purposes, it is usually administered systemically or topically in the form of oral or parenteral.
    Dosages vary depending on age, weight, symptoms, therapeutic effect, method of administration, treatment time, etc., but are usually orally administered once per day, in the range of 1 mg to 1000 mg per adult, or One parenteral administration (preferably intravenously) once a day, in the range of 1 mg to 100 mg, once per adult, or sustained intravenously in the range of 1 hour to 24 hours per day Administered.
    Of course, as mentioned above, since a dosage varies with various conditions, an amount smaller than the said dosage may be sufficient, and it may be necessary beyond the range.
    When administering the compounds of the present invention, they are used as solid compositions, liquid compositions and other compositions for oral administration, and injections, external preparations, suppositories, and the like for parenteral administration.
    Solid compositions for oral administration include tablets, pills, capsules, powders, granules and the like.
    Capsules include hard capsules and soft capsules.
    In this solid composition one or more active substances are admixed with at least one inert diluent such as lactose, mannitol, glucose, hydroxypropylcellulose, microcrystalline cellulose, starch, polyvinylpyrrolidone, magnesium metasilicate aluminate. The composition may contain additives other than inert diluents, such as lubricants such as magnesium stearate, disintegrants such as calcium cellulose glycolate, stabilizers such as lactose, dissolution aids such as glutamic acid or aspartic acid, according to conventional methods. If necessary, the tablets or pills may be coated with a film of gastric or enteric substances such as white sugar, gelatin, hydroxypropyl cellulose, and hydroxypropyl methyl cellulose phthalate, or may be coated with two or more layers. Also included are capsules of absorbable materials, such as gelatin.
    Liquid compositions for oral administration include pharmaceutically acceptable emulsions, solutions, syrups, elixirs, and the like. In such liquid compositions, one or more active substances are contained in commonly used inert diluents (eg, purified water, ethanol). In addition to the inert diluent, the composition may contain an adjuvant such as a wetting agent or suspending agent, a sweetening agent, a flavoring agent, a fragrance or a preservative.
    Other compositions for oral administration include sprays containing one or more active substances and prescribed by methods known per se. The composition may contain, in addition to an inert diluent, a stabilizer such as sodium hydrogen sulfite and a buffer to impart isotonicity, such as isotonic agents such as sodium chloride, sodium citrate or citric acid. Methods of making sprays are described in detail, for example, in US Pat. No. 2,868,691 and US Pat. No. 3,095,355.
    Injections for parenteral administration according to the present invention include sterile aqueous or non-aqueous solutions, suspensions, emulsions. Aqueous solutions and suspensions include, for example, distilled water for injection and physiological saline. Examples of water-insoluble solutions and suspending agents include propylene glycol, polyethylene glycol, vegetable oils such as olive oil, alcohols such as ethanol, polysorbate 80 (registered trademark), and the like. Such compositions may also contain adjuvants such as preservatives, wetting agents, emulsifiers, dispersants, stabilizers (eg lactose), dissolution aids (eg glutamic acid, aspartic acid). They are sterilized by filtration through a bacterial retention filter, combination of bactericides or irradiation. They may also be prepared by sterile solid compositions, for example, dissolved in sterile or sterile distilled water or other solvents prior to use of the freeze-dried product.
    Other compositions for parenteral administration include one or more active substances, and include external preparations, ointments, coatings, suppositories for rectal administration and pessaries for vaginal administration, etc., which are prescribed by conventional methods.
    Best Mode for Carrying Out the Invention
    Hereinafter, although this invention is demonstrated in detail by reference example and an Example, this invention is not limited to these.
    The solvent in brackets shown in the separation part by chromatography and in TLC indicates the elution solvent or developing solvent used, and the ratio indicates the volume ratio.
    The solvent in parentheses shown in the NMR portion indicates the solvent used for the measurement.
    Reference Example 1
    2- (dihydroxyboronyl) benzofuran

    To a solution of benzofuran (128 g) in tetrahydrofuran (540 ml) was added dropwise 1.6 N of n-butyllithium hexane solution (750 ml) under dry ice-methanol bath cooling. The reaction mixture was stirred at 0 ° C. for 30 minutes, and then triisopropyl borate (275 ml) was added dropwise under cooling with a dry ice-methanol bath. The reaction mixture was stirred at 0 ° C. for 1 hour. The reaction mixture was concentrated, 1N aqueous hydrochloric acid solution was added to the residue, and the mixture was extracted with ethyl acetate. The extract was washed with water and saturated aqueous sodium chloride solution, dried over anhydrous magnesium sulfate and concentrated. The fish crystals were washed with hexane and dried to give the title compound (157 g) having the following physical properties.
    TLC: Rf 0.28 (n-hexane: ethyl acetate = 1: 1).
    Reference Example 2
    4- (benzofuran-2-yl) benzoic acid ethyl ester

    To a solution of 4-dimethyl iodine ethyl ester (5 g) in dimethylformamide (10 ml), the compound (2.64 g) prepared in Reference Example 1 and dichlorobis (triphenylphosphine) palladium (II) [PdCl 2 (PPh 3 ) 2 ] (0.635 g) and triethylamine (10 ml) were added. The reaction mixture was stirred at 80 ° C. for 6 hours. 1N aqueous hydrochloric acid solution was added to the reaction mixture, and the mixture was extracted with ethyl acetate. The extract was washed with saturated aqueous sodium chloride solution, dried over anhydrous sodium sulfate and concentrated. The resulting crystals were washed with hexane / diethyl ether and dried to give the title compound (3.6 g) having the following physical properties.
    TLC: Rf 0.61 (n-hexane: ethyl acetate = 9: 1).
    Reference Example 3
    4- (benzofuran-2-yl) benzoic acid

    To a dioxane (l 5 ml) solution of the compound (3.4 g) prepared in Reference Example 2 was added 1N aqueous sodium hydroxide solution (15.3 ml) at room temperature. The reaction mixture was stirred at room temperature for 9 hours. 1N hydrochloric acid aqueous solution was added to the reaction mixture until it became acidic, and extracted with ethyl acetate: tetrahydrofuran (2: 1). The extract was washed with saturated aqueous sodium chloride solution, dried over anhydrous sodium sulfate and concentrated. The resulting crystals were washed with ethyl acetate / diethyl ether and dried to give the title compound (2.1 g) having the following physical properties.
    TLC: Rf 0.43 (chloroform: methanol: acetic acid = 100: 10: 1).
    Reference Example 4
    4- (benzofuran-2-yl) benzoyl chloride

    The mixture prepared in Reference Example 3 (13.4 g) and thionyl chloride (80 ml) were stirred at 80 ° C for 6 hours. The reaction mixture was cooled to room temperature and concentrated. The obtained residue was washed with hexane / diethyl ether to give the title compound (12.7 g) having the following physical properties.
    NMR (CDCl 3 ): δ 8.19 (2H, d, J = 8.8 Hz), 7.98 (2H, d, J = 8.8 Hz), 7.68-7.61 (1H, m), 7.59-7.53 (1H, m), 7.42 -7.23 (3H, m).
    Example 1
    4- (N- (4- (benzofuran-2-yl) phenylcarbonyl) amino) butanoic acid ethyl ester

    Triethylamine (1 ml) was added to a dichloromethane (20 ml) solution of 4-aminobutanoic acid ethyl ester (0.5 g). To the mixture was added a dichloromethane (10 ml) solution of compound (0.72 g) prepared in Reference Example 4 at 0 ° C. The reaction mixture was stirred for 30 minutes at room temperature. 1N aqueous hydrochloric acid solution was added to the reaction mixture, and the mixture was extracted with ethyl acetate. The extract was washed with saturated aqueous sodium chloride solution, dried over anhydrous sodium sulfate and concentrated. The obtained residue was washed with ethyl acetate / diethyl ether and dried to obtain the title compound (0.732 g) having the following physical properties.
    TLC: Rf 0.38 (n-hexane: ethyl acetate = 1: 1).
    Example 2
    4- (N- (4- (benzofuran-2-yl) phenylcarbonyl) amino) butanoic acid

    To a solution of compound (670 mg) in tetrahydrofuran (5 ml) prepared in Example 1 was added 1N aqueous sodium hydroxide solution (4.4 ml). The reaction mixture was stirred for 3 hours at room temperature. 1N hydrochloric acid aqueous solution was added to the reaction mixture until it became acidic, and extracted with ethyl acetate / tetrahydrofuran. The extract was washed with saturated aqueous sodium chloride solution, dried over anhydrous sodium sulfate and concentrated to give the title compound (0.617 g) having the following physical properties.
    TLC: Rf 0.40 (Chloroform: Methanol: Acetic Acid = 100: 10: 1);
    NMR (CD 3 OD): δ 8.58 (1H, t, J = 5.6 Hz), 8.01 (2H, d, J = 8.8 Hz), 7.96 (2H, d, J = 8.8 Hz), 7.71-7.63 (2H, m), 7.57 (1H, d, J = 0.8 Hz), 7.39-7.23 (2H, m), 3.32-3.25 (2H, m), 2.29 (2H, t, J = 7.6 Hz), 1.84-1.70 (2H , m).
    Example 2 (1)-2 (24)
    Using the corresponding acid halide instead of the compound prepared in Reference Example 4, the same procedure as described in Example 1-Example 2 was conducted to obtain a compound shown below.
    Example 2 (1)
    4- (N- (4-methylphenylcarbonyl) amino) butanoic acid

    TLC: Rf 0.50 (Chloroform: Methanol: Acetic Acid = 18: 2: 1);
    NMR (CD 3 OD): δ 12.10 (1H, brs), 8.30 (1H, t, J = 5.5 Hz), 7.76 (2H, d, J = 8.0 Hz), 7.28 (2H, d, J = 8.0 Hz) , 3.30 (2H, m), 2.30 (2H, t, J = 7.2 Hz), 1.75 (2H, m).
    Example 2 (2)
    4- (N- (4-butyloxyphenylcarbonyl) amino) butanoic acid

    TLC: Rf 0.48 (CHCl 3: MeOH: Acetic Acid = 18: 2: 1);
    NMR (d 6 -DMSO): δ 12.03 (1H, brs), 8.29 (1H, t, J = 5.5 Hz), 7.78 (2H, d, J = 8.8 Hz), 6.95 (2H, d, J = 8.8 Hz ), 3.99 (2H, t, J = 6.4 Hz), 3.30-3.14 (2H, m), 2.24 (2H, t, J = 7.6 Hz), 1.79-1.62 (4H, m), 1.51-1.32 (2H, m), 0.91 (3H, t, J = 7.4 Hz).
    Example 2 (3)
    4- (N- (3-butyloxyphenylcarbonyl) amino) butanoic acid

    TLC: Rf 0.58 (CHCl 3: MeOH: Acetic Acid = 18: 2: 1);
    NMR (d 6 -DMSO): δ 12.04 (1H, brs), 8.42 (1H, t, J = 5.4 Hz), 7.41-7.28 (3H, m), 7.07-7.00 (1H, m), 3.99 (2H, t, J = 6.4 Hz), 3.24 (2H, m), 2.25 (2H, t, J = 7.3 Hz), 1.80-1.64 (4H, m), 1.42 (2H, m), 0.92 (3H, t, J = 7.3 Hz).
    Example 2 (4)
    4- [N- [4- (2- (4-methylphenyl) ethynyl) furan-2-ylcarbonyl] amino] butanoic acid

    TLC: Rf 0.54 (chloroform: methanol: acetic acid = 18: 2: 1);
    NMR (d 6 -DMSO): δ 12.07 (1H, brs), 8.51 (1H, t, J = 6.0 Hz), 7.44 (2H, d, J = 8.1 Hz), 7.25 (2H, d, J = 8.1 Hz ), 7.12 (1H, d, J = 3.7 Hz), 6.94 (1H, d, J = 3.7 Hz), 3.26-3.23 (2H, m), 2.33 (3H, s), 2.23 (2H, d, J = 7.5 Hz), 1.79-1.63 (2H, m).
    Example 2 (5)
    4- (N- (4- (pyrrole-1-yl) phenylcarbonyl) amino) butanoic acid

    TLC: Rf 0.59 (CHCl 3: MeOH: Acetic Acid = 18: 2: 1);
    NMR (d 6 -DMSO): δ 12.04 (1H, brs), 7.94 (2H, d, J = 8.8 Hz). 7.66 (2H, d, J = 8.8 Hz), 7.47-7.44 (2H, m), 6.31-6.28 (2H, m), 3.32-3.25 (2H, m), 2.29 (2H, t, J = 7.3 Hz) , 1.77 (2H, m).
    Example 2 (6)
    4- (N- (trans-4-methylcyclohexylcarbonyl) amino) butanoic acid

    TLC: Rf 0.55 (CHCl 3: MeOH: Acetic Acid = 18: 2: 1);
    NMR (d 6 -DMSO): δ 12.01 (1H, bs), 7.67 (1H, t, J = 6.0 Hz), 3.02 (2H, m), 2.19 (2H, t, J = 7.5 Hz), 2.06-1.91 (1H, m), 1.74-1.52 (6H, m), 1.46-1.18 (4H, m), 0.98-0.76 (4H, m).
    Example 2 (7)
    4- (N- (4- (3-methoxy-1-propynyl) phenylcarbonyl) amino) butanoic acid

    TLC: Rf 0.45 (CHCl 3: MeOH: Acetic Acid = 18: 2: 1);
    NMR (d 6 -DMSO): δ 12.03 (1H, brs), 8.54 (1H, t, J = 5.3 Hz), 7.85 (2H, d, J = 8.2 Hz), 7.52 (2H, d, J = 8.2 Hz ), 4.34 (2H, s), 3.35 (3H, s), 3.34-3.22 (2H, m), 2.28 (2H, t, J = 7.0 Hz), 1.76 (2H, m).
    Example 2 (8)
    4- (N- (4-butylphenylcarbonyl) amino) butanoic acid

    TLC: Rf 0.54 (chloroform: methanol: acetic acid = 18: 2: 1);
    NMR (CD 3 OD): δ 12.03 (1H, brs), 8.37 (1H, t, J = 5.5 Hz), 7.75 (2H, d, J = 8.2 Hz), 7.25 (2H, d, J = 8.2 Hz) , 3.33-3.22 (2H, m), 2.62 (2H, t, J = 7.5 Hz), 2.27 (2H, t, J = 7.4 Hz), 1.83-1.67 (2H, m), 1.65-1.48 (2H, m ), 1.40-1.22 (2H, m), 0.90 (3H, t, J = 7.1 Hz).
    Example 2 (9)
    4- (N- (benzofuran-2-ylcarbonyl) amino) butanoic acid

    TLC: Rf 0.32 (CHCl 3: MeOH: Acetic Acid = 100: 10: 1);
    NMR (d 6 -DMSO): δ 8.73 (1H, t, J = 5.4 Hz), 7.78-7.73 (1H, m), 7.66-7.61 (1H, m), 7.51 (1H, d, J = 0.8 Hz) , 7.49-7.41 (1H, m), 7.36-7.28 (1H, m), 3.28 (2H, m), 2.27 (2H, t, J = 7.4 Hz), 1.83-1.68 (2H, m).
    Example 2 (10)
    4- [N- [4- (2- (4-chlorophenyl) ethenyl) phenylcarbonyl] amino] butanoic acid

    TLC: Rf 0.28 (CHCl 3: MeOH = 10: 1);
    NMR (d 6 -DMSO): δ 8.48 (1H, t, J = 5.6 Hz), 7.85 (2H, d, J = 8.4 Hz), 7.67 (2H, d, J = 8.4 Hz), 7.65 (2H, d , J = 8.8 Hz), 7.44 (2H, d, J = 8.8 Hz), 7.40 (1H, d, J = 16.4 Hz), 7.30 (1H, d, J = 16.4 Hz), 3.27 (2H, m), 2.27 (2H, t, J = 7.4 Hz), 1.82-1.68 (2H, m).
    Example 2 (11)
    4- [N- [4- (2- (4- (imidazol-1-yl) phenyl) ethynyl) phenylcarbonyl] amino] butanoic acid

    TLC: Rf 0.29 (CHCl 3: MeOH: Acetic Acid = 100: 10: 1);
    NMR (d 6 -DMSO): δ 8.65 (1H, t, J = 5.4 Hz), 8.36 (1H, brs), 7.90 (2H, d, J = 8.4 Hz), 7.84 (1H, brs), 7.77 (2H , d, J = 9.2 Hz), 7.71 (2H, d, J = 9.2 Hz), 7.65 (2H, d, J = 8.4 Hz), 7.13 (1H, brs), 3.28 (2H, m), 2.31 (2H , t, J = 7.2 Hz), 1.82-1.68 (2H, m).
    Example 2 (12)
    4- (N- (trans-4-propylcyclohexylcarbonyl) amino) butanoic acid

    TLC: Rf 0.65 (CHCl 3: MeOH: Acetic Acid = 18: 2: 1);
    NMR (d 6 -DMSO): δ 12.00 (1H, s), 7.74-7.61 (1H, t, J = 6.0 Hz), 3.02 (2H, m), 2.19 (2H, t, J = 7.2 Hz), 2.11 -1.92 (1H, m), 1.78-1.53 (6H, m), 1.43-1.08 (7H, m), 0.95-0.89 (5H, m).
    Example 2 (13)
    4- [N- [4- (2- (4-methylphenyl) ethynyl) phenylcarbonyl] amino] butanoic acid

    TLC: Rf 0.57 (Chloroform: Methanol: Acetic Acid = 18: 2: 1);
    NMR (CD 3 OD): δ 12.05 (1H, s), 8.57 (1H, t, J = 5.5 Hz), 7.88 (2H, d, J = 8.3 Hz), 7.61 (2H, d, J = 8.3 Hz) , 7.47 (2H, d, J = 8.3 Hz), 7.25 (2H, d, J = 8.3 Hz), 3.34-3.24 (2H, m), 2.35 (3H, s), 2.29 (2H, t, J = 7.2 Hz), 1.77 (2H, m).
    Example 2 (14)
    4- [N- [4-((4-bromophenyl) aminosulfonyl) phenylcarbonyl] amino] butanoic acid

    TLC: Rf 0.45 (CHCl 3: MeOH: Acetic Acid = 18: 2: 1);
    NMR (d 6 -DMSO): δ 12.03 (1H, brs), 10.53 (1H, brs), 8.68-8.62 (1H, m), 7.95 (2H, d, J = 8.6 Hz), 7.81 (2H, d, J = 8.6 Hz), 7.42 (2H, d, J = 9.0 Hz), 7.05 (2H, d, J = 9.0 Hz), 3.33-3.21 (2H, m), 2.27 (2H, t, J = 7.3 Hz) , 1.74 (2H, m).
    Example 2 (15)
    4- [N- (4-cyclohexylphenylcarbonyl) amino] butanoic acid

    TLC: Rf 0.33 (CHCl 3: MeOH = 9: 1);
    NMR (d 6 -DMSO): δ 12.04 (1H, s), 8.45-8.27 (1H, m), 7.75 (2H, d, J = 8.4 Hz), 7.28 (2H, d, J = 8.4 Hz), 3.34 -3.21 (2H, m), 2.64-2.44 (1H, m), 2.26 (2H, t, J = 7.3 Hz), 1.85-1.61 (7H, m), 1.56-1.19 (5H, m).
    Example 2 (16)
    4- [N- [4- (4-propylphenyl) phenylcarbonyl] amino] butanoic acid

    TLC: Rf 0.32 (CHCl 3: MeOH = 9: 1);
    NMR (d 6 -DMSO): δ 12.05 (1H, s), 8.56-8.44 (1H, m), 7.93 (2H, d, J = 8.4 Hz), 7.73 (2H, d, J = 8.4 Hz), 7.64 (2H, d, J = 8.4 Hz), 7.30 (2H, d, J = 8.4 Hz), 3.40-3.25 (2H, m), 2.61 (2H, t, J = 7.4 Hz). 2.29 (2H, t, J = 7.3 Hz), 1.86-1.54 (4H, m), 0.92 (3H, t, J = 7.4 Hz).
    Example 2 (17)
    4- [N- [4- (4-hydroxyphenyl) phenylcarbonyl] amino] butanoic acid

    TLC: Rf 0.17 (CHCl 3: MeOH = 9: 1);
    NMR (d 6 -DMSO): δ 12.05 (1H, s), 9.62 (1H, s), 8.53-8.42 (1H, m), 7.89 (2H, d, J = 8.5 Hz), 7.66 (2H, d, J = 8.2 Hz), 7.56 (2H, d, J = 8.5 Hz), 6.87 (2H, d, J = 8.2 Hz), 3.36-3.26 (2H, m), 2.29 (2H, t, J = 7.2 Hz) , 1.77 (2H, m).
    Example 2 (18)
    4- [N- [4- (4-chlorophenyl) furan-2-ylcarbonyl] amino] butanoic acid

    TLC: Rf 0.24 (CHCl 3: MeOH = 9: 1);
    NMR (d 6 -DMSO): δ 12.07 (1H, s), 8.62-8.51 (1H, m), 7.94 (2H, d, J = 8.4 Hz), 7.54 (2H, d, J = 8.4 Hz), 7.17 -7.11 (2H, m), 3.33-3.22 (2H, m), 2.29 (2H, t, J = 7.2 Hz), 1.77 (2H, m).
    Example 2 (19)
    4- [N- [4- (4-heptylphenyl) phenylcarbonyl] amino] butanoic acid

    TLC: Rf 0.65 (CHCl 3: MeOH: Acetic Acid = 18: 2: 1);
    NMR (d 6 -DMSO): δ 12.04 (1H, s), 8.55-8.45 (1H, m), 7.93 (2H, d, J = 8.4 Hz), 7.73 (2H, d, J = 8.4 Hz), 7.63 (2H, d, J = 8.4 Hz), 7.29 (2H, d, J = 8.4 Hz), 3.37-3.23 (2H, m), 2.62 (2H, t, J = 7.5 Hz), 2.29 (2H, t, J = 7.1 Hz), 1.78 (2H, m), 1.68-1.48 (2H, m), 1.39-1.15 (8H, m), 0.86 (3H, t, J = 6.6 Hz).
    Example 2 (20)
    4- [N- [4- (4-methoxyphenyl) phenylcarbonyl] amino] butanoic acid

    TLC: Rf 0.11 (CHCl 3: MeOH = 9: 1);
    NMR (d 6 -DMSO): δ 12.05 (1H, s), 8.55-8.45 (1H, m), 7.91 (2H, d, J = 8.4 Hz), 7.71 (2H, d, J = 8.4 Hz), 7.68 (2H, d, J = 8.9 Hz), 7.05 (2H, d, J = 8.9 Hz), 3.81 (3H, s), 3.35-3.22 (2H, m), 2.29 (2H, t, J = 7.3 Hz) , 1.76 (2H, m).
    Example 2 (21)
    4- [N- [4- (4-chlorophenyl) phenylcarbonyl] amino] butanoic acid

    NMR (d 6 -DMSO): δ 12.07 (1H, s), 8.59-8.50 (1H, m), 7.95 (2H, d, J = 8.4 Hz), 7.81-7.71 (4H, m), 7.54 (2H, d, J = 8.8 Hz), 3.33-3.24 (2H, m), 2.29 (2H, t, J = 7.3 Hz), 1.82-1.71 (2H, m).
    Example 2 (22)
    4- [N- (5-benzyloxyindol-2-ylcarbonyl) amino] butanoic acid

    TLC: Rf 0.13 (CHCl 3: MeOH = 9: 1);
    NMR (d 6 -DMSO): δ 11.39 (1H, s), 8.42 (1H, t, J = 5.6 Hz), 7.50-7.20 (6H, m), 7.15 (1H, d, J = 2.2 Hz), 6.99 (1H, d, J = 1.8 Hz), 6.89 (1H, dd, J = 8.6, 2.2 Hz), 5.07 (2H, s), 3.27 (2H, m). 2.27 (2H, t, J = 7.4 Hz), 1.73 (2H, m).
    Example 2 (23)
    4- [N- [5- (2- (4-chlorophenyl) ethenyl) furan-2-ylcarbonyl] amino] butanoic acid

    TLC: Rf 0.52 (CHCl 3: MeOH: Acetic Acid: Water = 100: 10: 1: 1);
    NMR (d 6 -DMSO): δ 12.06 (1H, brs), 8.43 (1H, t, J = 5.8 Hz), 7.59 (2H, d, J = 8.8 Hz), 7.42 (2H, d, J = 8.8 Hz ), 7.26 (1H, d, J = 16.6 Hz), 7.14 (1H, d, J = 16.6 Hz), 7.09 (1H, d, J = 3.2 Hz), 6.63 (1H, d, J = 3.2 Hz), 3.25 (2H, m), 2.26 (2H, t, J = 7.2 Hz), 1.73 (2H, m).
    Example 2 (24)
    4- [N- [4- (4-phenyloxyphenyl) phenylcarbonyl] amino] butanoic acid

    TLC: Rf 0.47 (CHCl 3: MeOH: Acetic Acid: Water = 100: 10: 1: 1);
    NMR (d 6 -DMSO): δ 8.41 (1H, t, J = 5.4 Hz), 7.85 (2H, d, J = 8.4 Hz), 7.42 (2H, t, J = 8.0 Hz), 7.18 (1H, t , J = 7.2 Hz), 6.97-7.08 (4H, m), 3.24 (2H, m), 2.25 (2H, t, J = 7.4 Hz), 1.72 (2H, m).
    Example 3
    N- (1-methoxy-1,1-dimethylmethyl) oxy-4- (N- (4- (benzofuran-2-yl) phenylcarbonyl) amino) butylamide

    N- (1-methoxy-1,1-dimethylmethyloxy) amine (0.455 g), 1-hydroxybenzotriazole in a dimethylformamide (10 ml) solution of the compound (0.55 g) prepared in Example 2 Hydrate (0.391 g) and 1-ethyl-3- (3-dimethylaminopropyl) carbodiimide hydrochloride (0.489 g) were added under ice-cooling, and it stirred at room temperature for 3 hours. Water was added to the reaction mixture, which was then extracted with ethyl acetate. The extract was washed with a saturated aqueous sodium hydrogen carbonate solution and a saturated aqueous sodium chloride solution, dried over anhydrous sodium sulfate, and concentrated to give the title compound (0.230 g) having the following physical properties.
    TLC: Rf 0.13 (chloroform: methanol = 10: 1).
    Example 4
    N-hydroxy-4- (N- (4- (benzofuran-2-yl) phenylcarbonyl) amino) butylamide

    To a methanol (10 ml) solution of the compound (0.230 g) prepared in Example 3 was added 1N aqueous hydrochloric acid solution (100 ml). The reaction mixture was stirred at room temperature for 10 minutes. The reaction mixture was concentrated and the residue obtained was washed with diethyl ether to give the title compound (0.218 g) having the following physical properties.
    TLC: Rf 0.22 (CHCl 3: MeOH: Acetic Acid = 100: 10: 1);
    NMR (d 6 -DMSO): δ 10.39 (1H, brs), 8.59 (1H, t, J = 5.8 Hz), 8.01 (2H, d, J = 9.0 Hz), 7.96 (2H, d, J = 9.0 Hz ), 7.67 (2H, m), 7.57 (1H, d, J = 0.5 Hz), 7.39-7.23 (2H, m), 3.27 (2H, q, J = 5.8 Hz), 2.03 (2H, t, J = 7.6 Hz), 1.76 (2H, m).
    Example 4 (1)-4 (36)
    Instead of the compound prepared in Example 2, a compound prepared in Examples 2 (1) to 2 (24), or an equivalent compound was used to obtain the same procedure as in Example 1 → Example 2 Using the compound, it operated in the same manner as the method shown in Example 3-Example 4, and obtained the compound shown below.
    Example 4 (1)
    N-hydroxy-4- (N- (4-methylphenylcarbonyl) amino) butylamide

    TLC: Rf 0.23 (CHCl 3: MeOH = 10: 1);
    NMR (d 6 -DMSO): δ 10.39 (1H, s), 8.70 (1H, s), 8.40 (1H, t, J = 5.2 Hz), 7.74 (2H, d, J = 8.1 Hz). 7.25 (2H, d, J = 8.1 Hz), 3.24 (2H, td, J = 6.6, 5.2 Hz), 2.35 (3H, s), 2.02 (2H, t, J = 7.7 Hz), 1.74 (2H, m ).
    Example 4 (2)
    N-hydroxy-4- (N- (4-butyloxyphenylcarbonyl) amino) butylamide

    TLC: Rf 0.29 (CHCl 3: MeOH: Acetic Acid = 18: 2: 1);
    NMR (d 6 -DMSO): δ 10.39 (1H, s), 8.70 (1H, brs), 8.32 (1H, t, J = 5.8 Hz), 7.80 (2H, d, J = 9.0 Hz), 6.96 (2H , d, J = 9.0 Hz, 4.01 (2H, t, J = 6.4 Hz), 3.35-3.15 (2H, m), 2.01 (2H, t, J = 7.3 Hz), 1.81-1.64 (4H, m) , 1.44 (2H, m), 0.94 (3H, t, J = 7.4 Hz).
    Example 4 (3)
    N-hydroxy-4- (N- (3-butyloxyphenylcarbonyl) amino) butylamide

    TLC: Rf 0.31 (CHCl 3: MeOH: Acetic Acid = 18: 2: 1);
    NMR (d 6 -DMSO): δ 10.39 (1H, s), 8.45 (1H, t, J = 5.2 Hz), 7.43 · 7.29 (3H, m), 7.19-7.01 (1H, m), 4.01 (2H, t, J = 6.3 Hz), 3.30-3.18 (2H, m), 2.02 (2H, t, J = 7.5 Hz), 1.83-1.64 (4H, m), 1.49 (2H, m), 0.95 (3H, t , J = 7.3 Hz).
    Example 4 (4)
    N-hydroxy-4- [N- [4-((4-methylphenyl) ethynyl) furan-2-ylcarbonyl] amino] butylamide

    TLC: Rf 0.32 (CHCl 3: MeOH: Acetic Acid = 18: 2: 1);
    NMR (d 6 -DMSO): δ 10.40 (1H, bs), 10.22 (1H, s), 8.56 (1H, t, J = 5.7 Hz), 7.47 (2H, d, J = 8.3 Hz), 7.28 (2H , d, J = 8.3 Hz), 7.16 (1H, d, J = 3.6 Hz), 6.96 (1H, d, J = 3.6 Hz), 3.28-3.14 (2H, m), 2.36 (3H, s), 2.00 (2H, t, J = 7.5 Hz), 1.83-1.64 (2H, m).
    Example 4 (5)
    N-hydroxy-4- (N- (4- (pyrrole-1-yl) phenylcarbonyl) amino) butylamide

    TLC: Rf 0.31 (CHCl 3: MeOH: Acetic Acid = 18: 2: 1);
    NMR (d 6 -DMSO): δ 10.40 (1H, s), 9.00-8.24 (1H, brs), 8.52 (1H, t, J = 5.6 Hz), 7.94 (2H, d, J = 8.5 Hz), 7.68 (2H, d, J = 8.5 Hz), 7.50-7.44 (2H, m), 6.34-6.29 (2H, m), 3.38-3.31 (2H, m), 2.04 (2H, t, J = 7.5 Hz), 1.76 (2 H, m).
    Example 4 (6)
    N-hydroxy-4- (N- (trans-4-methylcyclohexylcarbonyl) amino) butylamide

    TLC: Rf 0.29 (CHCl 3: MeOH: Acetic Acid = 18: 2: 1);
    NMR (d 6 -DMSO): δ 10.37 (1H, s), 10.20 (1H, s), 7.69 (1H, t J = 5.3 Hz), 3.07-2.92 (2H, m), 2.31-1.88 (3H, m ), 1.74-1.52 (6H, m), 1.46-1.18 (3H, m), 0.98-0.76 (2H, m), 0.85 (3H, d, J = 6.6 Hz).
    Example 4 (7)
    N-hydroxy-4- (N- (4- (3-methoxy-1-propynyl) phenylcarbonyl) amino) butylamide

    TLC: Rf 0.32 (CHCl 3: MeOH: Acetic Acid = 18: 2: 1);
    NMR (d 6 -DMSO): δ 10.39 (1H, s), 8.57 (1H, t J = 5.5 Hz), 7.85 (2H, d, J = 8.6 Hz), 7.53 (2H, d, J = 8.6 Hz) , 4.35 (2H, s), 3.35 (3H, s), 3.25 (2H, dt, J = 5.5, 7.2 Hz), 2.02 (2H, t, J = 7.2 Hz), 1.74 (2H, quint, J = 7.2 Hz).
    Example 4 (8)
    N-hydroxy-4- (N- (4-butylphenylcarbonyl) amino) butylamide

    TLC: Rf 0.37 (CHCl 3: MeOH: Acetic Acid = 18: 2: 1);
    NMR (d 6 -DMSO): δ 10.40 (1H, brs), 10.20 (1H, s), 8.41 (1H, t, J = 5.4 Hz), 7.76 (2H, d, J = 8.0 Hz), 7.25 (2H , d, J = 8.0 Hz), 3.23 (2H, dt, J = 5.4 Hz, J = 7.0 Hz), 2.62 (2H, t, J = 8.2 Hz), 2.02 (2H, t, J = 7.0 Hz), 1.83-1.66 (2H, m), 1.64-1.48 (2H, m), 1.30 (2H, m), 0.90 (3H, t, J = 7.2 Hz).
    Example 4 (9)
    N-hydroxy-4- (N- (benzofuran-2-ylcarbonyl) amino) butylamide

    TLC: Rf 0.16 (CHCl 3: MeOH: Acetic Acid = 100: 10: 1);
    NMR (d 6 -DMSO): δ 10.38 (1H, brs), 9.30-8.10 (1H, br), 8.75 (1H, t, J = 6.2 Hz), 7.76 (1H, m), 7.64 (1H, m) , 7.51 (1H, d, J = 0.6 Hz), 7.45 (1H, dt, J = 1.6, 7.0 Hz), 7.32 (1H, dt, J = 1.0, 7.6 Hz), 3.25 (2H, q, J = 6.2 Hz), 2.01 (2H, t, J = 7.0 Hz), 1.74 (2H, m).
    Example 4 (10)
    N-hydroxy-4- [N- [4- (2- (4-chlorophenyl) ethenyl) phenylcarbonyl] amino] butylamide

    TLC: Rf 0.17 (CHCl 3: MeOH: Acetic Acid = 100: 10: 1);
    NMR (d 6 -DMSO): δ 10.39 (1H, brs), 8.50 (1H, t, J = 5.8 Hz), 7.86 (2H, d, J = 8.4 Hz), 7.67 (2H, d, J = 8.4 Hz ), 7.65 (2H, d, J = 8.4 Hz), 7.44 (2H, d, J = 8.4 Hz), 7.39 (1H, d, J = 16.2 Hz), 7.30 (1H, d, J = 16.2 Hz), 3.25 (2H, m), 2.02 (2H, t, J = 7.6 Hz), 1.74 (2H, m).
    Example 4 (11)
    N-hydroxy-4- [N- [4-((4- (imidazol-1-yl) phenyl) ethynyl) phenylcarbonyl] amino] butylamide

    TLC: Rf 0.14 (chloroform: methanol: acetic acid = 100: 10: 1);
    NMR (d 6 -DMSO): δ 10.43 (1H, brs), 9.71 (1H, s). 8.67 (1H, t, J = 5.6 Hz), 8.33 (1H, brs), 7.95-7.82 (8H, m), 7.67 (2H, d, J = 8.4 Hz), 3.25 (2H, m), 2.02 (2H , t, J = 7.4 Hz), 1.74 (2H, m).
    Example 4 (12)
    N-hydroxy-4- (N- (trans-4-propylcyclohexylcarbonyl) amino) butylamide

    TLC: Rf 0.34 (CHCl 3: MeOH: Acetic Acid = 18: 2: 1);
    NMR (d 6 -DMSO): δ 10.35 (1H, s), 7.67 (1H, t, J = 5.3 Hz), 2.99 (2H, m), 2.39-1.88 (3H, m), 1.78-1.61 (6H, m), 1.45-1.07 (7H, m), 0.95-0.76 (5H, m).
    Example 4 (13)
    N-hydroxy-4- [N- [4-((4-methylphenyl) ethynyl) phenylcarbonyl] amino] butylamide

    TLC: Rf 0.38 (CHCl 3: MeOH: Acetic Acid = 18: 2: 1);
    NMR (d 6 -DMSO): δ 10.39 (1H, s), 8.62-8.53 (1H, t, J = 5.3 Hz), 7.89 (2H, d, J = 8.6 Hz), 7.61 (2H, d, J = 8.6 Hz), 7.47 (2H, d, J = 8.0 Hz), 7.25 (2H, d. J = 8.0 Hz), 3.27 (2H, m), 2.35 (3H, s), 2.03 (2H, t, J = 6.8 Hz). 1.76 (2 H, m).
    Example 4 (14)
    N-hydroxy-4- [N- [4-((4-bromophenyl) aminosulfonyl) phenylcarbonyl] amino] butylamide

    TLC: Rf 0.16 (CHCl 3: MeOH: Acetic Acid = 18: 2: 1);
    NMR (d 6 -DMSO): δ 10.55 (1H, s), 10.38 (1H, brs), 8.67 (1H, m), 7.96 (2H, d, J = 8.4 Hz), 7.82 (2H, d, J = 8.4 Hz), 7.43 (2H, d, J = 9.0 Hz), 7.06 (2H, d, J = 9.0 Hz), 3.32-3.16 (2H, m), 2.01 (2H, t, J = 7.4 Hz), 1.82 -1.66 (2H, m).
    Example 4 (15)
    N-hydroxy-4- [N- (4-cyclohexylphenylcarbonyl) amino] butylamide

    TLC: Rf 0.40 (CHCl 3: MeOH: Acetic Acid = 18: 2: 1);
    NMR (d 6 -DMSO): δ 10.39 (1H, s), 8.43-8.36 (H, m), 7.76 (2H, d, J = 8.4 Hz), 7.34 (2H, d, J = 8.4 Hz), 3.30 -3.13 (2H, m), 2.63-2.54 (1H, m), 2.01 (2H, t, J = 7.6 Hz), 1.86-1.65 (6H, m), 1.48-1.24 (6H, m).
    Example 4 (16)
    N-hydroxy-4- [N- [4- (4-propylphenyl) phenylcarbonyl] amino] butylamide

    TLC: Rf 0.40 (CHCl 3: MeOH: Acetic Acid = 18: 2: 1);
    NMR (d 6 -DMSO): δ 10.40 (1H, s), 8.70 (1H, brs), 8.57-8.49 (1H, m), 7.93 (2H, d, J = 8.5 Hz), 7.74 (2H, d, J = 8.5 Hz), 7.64 (2H, d, J = 8.5 Hz), 7.31 (2H, d, J = 8.5 Hz), 3.31-3.20 (2H, m), 2.61 (2H, t, J = 7.4 Hz) , 2.04 (2H, t, J = 7.2 Hz), 1.76 (2H, m), 1.62 (2H, m), 0.92 (3H, t, J = 7.4 Hz).
    Example 4 (17)
    N-hydroxy-4- [N- [4- (4-hydroxyphenyl) phenylcarbonyl] amino] butylamide

    TLC: Rf 0.23 (chloroform: methanol: acetic acid = 18: 2: 1);
    NMR (d 6 -DMSO): δ 10.40 (1H, s), 9.80-9.45 (1H, brs), 8.53-8.44 (1H, m), 7.89 (2H, d, J = 8.5 Hz), 7.67 (2H, dJ = 8.5 Hz), 7.56 (2H, d, J = 8.8 Hz), 6.87 (2H, d, J = 8.8 Hz), 3.31-3.20 (2H, m), 2.03 (2H, t, J = 7.4 Hz) , 1.83-1.68 (2H, m).
    Example 4 (18)
    N-hydroxy-4- [N- [4- (4-chlorophenyl) furan-2-ylcarbonyl] amino] butylamide

    TLC: Rf 0.38 (CHCl 3: MeOH: Acetic Acid = 18: 2: 1);
    NMR (d 6 -DMSO): δ 10.40 (1H, s), 8.64-8.51 (1H, m), 7.95 (2H, d, J = 8.4 Hz), 7.54 (2H, d, J = 8.4 Hz), 7.16 -7.11 (2H, m), 3.31-3.18 (2H, m), 2.08-1.95 (2H, m), 1.76 (2H, m).
    Example 4 (19)
    N-hydroxy-4- [N- [4- (4-heptylphenyl) phenylcarbonyl] amino] butylamide

    TLC: Rf 0.34 (CHCl 3: MeOH: Acetic Acid = 18: 2: 1);
    NMR (d 6 -DMSO): δ 10.40 (1H, brs), 8.57-8.50 (1H, m), 7.93 (2H, d, J = 8.4 Hz), 7.74 (2H, d, J = 8.4 Hz), 7.64 (2H, d, J = 8.4 Hz), 7.30 (2H, d, J = 8.4 Hz), 3.32-3.22 (2H, m), 2.62 (2H, t, J = 7.7 Hz), 2.04 (2H, t, J = 7.3 Hz), 1.76 (2H, m), 1.69-1.52 (2H, m), 1.38-1.17 (8H, m), 0.86 (3H, t, J = 6.6 Hz).
    Example 4 (20)
    N-hydroxy-4- [N- [4- (4-methoxyphenyl) phenylcarbonyl] amino] butylamide

    TLC: Rf 0.26 (CHCl 3: MeOH = 9: 1);
    NMR (d 6 -DMSO): δ 10.40 (1H, s), 8.57-8.47 (1H, m), 7.91 (2H, d, J = 8.5 Hz), 7.71 (2H, d, J = 8.5 Hz), 7.68 (2H, d, J = 8.8 Hz), 7.05 (2H, d, J = 8.8 Hz), 3.81 (3H, s), 3.26 (2H, m), 2.03 (2H, t, J = 7.5 Hz), 1.83 -1.69 (2H, m).
    Example 4 (21)
    N-hydroxy-4- [N- [4- (4-chlorophenyl) phenylcarbonyl] amino] butylamide

    TLC: Rf 0.34 (CHCl 3: MeOH: Acetic Acid = 18: 2: 1);
    NMR (d 6 -DMSO): δ 10.41 (1H, s), 8.62-8.52 (1H, m), 7.95 (2H, d, J = 8.4 Hz), 7.82-7.72 (4H, m), 7.55 (2H, d, J = 8.4 Hz), 3.35-3.20 (2H, m), 2.04 (2H, t, J = 7.5 Hz), 1.83-1.69 (2H, m).
    Example 4 (22)
    N-hydroxy-4- [N- (5-benzyloxyindol-2-ylcarbonyl) amino] butylamide

    TLC: Rf 0.26 (CHCl 3: MeOH: Acetic Acid: Water = 100: 10: 1: 1);
    NMR (d 6 -DMSO): δ 11.38 (1H, brs), 10.38 (1H, brs), 8.70 (1H, brs), 8.43 (1H, t, J = 5.8 Hz), 7.28-7.48 (6H, m) , 7.16 (1H, d, J = 2.2 Hz), 6.99 (1H, d, J = 1.4 Hz), 6.89 (1H, dd, J = 8.7 Hz, 2.4 Hz), 5.07 (2H, s), 3.25 (2H m), 2.02 (2H, t, J = 6.8 Hz), 1.70-1.81 (2H, m).
    Example 4 (23)
    N-hydroxy-4- [N- [5- (2- (4-chlorophenyl) ethenyl) furan-2-ylcarbonyl] amino] butylamide

    TLC: Rf 0.27 (CHCl 3: MeOH: Acetic Acid: Water = 100: 10: 1: 1);
    NMR (d 6 -DMSO): δ 10.38 (1H, brs), 8.71 (1H, brs), 8.46 (1H, t, J = 5.8 Hz), 7.60 (2H, d, J = 8.8 Hz), 7.43 (2H , d, J = 8.8 Hz, 7.23 (1H, d, J = 16.6 Hz), 7.15 (1H, d, J = l6.6 Hz), 7.09 (1H, d, J = 3.4 Hz), 6.63 (1H, d, J = 3.4 Hz), 3.22 (2H, m), 2.00 (2H, t, J = 7.4 Hz), 1.73 (2H, m).
    Example 4 (24)
    N-hydroxy-4- [N- [4- (4-phenyloxyphenyl) phenylcarbonyl] amino] butylamide

    TLC: Rf 0.25 (chloroform: methanol: acetic acid: water = 100: 10: 1: 1);
    NMR (d 6 -DMSO): δ 10.36 (1H, brs), 8.69 (1H, brs), 8.41 (1H, t, J = 5.6 Hz), 7.85 (2H, d, J = 8.8 Hz), 7.41 (2H , t, J = 7.4 Hz), 7.19 (1H, t, J = 7.4 Hz), 6.97-7.09 (4H, m), 3.22 (2H, m), 1.99 (2H, t, J = 7.6 Hz), 1.71 (2H, m).
    Example 4 (25)
    N-hydroxy-5- [N- [4- (benzofuran-2-yl) phenylcarbonyl] amino] pentylamide

    TLC: Rf 0.26 (CHCl 3: MeOH = 10: 1);
    NMR (d 6 -DMSO): δ 10.36 (1H, s), 8.67 (1H, br.s), 8.57 (1H, t, J = 5.6 Hz). 8.01 (2H, d, J = 8.8 Hz), 7.96 (2H, d, J = 8.8 Hz), 7.71-7.63 (2H, m), 7.57 (1H, br.s), 7.39-7.23 (2H, m) , 3.30-3.23 (2H, m), 2.02-1.94 (2H, m), 1.60-1.44 (4H, m).
    Example 4 (26)
    N-hydroxy-6- [N- [4- (benzofuran-2-yl) phenylcarbonyl] amino] hexylamide

    TLC: Rf 0.28 (CHCl 3: MeOH = 10: 1);
    NMR (d 6 -DMSO): δ 10.33 (1H, s), 8.80-8.50 (1H, br.s), 8.54 (1H, t, J = 5.6 Hz), 8.01 (2H, d, J = 8.8 Hz) , 7.95 (2H, d, J = 8.8H), 7.71-7.62 (2H, m), 7.56 (1H, s), 7.39-7.23 (2H, m), 3.30-3.21 (2H, m), 1.95 (2H , t, J = 7.2 Hz), 1.59-1.46 (4H, m), 1.36-1.20 (2H, m).
    Example 4 (27)
    N-hydroxy-4- [N-[[(4'-carbamoylmethoxy) biphenyl-4-yl] carbonyl] amino] butylamide

    TLC: Rf 0.22 (CHCl 3: MeOH: Acetic Acid: Water = 50: 10: 1: 1);
    NMR (d 6 -DMSO): δ 10.37 (1H, brs), 8.70 (1H, brs), 8.49 (1H, t, J = 5.4 Hz), 7.89 (2H, d, J = 8.8 Hz), 7.70 (2H , d, J = 8.2 Hz), 7.67 (2H, d, J = 8.2 Hz), 7.54 (1H, brs), 7.39 (1H, brs), 7.04 (2H, d, J = 8.8 Hz), 4.46 (2H , s), 3.20-3.31 (2H, m), 2.01 (2H, t, J = 7.2 Hz), 1.66-1.80 (2H, m).
    Example 4 (28)
    N-hydroxy-4- [N- [4- (4-phenylpiperidin-1-yl) phenylcarbonyl] amino] butylamide

    NMR (d 6 -DMSO): δ 10.39 (1H, s), 8.69 (1H, s), 8.20 (1H, t, J = 5.8 Hz), 7.73 (2H, d, J = 8.6 Hz). 7.40-7.12 (5H, m), 6.98 (2H, d, J = 8.6 Hz), 4.06-3.90 (2H, m), 3.30-3.16 (2H, m), 2.96-2.60 (3H, m), 2.00 ( 2H, t, J = 7.6 Hz), 1.95-1.59 (6H, m).
    Example 4 (29)
    N-hydroxy-4- [N- [4- [3- (4-chlorophenoxy) -1-propynyl] phenylcarbonyl] amino] butylamide

    TLC: Rf 0.26 (CHCl 3: MeOH = 8: 1);
    NMR (d 6 -DMSO): δ 10.38 (1H, s), 8.71 (1H, s), 8.57 (1H, t, J = 5.4 Hz), 7.85 (2H, d, J = 8.4 Hz), 7.53 (2H , d, J = 8.4 Hz), 7.38 (2H, d, J = 9.2 Hz), 7.08 (2H, d, J = 9.2 Hz), 5.08 (2H, s), 3.40-3.15 (2H, m, overlap with H 2 O in dmso), 2.02 (2H, t, J = 7.2 Hz), 1.74 (2H, m).
    Example 4 (30)
    N-hydroxy-4- [N- [4- (3-phenoxy-1-propynyl) phenylcarbonyl] amino] butylamide

    TLC: Rf 0.38 (CHCl 3: MeOH = 9: 1);
    NMR (d 6 -DMSO): δ 10.38 (1H, s), 8.70 (1H, s), 8.57 (1H, t, J = 5.4 Hz), 7.85 (2H, d, J = 8.3 Hz), 7.52 (2H , d, J = 8.3 Hz), 7.34 (2H, dd, J = 7.0 and 8.6 Hz), 7.10-6.90 (3H, m), 5.06 (2H, s), 3.25 (2H, dt, J = 5.4 and 7.2 Hz), 2.02 (2H, t, J = 7.2 Hz), 1.74 (2H, m).
    Example 4 (31)
    N-hydroxy-4- [N- [4- (4-methoxyphenoxy) phenylcarbonyl] amino] butylamide

    TLC: Rf 0.40 (Chloroform: Methanol: Acetic Acid: Water = 50: 10: 1: 1);
    NMR (d 6 -DMSO): δ 10.37 (1H, brs), 8.70 (1H, brs), 8.40 (1H, t, J = 5.5 Hz), 7.82 (2H, d, J = 9.1 Hz), 7.06-6.91 (6H, m), 3.79 (3H, s), 3.21 (2H, m), 1.96 (2H, m), 1.72 (2H, m).
    Example 4 (32)
    N-hydroxy-4- [N- [4- (4-hydroxyphenoxy) phenylcarbonyl] amino] butylamide

    TLC: Rf 0.25 (chloroform: methanol: acetic acid: water = 50: 10: 1: 1);
    NMR (d 6 -DMSO): δ 8.37 (1H, t, J = 5.5 Hz), 7.81 (2H, d, J = 8.8 Hz), 6.92 (2H, d, J = 9.1 Hz), 6.90 (2H, d , J = 8.8 Hz), 6.80 (2H, d, J = 9.1 Hz), 3.21 (2H, m), 1.99 (2H, m), 1.71 (2H, m).
    Example 4 (33)
    N-hydroxy-4- [N- [4- (4-phenoxypiperazin-1-yl) phenylcarbonyl] amino] butylamide

    TLC: Rf 0.31 (CHCl 3: MeOH = 9: 1);
    NMR (d 6 -DMSO): δ 10.38 (1H, s), 8.69 (1H, s), 8.19 (1H, t, J = 5.2 Hz), 7.73 (2H, d, J = 8.8 Hz), 7.28 (2H , dd, J = 8.8, 7.4 Hz), 7.02-6.87 (5H, m), 4.68-4.52 (1H, m), 3.73-3.56 (2H, m), 3.32-3.10 (4H, m), 2.11-1.92 (4H, m), 1.82-1.59 (4H, m).
    Example 4 (34)
    N-hydroxy-4- [N- [4- (4-phenyl-1,2,5,6-tetrahydropyridin-1-yl) phenylcarbonyl] amino] butylamide

    TLC: Rf 0.42 (CHCl 3: MeOH: Acetic Acid: Water = 50: 10: 1: 1);
    NMR (d 6 -DMSO): δ 10.38 and 9.78 (total 1H, both brs), 9.02 and 8.69 (total 1H, both brs), 8.20 (1H, t, J = 5.5 Hz), 7.75 (2H, d, J = 9.1 Hz), 7.48 (2H, m), 7.36 (2H, m), 7.26 (1H, m), 6.98 (2H, d, J = 9.1 Hz), 6.29 (1H, brs), 3.94 (2H, m ), 3.58 (2H, m), 3.20 (2H, m), 2.62 (2H, m), 1.99 (2H, m), 1.71 (2H, m).
    Example 4 (35)
    N-hydroxy-4- [N- [4- (1-heptinyl) phenylcarbonyl] amino] butylamide

    TLC: Rf 0.24 (CHCl 3: MeOH = 10: 1);
    NMR (d 6 -DMSO): δ 10.37 (1H, s), 8.52 (1H, t, J = 5.6 Hz), 7.80 (2H, d, J = 8.4 Hz), 7.44 (2H, d, J = 8.4 Hz ), 3.23 (2H, br.q, J = 5.8 Hz), 2.43 (2H, t, J = 6.6 Hz), 2.00 (2H, t, J = 7.4 Hz), 1.79-1.65 (2H, m), 1.62 -1.48 (2H, m), 1.44-1.22 (4H, m), 0.88 (3H, t, J = 6.6 Hz).
    Example 4 (36)
    N-hydroxy-4- [N- (4-benzyloxyphenylcarbonyl) amino] butylamide

    TLC: Rf 0.11 (CHCl 3: MeOH: Acetic Acid: Water = 100: 10: 1: 1);
    NMR (d 6 -DMSO): δ 10.36 and 9.78 (total 1H, each br), 8.99 and 8.68 (total 1H, each br), 8.31 (1H, m), 7.80 (2H, d, J = 8.8 Hz), 7.45-7.3 (5H, m), 7.05 (2H, d, J = 8.8 Hz), 5.15 (2H, s), 3.21 (2H, m), 1.99 (2H, t, J = 7.4 Hz), 1.72 (2H , m).
    Example 5
    4- (N-methyl-N- (4- (benzofuran-2-yl) phenylcarbonyl) amino) butanoic acid ethyl ester

    Methyl iodide (0.35 ml) was added to a solution of dimethylformamide (3 ml) of the compound (0.1 g) prepared in Example 1. To the mixture was added 60% sodium hydride (13 mg) at 0 ° C. The reaction mixture was stirred at room temperature for 1 hour. 1N aqueous hydrochloric acid solution was added to the reaction mixture, and the mixture was extracted with ethyl acetate. The extract was washed with saturated aqueous sodium chloride solution, dried over anhydrous sodium sulfate, and concentrated to give the title compound (113 mg) having the following physical properties.
    TLC: Rf 0.33 (n-hexane: ethyl acetate = 1: 1).
    Example 6
    4- (N-methyl-N- (4- (benzofuran-2-yl) phenylcarbonyl) amino) butanoic acid

    The title compound was obtained in the same manner as the method shown in Example 2, using the compound prepared in Example 5 instead of the compound prepared in Example 1.
    TLC: Rf 0.51 (CHCl 3: MeOH = 9: 1);
    NMR (CD 3 OD): δ 7.98 (2H, d, J = 8.4 Hz), 7.66-7.59 (1H, m), 7.57-7.46 (3H, m), 7.37-7.19 (3H, m), 3.62 and 3.40 (2H, t, J = 7.5 Hz), 3.10 and 3.03 (3H, s), 2.45 and 2.20 (2H, t, J = 7.5 Hz), 2.10-1.75 (2H, m).
    Example 7
    N-hydroxy-4- (N-methyl-N- (4- (benzofuran-2-yl) phenylcarbonyl) amino) butylamide

    Using the compound prepared in Example 6 instead of the compound prepared in Example 2, the same procedure as in Example 3-Example 4 was carried out to obtain the title compound having the following physical properties.
    TLC: Rf 0.31 (CHCl 3: MeOH = 9: 1);
    NMR (CD 3 OD): δ 7.99 (2H, d, J = 8.4 Hz), 7.66-7.59 (1H, m), 7.58-7.45 (3H, m), 7.37-7.20 (3H, m), 3.70-3.54 and 3.42-3.30 (2H, m), 3.16-2.95 (3H, m), 2.30-1.80 (4H, m).
    Example 8
    4- (N- (4- (benzofuran-2-yl) phenylcarbonyl) amino) -2 (S) -hydroxybutanoic acid methyl ester

    4-amino-2 (S) -hydroxybutanoic acid methyl ester (prepared in the same manner as described in EP 393441) instead of 4-aminobutanoic acid ethyl ester, Operation in the same manner to obtain the title compound having the following physical properties.
    TLC: Rf 0.11 (n-hexane: ethyl acetate = 1: 1);
    NMR (d 6 -DMSO): δ 8.58 (1H, t, J = 6.0 Hz), 8.01 (2H, d, J = 8.8 Hz), 7.96 (2H, d, J = 8.8 Hz), 7.71-7.63 (2H , m), 7.57 (1H, brs), 7.39-7.24 (2H, m), 4.19-4.10 (1H, m), 3.62 (3H, s), 3.38 (2H, q, J = 6.0 Hz), 2.06- 1.68 (2 H, m).
    Example 9
    4- (N- (4- (benzofuran-2-yl) phenylcarbonyl) amino) -2 (S) -hydroxybutanoic acid

    The title compound was obtained in the same manner as the method shown in Example 2, using the compound prepared in Example 8 instead of the compound prepared in Example 1.
    TLC: Rf 0.10 (CHCl 3: MeOH: Acetic Acid = 100: 10: 1);
    NMR (d 6 -DMSO): δ 8.49 (1H, t, J = 5.6 Hz), 7.92 (2H, d, J = 8.8 Hz), 7.87 (2H, d, J = 8.8 Hz), 7.62-7.53 (2H , m), 7.48 (1H, d, J = 0.6 Hz), 7.30-7.14 (2H, m), 3.95 (1H, dd, J = 4.4, 8.4 Hz), 3.29 (2H, m), 1.98-1.58 ( 2H, m).
    Example 9 (1)
    4- (N- (4- (benzofuran-2-yl) phenylcarbonyl) amino) -2 (R) -hydroxybutanoic acid

    In the same manner as in Example 8 → Example 9, using 4-amino-2 (R) -hydroxybutanoic acid methyl ester instead of 4-amino-2 (S) -hydroxybutanoic acid methyl ester , The title compound having the following physical properties was obtained.
    TLC: Rf 0.10 (CHCl 3: MeOH: Acetic Acid = 100: 10: 1);
    NMR (d 6 -DMSO): δ 8.49 (1H, t, J = 5.6 Hz), 7.92 (2H, d, J = 8.8 Hz). 7.87 (2H, d, J = 8.8 Hz), 7.62-7.53 (2H, m), 7.48 (1H, d, J = 0.6 Hz), 7.30-7.14 (2H, m), 3.95 (1H, dd, J = 4.4, 8.4 Hz), 3.29 (2H, m), 1.98-1.58 (2H, m).
    Example 10
    4- (N- (4- (benzofuran-2-yl) phenylcarbonyl) amino) -2 (S) -benzyloxymethoxybutanoic acid methyl ester

    Diisopropylethylamine (2 ml) was added to a dichloromethane (1 ml) solution of compound (0.2 g) prepared in Example 8. Benzyloxymethylchloride (0.79 ml) was added to the mixture. The reaction mixture was stirred at 50 ° C. for 30 minutes. 1N aqueous hydrochloric acid solution was added to the reaction mixture, and the mixture was extracted with ethyl acetate. The extract was washed with water and saturated aqueous sodium chloride solution, dried over anhydrous sodium sulfate and concentrated. The residue was purified by silica gel column chromatography (n-hexane: ethyl acetate = 3: 2) to obtain the title compound (0.176 g) having the following physical properties.
    TLC: Rf 0.47 (n-hexane: ethyl acetate = 1: 1).
    Example 11
    4- (N- (4- (benzofuran-2-yl) phenylcarbonyl) amino) -2 (S) -benzyloxymethoxybutanoic acid

    Using the compound prepared in Example 10 instead of the compound prepared in Example 1, the same procedure as described in Example 2 was carried out to obtain the title compound having the following physical properties.
    TLC: Rf 0.45 (chloroform: methanol: acetic acid = 100: 20: 1);
    NMR (d 6 -DMSO): δ 8.61 (1H, t, J = 5.4 Hz), 8.01 (2H, d, J = 8.8 Hz). 7.95 (2H, d, J = 8.8 Hz), 7.709-7.63 (2H, m), 7.57 (1H, brs), 4.80 (1H, d, J = 8.8 Hz), 4.79 (1H, d, J = 8.8 Hz ), 4.64 (1H, d, J = 11.8 Hz), 4.54 (1H, d, J = 11.8 Hz), 4.13 (1H, dd, J = 4.2, 8.2 Hz), 3.52-3.28 (2H, m), 2.12 -1.82 (2H, m).
    Example 11 (1)-11 (3)
    Using the corresponding amine compound and the acid halide, the same procedure as described in Example 8-Example 10-Example 11 was performed, and the compound shown below was obtained.
    Example 11 (1)
    4- (N- (4- (benzofuran-2-yl) phenylcarbonyl) amino) -2 (R) -benzyloxymethoxybutanoic acid

    TLC: Rf 0.45 (chloroform: methanol: acetic acid = 100: 20: 1);
    NMR (d 6 -DMSO): δ 8.61 (1H, t, J = 5.4 Hz), 8.01 (2H, d, J = 8.8 Hz), 7.95 (2H, d, J = 8.8 Hz), 7.709-7.63 (2H , m), 7.57 (1H, brs), 4.80 (1H, d, J = 8.8 Hz), 4.79 (1H, d, J = 8.8 Hz), 4.64 (1H, d, J = 11.8 Hz), 4.54 (1H , d, J = 11.8 Hz), 4.13 (1H, dd, J = 4.2, 8.2 Hz), 3.52-3.28 (2H, m), 2.12-1.82 (2H, m).
    Example 11 (2)
    4- (N- (4- (2- (4-chlorophenyl) ethenyl) phenylcarbonyl) amino) -2 (S) -benzyloxymethoxybutanoic acid

    TLC: Rf 0.18 (CHCl 3: MeOH = 10: 1);
    NMR (d 6 -DMSO): δ 8.52 (1H, t, J = 5.4 Hz), 7.84 (2H, d, J = 8.4 Hz), 7.67 (2H, d, J = 8.4 Hz), 7.65 (2H, d , J = 8.8 Hz), 7.44 (2H, d, J = 8.8 Hz), 7.35-7.28 (7H, m), 4.80 (1H, d, J = 8.8 Hz), 4.77 (1H, d, J = 8.8 Hz ), 4.63 (1H, d, J = 11.8 Hz), 4.54 (1H, d, J = 11.8 Hz), 4.12 (1H, dd, J = 4.4, 8.0 Hz), 3.50-3.26 (2H, m), 2 .l 0-1.78 (2H, m).
    Example 11 (3)
    4- (N- (4-chlorophenylcarbonyl) amino) -2-benzyloxymethoxybutanoic acid

    TLC: Rf 0.32 (CHCl 3: MeOH: Acetic Acid = 100: 10: 1);
    NMR (d 6 -DMSO): δ 8.57 (1H, t, J = 5.6 Hz), 7.84 (2H, d, J = 8.8 Hz), 7.52 (2H, d, J = 8.8 Hz), 7.30 (5H, s ), 4.80 (1H, d, J = 8.8 Hz), 4.76 (1H, d, J = 8.8 Hz), 4.63 (1H, d, J = 11.8 Hz), 4.53 (1H, d, J = 11.8 Hz), 4.11 (1H, doublet of doublets, J = 4.4, 8.2 Hz), 3.49-3.24 (2H, m), 2.08-1.77 (2H, m).
    Example 12
    N-hydroxy-4- (N- (4- (benzofuran-2-yl) phenylcarbonyl) amino) -2 (S) -hydroxybutylamide

    Using the compound prepared in Example 9 instead of the compound prepared in Example 2, the title compound was obtained in the same manner as the method shown in Example 3-Example 4, to obtain the title compound having the following physical properties.
    TLC: Rf 0.42 (CHCl 3: MeOH: Water = 100: 20: 1);
    NMR (d 6 -DMSO): δ 10.49 (1H, brs), 8.55 (1H, t, J = 5.4 Hz), 8.01 (2H, d, J = 9.0 Hz), 7.96 (2H, d, J = 9.0 Hz ), 7.71-7.62 (2H, m), 7.57 (1H, brs), 7.39-7.23 (2H, m), 3.94 (1H, dd, J = 4.2, 8.2 Hz), 3.41-3.31 (2H, m), 2.02-1.64 (2H, m).
    Example 12 (1)-12 (5)
    Operation was carried out in the same manner as in Example 12, using the compound prepared in Example 9 (1), Example 11 and Example 11 (1) to 11 (3) instead of the compound prepared in Example 9. Thus, the compound shown below was obtained.
    Example 12 (1)
    N-hydroxy-4- (N- (4- (benzofuran-2-yl) phenylcarbonyl) amino) -2 (R) -hydroxybutylamide

    TLC: Rf 0.42 (CHCl 3: MeOH: Water = 100: 20: 1);
    NMR (d 6 -DMSO): δ 10.49 (1H, brs), 8.55 (1H, t, J = 5.4 Hz), 8.01 (2H, d, J = 9.0 Hz), 7.96 (2H, d, J = 9.0 Hz ), 7.71-7.63 (2H, m), 7.57 (1H, brs), 7.39-7.23 (2H, m), 3.94 (1H, dd, J = 4.2, 8.2 Hz), 3.41-3.31 (2H, m), 2.02-1.62 (2H, m).
    Example 12 (2)
    N-hydroxy-4- (N- (4- (benzofuran-2-yl) phenylcarbonyl) amino) -2 (S) -benzyloxymethoxybutylamide

    TLC: Rf 0.24 (CHCl 3: MeOH = 10: 1);
    NMR (d 6 -DMSO): δ 10.75 (1H, brs), 8.90 (1H, brs), 8.55 (1H, t, J = 5.6 Hz), 8.01 (2H, d, J = 8.8 Hz), 7.96 (2H , d, J = 8.8 Hz), 7.71-7.63 (2H, m), 7.58 (1H, brs), 7.39-7.24 (7H, m), 4.77 (1H, d, J = 8.8 Hz), 4.68 (1H, d, J = 8.8 Hz), 4.58 (2H, s), 4.04 (1H, t, J = 5.8 Hz), 3.49-3.25 (2H, m), 1.93 (2H, m).
    Example 12 (3)
    N-hydroxy-4- (N- (4- (benzofuran-2-yl) phenylcarbonyl) amino) -2 (R) -benzyloxymethoxybutylamide

    TLC: Rf 0.24 (CHCl 3: MeOH = 10: 1);
    NMR (d 6 -DMSO): δ 10.75 (1H, brs), 8.90 (1H, brs), 8.55 (1H, t, J = 5.6 Hz), 8.01 (2H, d, J = 8.8 Hz), 7.96 (2H , d, J = 8.8 Hz), 7.71-7.63 (2H, m), 7.58 (1H, brs), 7.39-7.24 (7H, m), 4.77 (1H, d, J = 8.8 Hz), 4.68 (1H, d, J = 8.8 Hz), 4.58 (2H, s), 4.04 (1H, t, J = 5.8 Hz), 3.49-3.25 (2H, m), 1.93 (2H, m).
    Example 12 (4)
    N-hydroxy-4- (N- (4- (2- (4-chlorophenyl) ethenyl) phenylcarbonyl) amino) -2 (S) -benzyloxymethoxybutylamide

    TLC: Rf 0.22 (CHCl 3: MeOH = 10: 1);
    NMR (d 6 -DMSO): δ 10.74 (1H, brs), 8.89 (1H, brs), 8.45 (1H, t, J = 5.6 Hz), 7.85 (2H, d, J = 8.4 Hz), 7.67 (2H , d, J = 8.4 Hz), 7.65 (2H, d, J = 8.6 Hz), 7.45 (2H, d, J = 8.6 Hz), 7.35-7.26 (7H, m), 4.76 (1H, d, J = 8.8 Hz), 4.67 (1H, d, J = 8.8 Hz), 4.57 (2H, s), 4.02 (1H, t, J = 5.8 Hz), 3.48-3.28 (2H, m), 1.91 (2H, m) .
    Example 12 (5)
    N-hydroxy-4- (N- (4-chlorophenylcarbonyl) amino) -2-benzyloxymethoxybutylamide

    TLC: Rf 0.34 (CHCl 3: MeOH = 10: 1);
    NMR (d 6 -DMSO): δ 10.73 (1H, brs), 8.89 (1H, brs), 8.52 (1H, m), 7.84 (2H, d, J = 8.4 Hz), 7.52 (2H, d, J = 8.4 Hz), 7.30 (5H, brs), 4.75 (1H, d, J = 8.8 Hz), 4.66 (1H, d, J = 8.8 Hz), 4.56 (2H, s), 4.01 (1H, t, J = 6.6 Hz), 3.45-3.25 (2H, m), 1.89 (2H, m).
    Example 13
    4- (N- (4-chlorophenylcarbonyl) amino) -2- (t-butyloxycarbonylmethoxy) butanoic acid methyl ester

    To a tetrahydrofuran (10 ml) mixture of 60% sodium hydride (2.38 g) at -78 ° C. 4- (N- (4-chlorophenylcarbonyl) amino) -2-hydroxybutanoic acid methyl ester (3 g) Tetrahydrofuran (15 ml) solution was added dropwise. The reaction mixture was stirred at 0 ° C. for 30 minutes, and then t-butylbromoacetate (0.975 g) was added dropwise at −78 ° C. The reaction mixture was stirred at 0 ° C. for 1.5 hours. 1N aqueous hydrochloric acid solution was added to the reaction mixture, and the mixture was extracted with ethyl acetate. The extract was washed with saturated aqueous sodium hydrogen carbonate solution and saturated aqueous sodium chloride solution, dried over anhydrous sodium sulfate, and then concentrated. The residue was purified by silica gel column chromatography (n-hexane: ethyl acetate = 1: 1) to obtain the title compound (3.194 g) having the following physical properties.
    TLC: Rf 0.63 (n-hexane: ethyl acetate = 1: 1).
    Example 14
    4- (N- (4-chlorophenylcarbonyl) amino) -2- (carboxymethoxy) butanoic acid methyl ester

    A trifluoroacetic acid (50 ml) solution of the compound (3.194 g) prepared in Example 13 was stirred at room temperature for 1 hour. The reaction mixture was concentrated, crystallized by addition of diethyl ether, washed with diethyl ether and dried to give the title compound (2.275 g) having the following physical properties.
    TLC: Rf 0.28 (CHCl 3: MeOH: Acetic Acid = 100: 10: 1).
    Example 15
    4- (N- (4-chlorophenylcarbonyl) amino) -2-((N-benzyl-N-methylamino) carbonylmethoxy) butanoic acid methyl ester

    To a solution of dimethylformamide (5 ml) of the compound (0.5 g) prepared in Example 14, N-benzyl-N-methylamine (0.213 g), 1-hydroxybenzotriazole hydrate (0.27 g), 1- Ethyl-3- (3-dimethylaminopropyl) carbodiimide hydrochloride (0.337 g) was added under ice-cooling, and the mixture was stirred at room temperature for 1 hour. 1N aqueous hydrochloric acid solution was added to the reaction mixture, and the mixture was extracted with ethyl acetate. The extract was washed with a saturated aqueous sodium bicarbonate solution and a saturated aqueous sodium chloride solution, dried over anhydrous sodium sulfate, and concentrated to give the title compound (0.664 g) having the following physical properties.
    TLC: Rf 0.60 (n-hexane: ethyl acetate = 1: 1).
    Example 16
    4- (N- (4-chlorophenylcarbonyl) amino) -2-((N-benzyl-N-methylamino) carbonylmethoxy) butanoic acid

    Using the compound prepared in Example 15 instead of the compound prepared in Example 1, the same procedure as described in Example 2 was carried out to obtain the title compound having the following physical properties.
    TLC: Rf 0.21 (CHCl 3: MeOH: Acetic Acid = 100: 10: 1);
    NMR (d 6 -DMSO): δ 8.83 and 8.72 (total 1H, m), 7.87 and 7.86 (total 2H, d, J = 8.8 Hz), 7.53-7.23 (7H, m), 4.53 and 4.49 (total 2H, s), 4.38 (1H, d, J = 15.0 Hz), 4.24 (1H, d, J = 15.0 Hz), 3.52-3.37 (1H, m), 2.86 and 2.80 (tota1 3H, s), 2.08-1.72 ( 2H, m).
    Example 16 (1) and 16 (2)
    Using the corresponding amine compound instead of N-benzyl-N-methylamine, the same procedure as described in Example 15-Example 16 was carried out to obtain a compound shown below.
    Example 16 (1)
    4- (N- (4-chlorophenylcarbonyl) amino) -2-((N-phenyl-N-methylamino) carbonylmethoxy) butanoic acid

    TLC: Rf 0.29 (CHCl 3: MeOH: Acetic Acid = 100: 10: 1);
    NMR (d 6 -DMSO): δ 8.72 (1H, t, J = 5.8 Hz), 7.88 (2H, d, J = 8.4 Hz), 7.53 (2H, d, J = 8.4 Hz), 7.49-7.34 (5H m), 4.05-3.82 (3H, m), 3.44-3.33 (2H, m), 3.19 (3H, s), 2.04-1.64 (2H, m).
    Example 16 (2)
    4- (N- (4-chlorophenylcarbonyl) amino) -2-((N-phenylethyl-N-methylamino) carbonylmethoxy) butanoic acid

    TLC: Rf 0.32 (CHCl 3: MeOH: Acetic Acid = 100: 10: 1);
    NMR (d 6 -DMSO): δ 8.83 (0.5H, t, J = 5.5Hz), 8.75 (0.5H, t, J = 5.5Hz), 7.89 (1H, d, J = 8.4Hz), 7.86 (1H , d, J = 8.4 Hz, 7.53 (1H, d, J = 8.4 Hz), 7.49 (1H, d, J = 8.4 Hz), 7.30 (5H, s), 4.39 (0.5H, d, J = 15.4 Hz), 4.17 (0.5H, d, J = 15.4 Hz), 4.13 (0.5H, d, J = 14.6 Hz), 3.95 (0.5H, dd, J = 8.8, 3.0 Hz), 3.90 (0.5H, d , J = 14.6 Hz), 3.79 (0.5H, dd, J = 9.0, 3.6 Hz), 3.60-3.30 (4H, m), 2.90-2.70 (2H, m), 2.10-1.60 (2H, m).
    Example 17
    N-hydroxy-4- (N- (4-chlorophenylcarbonyl) amino) -2-((N-benzyl-N-methylamino) carbonylmethoxy) butylamide

    Using the compound prepared in Example 16 instead of the compound prepared in Example 2, the same procedure as in Example 3-Example 4 was carried out to obtain the title compound having the following physical properties.
    TLC: Rf 0.39 (CHCl 3: MeOH = 10: 1);
    NMR (d 6 -DMSO): δ 10.93 and 10.90 (total 1H, brs, and brs), 9.05-8.65 (2H, m), 7.87 and 7.86 (total 2H, d and d, J = 8.8 Hz and J = 8.8 Hz), 7.52 and 7.45 (total 2H, d and d, J = 8.8 Hz and J = 8.8 Hz), 7.37-7.19 (5H, m), 4.54 and 4.50 (total 2H, s and s), 4.44 and 4.36 ( total 1H, d and d, J = 14.2 Hz and J = 15.0 Hz, 4.24 and 4.20 (total 1H, d and d, J = 14.2 Hz and J = 15.0 Hz), 3.94-3.88 (1H, m), 2.84 and 2.80 (total 3H, s and s), 2.00-1.68 (2H, m).
    Example 17 (1) and 17 (2)
    Using the compound prepared in Example 16 (1) and 16 (2) instead of the compound prepared in Example 16, it was operated in the same manner as the method shown in Example 17 to obtain a compound shown below.
    Example 17 (1)
    N-hydroxy-4- (N- (4-chlorophenylcarbonyl) amino) -2-((N-phenyl-N-methylamino) carbonylmethoxy) butylamide

    TLC: Rf 0.48 (CHCl 3: MeOH = 10: 1);
    NMR (d 6 -DMSO): δ 10.79 (1H, brs), 9.20-8.40 (1H, br), 8.68 (1H, m), 7.87 (2H, d, J = 8.8 Hz), 7.53 (2H, d, J = 8.8 Hz), 7.46-7.34 (5H, m), 4.14-3.67 (3H, m), 3.55-3.25 (2H, m), 3.19 (3H, s), 1.95-1.60 (2H, m).
    Example 17 (2)
    N-hydroxy-4- (N- (4-chlorophenylcarbonyl) amino) -2-((N-phenylethyl-N-methylamino) carbonylmethoxy) butylamide

    TLC: Rf 0.40 (CHCl 3: MeOH = 10: 1);
    NMR (d 6 -DMSO): δ 10.90 (1H, brs), 8.87 (1H, brs), 8.83-8.67 (1H, m), 7.89 and 7.87 (tota1 2H, d and d, J = 8.4 Hz and J = 8.4 Hz), 7.53 and 7.49 (total 2H, d and d, J = 8.4 Hz and J = 8.4 Hz), 7.33-7.17 (5H, m), 4.31 and 4.10 and 3.99 (total 2H, d and d and s, J = 15.4 Hz and J = 15.4 Hz), 3.85 and 3.69 (total 1H, dd and dd, J = 4.4, 8.8 Hz and J = 4.0.8.4 Hz), 3.56-3.32 (2H, m), 2.84-2.72 ( 2H, m), 1.97-1.68 (2H, m).
    Example 18
    3 (S) -hydroxy-4- (N- (4- (benzofuran-2-yl) phenylcarbonyl) amino) butanoic acid methyl ester

    Example using 3 (S) -hydroxy-4-aminobutanoic acid ethyl ester (compound described in Acta Chem. Scand., Ser. B, 37, 341 (1983)) instead of 4-aminobutanoic acid ethyl ester The title compound having the following physical properties was obtained in the same manner as the method shown in (1).
    TLC: Rf 0.31 (n-hexane: ethyl acetate = 1: 1);
    NMR (d 6 -DMSO): δ 8.57 (1H, t, J = 6.0 Hz), 8.00 (4H, s), 7.71-7.63 (2H, m), 7.57 (1H, brs), 7.40-7.24 (2H, m), 5.13 (1H, d, J = 5.6 Hz), 4.18-4.00 (1H, m), 3.57 (3H, s), 3.30 (2H, t, J = 6.0 Hz), 2.55 (1H, dd, J = 4.0, 15.0 Hz), 2.31 (1H, dd, J = 4.0, 15.0 Hz).
    Example 19
    3 (S) -hydroxy-4- (N- (4- (benzofuran-2-yl) phenylcarbonyl) amino) butanoic acid

    The title compound was obtained in the same manner as the method shown in Example 2, using the compound prepared in Example 18 instead of the compound prepared in Example 1.
    TLC: Rf 0.24 (CHCl 3: MeOH: Acetic Acid = 100: 10: 1);
    NMR (d 6 -DMSO): δ 8.55 (1H, t, J = 5.8 Hz), 8.00 (4H, s), 7.71-7.63 (2H, m), 7.58 (1H, brs), 7.39-7.23 (2H, m), 5.16-4.92 (1H, brs), 4.14-4.00 (1H, m), 3.30 (2H, t, J = 5.8 Hz), 2.46 (1H, dd, J = 4.2, 15.0 Hz), 2.23 (1H) , dd, J = 8.4, 15.0 Hz).
    Example 19 (1)
    3 (R) -hydroxy-4- (N- (4- (benzofuran-2-yl) phenylcarbonyl) amino) butanoic acid

    Operating in the same manner as in Example 18-19 using 3 (R) -hydroxy-4-aminobutanoic acid ethyl ester instead of 3 (S) -hydroxy-4-aminobutanoic acid ethyl ester The title compound which has the following physical property value was obtained.
    TLC: Rf 0.24 (CHCl 3: MeOH: Acetic Acid = 100: 10: 1);
    NMR (d 6 -DMSO): δ 8.55 (1H, t, J = 5.8 Hz), 8.00 (4H, s), 7.71-7.63 (2H, m), 7.58 (1H, brs), 7.39-7.23 (2H, m), 5.16-4.92 (1H, brs), 4.14-4.00 (1H, m), 3.30 (2H, t, J = 5.8 Hz), 2.46 (1H, dd, J = 4.2, 15.0 Hz), 2.23 (1H) , dd, J = 8.4, 15.0 Hz).
    Example 20
    3 (S) -methoxymethyloxy-4- (N- (4- (benzofuran-2-yl) phenylcarbonyl) amino) butanoic acid and 4- (N- (4- (benzofuran-2-yl ) Phenylcarbonyl) amino) -2-butenoic acid
    20 (1)
    20 (2)
    Example 10 (Using methoxymethylchloride instead of benzyloxymethylchloride) using the compound prepared in Example 18-the same manner as the method shown in Example 11 to give the title compound having the following physical properties Respectively obtained.
    Example 20 (1)
    TLC: Rf 0.21 (CHCl 3: MeOH = 10: 1):
    NMR (d 6 -DMSO): δ 8.72 (1H, t, J = 5.6 Hz), 8.00 (4H, s), 7.72-7.64 (2H, m), 7.60 (1H, brs), 7.40-7.20 (2H, m), 4.63 (2H, s), 4.08 (1H, m), 3.40 (2H, m), 2.40-2.20 (2H, m).
    Example 20 (2)
    TLC: Rf 0.12 (CHCl 3: MeOH = 10: 1);
    NMR (d 6 -DMSO): δ 8.88 (1H, t, J = 5.6 Hz), 8.02 (4H, s), 7.71-7.62 (2H, m), 7.59 (1H, bs), 7.40-7.20 (2H, m), 6.80 (1H, dt, J = 15.0, 5.0 Hz), 5.85 (1H, d, J = 15.0 Hz), 4.09-4.01 (2H, m).
    Example 20 (3)
    3 (R) -methoxymethyloxy-4- (N- (4- (benzofuran-2-yl) phenylcarbonyl) amino) butanoic acid

    Operation was carried out in the same manner as in Example 18-20, using 3 (R) -hydroxy-4-aminobutanoic acid ethyl ester instead of 3 (S) -hydroxy-4-aminobutanoic acid ethyl ester The title compound which has the following physical property value was obtained.
    TLC: Rf 0.21 (CHCl 3: MeOH = 10: 1);
    NMR (d 6 -DMSO): δ 8.72 (1H, t, J = 5.6 Hz), 8.01 (4H, s), 7.70-7.65 (2H, m), 7.61 (1H, brs), 7.40-7.20 (2H, m), 4.62 (2H, s), 4.08 (1H, m), 3.42 (2H, m), 2.40-2.20 (2H, m).
    Example 21
    3 (S) -acetyloxy-4- (N- (4- (benzofuran-2-yl) phenylcarbonyl) amino) butanoic acid methyl ester

    Acetic anhydride (0.6 ml) was added to a pyridine (5 ml) solution of the compound (0.3 g) prepared in Example 18 at 0 ° C. The reaction mixture was stirred at room temperature for 2 hours. 1N aqueous hydrochloric acid solution was added to the reaction mixture, and the mixture was extracted with ethyl acetate. The extract was washed with water and saturated aqueous sodium chloride solution, dried over anhydrous sodium sulfate and concentrated to give the title compound (0.325 g) having the following physical properties.
    TLC: Rf 0.52 (n-hexane: ethyl acetate = 1: 2).
    Example 22
    4- (N- (4- (benzofuran-2-yl) phenylcarbonyl) amino) -3-butene acid methyl ester

    To a tetrahydrofuran (1 ml) solution of the compound (0.15 g) prepared in Example 21, 1,8-diazabicyclo [5. 4. 0] undec-7-ene [DBU] (0.13 ml) was added. The reaction mixture was stirred at 50 ° C. for 3 hours. 1N aqueous hydrochloric acid solution was added to the reaction mixture, and the mixture was extracted with ethyl acetate. The extract was washed with water and saturated aqueous sodium chloride solution, dried over anhydrous sodium sulfate and concentrated to give the title compound (0.096 g) having the following physical properties.
    TLC: Rf 0.70 (n-hexane: ethyl acetate = 1: 2).
    Example 23
    4- (N- (4- (benzofuran-2-yl) phenylcarbonyl) amino) -3-butenoic acid

    The title compound was obtained in the same manner as the method shown in Example 2, using the compound prepared in Example 22 instead of the compound prepared in Example 1.
    TLC: Rf 0.22 (CHCl 3: MeOH: Acetic Acid = 100: 10: 1);
    NMR (d 6 -DMSO): δ 10.39 (1H, d, J = 9.8 Hz), 8.05 (4H, s), 7.72-7.64 (2H, m), 7.61 (1H, d, J = 0.6 Hz), 7.41 -7.24 (2H, m), 6.95 (1H, doublet of doublets, J = 9.8, 14.4 Hz), 5.54 (1H, dt, J = 14.4, 7.2 Hz), 3.05 (2H, d, J = 7.2 Hz).
    Example 24
    N-hydroxy-3 (S) -hydroxy-4- (N- (4- (benzofuran-2-yl) phenylcarbonyl) amino) butylamide

    The title compound was obtained in the same manner as the method shown in Example 3-Example 4 using the compound prepared in Example 19 instead of the compound prepared in Example 2, to obtain the title compound having the following physical properties.
    TLC: Rf 0.41 (CHCl 3: MeOH: Water = 100: 20: 1);
    NMR (d 6 -DMSO): δ 10.39 (1H, brs), 8.55 (1H, m), 8.00 (4H, s), 7.71-7.63 (2H, m), 7.57 (1H, brs), 7.39-7.23 ( 2H, m), 5.50-4.30 (1H, br), 4.12-3.98 (1H, m), 3.40-3.18 (2H, m), 2.16 (1H, dd, J = 4.8, 14.0 Hz), 2.03 (1H, dd, J = 8.2, 14.0 Hz).
    Example 24 (1) -24 (6)
    Instead of the compound prepared in Example 19, the compound prepared in Example 19 (1), Example 20 (1) to 20 (3), and Example 23 was used and was operated in the same manner as in Example 24; Alternatively, using the compound prepared in Example 18, the same procedure as described in Example 10-Example 11-Example 24 was carried out to obtain the title compound having the following physical properties.
    Example 24 (1)
    N-hydroxy-3 (R) -hydroxy-4- (N- (4- (benzofuran-2-yl) phenylcarbonyl) amino) butylamide

    TLC: Rf 0.41 (CHCl 3: MeOH: Water = 100: 20: 1);
    NMR (d 6 -DMSO): δ 10.39 (1H, bs), 8.55 (1H, m), 8.00 (4H, s), 7.71-7.63 (2H, m), 7.58 (1H, brs), 7.39-7.24 ( 2H, m), 5.20-3.80 (1H, br), 4.12-3.98 (1H, m), 3.40-3.18 (2H, m), 2.16 (1H, dd, J = 4.8, 14.0 Hz), 2.03 (1H, dd, J = 8.2, 14.0 Hz).
    Example 24 (2)
    N-hydroxy-3 (S) -methoxymethyloxy-4- (N- (4- (benzofuran-2-yl) phenylcarbonyl) amino) butylamide

    TLC: Rf 0.19 (CHCl 3: MeOH = 10: 1);
    NMR (d 6 -DMSO): δ 10.47 (1H, brs), 8.80 (1H, brs), 8.64 (1H, t, J = 5.8 Hz), 8.02 (2H, d, J = 9.2 Hz), 7.97 (2H , d, J = 9.2 Hz), 7.71-7.63 (2H, m), 7.57 (1H, brs), 7.40-7.24 (2H, m), 4.60 (2H, s), 4.16-4.04 (1H, m), 3.41 (2H, t, J = 5.8 Hz), 3.21 (3H, s), 2.22-2.18 (2H, m).
    Example 24 (3)
    N-hydroxy-4- (N- (4- (benzofuran-2-yl) phenylcarbonyl) amino) -2-butylamide

    TLC: Rf 0.20 (CHCl 3: MeOH: Acetic Acid = 100: 10: 1);
    NMR (d 6 -DMSO): δ 10.60 (1H, brs), 8.89 (1H, t, J = 5.8 Hz), 8.02 (4H, s), 7.71-7.63 (2H, m), 7.59 (1H, brs) , 7.40 (2H, m), 6.69 (1H, dt, J = 15.4, 4.8 Hz), 5.86 (1H, d, J = 15.4 Hz), 4.08-4.02 (2H, m).
    Example 24 (4)
    N-hydroxy-3 (R) -methoxymethyloxy-4- (N- (4- (benzofuran-2-yl) phenylcarbonyl) amino) butylamide

    TLC: Rf 0.19 (CHCl 3: MeOH = 10: 1);
    NMR (d 6 -DMSO): δ 10.46 (1H, brs), 8.77 (1H, brs), 8.64 (1H, t, J = 5.8 Hz), 8.02 (2H, d, J = 9.2 Hz), 7.97 (2H , d, J = 9.2 Hz), 7.71-7.63 (2H, m), 7.58 (1H, brs), 7.40-7.24 (2H, m), 4.60 (2H, s), 4.16-4.05 (1H, m), 3.42 (2H, t, J = 5.8 Hz), 3.22 (3H, s), 2.22-2.19 (2H, m).
    Example 24 (5)
    N-hydroxy-4- (N- (4- (benzofuran-2-yl) phenylcarbonyl) amino) -3-butylamide

    TLC: Rf 0.21 (CHCl 3: MeOH: Acetic Acid = 100: 10: 1);
    NMR (d 6 -DMSO): δ 10.45 (1H, brs), 10.37 (1H, d, J = 9.6 Hz), 8.98-8.52 (1H, brs), 8.04 (4H, s), 7.72-7.63 (2H, m), 7.61 (1H, brs), 7.41-7.24 (2H, m), 6.94 (1H, dd, J = 9.6, 14.2 Hz), 5.53 (1H, dt, J = 14.2, 7.8 Hz), 2.76 (2H , d, J = 7.8 Hz).
    Example 24 (6)
    N-hydroxy-4- [N- [4- (benzofuran-2-yl) phenylcarbonyl] amino] -3 (S) -benzyloxymethoxybutylamide

    TLC: Rf 0.31 (CHCl 3: MeOH = 10: 1);
    NMR (d 6 -DMSO): δ 10.51 (1H, s), 8.67 (1H, t, J = 5.6 Hz), 7.98 (4H, m), 7.71-7.60 (2H, m), 7.57 (1H, br. s), 7.39-7.20 (7H, m), 4.77 (1H, d, J = 6.8 Hz), 4.73 (1H, d, J = 6.8 Hz), 4.51 (2H, s), 4.20 (1H, m), 3.49-3.43 (2H, m), 2.25 (2H, d, J = 6.2 Hz).
    Example 25
    2-benzyloxymethyl-4- (N- (4-methylphenylcarbonyl) amino) butanoic acid

    To a solution of tetrahydrofuran (5 ml) and hexamethylphosphoramide (HMPA) (3 ml) of diisopropylamine (0.925 ml) in 1.63M n-butyllithium hexane solution at -78 ° C under argon atmosphere ( 4.05 ml) was added. The mixture was stirred at -78 ° C for 15 minutes. To this solution was added a solution of tetrahydrofuran (3 ml) of compound (0.442 g) prepared in Example 2 (1) at -78 ° C. The reaction mixture was stirred for 30 minutes at room temperature. Benzyloxymethylchloride (0.313 g) was added to the reaction mixture at -78 ° C. The reaction mixture was stirred at -78 ° C for 2 hours. 1N aqueous hydrochloric acid solution was added to the reaction mixture, and the mixture was extracted with ethyl acetate. The extract was washed with saturated aqueous sodium chloride solution, dried over anhydrous magnesium sulfate and concentrated to give the title compound (0.22 g) having the following physical properties.
    TLC: Rf 0.67 (CHCl 3: MeOH: Acetic Acid = 18: 2: 1).
    Example 26
    N-hydroxy-2-benzyloxymethyl-4- (N- (4-methylphenylcarbonyl) amino) butylamide

    The title compound was obtained in the same manner as the method shown in Example 3-Example 4 using the compound prepared in Example 25 instead of the compound prepared in Example 2.
    TLC: Rf 0.36 (CHCl 3: MeOH = 10: 1);
    NMR (d 6 -DMSO): δ 10.52 (1H, s), 8.86 (1H, s), 8.32 (1H, t, J = 8.4 Hz), 7.74 (2H, d, J = 8.4 Hz), 7.31 (5H , m), 7.24 (2H, d, J = 8.4 Hz), 4.46 (1H, d, J = 12.5 Hz), 4.44 (1H, d, J = 12.5 Hz), 3.59 (1H, dd, J = 8.8, 8.8 Hz), 3.41 (1H, dd, J = 8.8, 5.5 Hz), 3.21 (2H, m), 2.44 (1H, m), 2.35 (3H, s), 1.66 (2H, m).
    Example 27
    N-hydroxy-2-hydroxymethyl-4- (N- (4-methylphenylcarbonyl) amino) butylamide

    To a methanol (10 ml) solution of the compound (0.24 g) prepared in Example 26 was added 10% palladium-carbon (0.024 g) under argon atmosphere. The reaction mixture was stirred at room temperature under hydrogen atmosphere for 2 hours. The reaction mixture was filtered through celite (trade name) and the filtrate was concentrated. The residue was purified by silica gel column chromatography (chloroform: methanol = 10: 1) to give the title compound (0.158 g) having the following physical properties.
    TLC: Rf 0.39 (ethyl acetate: acetic acid: water = 16: 3: 2);
    NMR (d 6 -DMSO): δ 8.41 (1H, m), 7.76 (2H, d, J = 8.0 Hz), 7.24 (2H, d, J = 8.0 Hz), 3.52 (1H, m), 3.37 (1H , m), 3.20 (2H, m), 2.35 (3H, s), 2.23 (1H, m), 1.64 (2H, m).
    Example 27 (1) and 27 (2)
    The compound prepared in Example 25 was operated in the same manner as the method shown in Example 3-Example 4-Example 27 using the compound separated by liquid chromatography, to obtain the compound shown below.
    Example 27 (1)
    N-hydroxy-2-hydroxymethyl-4- (N- (4-methylphenylcarbonyl) amino) butylamide

    (In formula, * represents R or S body. The three-dimensional structure is not determined to date. However, the three-dimensional structure opposite to Example 27 (2) is shown.)
    TLC: Rf 0.17 (CHCl 3: MeOH = 4: 1);
    NMR (CD 3 OD): δ 7.70 (2H, d, J = 8.2 Hz), 7.26 (2H, d, J = 8.2 Hz), 3.79-3.52 (2H, m), 3.50-3.25 (2H, m), 2.38 (3H, s), 2.38-2.25 (1H, m), 1.80 (2H, q-like).
    Example 27 (2)
    N-hydroxy-2-hydroxymethyl-4- (N- (4-methylphenylcarbonyl) amino) butylamide

    (In formula, * represents R or S chain. The three-dimensional structure is not determined to date. However, the three-dimensional structure opposite to Example 27 (1) is shown.)
    TLC: Rf 0.17 (CHCl 3: MeOH = 4: 1);
    NMR (CD 3 OD): δ 7.70 (2H, d, J = 8.2 Hz), 7.26 (2H, d, J = 8.2 Hz), 3.79-3.52 (2H, m), 3.50-3.25 (2H, m), 2.38 (3H, s), 2.38-2.25 (1H, m), 1.80 (2H, q-like).
    Reference Example 5
    4 (S) -methylaminocarbonyl-4- (N-benzyloxycarbonylamino) butanoic acid t-butyl ester

    Using the 4 (S) -carboxy-4- (N-benzyloxycarbonylamino) butanoic acid t-butylester and methylamine in the same manner as in the method shown in Example 15, the title was: The compound was obtained.
    TLC: Rf 0.73 (CHCl 3: MeOH = 9: 1);
    NMR (CDCl 3 ): δ 7.38-7.31 (5H, m), 6.24 (1H, m), 5.65 (1H, m), 5.10 (2H, s), 4.20-4.12 (1H, m), 2.81 (3H, d, J = 5.0 Hz), 2.49-2.24 (2H, m), 2.17-1.85 (2H, m), 1.44 (9H, s).
    Reference Example 6
    4 (S) -methylaminocarbonyl-4-aminobutanoic acid t-butyl ester

    The title compound was obtained in the same manner as the method shown in Example 27, using the compound prepared in Reference Example 5 instead of the compound prepared in Example 26.
    TLC: Rf 0.28 (CHCl 3: MeOH = 9: 1).
    Example 28
    4 (S) -methylaminocarbonyl-4- (N- (4-methylphenylcarbonyl) amino) butanoic acid t-butylester

    The title compound was obtained in the same manner as the method shown in Example 1, using the compound prepared in Reference Example 6 instead of the compound prepared in Reference Example 4.
    TLC: Rf 0.46 (CHCl 3: MeOH = 9: 1).
    Example 29
    4 (S) -methylaminocarbonyl-4- (N- (4-methylphenylcarbonyl) amino) butanoic acid

    The title compound was obtained in the same manner as the method shown in Example 14, using the compound prepared in Example 28 instead of the compound prepared in Example 13.
    TLC: Rf 0.40 (CHCl 3: MeOH = 9: 1).
    NMR (d 6 -DMSO): δ 12.13 (1H, brs), 8.33 (1H, d, J = 7.8 Hz), 7.86-7.78 (3H, m), 7.26 (2H, d, J = 8.1 Hz), 4.40 -4.25 (1H, m), 2.59 (3H, d, J = 4.8 Hz), 2.36 (3H, s), 2.30-2.23 (2H, m), 2.05-1.82 (2H, m).
    Example 29 (1)-29 (3)
    The compound shown below was obtained by operation similar to the method shown in Reference Example 5-Reference Example 6-Example 28-Example 29 using the amine compound instead of a methylamine compound.
    Example 29 (1)
    4 (R) -methylaminocarbonyl-4- (N- (4-methylphenylcarbonyl) amino) butanoic acid

    TLC: Rf 0.20 (CHCl 3: MeOH = 5: 1);
    NMR (CDCl 3 + CD 3 OD): δ 7.60-7.33 (2H, m), 7.14-7.22 (2H, m), 4.52-4.66 (1H, m), 2.76 (3H, s), 2.30-2.56 (2H m), 2.34 (3H, s), 1.84-2.22 (2H, m).
    Example 29 (2)
    4 (S) -benzylaminocarbonyl-4- (N- (4-methylphenylcarbonyl) amino) butanoic acid

    TLC: Rf 0.51 (CHCl 3: MeOH = 4: 1);
    NMR (d 6 -DMSO): δ 12.10 (1H, brs), 8.44 (2H, d, J = 8.0 Hz), 7.82 (2H, d, J = 8.0 Hz), 7.27-7.21 (5H, m), 4.49 -4.40 (1H, m), 3.60 (1H, brs), 3.17 (2H, s), 2.36 (3H, s), 2.40-2.25 (2H, m), 2.20-1.95 (2H, m).
    Example 29 (3)
    4 (S)-(4-hydroxybutyl) aminocarbonyl-4- (N- (4-methylphenylcarbonyl) amino) butanoic acid

    TLC: Rf 0.33 (CHCl 3: MeOH = 4: 1).
    Example 30
    N-hydroxy-4 (S) -methylaminocarbonyl-4- (N- (4-methylphenylcarbonyl) amino) butylamide

    The title compound was obtained in the same manner as the method shown in Example 3-Example 4 using the compound prepared in Example 29 instead of the compound prepared in Example 2.
    TLC: Rf 0.69 (CHCl 3: MeOH = 4: 1);
    NMR (d 6 -DMSO): δ 10.37 (1H, brs), 8.69 (1H, m), 8.43 (1H, d, J = 7.6 Hz), 7.85-7.79 (3H, m), 7.25 (2H, d, J = 8.0 Hz), 4.40-4.25 (1H, m), 2.59 (3H, d, J = 4.6 Hz), 2.06 (3H, s), 2.10-1.85 (4H, m).
    Example 30 (1)-30 (3)
    The compound shown below was obtained by operation in the same manner as the method shown in Example 30 using the compound prepared in Examples 29 (1) to 29 (3) instead of the compound prepared in Example 29.
    Example 30 (1)
    N-hydroxy-4 (R) -methylaminocarbonyl-4- (N- (4-methylphenylcarbonyl) amino) butylamide

    TLC: Rf 0.30 (CHCl 3: MeOH = 10: 1);
    NMR (CD 3 OD): δ 7.72 (2H, d, J = 8 Hz), 7.20 (2H, d, J = 8 Hz), 4.44-4.50 (1H, m), 2.67 (3H, s), 2.31 (3H, s), 2.22-1.85 (4H, m).
    Example 30 (2)
    N-hydroxy-4 (S) -benzylaminocarbonyl-4- (N- (4-methylphenylcarbonyl) amino) butylamide

    TLC: Rf 0.42 (CHCl 3: MeOH = 4: 1).
    Example 30 (3)
    N-hydroxy-4 (S)-(4-hydroxybutyl) aminocarbonyl-4- (N- (4-methylphenylcarbonyl) amino) butylamide

    TLC: Rf 0.23 (chloroform: methanol: acetic acid = 18: 2: 1);
    NMR (CDCl 3 ): δ 7.74 (2H, d, J = 7.5 Hz), 7.39 (1H, s), 7.25 (2H, d, J = 7.5 Hz), 4.60-4.43 (1H, m), 3.61-3.56 (2H, m), 3.31-3.15 (2H, m), 2.40 (3H, s), 2.30-2.04 (4H, m), 1.62-1.48 (4H, m).
    Example 31
    4 (S) -methoxycarbonyl-4- [N- [4- (4- (tetrahydropyran-2-yloxy) -1-butynyl) phenylcarbonyl] amino] butanoic acid t-butylester

    The title compound having the following physical properties was obtained in the same manner as the method shown in Example 1 using 4 (S) -methoxycarbonyl-4-aminobutanoic acid t-butylester and the corresponding acid halide.
    TLC: Rf 0.35 (n-hexane: ethyl acetate = 1: 2);
    NMR (CDCl 3 ): δ 7.78 (2H, d, J = 8.4 Hz), 7.44 (2H, d, J = 8.4 Hz), 7.21 (3H, s), 3.70-3.50 (2H, m), 2.75 (2H , t, J = 6.9 Hz), 2.42 (2H, m), 2.30-2.00 (2H, m), 2.00-1.50 (6H, m), 1.42 (9H, s).
    Example 32
    4 (S) -methoxycarbonyl-4- [N- [4- (4-hydroxy-1-butynyl) phenylcarbonyl] amino] butanoic acid

    The title compound was obtained in the same manner as the method shown in Example 14, using the compound prepared in Example 31 instead of the compound prepared in Example 13.
    TLC: Rf 0.11 (n-hexane: ethyl acetate = 1: 1);
    NMR (CDCl 3 + CD 3 OD): δ 8.02 (1H, d, J = 7.6 Hz), 7.77 (2H, d, J = 8.6 Hz), 7.44 (2H, d, J = 8.6 Hz), 4.82-4.70 (1H, m), 3.83-3.69 (5H, m), 2.68 (2H, t, J = 6.6 Hz), 2.41 (2H, t, J = 6.6 Hz), 2.26-1.99 (2H, m).
    Example 33
    N-hydroxy-4 (S) -methoxycarbonyl-4- [N- [4- (4-hydroxy-1-butynyl) phenylcarbonyl] amino] butylamide

    The title compound was obtained in the same manner as the method shown in Example 3-Example 4 using the compound prepared in Example 32 instead of the compound prepared in Example 2.
    TLC: Rf 0.30 (CHCl 3: MeOH: Acetic Acid = 18: 2: 1);
    NMR (d 6 -DMSO): δ 10.44 (1H, s), 10.20 (1H, s), 8.89 (1H, d, J = 6.6 Hz), 7.87 (2H, d, J = 7.8 Hz), 7.47 (2H , d, J = 7.8 Hz), 4.41 (1H, m), 3.66 (3H, s), 3.65-3.59 (2H, m), 2.58 (2H, t, J = 6.6 Hz), 2.18-1.95 (2H, m), 1.28-1.21 (2H, m).
    Example 33 (1)
    N-hydroxy-4 (R) -carbonyl-4- [N- [4- (3-methoxy-1-propynyl) phenylcarbonyl] amino] butylamide

    Operation was carried out in the same manner as described in Example 31-Example 2-Example 33-Example 14 using an acid halide corresponding to 4 (R) -t-butoxycarbonyl-4-aminobutanoic acid methyl ester The title compound which has the following physical property value was obtained.
    TLC: Rf 0.18 (CHCl 3: MeOH: Acetic Acid: Water = 85:15: 1: 1);
    NMR (d 6 -DMSO): δ 7.86 (2H, d, J = 8.8 Hz), 7.53 (2H, d, J = 8.8 Hz), 4.54-4.59 (1H, m), 4.34 (2H, s), 3.43 (3H, s), 2.05-2.36 (4H, m).
    Example 34
    4 (S) -t-butoxycarbonyl-4- (N- (4-methylphenylcarbonyl) amino) butanoic acid benzyl ester

    The title compound having the following physical properties was obtained in the same manner as the method shown in Example 1 using 4 (S) -t-butoxycarbonyl-4-aminobutanoic acid benzyl ester and the corresponding acid halide.
    TLC: Rf 0.19 (n-hexane: ethyl acetate = 4: 1).
    Example 35
    4 (S) -t-butoxycarbonyl-4- (N- (4-methylphenylcarbonyl) amino) butanoic acid

    The title compound was obtained in the same manner as the method shown in Example 27 using the compound prepared in Example 34 instead of the compound prepared in Example 26.
    TLC: Rf 0.38 (CHCl 3: MeOH = 5: 1);
    NMR (CDC1 3 ): δ 7.70 (2H, d, J = 8.2 Hz), 7.22 (2H, d, J = 8.2 Hz), 6.97 (1H, d, J = 7.5 Hz), 4.71 (1H, m), 2.47 (2H, m), 2.38 (3H, s), 2.28 (1H, m), 2.05 (1H, m), 1.49 (9H, s).
    Example 36
    N-hydroxy-4 (S) -carboxy-4- (N- (4-methylphenylcarbonyl) amino) butylamide

    The title compound was obtained in the same manner as the method shown in Example 3-Example 14 using the compound prepared in Example 35 instead of the compound prepared in Example 2.
    TLC: Rf 0.43 (ethyl acetate: acetic acid: water = 8: 1: 1);
    NMR (CD 3 OD): δ 7.78 (2H, d, J = 8.0 Hz), 7.28 (2H, d, J = 8.0 Hz), 4.56 (1H, m), 2.40 (3H, s), 2.00-2.38 ( 4H, m).
    Example 37
    4 (S) -carboxy-4- (N- (4- (benzofuran-2-yl) phenylcarbonyl) amino) butanoic acid methyl ester

    The title compound having the following physical properties was obtained in the same manner as the method shown in Example 1 using 4 (S) -carboxy-4-aminobutanoic acid methyl ester and the compound prepared in Reference Example 4.
    TLC: Rf 0.64 (chloroform: methanol: acetic acid = 18: 2: 1);
    NMR (CD 3 OD): δ 12.74 (1H, brs), 8.74 (1H, d, J = 7.8 Hz), 8.04 (4H, s), 7.71-7.58 (3H, m), 7.42-7.26 (2H, m ), 4.45 (1H, m), 3.60 (3H, s), 2.51-2.44 (2H, m), 2.26-1.96 (2H, m).
    Example 38
    4 (S)-(morpholin-1-yl) carbonyl-4- (N- (4- (benzofuran-2-yl) phenylcarbonyl) amino) butanoic acid

    The title compound was obtained in the same manner as the method shown in Example 15-Example 16 using the compound prepared in Example 37 instead of the compound prepared in Example 14.
    TLC: Rf 0.48 (CHCl 3: MeOH = 4: 1);
    NMR (d 6 -DMSO): δ 12.23 (1H, brs), 8.72 (1H, d, J = 8.0 Hz), 8.05-8.01 (4H, m), 7.74-7.58 (3H, m), 7.42-7.24 ( 2H, m), 5.03-4.86 (1H, m), 3.63-3.45 (8H, m), 2.37 (2H, t, J = 7.0 Hz), 2.04-1.84 (2H, m).
    Example 39
    4 (S) -hydroxymethyl-4- (N- (4- (benzofuran-2-yl) phenylcarbonyl) amino) butanoic acid methyl ester

    To a solution of compound (5.7 g) in tetrahydrofuran (30 ml) prepared in Example 37 was added N-hydroxysuccimid (2.2 g) and dichlorohexylcarbodiimide (4.01 g) at 0 ° C. The reaction mixture was stirred at 0 ° C. for 5 hours. The reaction mixture was filtered, and sodium borohydride (1.19 g) and water (5 ml) were added to the filtrate at 0 deg. The reaction mixture was stirred for 30 minutes at room temperature. Saturated aqueous ammonium chloride solution was added to the reaction mixture, which was then extracted with ethyl acetate. The extract was washed with saturated aqueous sodium chloride solution, dried over anhydrous magnesium sulfate, and concentrated to give the title compound (4.89 g) having the following physical properties.
    TLC: Rf 0.21 (n-hexane: ethyl acetate = 3: 7);
    NMR (d 6 -DMSO): δ 8.14 (1H, d, J = 8.4 Hz), 7.99 (4H, s), 7.72-7.60 (2H, m), 7.55 (1H, d, J = 0.8 Hz), 7.40 -7.24 (2H, m), 4.75 (1H, t, J = 5.8 Hz), 4.10-3.90 (1H, m), 3.56 (3H, s), 3.55-3.39 (2H, m), 2.36 (2H, t , J = 7.4 Hz), 2.06-1.62 (2H, m).
    Example 40
    4 (S) -hydroxymethyl-4- (N- (4- (benzofuran-2-yl) phenylcarbonyl) amino) butanoic acid

    The title compound having the following physical properties was obtained in the same manner as the method shown in Example 2 using the compound prepared in Example 39 instead of the compound prepared in Example 1.
    TLC: Rf 0.33 (CHCl 3: MeOH: Acetic Acid = 190: 10: 1);
    NMR (d 6 -DMSO): δ 12.10-11.90 (1H, br), 8.14 (1H, d, J = 8.8 Hz), 8.00 (4H, s), 7.73-7.60 (2H, m), 7.55 (H, s), 7.41-7.22 (2H, m), 4.80-4.64 (1H, m), 4.10-3.90 (1H, m), 3.54-3.35 (2H, m), 2.28 (2H, t, J = 6.8 Hz) , 2.02-1.60 (2H, m).
    Example 41
    4 (S) -methoxymethyloxymethyl-4- (N- (4- (benzofuran-2-yl) phenylcarbonyl) amino) butanoic acid methyl ester

    Using the compound prepared in Example 39 instead of the compound prepared in Example 8, it was operated in the same manner as the method described in Example 10 (using methoxymethyl chloride instead of benzyloxymethylchloride). The title compound having was obtained.
    TLC: Rf 0.65 (n-hexane: ethyl acetate = 3: 7);
    NMR (CDCl 3 ): δ 7.94 (2H, d, J = 8.8 Hz), 7.87 (2H, d, J = 8.8 Hz), 7.64-7.50 (2H, m), 7.38-7.21 (2H, m), 7.13 (1H, d, J = 0.8 Hz), 6.78 (1H, d, J = 7.8 Hz), 4.67 (2H, s), 4.46-4.28 (1H, m), 3.78 (1H, dd, J = 10.2, 3.4 Hz), 3.65 (1H, dd, J = 10.2, 4.4 Hz), 3.64 (3H, s), 3.39 (3H, s), 2.62-2.38 (2H, m), 2.16-2.00 (2H, m).
    Example 42
    4 (S) -methoxymethyloxymethyl-4- (N- (4- (benzofuran-2-yl) phenylcarbonyl) amino) butanoic acid

    The title compound having the following physical properties was obtained in the same manner as the method shown in Example 2, using the compound prepared in Example 41 instead of the compound prepared in Example 1.
    TLC: Rf 0.19 (CHCl 3: MeOH = 19: 1);
    NMR (d 6 -DMSO): δ 12.02 (1H, s), 8.30 (1H, d, J = 8.2 Hz), 8.00 (4H, s), 7.73-7.60 (2H, m), 7.56 (1H, s) , 7.41-7.22 (2H, m), 4.58 (2H, s), 4.26-4.08 (1H, m), 3.62-3.42 (2H, m), 3.32 (3H, s), 3.26 (3H, s), 2.29 (2H, t, J = 6.8 Hz), 2.02-1.62 (2H, m).
    Example 43
    2 (S) -benzyl-4 (S) -methoxymethyloxymethyl-4- (N- (4- (benzofuran-2-yl) phenylcarbonyl) amino) butanoic acid methyl ester

    In a tetrahydrofuran (5 ml) solution of a tetrahydrofuran solution (0.695 ml) of 1.0 M lithium bis (trimethylsilyl) amide, tetrahydrofuran (5 ml) of the compound (0.474 g) prepared in Example 41 at −78 ° C. ) Solution was added. The mixture was stirred at −78 ° C. for 1 hour and then benzyl bromide (0.113 ml) was added. The reaction mixture was stirred at -78 ° C for 3 hours. Saturated aqueous ammonium chloride solution was added to the reaction mixture, which was then extracted with ethyl acetate. The extract was washed with saturated aqueous sodium chloride solution, dried over anhydrous magnesium sulfate and concentrated. The residue was purified by silica gel column chromatography (n-hexane: ethyl acetate = 3: 2) to obtain the title compound (0.429 g) having the following physical properties.
    TLC: Rf 0.51 (n-hexane: ethyl acetate = 1: 1);
    NMR (CDCl 3 ): δ 7.96 (2H, d, J = 8.8 Hz), 7.84 (2H, d, J = 8.8 Hz), 7.63-7.50 (2H, m), 7.38-7.10 (8H, m), 6.57 (1H, d, J = 8.8 Hz), 4.64 (1H, d, J = 8.8 Hz), 4.60 (1H, d, J = 8.8 Hz), 4.50-4.30 (1H, m), 3.70 (1H, dd, J = 10.2, 3.2 Hz), 3.59 (1H, dd, J = 10.2, 3.8 Hz), 3.40 (3H, s), 3.35 (3H, s), 3.04-2.72 (3H, m), 2.19 (1H, ddd) , J = 14.2, 10.4, 8.4 Hz), 1.82 (1H, dt, J = 14.2, 4.4 Hz).
    Example 44
    2 (S) -benzyl-4 (S) -methoxymethyloxymethyl-4- (N- (4- (benzofuran-2-yl) phenylcarbonyl) amino) butanoic acid

    The title compound having the following physical properties was obtained in the same manner as the method shown in Example 2, using the compound prepared in Example 41 instead of the compound prepared in Example 1.
    TLC: Rf 0.31 (CHCl 3: MeOH = 19: 1);
    NMR (CDCl 3 ): δ 7.85 (2H, d, J = 8.8 Hz), 7.79 (2H, d, J = 8.8 Hz), 7.58-7.45 (2H, m), 7.36-7.10 (7H, m), 7.04 (1H, d, J = 0.8 Hz), 6.73 (1H, d, J = 8.8 Hz), 4.60 (1H, d, J = 8.8 Hz), 4.56 (1H, d, J = 8.8 Hz), 4.50-4.30 (1H, m), 3.70 (1H, dd, J = 10.6, 3.2 Hz), 3.57 (1H, dd, J = 10.6, 3.8 Hz), 3.29 (3H, s), 3.11-2.95 (1H, m), 2.90-2.75 (2H, m), 2.24-2.01 (1H, m), 1.90-1.72 (1H, m).
    Example 44 (1) -44 (29)
    Example 37-Example 39-Example 41 (The equivalent compound may be used instead of methoxymethyl chloride)-Example 43 (Benzyl bromide instead of the compound manufactured by the reference example 4 using the compound equivalent. Using a compound corresponding to the same method as in Example 44-26, to obtain a compound shown below.
    Example 44 (1)
    2 (S) -Methyl-4 (S) -methoxymethyloxymethyl-4- (N- (4- (benzofuran-2-yl) phenylcarbonyl) amino) butanoic acid

    TLC: Rf 0.25 (chloroform: methanol = 19: 1);
    NMR (CDCl 3 ): δ 7.89 (2H, d, J = 8.8 Hz), 7.83 (2H, d, J = 8.8 Hz), 7.62-7.50 (2H, m), 7.37-7.20 (2H, m), 7.09 (1H, d, J = 1.0 Hz), 6.63 (1H, d, J = 8.8 Hz), 4.65 (2H, s), 4.55-4.36 (1H, m), 3.75 (1H, dd, J = 10.2, 3.2 Hz), 3.62 (1H, dd, J = 10.2, 4.0 Hz), 3.38 (3H, s), 2.70-2.50 (1H, m), 2.23 (1H, ddd, J = 14.0, 11.0, 8.2 Hz), 1.72 (1H, ddd, J = 14.0, 6.0, 4.4 Hz), 1.30 (3H, d, J = 6.8 Hz).
    Example 44 (2)
    2 (S)-(3-phenyl-2-propenyl) -4 (S) -methoxymethyloxymethyl-4- (N- (4- (benzofuran-2-yl) phenylcarbonyl) amino) moiety Carbonic acid

    TLC: Rf 0.44 (n-hexane: ethyl acetate = 3: 7);
    NMR (d 6 -DMSO): δ 12.23 (1H, s), 8.34 (1H, d, J = 8.4 Hz), 8.00 (4H, s), 7.74-7.61 (2H, m), 7.57 (1H, s) , 7.41-7.18 (7H, m), 6.43 (1H, d, J = 15.6 Hz), 6.20 (1H, dt, J = 15.6, 6.4 Hz), 4.57 (2H, s), 4.40-4.20 (1H, m ), 3.62-3.48 (2H, m), 3.23 (3H, s), 2.60-2.40 (3H, m), 1.92-1.80 (2H, m).
    Example 44 (3)
    2 (S)-(3-phenylpropyl) -4 (S) -methoxymethyloxymethyl-4- (N- (4- (benzofuran-2-yl) phenylcarbonyl) amino) butanoic acid

    TLC: Rf 0.44 (n-hexane: ethyl acetate = 3: 7);
    NMR (CDCl 3 ): δ 7.85 (2H, d, J = 8.8 Hz), 7.79 (2H, d, J = 8.8 Hz), 7.60-7.44 (2H, m), 7.34-7.06 (7H, m), 7.03 (1H, d, J = 0.8 Hz), 6.69 (1H, d, J = 8.8 Hz), 4.62 (1H, d, J = 8.8 Hz), 4.60 (1H, d, J = 8.8 Hz), 4.48-4.28 (1H, m), 3.73 (1H, dd, J = 10.2, 3.4 Hz), 3.59 (1H, dd, J = 10.2, 4.0 Hz), 3.34 (3H, s), 2.68-2.42 (3H, m), 2.21-2.00 (1 H, m), 1.86-1.52 (5 H, m).
    Example 44 (4)
    2 (S) -Methyl-5-ethoxymethoxy-4 (S)-[N- (4-chlorophenylcarbonyl) amino] pentanoic acid

    TLC: Rf 0.46 (CHCl 3: MeOH = 9: 1);
    NMR (d 6 -DMSO): δ 12.06 (1H, s), 8.24 (1H, d, J = 8.7Hz), 7.83 (2H, d, J = 8.4Hz), 7.51 (2H, d, J = 8.4Hz ), 4.57 (2H, s), 4.24-4.13 (1H, m), 3.52-3.42 (4H, m), 2.37-2.25 (1H, m), 1.92-1.80 (1H, m), 1.63-1.52 (1H) m), 1.06 (3H, t, J = 6.9 Hz), 1.05 (3H, d, J = 6.9 Hz).
    Example 44 (5)
    2 (S) -Methyl-5-ethoxymethoxy-4 (S)-[N- (4-nitrophenylcarbonyl) amino] pentanoic acid

    TLC: Rf 0.45 (methylene chloride: methanol = 9: 1);
    NMR (CDCl 3 ): δ 8.27 (d, J = 9.0 Hz, 2H), 7.96 (d, J = 9.0 Hz, 2H), 6.89 (brd, J = 9.0 Hz, 1H), 4.73 (d, J = 7.0 Hz, 1H), 4.68 (d, J = 7.0 Hz, 1H), 4.40 (m, 1H), 3.78 (dd, J = 10.6, 3.2 Hz, 1H), 3.68-3.55 (m, 3H), 2.55 (m , 1H), 2.16 (ddd, J = 14.4, 10.2, 7.6 Hz, 1H), 1.70 (ddd, J = 14.4, 5.8, 5.0 Hz, 1H), 1.28 (d, J = 7.0 Hz, 3H), 1.20 ( t, J = 7.0 Hz, 3H).
    Example 44 (6)
    2 (S) -Methyl-5-ethoxymethoxy-4 (S)-[N- (4-bromophenylcarbonyl) amino] pentanoic acid

    TLC: Rf 0.47 (methylene chloride: methanol = 9: 1);
    NMR (CDCl 3 ): δ 7.65 (d, J = 8.8H 42H), 7.54 (d, J = 8.8Hz, 2H), 6.67 (brd, J = 9.2Hz, 1H), 4.72 (d, J = 7.0Hz , 1H), 4.67 (d, J = 7.0 Hz, 1H), 4.40 (m, 1H), 3.75 (dd, J = 10.4, 3.2 Hz, 1H), 3.66-3.55 (m, 3H), 2.55 (m, 1H), 2.16 (ddd, J = 14.4, 10.2, 7.6 Hz, 1H), 1.70 (ddd, J = 14.4, 6.6, 4.8 Hz, 1H), 1.27 (d, J = 7.0 Hz, 3H), 1.20 (t , J = 7.0 Hz, 3H).
    Example 44 (7)
    2 (S) -allyl-5-ethoxymethoxy-4 (S)-[N- (4-nitrophenylcarbonyl) amino] pentanoic acid

    TLC: Rf 0.31 (CHCl 3: MeOH = 9: 1):
    NMR (CDCl 3 ): δ 8.25 (d, J = 8.7 Hz, 2H), 7.94 (d, J = 8.7 Hz, 2H), 6.92 (d, J = 8.7 Hz, 1H), 5.82-5.68 (m, 1H ), 5.14-5.06 (m, 2H), 4.73 (d, J = 6.9 Hz, 1H), 4.68 (d, J = 6.9 Hz, 1H), 4.45-4.32 (m, 1H), 3.79 (dd, J = 10.2, 3.3 Hz, 1H), 3.66-3.56 (m, 3H), 2.63-2.31 (m, 3H), 2.14-2.03 (m, 1H), 1.82 (dt, J = 14.1, 5.4 Hz, 1H), 1.20 (t, J = 7.2 Hz, 3H).
    Example 44 (8)
    2 (R) -methoxymethyl-5-ethoxymethoxy-4 (S)-[N- (4-nitrophenylcarbonyl) amino] pentane

    TLC: Rf 0.24 (CHCl 3: MeOH = 19: 1);
    NMR (CDCl 3 ): δ 8.25 (d, J = 8.7 Hz, 2H), 7.95 (d, J = 8.7 Hz, 2H), 7.11 (d, J = 8.4 Hz, 1H), 4.73 (d, J = 5.7 Hz, 1H), 4.67 (d, J = 5.7 Hz, 1H), 4.42-4.31 (m, 1H), 3.80 (dd, J = 10.2, 3.3 Hz, 1H), 3.69-3.57 (m, 5H), 3.39 (s, 3H), 2.82-2.70 (m, 1H), 2.17 (ddd, J = 14.4, 10.2, 8.1 Hz, H), 1.88 (dt, J = 14.4, 5.1 Hz, 1H), 1.20 (t, J = 7.2 Hz, 3H).
    Example 44 (9)
    2 (R) -benzyloxymethyl-5-ethoxymethoxy-4 (S)-[N- (4-nitrophenylcarbonyl) amino] pentanoic acid

    TLC: Rf 0.41 (CHCl 3: MeOH = 19: 1);
    NMR (CDCl 3 ): δ 8.24 (d, J = 8.8 Hz, 2H), 7.93 (d, J = 8.8 Hz, 2H), 7.41-7.20 (m, 5H), 7.01 (d, J = 8.8 Hz, 1H ), 4.72 (d, J = 7.4 Hz, 1H), 4.67 (d, J = 7.4 Hz, 1H), 4.57 (s, 2H), 4.43-4.25 (m, 1H), 3.82-3.52 (m, 6H) , 2.89-2.70 (m, 1H), 2.19 (ddd, J = 14.8, 10.2, 8.0 Hz, 1H), 1.70 (dt, J = 14.8, 5.0 Hz, 1H), 1.19 (t, J = 7.0 Hz, 3H ).
    Example 44 (10)
    2 (S) -Methyl-5- (2-methoxyethoxy) methoxy-4 (S)-[N- (4-cyanophenylcarbonyl) amino] pentanoic acid

    TLC: Rf 0.40 (CHCl 3: MeOH = 19: 1);
    NMR (CDCl 3 ): δ 7.91 (d, J = 8.4 Hz, 2H), 7.70 (d, J = 8.4 Hz, 2H), 7.07 (d, J = 9.0 Hz, 1H), 4.75 (d, J = 6.9 Hz, 1H), 4.70 (d, J = 6.9 Hz, 1H), 4.45-4.34 (m, 1H), 3.84 (dd, J = 10.5, 3.3 Hz, 1H), 3.78-3.60 (m, 3H), 3.54 -3.51 (m, 2H), 3.29 (s, 3H), 2.61-2.49 (m, 1H), 2.15 (ddd, J = 14.1, 10.2, 7.5 Hz, 1H), 1.70 (ddd, J = 14.1, 6.6, 5.1 Hz, 1H), 1.20 (d, J = 6.9 Hz, 3H).
    Example 44 (11)
    2 (R)-(2-methoxyethoxy) methyl-5-ethoxymethoxy-4 (S)-[N- (4-nitrophenylcarbonyl) amino] pentanoic acid

    TLC: Rf 0.17 (CHCl 3: MeOH = 19: 1);
    NMR (CDCl 3 ): δ 8.26 (d, J = 8.8 Hz, 2H), 7.97 (d, J = 8.8 Hz, 2H), 7.08 (d, J = 8.8 Hz, 1H), 4.75-4.62 (m, 2H ), 4.44-4.28 (m, 1H), 3.82-3.48 (m, 10H), 3.37 (s, 3H), 2.90-2.66 (m, 1H), 2.21 (ddd, J = 14.4, 10.0, 8.6 Hz, 1H) ), 1.92 (dt, J = 14.4, 4.8 Hz, 1H), 1.20 (t, J = 7.0 Hz, 3H).
    Example 44 (12)
    2 (S)-(2-propynyl) -5-ethoxymethoxy-4 (S)-[N- (4-nitrophenylcarbonyl) amino] pentanoic acid

    TLC: Rf 0.30 (CHCl 3: MeOH = 9: 1);
    NMR (CDCl 3 ): δ 8.28 (d, J = 9.0 Hz, 2H), 7.96 (d, J = 9.0 Hz, 2H), 6.98 (d, J = 8.7 Hz, 1H), 4.75 (d, J = 6.9 Hz, 1H), 4.70 (d, J = 6.9 Hz, 1H), 4.50-4.38 (m, 1H), 3.84 (dd, J = 10.5, 3.0 Hz, 1H), 3.70-3.55 (m, 3H), 2.80 -2.40 (m, 3H), 2.28-2.10 (m, 1H), 2.10-1.95 (m, 2H), 1.21 (t, J = 7.2 Hz, 3H).
    Example 44 (13)
    2 (S) -allyl-5- (2-methoxyethoxy) methoxy-4 (S)-[N- (4-cyanophenylcarbonyl) amino] pentanoic acid

    TLC: Rf 0.26 (CHCl 3: MeOH = 19: 1);
    NMR (CDCl 3 ): δ 7.90 (d, J = 8.4 Hz, 2H), 7.71 (d, J = 8.4 Hz, 2H), 7.10 (d, J = 9.0 Hz, 1H), 5.82-5.66 (m, 1H ), 5.16-5.03 (m, 2H), 4.75 (d, J = 6.9 Hz, 1H), 4.70 (d, J = 6.9 Hz. 1H), 4.38 (m, 1H), 3.85 (dd, J = 10.5, 3.6 Hz, 1H), 3.80-3.58 (m, 3H), 3.54 (t, J = 4.5 Hz, 2H), 3.31 (s, 3H), 2.62-2.50 (m, 1H), 2.49-2.30 (m, 2H ), 2.07 (dt, J = 14.4, 9.0 Hz, 1H), 1.83 (dt, J = 14.4, 5.4 Hz, 1H).
    Example 44 (14)
    2 (S) -methoxymethyl-5- (2-methoxyethoxy) methoxy-4 (S)-[N- (4-cyanophenylcarbonyl) amino] pentanoic acid

    TLC: Rf 0.35 (CHCl 3: MeOH = 9: 1);
    NMR (CD 3 OD): δ 7.94 (d, J = 8.7 Hz, 2H), 7.82 (d, J = 8.7 Hz, 2H), 4.71 (d, J = 6.6 Hz, 1H), 4.68 (d, J = 6.6 Hz, 1H), 4.39-4.31 (m, 1H), 3.68-3.49 (m, 8H), 3.32 (s, 3H), 3.31 (s, 3H), 2.76-2.66 (m, 1H), 2.08-1.86 (m, 2 H).
    Example 44 (15)
    2 (S)-(2-propynyl) -5-ethoxymethoxy-4 (S)-[N- (4-bromophenylcarbonyl) amino] pentanoic acid

    TLC: Rf 0.36 (CHCl 3: MeOH = 9: 1);
    NMR (CDCl 3 ): δ 7.64 (d, J = 8.6 Hz, 2H), 7.54 (d, J = 8.6 Hz, 2H), 6.82 (d, J = 9.0 Hz, 1H), 4.72 (d, J = 6.9 Hz, 1H), 4.69 (d, J = 6.9 Hz, 1H), 4.50-4.35 (m, 1H), 3.80 (dd, J = 10.4, 3.2 Hz, 1H), 3.70-3.55 (m, 3H), 2.78 -2.45 (m, 3H), 2.25-2.10 (m, 1H), 2.10-1.95 (m, 2H), 1.20 (t, J = 7.2 Hz, 3H).
    Example 44 (16)
    2 (S)-(2-propynyl) -5-ethoxymethoxy-4 (S)-[N- (4-chlorophenylcarbonyl) amino] pentanoic acid

    TLC: Rf 0.36 (CHCl 3: MeOH = 9: 1);
    NMR (CDCl 3 ): δ 7.71 (d, J = 8.7 Hz, 2H), 7.38 (d, J = 8.7 Hz, 2H), 6.81 (d, J = 8.7 Hz, 1H), 4.73 (d, J = 6.8 Hz, 1H), 4.69 (d, J = 6.8 Hz, 1H), 4.50-4.35 (m, 1H), 3.80 (dd, J = 10.2, 3.0 Hz, 1H), 3.70-3.55 (m, 3H), 2.78 -2.45 (m, 3H), 2.25-2.10 (m, 1H), 2.10-1.95 (m, 2H), 1.20 (t, J = 7.2 Hz, 3H).
    Example 44 (17)
    2 (R) -methoxymethyl-5-ethoxymethoxy-4 (S)-[N- (4-bromophenylcarbonyl) amino] pentanoic acid

    TLC: Rf 0.39 (CHCl 3: MeOH = 9: 1);
    NMR (CD 3 OD): δ 7.73-7.69 (m, 2H), 7.65-7.59 (m, 2H), 4.67 (s, 2H), 4.37-4.28 (m, 1H), 3.63-3.53 (m, 6H) , 3.32 (s, 3H), 2.75-2.64 (m, 1H), 1.96-1.89 (m, 2H), 1.15 (t, J = 7.2 Hz, 3H).
    Example 44 (18)
    2 (R) -methoxymethyl-5-ethoxymethoxy-4 (S)-[N- (4-chlorophenylcarbonyl) amino] pentanoic acid

    TLC: Rf 0.32 (CHCl 3: MeOH = 9: 1);
    NMR (CD 3 OD): δ 7.78 (d, J = 8.7 Hz, 2H), 7.45 (d, J = 8.7 Hz, 2H), 4.66 (s, 2H), 4.37-4.27 (m, 1H), 3.63- 3.54 (m, 6H), 3.32 (s, 3H), 2.74-2.62 (m, 1H), 1.97-1.88 (m, 2H), 1.15 (t, J = 7.2 Hz, 3H).
    Example 44 (19)
    2 (R) -benzyloxymethyl-5- (2-methoxyethoxy) methoxy-4 (S)-[N- (4-cyanophenylcarbonyl) amino] pentanoic acid

    TLC: Rf 0.48 (methylene chloride: methanol = 9: 1);
    NMR (CDCl 3 ): δ 7.87 (d, J = 8.4 Hz, 2H), 7.67 (d, J = 8.4 Hz, 2H), 7.31 (m, 5H), 7.16 (brd, J = 9.0 Hz, 1H), 4.74 (d, J = 7.2 Hz, 1H), 4.69 (d, J = 7.2 Hz, 1H), 4.55 (s, 2H), 4.34 (m, 1H), 3.83 (dd, J = 10.2, 3.6 Hz, 1H ), 3.77-3.66 (m, 4H), 3.62 (dd, J = 10.2, 4.2 Hz, 1H), 3.51 (t, J = 4.5 Hz, 2H), 3.29 (s, 3H), 2.79 (m, 1H) , 2.15 (ddd, J = 14.1, 9.6, 7.5 Hz, 1H), 1.91 (ddd, J = 14.1, 5.4, 5.4 Hz, 1H).
    Example 44 (20)
    2 (R) -benzyloxymethyl-5-ethoxymethoxy-4 (S)-[N- (4-chlorophenylcarbonyl) amino] pentanoic acid

    TLC: Rf 0.50 (methylene chloride: methanol = 9: 1);
    NMR (CDCl 3 ): δ 7.69 (d, J = 8.8 Hz, 2H), 7.35 (d, J = 8.8 Hz, 2H), 7.31 (m, 5H), 6.81 (brd, J = 8.8 Hz, 1H), 4.70 (d, J = 7.5 Hz, 1H), 4.66 (d, J = 7.5 Hz, 1H), 4.55 (s, 2H), 4.33 (m, 1H), 3.80-3.50 (m, 6H), 2.80 (m , 1H), 2.15 (ddd, J = 14.2, 9.8, 7.6 Hz, 1H), 1.89 (ddd, J = 14.2, 5.2, 5.2 Hz, 1H), 1.17 (t, J = 7.4 Hz, 3H).
    Example 44 (21)
    2 (R) -benzyloxymethyl-5-ethoxymethoxy-4 (S)-[N- (4-bromophenylcarbonyl) amino] pentanoic acid

    TLC: Rf 0.50 (methylene chloride: methanol = 9: 1);
    NMR (CDCl 3 ): δ 7.62 (d, J = 8.8 Hz, 2H), 7.51 (d, J = 8.8 Hz, 2H), 7.31 (m, 5H), 6.81 (brd, J = 8.8 Hz, 1H), 4.70 (d, J = 7.0 Hz, 1H), 4.65 (d, J = 7.0 Hz, 1H), 4.54 (s, 2H), 4.33 (m, 1H), 3.80-3.50 (m, 6H), 2.79 (m , 1H), 2.15 (ddd, J = 14.2, 9.8, 7.6 Hz, 1H), 1.89 (ddd, J = 14.2, 5.2, 5.2 Hz, 1H), 1.18 (t, J = 7.4 Hz, 3H).
    Example 44 (22)
    2 (S) -allyl-5-ethoxymethoxy-4 (S)-[N- (4-bromophenylcarbonyl) amino] pentanoic acid

    TLC: Rf 0.43 (CHCl 3: MeOH = 9: 1);
    NMR (CDCl 3 ): δ 7.63 (d, J = 8.7 Hz, 2H), 7.53 (d, J = 8.7 Hz, 2H), 6.72 (d, J = 9.0 Hz, 1H), 5.83-5.65 (m, 1H ), 5.18-5.02 (m, 2H), 4.71 (d, J = 6.8 Hz, 1H), 4.67 (d, J = 6.8 Hz, 1H), 4.45-4.30 (m, 1H), 3.76 (dd, J = 10.4, 3.2 Hz, 1H), 3.70-3.50 (m, 3H), 2.62-2.50 (m, 1H), 2.50-2.25 (m, 2H), 2.18-2.00 (m, 1H), 1.81 (td, J = 14.1, 5.1 Hz, 1H), 1.20 (t, J = 7.1 Hz, 3H).
    Example 44 (23)
    2 (S) -allyl-5-ethoxymethoxy-4 (S)-[N- (4-chlorophenylcarbonyl) amino] pentanoic acid

    TLC: Rf 0.45 (CHCl 3: MeOH = 9: 1);
    NMR (CDCl 3 ): δ 7.70 (d, J = 8.7 Hz, 2H), 7.38 (d, J = 8.7 Hz, 2H), 6.73 (d, J = 9.0 Hz, 1H), 5.82-5.65 (m, 1H ), 5.18-5.02 (m, 2H), 4.71 (d, J = 6.8 Hz, 1H), 4.67 (d, J = 6.8 Hz, 1H), 4.45-4.30 (m, 1H), 3.76 (dd, J = 10.5, 3.3 Hz, 1H), 3.70-3.50 (m, 3H), 2.62-2.50 (m, 1H), 2.50-2.25 (m, 2H), 2.18-2.00 (m, 1H), 1.81 (d, J = 14.1, 5.3 Hz, 1H), 1.20 (t, J = 6.9 Hz, 3H).
    Example 44 (24)
    2 (R)-(2-methoxyethoxy) methyl-5-ethoxymethoxy-4 (S)-[N- (4-bromophenylcarbonyl) amino] pentanoic acid

    TLC: Rf 0.41 (CHCl 3: MeOH = 9: 1);
    NMR (CDCl 3 ): δ 7.65 (d, J = 8.8 Hz, 2H), 7.54 (d, J = 8.8 Hz, 2H), 6.85 (d, J = 8.8 Hz, 1H), 4.70 (d, J = 7.0 Hz, 1H), 4.66 (d, J = 7.0 Hz, 1H), 4.42-4.27 (m, 1H), 3.78-3.50 (m, 10H), 3.35 (s, 3H), 2.83-2.70 (m, 1H) , 2.18 (ddd, J = 14.0, 9.8, 7.0 Hz, 1H), 1.82 (ddd, J = 14.0, 5.6, 4.4 Hz, 1H), 1.18 (t, J = 7.4 Hz, 3H).
    Example 44 (25)
    2 (R)-(2-methoxyethoxy) methyl-5- (2-methoxyethoxy) methoxy-4 (S)-[N- (4-cyanophenylcarbonyl) amino] pentanoic acid

    TLC: Rf 0.16 (CHCl 3: MeOH = 19: 1);
    NMR (CDCl 3 ): δ 7.91 (d, J = 8.4 Hz, 2H), 7.71 (d, J = 8.4 Hz, 2H), 7.20 (d, J = 8.7 Hz, 1H), 4.75 (d, J = 6.9 Hz, 1H), 4.70 (d, J = 6.9 Hz, 1H), 4.42-4.31 (m, 1H), 3.84 (dd, J = 10.5, 3.9 Hz, 1H), 3.78-3.60 (m, 7H), 3.57 -3.50 (m, 4H), 3.36 (s, 3H), 3.32 (s, 3H), 2.82-2.72 (m, 1H), 2.18 (ddd, J = 14.4, 10.2, 7.2 Hz, 1H), 1.85 (dt , J = 14.4, 5.7 Hz, 1H).
    Example 44 (26)
    2 (R)-(2-methoxyethoxy) methyl-5-ethoxymethoxy-4 (S)-[N- (4-chlorophenylcarbonyl) amino] pentanoic acid

    TLC: Rf 0.31 (CHCl 3: MeOH = 9: 1);
    NMR (CDCl 3 ): δ 7.72 (d, J = 8.8 Hz, 2H), 7.39 (d, J = 8.8 Hz, 2H), 6.84 (d, J = 9.0 Hz, 1H), 4.70 (d, J = 7.0 Hz, 1H), 4.66 (d, J = 7.0 Hz, 1H), 4.43-4.27 (m, 1H), 3.78-3.50 (m, 10H), 3.35 (s, 3H), 2.82-2.69 (m, 1H) , 2.19 (ddd, J = 14.4, 10.6, 7.4 Hz, 1H), 1.82 (ddd, J = 14.4, 5.6, 4.4 Hz, 1H), 1.19 (t, J = 7.2 Hz, 3H).
    Example 44 (27)
    2 (S)-(2-propynyl) -5- (2-methoxyethoxy) methoxy-4 (S)-[N- (4-cyanophenylcarbonyl) amino] pentanoic acid

    TLC: Rf 0.37 (CHCl 3: MeOH = 9: 1);
    NMR (CDCl 3 ): δ 7.92 (d, J = 8.7 Hz, 2H), 7.69 (d, J = 8.7 Hz, 2H), 7.17 (d, J = 9.0 Hz, 1H), 4.77 (d, J = 7.1 Hz, 1H), 4.71 (d, J = 7.1 Hz, 1H), 4.48-4.32 (m, 1H), 3.89 (dd, J = 10.5, 3.6 Hz, 1H), 3.82-3.60 (m, 3H), 3.55 (t, J = 4.5 Hz, 2H), 3.31 (s, 3H), 2.78-2.50 (m, 3H), 2.25-2.10 (m. 1H), 2.10-1.95 (m, 2H).
    Examples 44 (28) -44 (29)
    Example 37-Example 39-Example 41 (The equivalent compound is used instead of methoxymethyl chloride)-Example 43 (The equivalent of benzyl bromide instead of the compound prepared by the reference example 4 using compound equivalent. Using a compound) → Example 5 → Example 44, and a compound shown below was obtained.
    Example 44 (28)
    2 (S) -Methyl-5-ethoxymethoxy-4 (S)-[N-methyl-N- (4-bromophenylcarbonyl) amino] pentanoic acid

    TLC: Rf 0.23 (CHCl 3: MeOH = 9: 1);
    NMR (d 6 -DMSO): δ 12.15 (1H, brs), 7.63-7.56 (2H, m), 7.34-7.25 (2H, m), 4.82-4.72 & 3.79-3.69 (1H, m), 4.59 & 4 .55 (2H, s), 3.61-3.37 (4H, m), 2.76 & 2.64 (3H, s), 2.08 (1H, sxt, J = 6.9 Hz), 2.01-1.91 & 1.51-1.41 & 1.37 -1.27 (2H, m), 1.14-1.04 (3H, m), 0.82 (3H, d, J = 6.9 Hz).
    Example 44 (29)
    2 (S) -Methyl-5-ethoxymethoxy-4 (S)-[N-methyl-N- (4-nitrophenylcarbonyl) amino] pentanoic acid

    TLC: Rf 0.42 (CHCl 3: MeOH = 9: 1);
    NMR (CDCl 3 ): δ 8.27 and 8.25 (d and d, J = 8.7 Hz and J = 8.7 Hz, 2H), 7.68 and 7.58 (d and d, J = 8.7 Hz and J = 8.7 Hz, 2H), 5.10 -4.98 and 3.92-3.80 (m and m, 1H), 4.76-4.63 (m, 2H), 3.72-3.42 (m, 4H), 2.96 and 2.80 (s and s, 3H), 2.62-2.50 and 2.27-2.21 (m and m, 1H), 2.12 and 1.59 (ddd and ddd, J = 14.4, 10.5, 6.3 Hz and 14.4, 7.5, 4.2 Hz, 1H), 2.02 and 1.41 (dt and dt, J = 14.4, 9.0 Hz and 14.4, 5.4 Hz, 1H), 1.32 and 1.08 (d and d, J = 7.2 Hz and 6.9 Hz, 3H), 1.23 and 1.22 (t and t, J = 7.2 and 7.2 Hz, 3H).
    Example 45
    4 (S) -t-butyldimethylsilyloxymethyl-4- (N- (4- (benzofuran-2-yl) phenylcarbonyl) amino) butanoic acid methyl ester

    To a solution of dimethylformamide (5 ml) of the compound (0.294 g) prepared in Example 39, imidazole (0.107 g) and t-butyldimethylsilyl chloride (0.241 g) were added. The reaction mixture was stirred at room temperature for 2 hours. The reaction mixture was diluted with ethyl acetate, washed with water and saturated aqueous sodium chloride solution, dried over anhydrous magnesium sulfate and concentrated. The residue was purified by silica gel column chromatography (n-hexane: ethyl acetate = 3: 1) to obtain the title compound (0.361 g) having the following physical properties.
    TLC: Rf 0.83 (n-hexane: ethyl acetate = 1: 1);
    NMR (CDCl 3 ): δ 7.94 (2H, d, J = 8.8 Hz), 7.84 (2H, d, J = 8.8 Hz), 7.63-7.52 (2H, m), 7.37-7.20 (3H, m), 7.13 (1H, d, J = 0.8 Hz), 6.62 (1H, d, J = 8.8 Hz), 4.30-4.16 (1H, m), 3.74 (2H, d, J = 3.6 Hz), 3.64 (3H, s) , 2.59-2.38 (2H, m), 2.10-1.92 (2H, m), 0.92 (9H, s), 0.086 (3H, s), 0.066 (3H, s).
    Example 46
    2 (S) -benzyl-4 (S) -t-butyldimethylsilyloxymethyl-4- (N- (4- (benzofuran-2-yl) phenylcarbonyl) amino) butanoic acid methyl ester

    The title compound having the following physical properties was obtained in the same manner as the method shown in Example 42 using the compound prepared in Example 45 instead of the compound prepared in Example 41.
    TLC: Rf 0.43 (n-hexane: ethyl acetate = 7: 3);
    NMR (CDCl 3 ): δ 7.93 (2H, d, J = 8.4 Hz), 7.83 (2H, d, J = 8.4 Hz), 7.63-7.50 (2H, m), 7.38-7.10 (8H, m), 6.35 (1H, d, J = 8.8 Hz), 4.36-4.17 (1H, m), 3.74-3.60 (2H, m), 3.43 (3H, s), 3.02-2.68 (3H, m), 2.20-2.00 (1H m), 1.90-1.74 (1H, m), 0.88 (9H, s), 0.038 (3H, s), 0.026 (3H, s).
    Example 47
    2 (S) -benzyl-4 (S) -t-butylmethylsilyloxymethyl-4- (N- (4- (benzofuran-2-yl) phenylcarbonyl) amino) butanoic acid

    The title compound was obtained in the same manner as the method shown in Example 2, using the compound prepared in Example 46 instead of the compound prepared in Example 1.
    TLC: Rf 0.44 (CHCl 3: MeOH = 19: 1);
    NMR (CD 3 OD): δ 7.97 (2H, d, J = 8.4 Hz), 7.90 (2H, d, J = 8.4 Hz), 7.63-7.49 (2H, m), 7.37-7.10 (8H, m), 4.35-4.18 (1H, m), 3.74-3.60 (2H, m), 3.05-2.82 (2H, m), 2.80-2.64 (1H, m), 1.93 (2H, m), 0.87 (9H, s), 0.048 (6H, s).
    Example 48
    2 (R) -benzyl-4 (S) -hydroxymethyl-4- (N- (4- (benzofuran-2-yl) phenylcarbonyl) amino) butanoic acid

    To a solution of tetrahydrofuran (5 ml) of the compound prepared in Example 47 (0.162 g) was added a solution of tetrahydrofuran (0.4 ml) of 1M tetrabutylammonium fluoride at room temperature. The reaction mixture was stirred at room temperature for 2 hours. Water was added to the reaction mixture, which was then extracted with ethyl acetate. The extract was washed with saturated aqueous sodium chloride solution, dried over anhydrous magnesium sulfate and concentrated. The residue was purified by silica gel column chromatography (n-hexane: ethyl acetate = 9: 1-1: 9) to obtain the title compound (0.088 g) having the following physical properties.
    TLC: Rf 0.22 (CHCl 3: MeOH = 19: 1);
    NMR (CD 3 OD): δ 7.92 (4H, s), 7.60-7.42 (2H, m), 7.38-7.06 (8H, m), 4.40-4.20 (1H, m), 3.64 (2H, d, J = 5.4 Hz), 3.02-2.82 (2H, m), 2.80-2.62 (1H, m), 2.10-1.75 (2H, m).
    Example 48 (1)
    2 (S) -benzyl-4 (S) -hydroxymethyl-4- (N- (4- (3-methoxy-1-propynyl) phenylcarbonyl) amino) butanoic acid

    Instead of the compound prepared in Reference Example 4, using the corresponding acid halide, it was operated in the same manner as the method shown in Example 37-Example 39-Example 45-Example 46-Example 47-Example 48, and then The title compound having the physical property value of was obtained.
    TLC: Rf 0.21 (CHCl 3: MeOH = 19: 1).
    Example 49
    N-hydroxy-4 (S)-(morpholin-1-yl) carbonyl-4- (N- (4- (benzofuran-2-yl) phenylcarbonyl) amino) butylamide

    The title compound was obtained in the same manner as the method shown in Example 3-Example 4 using the compound prepared in Example 38 instead of the compound prepared in Example 2.
    TLC: Rf 0.39 (CHCl 3: MeOH = 9: 1);
    NMR (d 6 -DMSO): δ 10.42 (1H, s), 8.75 (1H, d, J = 7.6 Hz), 8.04 (4H, s), 7.74-7.57 (3H, m), 7.42-7.25 (2H, m), 5.00-4.82 (1H, m), 3.71-3.40 (8H, m), 2.19-1.82 (4H, m).
    Examples 49 (1) to 49 (8)
    Instead of the compound prepared in Example 38, using the compound prepared in Example 40, Example 42, Example 44, Example 44 (1) to 44 (3), Example 48, or Example 48 (1) The compound shown below was obtained by operation in the same manner as the method shown in Example 49.
    Example 49 (1)
    N-hydroxy-4 (S) -hydroxymethyl-4- (N- (4- (benzofuran-2-yl) phenylcarbonyl) amino) butylamide

    TLC: Rf 0.22 (CHCl 3: MeOH = 9: 1);
    NMR (d 6 -DMSO): δ 10.36 (1H, d, J = 1.5 Hz), 8.67 (1H, d, J = 1.5 Hz), 8.19 (1H, d, J = 8.4 Hz), 8.00 (4H, s ), 7.73-7.61 (2H, m), 7.57 (1H, d, J = 0.8 Hz), 7.42-7.23 (2H, m), 4.73 (1H, t, J = 5.8 Hz), 4.08-3.85 (1H, m), 3.58-3.38 (2H, m), 2.12-1.60 (4H, m).
    Example 49 (2)
    N-hydroxy-4 (S) -methoxymethyloxymethyl-4- (N- (4- (benzofuran-2-yl) phenylcarbonyl) amino) butylamide

    TLC: Rf 0.47 (CHCl 3: MeOH = 9: 1);
    NMR (d 6 -DMSO): δ 10.37 (1H, s), 8.34 (1H, d, J = 8.4 Hz), 8.00 (4H, s), 7.73-7.61 (2H, m), 7.56 (1H, s) , 7.41-7.24 (2H, m), 4.58 (2H, s), 4.23-4.04 (1H, m), 3.62-3.44 (2H, m), 3.26 (3H, s), 2.12-1.62 (4H, m) .
    Example 49 (3)
    N-hydroxy-2 (S) -benzyl-4 (S) -methoxymethyloxymethyl-4- (N- (4- (benzofuran-2-yl) phenylcarbonyl) amino) butylamide

    TLC: Rf 0.35 (CHCl 3: MeOH = 19: 1);
    NMR (d 6 -DMSO): δ 10.37 (1H, s), 8.69 (1H, s), 8.25 (1H, d, J = 8.6 Hz), 8.01 (4H, s), 7.72-7.61 (2H, m) , 7.57 (1H, s), 7.41-7.09 (7H, m), 4.55 (2H, s), 4.40-4.20 (1H, m), 3.53 (2H, d, J = 5.6 Hz), 3.22 (3H, s ), 2.79 (2H, d, J = 7.4 Hz), 2.50-2.34 (1H, m), 1.90-1.60 (2H, m).
    Example 49 (4)
    N-hydroxy-2 (S) -methyl-4 (S) -methoxymethyloxymethyl-4- (N- (4- (benzofuran-2-yl) phenylcarbonyl) amino) butylamide

    TLC: Rf 0.23 (chloroform: methanol = 19: 1);
    NMR (d 6 -DMSO): δ 10.41 (1H, d, J = 1.6 Hz), 8.68 (1H, d, J = 1.6 Hz), 8.20 (1H, d, J = 8.4 Hz), 8.00 (4H, s ), 7.74-7.60 (2H, m), 7.56 (1H, d, J = 0.8 Hz), 7.41-7.22 (2H, m), 4.58 (2H, s), 4.32-4.10 (1H, m), 3.62- 3.41 (2H, m), 3.25 (3H, s), 2.30-2.14 (1H, m), 1.82-1.58 (2H, m), 1.05 (3H, d, J = 6.6 Hz).
    Example 49 (5)
    N-hydroxy-2 (S)-(3-phenyl-2-propenyl) -4 (S) -methoxymethyloxymethyl-4- (N- (4- (benzofuran-2-yl) phenylcart Carbonyl) amino) butylamide

    TLC: Rf 0.36 (CHCl 3: MeOH = 19: 1);
    NMR (d 6 -DMSO): δ 10.50 (1H, s), 8.78 (1H, s), 8.25 (1H, d, J = 8.4 Hz), 8.00 (4H, s), 7.67 (2H, t, J = 8.6 Hz), 7.56 (1H, s), 7.40-7.14 (7H, m), 6.41 (1H, d, J = 16.0 Hz), 6.15 (1H, dt, J = 16.0, 5.8 Hz), 4.57 (2H, s), 4.32-4.14 (1H, m), 3.62-3.45 (2H, m), 3.24 (3H, s), 2.46-2.22 (3H, m), 1.96-1.78 (2H, m).
    Example 49 (6)
    N-hydroxy-2 (S)-(3-phenylpropyl) -4 (S) -methoxymethyloxymethyl-4- (N- (4- (benzofuran-2-yl) phenylcarbonyl) amino) Butylamide

    TLC: Rf 0.35 (CHCl 3: MeOH = 19: 1);
    NMR (d 6 -DMSO): δ 10.47 (1H, s), 8.82-8.66 (1H, brs), 8.20 (1H, dJ = 8.4 Hz), 7.99 (4H, s), 7.72-7.61 (2H, m) , 7.57 (1H, d, J = 0.6 Hz), 7.41-7.10 (7H, m), 4.57 (2H, s), 4.23-4.02 (1H, m), 3.60-3.42 (2H, m), 3.24 (3H , s), 2.62-2.40 (2H, m), 2.22-2.06 (1H, m), 1.84-1.64 (2H, m), 1.60-1.38 (4H, m).
    Example 49 (7)
    N-hydroxy-2 (R) -benzyl-4 (S) -hydroxymethyl-4- (N- (4- (benzofuran-2-yl) phenylcarbonyl) amino) butylamide

    TLC: Rf 0.37 (CHCl 3: MeOH = 9: 1);
    NMR (d 6 -DMSO): δ 10.32 (1H, s), 8.68 (1H, s), 8.08 (1H, d, J = 8.4 Hz), 8.02 (4H, s), 7.72-7.62 (2H, m) , 7.59 (1H, s), 7.41-7.06 (7H, m), 4.82-4.66 (1H, m), 4.24-4.04 (1H, m), 3.60-3.36 (2H, m), 2.92-2.66 (2H, m), 2.50-2.30 (1H, m), 1.92-1.52 (2H, m).
    Example 49 (8)
    N-hydroxy-2 (S) -benzyl-4 (S) -hydroxymethyl-4- (N- (4- (3-methoxy-1-propynyl) phenylcarbonyl) amino) butylamide

    TLC: Rf 0.23 (CHCl 3: MeOH = 9: 1);
    NMR (d 6 -DMSO): δ 10.28 (1H, brs), 8.62 (1H, brs), 8.04 (1H, d, J = 8.4 Hz), 7.87 (2H, d, J = 8.2 Hz), 7.53 (2H , d, J = 8.2 Hz), 7.24-7.05 (5H, m), 4.69 (1H, t, J = 5.7 Hz), 4.33 (2H, s), 4.18-4.02 (1H, m), 3.46-3.34 ( 2H, m), 3.31 (3H, s), 2.75 (2H, d, J = 7.0 Hz). 2.42-2.26 (1H, m), 1.89-1.52 (2H, m).
    Example 49 (9)
    N-hydroxy-5-hydroxy-4 (S)-[N- [4- (3-methoxy-1-propynyl) phenylcarbonyl] amino] pentanamide

    Using the corresponding compound instead of the compound prepared in Reference Example 4, the title compound was obtained in the same manner as the method described in Example 37-39-Example 40-49, to obtain the title compound having the following physical properties.
    TLC: Rf 0.36 (CHCl 3: MeOH = 4: 1);
    NMR (d 6 -DMSO): δ 10.35 (1H, s), 10.18 (1H, s), 8.18 (1H, d, J = 8.4 Hz), 7.88 (2H, d, J = 8.4 Hz), 7.55 (2H , d, J = 8.4 Hz), 4.53 (2H, s), 4.02-3.84 (1H, m), 3.73-3.34 (2H, m), 3.35 (3H, s), 2.07-1.59 (4H, m).
    Example 49 (10)
    N-hydroxy-5-hydroxy-4 (R)-[N- [4- (3-methoxy-1-propynyl) phenylcarbonyl] amino] pentanamide

    Instead of 4 (S) -carboxy-4-aminobutanoic acid methyl ester, Examples were used instead of 4 (R) -carboxy-4-aminobutanoic acid methyl ester and compounds corresponding to those prepared in Reference Example 4 37 → Example 39 → Example 40 → Operation was carried out in the same manner as in Example 49, whereby the title compound having the following physical properties was obtained.
    TLC: Rf 0.28 (CHCl 3: MeOH: Acetic Acid: Water = 85:15: 1: 1);
    NMR (CD 3 OD): δ 7.83 (2H, d, J = 8.4 Hz), 7.51 (2H, d, J = 8.4 Hz), 4.34 (2H, s), 4.03-4.15 (1H, m), 3.62 ( 2H, d, J = 5.6 Hz), 3.43 (3H, s), 2.19 (2H, t, J = 7.4 Hz), 1.77-2.10 (2H, m).
    Examples 49 (11) to 49 (21)
    The compound shown below was obtained by operation similar to the method shown in Example 37-Example 38 (using the equivalent amine compound)-Example 49 using the compound equivalent instead of the reference example 4.
    Example 49 (11)
    N-hydroxy-4 (S)-(4-hydroxybutylcarbamoyl) -4- [N- [4- (3-methoxy-1-propynyl) phenylcarbonyl] amino] butylamide

    TLC: Rf 0.40 (CHCl 3: MeOH = 4: 1);
    NMR (d 6 -DMSO): δ 10.41 (1H, s), 8.61 (1H, d, J = 7.8 Hz), 7.98-7.88 (3H, m), 7.55 (2H, d, J = 8.4 Hz), 4.44 -4.27 (3H, m), 3.38 (2H, t, J = 6.2 Hz), 3.35 (3H, s), 3.13-3.00 (2H, m), 2.09-1.83 (4H, m), 1.48-1.34 (4H , m).
    Example 49 (12)
    N-hydroxy-4 (S)-(3-phenylpropylcarbamoyl) -4- [N- [4- (3-methoxy-1-propynyl) phenylcarbonyl] amino] butylamide

    TLC: Rf 0.38 (CHCl 3: MeOH = 9: 1):
    NMR (d 6 -DMSO): δ 10.41 (1H, s). 8.72 (1H, s), 8.64 (1H, d, J = 7.6 Hz), 8.04-7.94 (1H, m), 7.92 (2H, d, J = 8.5 Hz), 7.55 (2H, d, J = 8.5 Hz ), 7.32-7.14 (5H, m), 4.431.35 (3H, m), 3.33 (3H, s), 3.16-3.02 (2H, m), 2.62-2.49 (2H, m), 2.14-1.84 (4H m), 1.80-1.62 (2H, m).
    Example 49 (13)
    N-hydroxy-4 (S) -propylcarbamoyl-4- [N- [4- (3-methoxy-1-propynyl) phenylcarbonyl] amino] butylamide

    TLC: Rf 0.23 (CHCl 3: MeOH = 9: 1);
    NMR (d 6 -DMSO): δ 10.40 (1H, s), 8.71 (1H, s), 8.61 (1H, d, J = 7.8 Hz), 7.96-7.88 (3H, m), 7.55 (2H, d, J = 8.3 Hz), 4.43-4.26 (3H, m), 3.32 (3H, s), 3.09-2.95 (2H, m), 2.07-1.79 (4H, m), 1.41 (2H, sextet, J = 7.3 Hz ), 0.83 (3H, t, J = 7.3 Hz).
    Example 49 (14)
    N-hydroxy-4 (S)-(2-hydroxyethylcarbamoyl) -4- [N- [4- (3-methoxy-1-propynyl) phenylcarbonyl] amino] butylamide

    TLC: Rf 0.09 (CHCl 3: MeOH = 9: 1);
    NMR (d 6 -DMSO): δ 10.39 (1H, s), 8.71 (1H, s), 8.63 (1H, d, J = 7.6 Hz), 7.97-7.87 (3H, m), 7.56 (2H, d, J = 8.2 Hz), 4.66 (1H, t, J = 5.4 Hz), 4.43-4.35 (3H, m), 3.40 (2H, m), 3.33 (3H, s), 3.19-3.08 (2H, m), 2.09-1.83 (4H, m).
    Example 49 (15)
    N-hydroxy-4 (S)-(6-hydroxyhexylcarbamoyl) -4- [N- [4- (3-methoxy-1-propynyl) phenylcarbonyl] amino] butylamide

    TLC: Rf 0.42 (CHCl 3: MeOH = 4: 1);
    NMR (d 6 -DMSO): δ 10.37 (1H, s), 8.68 (1H, s), 8.57 (1H, d, J = 7.6 Hz), 7.93-7.83 (3H, m), 7.53 (2H, d, J = 8.4 Hz), 4.37-4.25 (4H, m), 3.38-3.29 (5H, m), 3.09-2.93 (2H, m), 2.12-1.78 (4H, m), 1.43-1.15 (8H, m) .
    Example 49 (16)
    N-hydroxy-4 (S)-[2- (4-methoxyphenyl) ethylcarbamoyl] -4- [N- [4- (3-methoxy-1-propynyl) phenylcarbonyl] amino ] Butylamide

    TLC: Rf 0.25 (chloroform: methanol = 9: 1);
    NMR (d 6 -DMSO): δ 10.40 (1H, s), 8.72 (1H, s), 8.62 (1H, d, J = 8.4 Hz), 8.00-7.86 (3H, m), 7.60-7.52 (2H, m), 7.10-7.08 (2H, d, J = 8.4 Hz), 6.82-6.79 (2H, d, J = 8.4 Hz), 4.40-4.25 (3H, m), 3.70-3.69 (3H, s), 3.35 (3H, s), 3.36-3.15 (2H, m), 2.63 (2H, t, J = 7.3 Hz), 2.19-1.82 (4H, m).
    Example 49 (17)
    N-hydroxy-4 (S)-(2-morpholinoethylcarbamoyl) -4- [N- [4- (3-methoxy-1-propynyl) phenylcarbonyl] amino] butylamide

    TLC: Rf 0.70 (CHCl 3: MeOH = 4: 1);
    NMR (d 6 -DMSO): δ 10.32 (1H, s), 8.60 (1H, d, J = 7.6 Hz), 8.32 (1H, s), 7.92 (2H, d, J = 8.4 Hz), 7.83 (1H , t, J = 5.5 Hz), 7.56 (2H, d, J = 8.4 Hz), 4.42-4.30 (3H, m), 3.55-3.48 (4H, m), 3.35 (3H, s), 3.23-3.20 ( 4H, m), 2.39-2.29 (4H, m), 2.21-1.83 (4H, m).
    Example 49 (18)
    N-hydroxy-4 (S)-[2- (indol-3-yl) ethylcarbamoyl) -4- [N- [4- (3-methoxy-1-propynyl) phenylcarbonyl] amino ] Butylamide

    TLC: Rf 0.33 (CHCl 3: MeOH = 9: 1);
    NMR (d 6 -DMSO): δ 10.79 (1H, s), 10.41 (1H, s), 8.64 (1H, d, J = 7.6 Hz), 8.12-8.04 (1H, m), 7.92 (2H, d, J = 8.5 Hz), 7.61-7.52 (3H, m), 7.32 (1H, d, J = 7.6 Hz), 7.17-6.92 (3H, m), 4.45-4.35 (3H, m), 3.42-3.33 (4H m), 2.82 (2H, t, J = 7.4 Hz), 2.17-1.84 (4H, m).
    Example 49 (19)
    N-hydroxy-4 (S)-(4-phenylbutylcarbamoyl) -4- [N- [4- (3-methoxy-1-propynyl) phenylcarbonyl] amino] butylamide

    TLC: Rf 0.16 (CHCl 3: MeOH = 9: 1);
    NMR (d 6 -DMSO): δ 10.40 (1H, s), 8.70 (1H, brs), 8.62 (1H, d, J = 7.8 Hz), 7.98-7.87 (3H, m), 7.55 (2H, d, J = 8.5 Hz), 7.30-7.14 (5H, m), 4.40-4.34 (3H, m), 3.35 (3H, s), 3.09 (2H, q, J = 6.0 Hz), 2.56 (2H, t, J = 7.0 Hz), 2.12-1.83 (4H, m), 1.64-1.34 (4H, m).
    Example 49 (20)
    N-hydroxy-4 (S)-(2-phenylethylcarbamoyl) -4- [N- [4- (3-methoxy-1-propynyl) phenylcarbonyl] amino] butylamide

    TLC: Rf 0.36 (CHCl 3: MeOH = 9: 1);
    NMR (d 6 -DMSO): δ 10.39 (1H, s), 8.72 (1H, s), 8.63 (1H, d, J = 8.0 Hz), 8.01 (1H, t, J = 5.7 Hz), 7.92 (2H , d, J = 8.4 Hz), 7.57 (2H, d, J = 8.4 Hz), 7.29-7.14 (5H, m), 4.39-4.28 (3H, m), 3.35-3.23 (5H, m), 2.71 ( 2H, t, J = 7.5 Hz), 2.09-1.82 (4H, m).
    Example 49 (21)
    N-hydroxy-4 (S)-[3- (pyrazol-1-yl) propylcarbamoyl] -4- [N- [4- (3-methoxy-1-propynyl) phenylcarbonyl] Amino] butylamide

    TLC: Rf 0.23 (chloroform: methanol: acetic acid = 9: 1: 0.5);
    NMR (d 6 -DMSO): δ 10.43 (1H, s), 8.69 (1H, d, J = 7.5 Hz), 8.06 (1H, t, J = 5.6 Hz), 7.93 (2H, d, J = 8.4 Hz ), 7.71 (1H, d, J = 2.0 Hz), 7.56 (2H, d, J = 8.4 Hz), 7.42 (1H, d, J = 2.0 Hz), 6.21 (1H, t, J = 2.0 Hz), 4.37-4.27 (3H, m), 4.11 (2H, t, J = 6.8 Hz), 3.35 (3H, s), 3.09-2.99 (2H, m), 2.12-1.86 (6H, m).
    Example 49 (22)
    N-hydroxy-4 (R)-(3-phenylpropylcarbonyl) -4- [N- [4- (3-methoxy-1-propynyl) phenylcarbonyl] amino] butylamide

    Example 37 → Example 38 using 4 (R) -carboxy-4-aminobutanoic acid methyl ester and the corresponding compound instead of Reference Example 4 instead of 4 (S) -carboxy-4-aminobutanoic acid methyl ester (The equivalent amine compound was used) → The same procedure as in Example 49 was carried out to obtain the title compound having the following physical properties.
    TLC: Rf 0.44 (CHCl 3: MeOH = 9: 1);
    NMR (d 6 -DMSO): δ 10.39 (1H, brs), 8.70 (1H, brs), 8.63 (1H, d, J = 7.8 Hz), 7.98 (1H, t, J = 5.6 Hz), 7.90 (2H , d, J = 8.4 Hz), 7.54 (2H, d, J = 8.4 Hz), 7.10-7.28 (5H, m), 4.42-4.35 (3H, m), 3.32 (3H, s), 3.11-3.01 ( 2H, m), 2.57-2.47 (2H, m), 2.13-1.82 (4H, m), 1.74-1.60 (2H, m).
    Example 49 (23)
    N-hydroxy-2- (pyridin-3-yl) methyl-4- (2-phenylethylcarbamoyl) -4- [N- (4-phenoxyphenylcarbonyl) amino] butylamide

    Instead of 4 (S) -carboxy-4-aminobutanoic acid methyl ester, equivalent to 4 (S) -t-butoxycarbonyl-4- (N-benzyloxycarbonylamino) butanoic acid methyl ester and benzyl bromide Example 43 → Example 27 → Example 37 (using the equivalent compound instead of Reference Example 4) → Example 14 → Example 38 (using the corresponding amine compound) → Example 49 Operation was carried out in the same manner as the method to obtain the title compound having the following physical properties.
    TLC: Rf 0.30, 0.36 (chloroform: methanol: acetic acid = 9: 1: 0.5);
    NMR (d 6 -DMSO / MeOH): δ 8.33-8.26 (2H, m), 7.89-7.82 (2H, m), 7.48 (1H, t, J = 8.1 Hz), 7.39-7.31 (2H, m), 7.24-7.06 (5H, m), 7.02-6.90 (6H, m), 4.48 (1H in two isomers, dd, J = 5.0 Hz, 10.1 Hz), 4.29 (1H in two isomers, dd, J) = 4.2 Hz, 10.5 Hz), 3.20-3.02 (2H, m), 2.95-2.84 (1H in two isomers, m), 2.79-2.57 (1H + 2H in two isomers, m), 2.51-2.27 (2H, m), 2.04-1.92 (2H in two isomers, m), 1.88-1.77 (2H in two isomers, m).
    Examples 49 (24) -49 (35)
    Example 37-Example 39-Example 41 (The equivalent compound may be used instead of methoxymethyl chloride)-Example 42-Example 49 using the compound shown instead of the reference example 4. It operated in the same manner and obtained the compound shown below.
    Example 49 (24)
    N-hydroxy-5-methoxymethoxy-4 (S)-[N- [4- (3-methoxy-1-propynyl) phenylcarbonyl] amino] pentanamide

    TLC: Rf 0.22 (CHCl 3: MeOH = 9: 1);
    NMR (d 6 -DMSO): δ 10.35 (1H, s), 8.32 (1H, d, J = 8.6Hz), 7.87 (2H, d, J = 8.4Hz), 7.55 (2H, d, J = 8.4Hz ), 4.57 (2H, s), 4.36 (2H, s), 4.20-4.01 (1H, m), 3.55-3.44 (2H, m), 3.35 (3H, s), 3.24 (3H, s), 2.09- 1.64 (4 H, m).
    Example 49 (25)
    N-hydroxy-5-benzyloxymethoxy-4 (S)-[N- [4- (3-methoxy-1-propynyl) phenylcarbonyl] amino] pentanamide

    TLC: Rf 0.24 (CHCl 3: MeOH = 9: 1);
    NMR (d 6 -DMSO): δ 10.37 (1H, s), 8.36 (1H, d, J = 8.8 Hz), 7.88 (2H, d, J = 8.5 Hz), 7.55 (2H, d, J = 8.5 Hz ), 7.37-7.26 (5H, m), 4.72 (2H, s), 4.53 (2H, s), 4.35 (2H, s), 4.22-4.07 (1H, m), 3.63-3.55 (2H, m), 3.35 (3H, s), 2.09-1.68 (4H, m).
    Example 49 (26)
    N-hydroxy-5- (2-methoxyethoxy) methoxy-4 (S)-[N- [4- (3-phenoxy-1-propynyl) phenylcarbonyl] amino] pentanamide

    TLC: Rf 0.41 (CHCl 3: MeOH: Acetic Acid: Water = 100: 10: 1: 1);
    NMR (d 6 -DMSO): δ 10.32 (1H, s), 8.65 (1H, s), 8.30 (1H, d, J = 8.6 Hz), 7.84 (2H, d, J = 8.4 Hz), 7.52 (2H , d, J = 8.4 Hz), 7.28-7.36 (2H, m), 6.93-7.06 (3H, m), 5.04 (2H, s), 4.60 (2H, s), 3.95-4.16 (1H, m), 3.38-3.56 (6H, m), 3.19 (3H, s), 1.57-2.08 (4H, m).
    Example 49 (27)
    N-hydroxy-5-methoxymethoxy-4 (S)-[N- [4- (3-phenoxy-1-propynyl) phenylcarbonyl] amino] pentanamide

    TLC: Rf 0.27 (CHCl 3: MeOH: Acetic Acid: Water = 100: 10: 1: 1);
    NMR (d 6 -DMSO): δ 10.31 (1H, brs), 8.69 (1H, brs), 8.29 (1H, brs), 7.83 (2H, d, J = 8.7 Hz), 7.51 (2H, d, J = 8.4 Hz), 7.16 (2H, t, J = 8.0 Hz). 7.03 (2H, d. J = 8.7 Hz), 6.97 (1H, t, J = 7.5 Hz), 5.05 (2H, s), 4.54 (2H, s), 3.98-4.13 (1H, m), 3.42-3.52 (2H, m), 3.21 (3H, s), 1.62-2.02 (4H, m).
    Example 49 (28)
    N-hydroxy-5-benzyloxymethoxy-4 (S)-[N- [4- (3-phenoxy-1-propynyl) phenylcarbonyl] amino] pentanamide

    TLC: Rf 0.47 (CHCl 3: MeOH = 9: 1);
    NMR (d 6 -DMSO): δ 10.34 (1H, s), 8.67 (1H, s), 8.35 (1H, d, J = 8.0 Hz), 7.85 (2H, d, J = 8.4 Hz), 7.52 (2H , d, J = 8.4 Hz), 7.37-7.25 (7H, m), 7.07-6.94 (3H, m), 5.06 (2H, s), 4.70 (2H, s), 4.51 (2H, s), 4.01- 3.98 (1H, m), 3.56 (2H, d, J = 6.0 Hz), 2.09-1.58 (4H, m).
    Example 49 (29)
    N-hydroxy-5-methoxymethoxy-4 (S)-[N- (4-phenoxyphenylcarbonyl) amino] pentanamide

    TLC: Rf 0.36 (CHCl 3: MeOH: Acetic Acid: Water = 100: 10: 1: 1);
    NMR (d 6 -DMSO): δ 10.33 (1H, s), 8.66 (1H, s), 8.16 (1H, d, J = 8.4 Hz), 7.87 (2H, d, J = 8.8 Hz), 7.46-7.38 (2H, m), 7.22-7.15 (2H, m), 7.07-6.99 (3H, m), 4.54 (2H, s), 4.19-3.94 (1H, m), 3.49-3.45 (2H, m), 3.22 (3H, s), 2.07-1.57 (4H, m).
    Example 49 (30)
    N-hydroxy-5-methoxymethoxy-4 (S)-[N- [4- (4-chlorophenyl) phenylcarbonyl] amino] pentanamide

    TLC: Rf 0.28 (CHCl 3: MeOH = 9: 1);
    NMR (d 6 -DMSO): δ 10.37 (1H, s), 8.31 (1H, d, J = 8.2 Hz), 7.97 (2H, d, J = 8.6 Hz), 7.81-7.75 (4H, m), 7.55 (2H, d, J = 8.6 Hz), 4.58 (2H, s), 4.19-4.03 (1H, m), 3.56-3.49 (2H, m), 3.25 (3H, s), 2.09-1.77 (4H, m ).
    Example 49 (31)
    N-hydroxy-5-methoxymethoxy-4 (S)-[N- [4- [2- (4-methylphenyl) ethynyl] phenylcarbonyl] amino] pentanamide

    TLC: Rf 0.37 (CHCl 3: MeOH: Acetic Acid: Water = 100: 10: 1: 1);
    NMR (d 6 -DMSO): δ 10.35 (1H, brs.), 8.67 (1H, brs.), 8.33 (1H, d, J = 8.6 Hz), 7.89 (2H, d, J = 8.4 Hz), 7.62 (2H, d, J = 8.4 Hz), 7.47 (2H, d, J = 8.2 Hz), 7.25 (2H, d, J = 8.2 Hz), 4.56 (2H, s), 4.19-3.98 (1H, m) , 3.56-3.42 (2H, m), 3.23 (3H, s), 2.34 (3H, s), 2.09-1.58 (4H, m).
    Example 49 (32)
    N-hydroxy-5-methoxymethoxy-4 (S)-[N- [4- [2E- (4-chlorophenyl) ethenyl] phenylcarbonyl] amino] pentanamide

    TLC: Rf 0.38 (CHCl 3: MeOH = 9: 1);
    NMR (d 6 -DMSO): δ 10.35 (1H, brs.), 8.67 (1H, brs.), 8.23 (1H, d, J = 8.6 Hz). 7.87 (2H, d, J = 8.2 Hz), 7.68 (2H, d, J = 8.4 Hz), 7.66 (2H, d, J = 8.4 Hz), 7.41 (2H, d, J = 8.2 Hz), 7.40 ( 1H, d, J = 17.8 Hz, 7.31 (1H, d, J = 17.8 Hz), 4.56 (2H, s), 4.19-3.98 (1H, m), 3.58-3.41 (2H, m), 3.23 (3H , s), 2.11-1.56 (4H, m).
    Example 49 (33)
    N-hydroxy-5-methoxymethoxy-4 (S)-[N- [4- (1-heptinyl) phenylcarbonyl] amino] pentanamide

    TLC: Rf 0.46 (CHCl 3: MeOH = 9: 1);
    NMR (d 6 -DMSO): δ 10.34 (1H, s), 8.67 (1H, s), 8.27 (1H, d, J = 8.4 Hz), 7.82 (2H, d, J = 8.2 Hz), 7.45 (2H , d, J = 8.2 Hz), 4.55 (2H, s), 4.18-3.97 (1H, m), 3.57-3.41 (2H, m), 3.22 (3H, s), 2.49-2.40 (2H, m), 2.04-1.22 (10H, m), 0.88 (3H, t, J = 6.8 Hz).
    Example 49 (34)
    N-hydroxy-5-ethoxymethoxy-4 (S)-[N- (4-phenoxyphenylcarbonyl) amino] pentanamide

    TLC: Rf 0.34 (CHCl 3: MeOH = 9: 1);
    NMR (d 6 -DMSO): δ 10.36 (s, 1H), 8.68 (s, 1H), 8.17 (d, J = 8.4Hz, 1H), 7.89 (d, J = 8.9Hz, 2H), 7.43 (dd , J = 8.5, 7.5 Hz, 2H), 7.20 (t, J = 7.5 Hz, 1H), 7.07 (dd, J = 1.1, 8.5 Hz, 2H), 7.03 (d, J = 8.9 Hz, 2H), 4.61 (s, 2H), 4.15-4.00 (m, 1H), 3.60-3.40 (m, 4H), 2.10-1.95 (m, 2H), 1.95-1.80 (m, 1H), 1.80-1.60 (m, 1H) , 1.11 (t, J = 7.1 Hz, 3H).
    Example 49 (35)
    N-hydroxy-5-ethoxymethoxy-4 (S)-[N- (4-methylphenylcarbonyl) amino] pentanamide

    TLC: Rf 0.30 (CHCl 3: MeOH = 9: 1);
    NMR (d 6 -DMSO): δ 10.32 (s, 1H), 8.65 (s.1H), 8.10 (d, J = 8.4Hz, 1H), 7.73 (d, J = 8.3Hz, 2H), 7.22 (d , J = 8.3 Hz, 2H), 4.57 (s, 2H), 4.10-3.98 (m, 1H), 3.52-3.40 (m, 4H), 2.32 (s, 3H), 2.01-1.94 (m, 2H), 1.91-1.78 (m, 1H), 1.73-1.61 (m, 1H), 1.05 (t, J = 7.1 Hz, 3H).
    Example 49 (36)
    N-hydroxy-5-methoxymethoxy-4 (R)-[N- [4- (3-methoxy-1-propynyl) phenylcarbonyl] amino] pentanamide

    Example 37 → Example 39 using 4 (R) -carboxy-4-aminobutanoic acid methyl ester and the corresponding compound instead of Reference Example 4 instead of 4 (S) -carboxy-4-aminobutanoic acid methyl ester Example 41 → Example 42 → Operation in the same manner as in Example 49, to obtain the title compound having the following physical properties.
    TLC: Rf 0.25 (chloroform: methanol: acetic acid: water = 100: 10: 1: 1);
    NMR (CD 3 OD)): δ 8.32 (1H, d, J = 8.8 Hz), 7.82 (2H, d, J = 8.8 Hz), 7.52 (2H, d, J = 8.8 Hz), 4.62 (2H, s ), 4.34 (2H, s), 4.16-4.31 (1H, m), 3.62 (2H, d, J = 5.6 Hz), 3.43 (3H, s), 3.33 (3H, s), 2.20 (2H, t, J = 7.0 Hz), 1.17-2.11 (2H, m).
    Examples 49 (37) -49 (67)
    Example 37-Example 43 (using methyl iodide instead of benzyl bromide)-Example 44-Example 49 using equivalent compounds instead of the compounds prepared in Reference Example 4 It operated in the same manner as the method to obtain the compound shown below.
    Example 49 (37)
    N-hydroxy-2 (S) -methyl-5-methoxymethoxy-4 (S)-[N- [4- [2- (4-imidazolylphenyl) ethynyl] phenylcarbonyl] amino] Pentanamide

    TLC: Rf 0.33 (CHCl 3: MeOH = 10: 1);
    NMR (d 6 -DMSO): δ 10.40 (1H, brs), 8.68 (1H, brs), 8.36 (1H, s), 8.24 (1H, d, J = 9.0 Hz), 7.91 (2H, d, J = 8.4 Hz), 7.84 (1H, brs), 7.77 (2H, d, J = 9.0 Hz), 7.72 (2H, d, J = 9.0 Hz), 7.66 (2H, d, J = 8.4 Hz), 7.13 (1H) , brs), 4.56 (2H, s), 4.22-4.11 (1H, m), 3.54-3.44 (2H, m), 3.23 (3H, s), 2.25-2.14 (1H, m), 1.76-1.61 (2H m), 1.03 (3H, d, J = 6.6 Hz).
    Example 49 (38)
    N-hydroxy-2 (S) -methyl-5-methoxymethoxy-4 (S)-[N- [4- (4-phenyl-1,2,5,6-tetrahydropyridin-1-yl ) Phenylcarbonyl] amino] pentanamide

    TLC: Rf 0.32 (CHCl 3: MeOH = 9: 1):
    NMR (d 6 -DMSO): δ 10.39 (1H, brs), 8.67 (1H, brs), 7.90-7.70 (3H, m), 7.49 (2H, d, J = 7.5 Hz), 7.37 (2H, t, J = 7.5 Hz), 7.27 (1H, t, J = 7.5 Hz), 6.99 (2H, d, J = 9.0 Hz), 6.35-6.25 (1H, brs), 4.56 (2H, s), 4.25-4.05 ( 1H, m), 4.00-3.90 (2H, m), 3.59 (2H, t, J = 5.4 Hz), 3.55-3.40 (2H, m), 3.24 (3H, s), 2.70-2.55 (2H, m) , 2.30-2.10 (1H, m), 1.80-1.60 (2H, m), 1.03 (3H, d, J = 6.9 Hz).
    Example 49 (39)
    N-hydroxy-2 (S) -methyl-5-methoxymethoxy-4 (S)-[N- (4-phenoxyphenylcarbonyl) amino] pentanamide

    TLC: Rf 0.49 (CHCl 3: MeOH: Acetic Acid: Water = 100: 10: 1: 1);
    NMR (d 6 -DMSO): δ 10.38 (1H, d, J = 1.5 Hz), 8.66 (1H, d, J = 1.5 Hz), 8.05 (1H, d, J = 8.4 Hz), 7.88 (2H, d , J = 8.7 Hz), 7.45-7.40 (2H, m), 7.22-7.17 (1H, m), 7.08-7.01 (4H, m), 4.55 (2H, s), 4.21-4.08 (1H, m), 3.52-3.44 (2H, m), 3.22 (3H, s), 2.25-2.09 (1H, m), 1.67 (2H, t, J = 7.2 Hz), 1.01 (3H, d, J = 6.6 Hz).
    Example 49 (40)
    N-hydroxy-2 (S) -methyl-5-methoxymethoxy-4 (S)-[N- [4- [2- (4-chlorophenyl) ethenyl] phenylcarbonyl] amino] pentanamide

    TLC: Rf 0.41 (CHCl 3: MeOH: Acetic Acid: Water = 100: 10: 1: 1); .
    NMR (d 6 -DMSO): δ 10.39 (1H, s), 8.67 (1H, s), 8.10 (1H, d, J = 8.6 Hz), 7.86 (2H, d, J = 8.4 Hz), 7.70-7.63 (4H, m), 7.45 (2H, d, J = 8.6 Hz), 7.40 (1H, d, J = 16.6 Hz), 7.31 (1H, d, J = 16.6 Hz), 4.56 (2H, s), 4.25 -4.08 (1H, m), 3.57-3.41 (2H, m), 3.23 (3H, s), 2.25-2.15 (1H, m), 1.68 (2H, t, J = 6.6 Hz), 1.02 (3H, d , J = 7.0 Hz).
    Example 49 (41)
    N-hydroxy-2 (S) -methyl-5-methoxymethoxy-4 (S)-[N- [4- (4-propylphenyl) phenylcarbonyl] amino] pentanamide

    TLC: Rf 0.31 (CHCl 3: MeOH = 10: 1);
    NMR (d 6 -DMSO): δ 10.39 (1H, brs), 8.67 (1H, brs), 8.14 (1H, d, J = 8.7 Hz), 7.93 (2H, d, J = 8.4 Hz), 7.73 (2H , d, J = 8.4 Hz), 7.63 (2H, d, J = 8.1 Hz), 7.30 (2H, d, J = 8.1 Hz), 4.56 (2H, s), 4.24-4.12 (1H, m), 3.55 -3.44 (2H, m), 3.23 (3H, s), 2.59 (2H, t, J = 7.2 Hz), 2.26-2.35 (1H, m), 1.73-1.65 (2H, m), 1.61 (2H, m) ), 1.03 (3H, d, J = 6.9 Hz), 0.91 (3H, t, J = 7.2 Hz).
    Example 49 (42)
    N-hydroxy-2 (S) -methyl-5-methoxymethoxy-4 (S)-[N- [4- (benzothiophen-2-yl) phenylcarbonyl] amino] pentanamide

    TLC: Rf 0.33 (CHCl 3: MeOH = 10: 1);
    NMR (d 6 -DMSO): δ 10.40 (1H, brs), 8.68 (1H, brs), 8.19 (1H, d, J = 9.0 Hz), 8.01-7.94 (4H, m), 7.88-7.85 (3H, m), 7.44-44-7.35 (2H, m), 4.57 (2H, s), 4.24-4.12 (1H, m), 3.55-3.45 (2H, m), 3.24 (3H, s), 2.26-2.15 ( 1H, m), 1.77-1.62 (2H, m), 1.04 (3H, d, J = 6.6 Hz).
    Example 49 (43)
    N-hydroxy-2 (S) -methyl-5-methoxymethoxy-4 (S)-[N- [4- (3-methoxyphenoxy) phenylcarbonyl] amino] pentanamide

    TLC: Rf 0.38 (CHCl 3: MeOH: Acetic Acid: Water = 100: 10: 1: 1);
    NMR (d 6 -DMSO): δ 10.36 (s, 1H), 8.67 (s, 1H), 7.87 (d, J = 8.8Hz, 2H), 7.32 (m, 1H), 7.05 (d, J = 8.8Hz , 2H), 6.77 (m, 1H), 6.63 (m, 1H), 6.60 (m, 1H), 4.55 (s, 2H), 4.15 (m, 1H), 3.74 (s, 3H), 3.22 (s, 3H), 2.18 (m, 1H), 1.66 (m, 2H), 1.02 (d, J = 6.6 Hz, 3H).
    Example 49 (44)
    N-hydroxy-2 (S) -methyl-5-methoxymethoxy-4 (S)-[N- [4- (4-methoxyphenoxy) phenylcarbonyl] amino] pentanamide

    TLC: Rf 0.45 (CHCl 3: MeOH = 9: 1);
    NMR (d 6 -DMSO): δ 10.50-10.20 (br, 1H), 8.80-8.50 (br, 1H), 8.01 (d, J = 8.4 Hz, 1H), 7.85 (d, J = 8.7 Hz, 2H) , 7.05 (d, J = 9.2 Hz, 2H), 6.99 (d, J = 9.2 Hz, 2H), 6.94 (d, J = 8.7 Hz, 2H), 4.56 (s, 2H), 4.25-4.05 (m, 1H), 3.77 (s, 3H), 3.55-3.40 (m, 2H), 3.23 (s, 3H), 2.30-2.10 (m, 1H), 1.80-1.60 (m, 2H), 1.02 (d, J = 6.9 Hz, 3H).
    Example 49 (45)
    N-hydroxy-2 (S) -methyl-5-methoxymethoxy-4 (S)-[N- (4-benzoylphenylcarbonyl) amino] pentanamide

    TLC: Rf 0.36 (CHCl 3: MeOH = 9: 1);
    NMR (d 6 -DMSO): δ 10.38 (1H, s), 8.66 (1H, s), 8.31 (1H, d, J = 8.1 Hz), 7.98 (2H, d, J = 8.7 Hz), 7.79-7.65 (5H, m), 7.55 (2H, t, J = 7.5 Hz), 4.55 (2H, s), 4.24-4.12 (1H, m), 3.52-3.42 (2H, m), 3.21 (3H, s), 2.25-2.13 (1H, m), 1.71-1.63 (2H, m), 1.01 (3H, d, J = 6.9 Hz).
    Example 49 (46)
    N-hydroxy-2 (S) -methyl-5-methoxymethoxy-4 (S)-[N- [4- (naphthalan-2-yl) phenylcarbonyl] amino] pentanamide

    TLC: Rf 0.31 (CHCl 3: MeOH: Acetic Acid: Water = 100: 10: 1: 1);
    NMR (d 6 -DMSO): δ 10.41 (br, 1H), 8.68 (br, 1H), 8.30 (s, 1H), 8.05-7.9 (m, 8H), 7.6-7.5 (m, 2H), 4.58 ( s, 2H), 4.20 (m, 1H), 3.51 (m, 2H), 3.24 (s, 3H), 2.01 (m, 1H), 1.72 (m, 2H), 1.04 (d, J = 6.6 Hz, 3H ).
    Example 49 (47)
    N-hydroxy-2 (S) -methyl-5-methoxymethoxy-4 (S)-[N- [4-[(4-methoxybiphenyl-4'-yl) oxy] phenylcarbonyl] amino ] Pentanamide

    TLC: Rf 0.34 (CHCl 3: MeOH = 9: 1);
    NMR (d 6 -DMSO): δ 10.60-10.35 (br, 1H), 8.80-8.60 (br, 1H), 8.11 (d, J = 8.4Hz, 1H), 7.94 (d, J = 8.4Hz, 2H) , 7.66 (d, J = 8.8 Hz, 2H), 7.59 (d, J = 8.8 Hz, 2H), 7.20-6.95 (m, 6H), 4.57 (s, 2H), 4.30-4.10 (m, 1H), 3.81 (s, 3H), 3.60-3.40 (m, 2H), 3.25 (s, 3H), 2.40-2.10 (m, 1H), 1.90-1.60 (m, 2H), 1.04 (d, J = 6.6 Hz, 3H).
    Example 49 (48)
    N-hydroxy-2 (S) -methyl-5-methoxymethoxy-4 (S)-[N- [4- (4-ethoxyphenyl) phenylcarbonyl] amino] pentanamide

    TLC: Rf 0.41 (CHCl 3: MeOH = 10: 1);
    NMR (d 6 -DMSO): δ 10.39 (1H, brs), 8.67 (1H, brs), 8.11 (1H, d, J = 8.7 Hz), 7.91 (2H, d, J = 8.1 Hz), 7.70 (2H , d, J = 8.1 Hz), 7.66 (2H, d, J = 8.7 Hz), 7.02 (2H, d, J = 8.7 Hz), 4.56 (2H, s), 4.24-4.12 (1H, m), 4.07 (2H, q, J = 6.9 Hz). 3.54-3.44 (2H, m), 3.23 (3H, s), 2.26-2.34 (1H, m), 1.73-1.65 (2H, m), 1.34 (3H, t, J = 6.9 Hz), 1.03 (3H, d, J = 6.9 Hz).
    Example 49 (49)
    N-hydroxy-2 (S) -methyl-5-methoxymethoxy-4 (S)-[N- [4- (4-phenoxyphenyl) phenylcarbonyl] amino] pentanamide

    TLC: Rf 0.43 (CHCl 3: MeOH = 10: 1);
    NMR (d 6 -DMSO): δ 10.40 (1H, brs), 8.67 (1H, brs), 8.14 (1H, d, J = 8.6 Hz), 7.94 (2H, d, J = 8.4 Hz), 7.75 (2H , d, J = 8.8 Hz), 7.74 (2H, d, J = 8.4 Hz), 7.46-7.38 (2H, m), 7.21-7.05 (3H, m), 7.10 (2H, d, J = 8.8 Hz) , 4.57 (2H, s), 4.27-4.10 (1H, m), 3.58-3.42 (2H, m), 3.23 (3H, s), 2.29-2.12 (1H, m), 1.73-1.66 (2H, m) , 1.03 (3H, doublet, J = 6.6 Hz).
    Example 49 (50)
    N-hydroxy-2 (S) -methyl-5-methoxymethoxy-4 (S)-[N- [4- (3-cyanomethylphenyl) phenylcarbonyl] amino] pentanamide

    TLC: Rf 0.40 (CHCl 3: MeOH = 10: 1);
    NMR (d 6 -DMSO): δ 10.40 (1H, brs), 8.67 (1H, brs), 8.18 (1H, d, J = 8.7 Hz), 7.96 (2H, d, J = 8.4 Hz), 7.76 (2H , d, J = 8.4 Hz), 7.70 (1H, s), 7.69 (1H, d, J = 7.8 Hz), 7.52 (1H, t, J = 7.8 Hz), 7.39 (1H, d, J = 7.8 Hz ), 4.57 (2H, s), 4.24-4.13 (1H, m), 4.11 (2H, s), 3.52 (1H, dd, J = 5.3, 9.9 Hz), 3.47 (1H, dd, J = 6.0, 9.9 Hz), 3.23 (3H, s), 2.27-2.34 (1H, m), 1.77-1.62 (2H, m), 1.03 (3H, d, J = 6.6 Hz).
    Example 49 (51)
    N-hydroxy-2 (S) -methyl-5-methoxymethoxy-4 (S)-[N- [4- (biphenyl-4-yl) phenylcarbonyl] amino] pentanamide

    TLC: Rf 0.26 (CHCl 3: MeOH: Acetic Acid: Water = 100: 10: 1: 1);
    NMR (d 6 -DMSO): δ 10.40 (br, 1H), 8.67 (br, 1H), 8.18 (d, J = 8.8 Hz, 1H), 7.96 (d, J = 8.5 Hz, 2H), 7.85-7.75 (m, 6H), 7.73 (m, 2H), 7.49 (m, 2H), 7.39 (m, 1H), 4.57 (s, 2H), 4.19 (m, 1H), 3.50 (m, 2H), 3.24 ( s, 3H), 2.21 (m, 1H), 1.70 (m, 2H), 1.03 (d, J = 6.6 Hz, 3H).
    Example 49 (52)
    N-hydroxy-2 (S) -methyl-5-methoxymethoxy-4 (S)-[N- [4- (3-hydroxyphenoxy) phenylcarbonyl] amino] pentanamide

    TLC: Rf 0.17 (CHCl 3: MeOH: Acid: Water = 100: 10: 1: 1);
    NMR (d 6 -DMSO): δ 10.32 (br, 1H), 8.67 (br, 1H), 8.04 (d, J = 8.8 Hz, 1H), 7.87 (d, J = 8.8 Hz, 2H), 7.18 (t , J = 8.2 Hz, 1H), 7.02 (d, J = 8.8 Hz, 2H), 6.58 (m, 1H), 6.45 (m, 1H), 6.40 (m, 1H), 4.55 (s, 2H), 4.15 (m, 1H), 3.47 (m, 2H), 3.22 (s, 3H), 2.07 (m, 1H), 1.66 (m, 2H), 1.01 (d, J = 6.9 Hz, 3H).
    Example 49 (53)
    N-hydroxy-2 (S) -methyl-5-methoxymethoxy-4 (S)-[N- [4- [2- (4-methylphenyl) ethynyl] phenylcarbonyl] amino] pentanamide

    TLC: Rf 0.23 (chloroform: methanol = 19: 1);
    NMR (d 6 -DMSO): δ 10.40 (1H, s), 8.21 (1H, d, J = 8.4 Hz), 7.90 (2H, d, J = 8.4 Hz), 7.61 (2H, d. J = 8.4 Hz ), 7.47 (2H, d.J = 8.0 Hz), 7.25 (2H, d, J = 8.0 Hz), 4.57 (2H, s), 4.30-4.10 (1H, m), 3.60-3.40 (2H, m) , 3.24 (3H, s), 2.35 (3H, s), 2.28-2.10 (1H, m), 1.78-1.60 (2H, m), 1.04 (3H, d, J = 7.0 Hz).
    Example 49 (54)
    N-hydroxy-2 (S) -methyl-5-methoxymethoxy-4 (S)-[N- [4- (4-hydroxyphenoxy) phenylcarbonyl] amino] pentanamide

    TLC: Rf 0.23 (CHCl 3: MeOH = 9: 1);
    NMR (d 6 -DMSO): δ 10.38 (s, 1H), 9.41 (s, 1H), 8.67 (s, 1H), 7.98 (d, J = 8.7Hz, 1H), 7.84 (d, J = 8.9Hz , 2H), 6.95-6.85 (m, 4H), 6.81 (d, J = 8.9 Hz, 2H), 4.56 (s, 2H), 4.25-4.10 (m, 1H), 3.55-3.40 (m, 2H), 3.24 (s, 3H), 2.25-2.10 (m, 1H), 1.70-1.60 (m, 2H), 1.03 (d, J = 6.9 Hz, 3H).
    Example 49 (55)
    N-hydroxy-2 (S) -methyl-5-methoxymethoxy-4 (S)-[N- [4- (4-chlorophenyl) phenylcarbonyl] amino] pentanamide

    TLC: Rf 0.39 (CHCl 3: MeOH = 10: 1);
    NMR (d 6 -DMSO): δ 10.40 (1H, d, J = 1.8 Hz), 8.67 (1H, d, J = 1.8 Hz), 8.18 (1H, d, J = 8.4 Hz), 7.95 (2H, d , J = 8.4 Hz), 7.76 (2H, d, J = 8.4 Hz), 7.76 (2H, d, J = 8.7 Hz), 7.54 (2H, d, J = 8.7 Hz), 4.56 (2H, s), 4.24-4.12 (1H, m), 3.55-3.4 (2H, m), 3.23 (3H, s), 2.26-2.14 (1H, m), 1.77-1.62 (2H, m), 1.03 (3H, d, J = 6.9 Hz).
    Example 49 (56)
    N-hydroxy-2 (S) -methyl-5-methoxymethoxy-4 (S)-[N-[[5- (4-methoxyphenyl) -2-thienyl] carbonyl] amino] pentane amides

    TLC: Rf 0.29 (CHCl 3: MeOH = 9: 1);
    NMR (d 6 -DMSO): δ 10.41 (s, 1H), 8.69 (s, 1H), 8.14 (d, J = 8.7Hz, 1H), 7.75 (d, J = 3.9Hz, 1H), 7.63 (d , J = 8.7 Hz, 2H), 7.39 (d, J = 3.9 Hz, 1H), 7.00 (d, J = 8.7 Hz, 2H), 4.57 (s, 2H), 4.20-4.00 (m, 1H), 3.80 (s, 3H), 3.55-3.45 (m, 2H), 3.25 (s, 3H), 2.30-2.15 (m, 1H), 1.68 (t, J = 7.2 Hz, 2H), 1.04 (d, J = 6.9 Hz, 3H).
    Example 49 (57)
    N-hydroxy-2 (S) -methyl-5-methoxymethoxy-4 (S)-[N- [4-[(biphenyl-3-yl) oxy] phenylcarbonyl] amino] pentanamide

    TLC: Rf 0.42 (CHCl 3: MeOH: Acetic Acid = 100: 10: 1);
    NMR (d 6 -DMSO): δ 10.38 (1H, s), 8.66 (1H, s), 8.06 (1H, d, J = 8.4 Hz), 7.90 (2H, d, J = 8.4 Hz), 7.68-7.63 (2H, m), 7.52-7.33 (6H, m), 7.12-7.00 (3H, m), 4.55 (2H, s), 4.24-4.05 (1H, m), 3.54-3.40 (2H, m), 3.32 (3H, s), 2.15-2.25 (1H, m), 1.67 (2H, t, J = 7.0 Hz), 1.01 (3H, d, J = 7.0 Hz).
    Example 49 (58)
    N-hydroxy-2 (S) -methyl-5-methoxymethoxy-4 (S)-[N- [4- (1-heptinyl) phenylcarbonyl] amino] pentanamide

    TLC: Rf 0.49 (CHCl 3: MeOH = 9: 1);
    NMR (d 6 -DMSO): δ 10.38 (1H, s), 8.66 (1H, s), 8.13 (1H, d, J = 8.8 Hz), 7.82 (2H, d, J = 8.4 Hz), 7.44 (2H , d, J = 8.4 Hz), 4.56 (2H, s), 4.28-4.06 (1H, m), 3.60-3.40 (2H, m), 3.23 (3H, s), 2.43 (2H, t, J = 6.8 Hz), 2.27-2.10 (1H, m), 1.74-1.46 (4H, m), 1.45-1.20 (4H, m), 1.03 (3H, t, J = 6.6 Hz), 0.90 (3H, t, J = 7.0 Hz).
    Example 49 (59)
    N-hydroxy-2 (S) -methyl-5-methoxymethoxy-4 (S)-[N- [4- (3-phenoxy-1-propynyl) phenylcarbonyl] amino] pentanamide

    TLC: Rf 0.49 (CHCl 3: MeOH = 9: 1);
    NMR (d 6 -DMSO): δ 10.38 (1H, s), 8.66 (1H, s), 8.20 (1H, d, J = 8.7Hz), 7.85 (2H, d, J = 8.4Hz), 7.52 (2H , d, J = 8.4 Hz), 7.37-7.29 (2H, m), 7.08-6.96 (3H, m), 5.06 (2H, s), 4.55 (2H, s), 4.22-4.10 (1H, m), 3.55-3.40 (2H, m), 3.22 (3H, s), 2.24-2.12 (1H, m), 1.67-1.58 (2H, m), 1.02 (3H, d, J = 6.9 Hz).
    Example 49 (60)
    N-hydroxy-2 (S) -methyl-5-methoxymethoxy-4 (S)-[N- [4- (4-cyanophenyl) phenylcarbonyl] amino] pentanamide

    TLC: Rf 0.34 (CHCl 3: MeOH = 10: 1);
    NMR (d 6 -DMSO): δ 10.40 (1H, d, J = 1.5 Hz), 8.67 (1H, d, J = 1.5 Hz), 8.22 (1H, d, J = 8.7 Hz), 7.98 (2H, d , J = 8.4 Hz), 7.95 (4H, s), 7.85 (2H, d, J = 8.4 Hz), 4.56 (2H, s), 4.24-4.32 (1H, m), 3.55-3.45 (2H, m) , 3.23 (3H, s), 2.26-2.15 (1H, m), 1.77-1.62 (2H, m), 1.03 (3H, d, J = 6.9 Hz).
    Example 49 (61)
    N-hydroxy-2 (S) -methyl-5-methoxymethoxy-4 (S)-[N- [4- (3-cyanophenyl) phenylcarbonyl] amino] pentanamide

    TLC: Rf 0.35 (CHCl 3: MeOH = 10: 1);
    NMR (d 6 -DMSO): δ 10.40 (1H, d, J = 1.5 Hz), 8.67 (1H, d, J = 1.5 Hz), 8.24 (1H, t, J = 1.5 Hz), 8.21 (1H, d , J = 8.7 Hz), 8.10-8.07 (1H, m), 7.97 (2H, d, J = 8.4 Hz), 7.88-7.84 (1H, m), 7.85 (2H, d, J = 8.4 Hz), 7.69 (1H, t, J = 7.8 Hz), 4.57 (2H, s), 4.24-4.13 (1H, m), 3.55-3.45 (2H, m), 3.23 (3H, s), 2.26-2.15 (1H, m ), 1.77-1.62 (2H, m), 1.03 (3H, d, J = 6.9 Hz).
    Example 49 (62)
    N-hydroxy-2 (S) -methyl-5-methoxymethoxy-4 (S)-[N- (4-benzylphenylcarbonyl) amino] pentanamide

    TLC: Rf 0.43 (CHCl 3: MeOH = 9: 1);
    NMR (d 6 -DMSO): δ 10.34 (1H, s), 8.64 (1H, s), 7.98 (1H, d, J = 8.4 Hz), 7.74 (2H, d, J = 8.1 Hz), 7.30-7.12 (7H, m), 4.52 (2H, s), 4.16-4.07 (1H, m), 3.96 (2H, s), 3.50-3.38 (2H, m), 3.19 (3H, s), 2.19-2.09 (1H) m), 1.64 (2H, t, J = 7.4 Hz), 0.98 (3H, d, J = 6.6 Hz).
    Example 49 (63)
    N-hydroxy-2 (S) -methyl-5-methoxymethoxy-4 (S)-[N- [4- [2E- (pyridin-4-yl) ethenyl] phenylcarbonyl] amino] pentane amides

    TLC: Rf 0.18 (CHCl 3: MeOH: Acetic Acid = 100: 10: 1);
    NMR (d 6 -DMSO): δ 10.42 (1H, s), 8.67 (1H, d, J = 1.5 Hz), 8.56 (2H, d, J = 6.0 Hz), 8.16 (1H, d, J = 8.4 Hz ), 7.89 (2H, d, J = 8.4 Hz), 7.73 (2H, d, J = 8.4 Hz), 7.59 (1H, d, J = 16.5 Hz), 7.57 (2H, d, J = 6.0 Hz), 7.36 (1H, d, J = 16.5 Hz), 4.56 (2H, s), 4.23-4.08 (1H, m), 3.54-3.44 (2H, m), 3.22 (3H, s), 2.28-2.15 (1H, m), 1.72-1.66 (2H, m), 1.02 (3H, d, J = 6.6 Hz).
    Example 49 (64)
    N-hydroxy-2 (S) -methyl-5-methoxymethoxy-4 (S)-[N- [4- (benzooxazol-2-yl) phenylcarbonyl] amino] pentanamide

    TLC: Rf 0.28 (CHCl 3: MeOH = 10: 1);
    NMR (d 6 -DMSO): δ 10.41 (1H, bs), 8.68 (1H, brs), 8.35 (1H, d, J = 8.8 Hz), 8.28 (2H, d, J = 8.4 Hz), 8.07 (2H , d, J = 8.4 Hz), 7.86-7.80 (2H, m), 7.51-7.38 (2H, m), 4.57 (2H, s), 4.28-4.11 (1H, m), 3.59-3.42 (2H, m ), 3.24 (3H, s), 2.30-2.13 (1H, m), 1.81-1.59 (2H, m), 1.04 (3H, d, J = 6.6 Hz).
    Example 49 (65)
    N-hydroxy-2 (S) -methyl-5-methoxymethoxy-4 (S)-[N- [4- (3-ethoxyphenyl) phenylcarbonyl] amino] pentanamide

    TLC: Rf 0.35 (CHCl 3: MeOH = 10: 1);
    NMR (d 6 -DMSO): δ 10.39 (brs, 1 H), 8.67 (brs, 1 H), 8.16 (d, J = 8.4 Hz, 1H), 7.93 (d, J = 8.12 Hz, 2H), 7.75 (d , J = 8.1 Hz, 2H), 7.38 (t, J = 8.1 Hz, 1H), 7.26 (br.d, J = 8.1 Hz, 1H), 7.22 (brs, 1H), 6.96 (dd, J = 8.1, 2.1 Hz, 1H), 4.57 (s, 2H), 4.24-4.13 (m, 1H), 4.10 (q, J = 7.2 Hz, 2H), 3.55-3.45 (m, 2H), 3.23 (s, 3H), 2.26-2.14 (m, 1H), 1.77-1.62 (m, 2H), 1.35 (t, J = 7.2 Hz, 3H), 1.03 (d, J = 6.6 Hz, 3H).
    Example 49 (66)
    N-hydroxy-2 (S) -methyl-5-methoxymethoxy-4 (S)-[N- [4- (4-methylphenylcarbonylamino) phenylcarbonyl] amino] pentanamide

    TLC: Rf 0.22 (CHCl 3: MeOH = 9: 1):
    NMR (d 6 -DMSO): δ 10.38 (brs, 1H), 8.05 (d, J = 8.4 Hz, 1H), 7.96-7.84 (m, 6H), 7.34 (d, J = 8.1 Hz.2H), 4.57 (s, 2H), 4.25-4.10 (m, 1H), 3.60-3.40 (m, 2H), 3.25 (s, 3H), 2.40 (s, 3H), 2.30-2.15 (m, 1H), 1.85-1.60 (m, 2H), 1.04 (d, J = 6.9 Hz, 3H).
    Example 49 (67)
    N-hydroxy-2 (S) -methyl-5-methoxymethoxy-4 (S)-[N-[[5- [2- (4-methylphenyl) ethynyl] -2-thienyl] carbonyl ] Amino] pentanamide

    TLC: Rf 0.27 (CHCl 3: MeOH = 9: 1);
    NMR (d 6 -DMSO): δ 10.41 (s, 1H), 8.69 (s, 1H), 8.31 (d, J = 8.7Hz, 1H), 7.77 (d, J = 4.1Hz, 1H), 7.46 (d , J = 7.8Hz, 2H), 7.39 (d, J = 4.1Hz, 1H), 7.26 (d, J = 7.8Hz, 2H), 4.57 (s, 2H), 4.20-4.00 (m, 1H), 3.60 -3.40 (m, 2H), 3.24 (s, 3H), 2.35 (s, 2H), 2.20 (m, 1H), 1.68 (t, J = 7.2 Hz, 2H), 1.03 (d, J = 6.9 Hz, 3H).
    Examples 49 (68) -49 (92)
    Example 37 → Example 39 → Example 41 using the compound prepared in Examples 44 (4) to 44 (6), 44 (10) or the compound prepared in Reference Example 4 was used. Compounds obtained by operating in the same manner as described in Example 49 are used in the same manner as in Example 44 (using equivalent compound instead of oxymethyl chloride) Example 43 (using methyl iodide instead of benzyl bromide). It operated by the system and obtained the compound shown below.
    Example 49 (68)
    N-hydroxy-2 (S) -methyl-5- (2-methoxyethoxy) methoxy-4 (S)-[N- (4-phenoxyphenylcarbonyl) amino] pentanamide

    TLC: Rf 0.43 (CHCl 3: MeOH = 9: 1);
    NMR (d 6 -DMSO): δ 10.35 (1H, s), 8.64 (1H, s), 8.01 (1H, d, J = 8.7 Hz), 7.85 (2H, d, J = 8.7 Hz), 7.41 (2H , t, J = 7.7 Hz, 7.17 (1H, t, J = 7.7 Hz), 7.04 (2H, d, J = 7.7 Hz), 7.00 (2H, d, J = 8.7 Hz), 4.59 (2H, s ), 4.18-4.06 (1H, m), 3.55-3.37 (6H, m), 3.19 (3H, s), 2.15 (1H, m), 1.68-1.60 (2H, m), 0.99 (3H, d, J = 6.6 Hz).
    Example 49 (69)
    N-hydroxy-2 (S) -methyl-5-t-butylcarbonyloxy-4 (S)-[N- (4-phenoxyphenylcarbonyl) amino] pentanamide

    TLC: Rf 0.52 (CHCl 3: MeOH = 9: 1);
    NMR (d 6 -DMSO): δ 10.38 (1H, s), 8.07 (1H, d, J = 9.0Hz), 7.82 (2H, d, J = 8.7Hz), 7.41 (2H, t, J = 7.7Hz ), 7.18 (1H, t, J = 7.7 Hz), 7.07-6.99 (4H, m), 4.30-4.18 (1H, m), 4.07-3.94 (2H, m), 2.20-2.11 (1H, m), 1.73-1.49 (2H, m), 1.06 (9H, s), 0.99 (3H, d, J = 6.6 Hz).
    Example 49 (70)
    N-hydroxy-2 (S) -methyl-5-benzyloxymethoxy-4 (S)-[N- (4-phenoxyphenylcarbonyl) amino] pentanamide

    TLC: Rf 0.40 (CHCl 3: MeOH: Acetic Acid: Water = 100: 10: 1: 1);
    NMR (d 6 -DMSO): δ 10.38 (s, 1H), 8.64 (s, 1H), 8.07 (d, J = 8.5Hz, 1H), 7.88 (d, J = 8.8Hz, 2H), 7.45-7.4 (m, 2H), 7.35-7.25 (m, 5H), 7.19 (t, J = 7.4 Hz, 1H), 7.05 (d, J = 8.8 Hz, 2H), 7.01 (d, J = 8.5 Hz, 2H) , 4.70 (s, 2H), 4.50 (s, 2H), 4.18 (m, 1H), 3.58 (d, J = 11.3 Hz, 1H), 3.53 (d, J = 11.3 Hz, 1H), 2.19 (m, 1H), 1.30 (m, 2H), 1.01 (d, J = 6.9 Hz, 3H).
    Example 49 (71)
    N-hydroxy-2 (S) -methyl-5-ethoxymethoxy-4 (S)-[N- (trans-4-methylcyclohexylcarbonyl) amino] pentanamide

    TLC: Rf 0.39 (CHCl 3: MeOH = 10: 1);
    NMR (d 6 -DMSO): δ 10.37 (brs, 1 H), 8.66 (brs, 1 H), 7.39 (d, J = 8.4 Hz, 1 H), 4.56 (s, 2H), 3.89-3.77 (m, 1 H) , 3.47 (q, J = 7.2 Hz, 2H), 3.38-3.28 (m, 2H), 2.14-1.92 (m, 2H), 1.74-1.59 (m, 4H), 1.56-1.46 (m, 2H), 1.40 -1.21 (m, 3H), 1.10 (t, J = 7.2 Hz, 3H), 0.95 (d, J = 6.9 Hz, 3H), 0.93-0.78 (m, 2H), 0.84 (d, J = 6.6 Hz, 3H).
    Example 49 (72)
    N-hydroxy-2 (S) -methyl-5-ethoxymethoxy-4 (S)-[N- (4-methylphenylcarbonyl) amino] pentanamide

    TLC: Rf 0.29 (CHCl 3: MeOH = 9: 1);
    NMR (d 6 -DMSO): δ 10.35 (s, 1H), 8.63 (brs, 1H), 7.95 (d, J = 8.8Hz, 1H), 7.72 (d, J = 8.0Hz, 2H), 7.22 (d , J = 8.0 Hz, 2H), 4.58 (s, 2H), 4.18-4.04 (m, 1H), 3.53-3.39 (m, 4H), 2.32 (s, 3H), 2.15 (m, 1H), 1.64 ( t, J = 7.4 Hz, 2H), 1.06 (t, J = 7.1 Hz, 3H), 0.99 (d, J = 7.0 Hz, 3H).
    Example 49 (73)
    N-hydroxy-2 (S) -methyl-5-ethoxymethoxy-4 (S)-[N- (4-chlorophenylcarbonyl) amino] pentanamide

    TLC: Rf 0.44 (CHCl 3: MeOH = 9: 1);
    NMR (d 6 -DMSO): δ 10.36 (s, 1H), 8.15 (d, J = 8.4Hz, 1H), 7.83 (d, J = 8.8Hz, 2H), 7.50 (d, J = 8.8Hz, 2H ), 4.57 (s, 2H), 4.21-4.06 (m, 1H), 3.53-3.38 (m, 4H), 2.22-2.10 (m, 1H), 1.64 (t, J = 7.0 Hz, 2H), 1.06 ( t, J = 6.9 Hz, 3H), 0.99 (d, J = 6.6 Hz, 3H).
    Example 49 (74)
    N-hydroxy-2 (S) -methyl-5-ethoxymethoxy-4 (S)-[N- (adamantylcarbonyl) amino] pentanamide

    TLC: Rf 0.46 (CHCl 3: MeOH = 9: 1);
    NMR (d 6 -DMSO): δ 10.35 (s, 1H), 8.63 (s, 1H), 6.80 (d, J = 9.0Hz, 1H), 4.54 (s, 2H), 3.94-3.83 (m, 1H) , 3.43 (q, J = 7.2 Hz, 2H), 3.36-3.24 (m, 2H), 2.14-2.02 (m, 1H), 1.96-1.88 (m, 3H), 1.76-1.45 (m, 14H), 1.09 (t, J = 7.2 Hz, 3H), 0.92 (d, J = 6.6 Hz, 3H).
    Example 49 (75)
    N-hydroxy-2 (S) -methyl-5-ethoxymethoxy-4 (S)-[N- (2-furylcarbonyl) amino] pentanamide

    TLC: Rf 0.24 (CHCl 3: MeOH = 9: 1);
    NMR (d 6 -DMSO): δ 10.34 (s, 1H), 8.63 (s, 1H), 7.96 (d, J = 8.4Hz, 1H), 7.80-7.79 (m, 1H), 7.06 (d, J = 3.4 Hz, 1H), 6.58 (dd, J = 3.4 Hz, 1.7 Hz, 1H), 4.56 (s, 2H), 4.15-4.02 (m, 1H), 3.51-3.38 (m, 4H), 2.18-2.04 ( m, 1H), 1.61 (t, J = 6.2 Hz, 2H), 1.06 (t, J = 7.1 Hz, 3H), 0.97 (d, J = 6.8 Hz, 3H).
    Example 49 (76)
    N-hydroxy-2 (S) -methyl-5-ethoxymethoxy-4 (S)-[N-[(benzothiazol-6-yl) carbonyl] amino] pentanamide

    TLC: Rf 0.34 (CHCl 3: MeOH = 9: 1);
    NMR (d 6 -DMSO): δ 10.37 (s, 1H), 9.50 (s, 1H), 8.62 (d, J = 1.5Hz, 1H), 8.23 (d, J = 8.4Hz, 1H), 8.12 (d , J = 8.7 Hz, 1H), 7.97 (dd, J = 8.7 Hz, 1.9 Hz, 1H), 4.59 (s, 2H), 4.21-4.11 (m, 1H), 3.53-3.42 (m, 4H), 2.25 -2.14 (m, 1H), 1.72-1.61 (m, 2H), 1.06 (t, J = 7.2 Hz, 3H), 1.00 (d, J = 6.6 Hz, 3H).
    Example 49 (77)
    N-hydroxy-2 (S) -methyl-5-ethoxymethoxy-4 (S)-[N- (4-fluorophenylcarbonyl) amino] pentanamide

    TLC: Rf 0.34 (CHCl 3: MeOH = 9: 1);
    NMR (d 6 -DMSO): δ 10.36 (s, 1H), 8.09 (d, J = 8.7Hz, 1H), 7.88 (dd, J = 5.7Hz, 9.0Hz, 2H), 7.26 (t, J = 9.0 Hz, 2H), 4.57 (s, 2H), 4.16-4.05 (m, 1H), 3.50-3.41 (m, 4H), 2.15 (m, 1H), 1.68-1.61 (m, 2H), 1.06 (t, J = 7.0 Hz, 3H), 0.98 (d, J = 6.8 Hz, 3H).
    Example 49 (78)
    N-hydroxy-2 (S) -methyl-5-ethoxymethoxy-4 (S)-[N-[(2-bromofuryl-5-yl) carbonyl] amino] pentanamide

    TLC: Rf 0.28 (CHCl 3: MeOH = 9: 1);
    NMR (d 6 -DMSO): δ 10.35 (s, 1H), 9.64 (s.1H), 8.07 (d, J = 8.7Hz, 1H), 7.10 (d, J = 3.6Hz, 1H), 6.72 (d , J = 3.6 Hz, 1H), 4.56 (s, 2H), 4.11-4.00 (m, 1H), 3.49-3.40 (m, 4H), 2.16-2.05 (m, 1H), 1.67-1.53 (m, 2H ), 1.06 (t, J = 7.2 Hz, 3H), 0.97 (d, J = 6.3 Hz, 3H).
    Example 49 (79)
    N-hydroxy-2 (S) -methyl-5-ethoxymethoxy-4 (S)-[N- (4-nitrophenylcarbonyl) amino] pentanamide

    TLC: Rf 0.35 (CHCl 3: MeOH = 9: 1);
    NMR (d 6 -DMSO): δ 10.39 (brs, 1H), 8.66 (brs, 1H), 8.46 (brd, J = 8.8 Hz, 1H), 8.30 (d, J = 8.8 Hz, 1H), 8.06 (d , J = 8.8 Hz, 2H), 4.59 (s, 2H), 4.15 (m, 1H), 3.50 (d, J = 5.8 Hz, 1H), 3.47 (q, J = 6.8 Hz, 2H), 2.17 (m , 1H), 1.67 (m, 2H), 1.07 (t, J = 6.8 Hz, 3H), 1.02 (d, J = 6.8 Hz, 3H).
    Example 49 (80)
    N-hydroxy-2 (S) -methyl-5-ethoxymethoxy-4 (S)-[N- (4-bromophenylcarbonyl) amino] pentanamide

    TLC: Rf 0.35 (methylene chloride: methanol = 9: 1);
    NMR (d 6 -DMSO): δ 10.37 (brs, 1H), 8.65 (brs, 1H), 8.17 (brd, J = 8.4 Hz, 1H), 7.79 (d, J = 8.8 Hz, 2H), 7.66 (d , J = 8.8H 42H), 4.58 (s, 2H), 4.13 (m, 1H), 3.47 (d, J = 7.0 Hz, 2H), 3.47 (q, J = 7.0 Hz, 2H), 2.16 (m, 1H), 1.65 (m, 2H), 1.07 (t, J = 7.0 Hz, 3H), 1.01 (d, J = 6.6 Hz, 3H).
    Example 49 (81)
    N-hydroxy-2 (S) -methyl-5-ethoxymethoxy-4 (S)-[N- (4-cyanophenylcarbonyl) amino] pentanamide

    TLC: Rf 0.24 (CHCl 3: MeOH = 19: 1);
    NMR (d 6 -DMSO): δ 10.39 (s, 1H), 8.67 (s, 1H), 8.36 (d, J = 8.7Hz, 1H), 8.00 (d, J = 8.4Hz, 2H), 7.95 (d , J = 8.4 Hz, 2H), 4.60 (s, 2H), 4.22-4.08 (m, 1H), 3.58-3.40 (m, 4H), 2.23-2.12 (m, 1H), 1.78-1.58 (m, 2H ), 1.09 (t, J = 6.9 Hz, 3H), 1.03 (d, J = 6.9 Hz, 3H).
    Example 49 (82)
    N-hydroxy-2 (S) -methyl-5-ethoxymethoxy-4 (S)-[N- [4- (4-pyridyloxy) phenylcarbonyl] amino] pentanamide

    TLC: Rf 0.30 (CHCl 3: MeOH = 9: 1);
    NMR (d 6 -DMSO): δ 10.40 (s, 1H), 8.69 (s, 1H), 8.50 (dd, J = 4.7, 1.5Hz, 2H), 8.15 (d, J = 8.4Hz, 1H), 7.98 (d, J = 8.7 Hz, 2H), 7.25 (d, J = 8.7 Hz, 2H), 6.97 (dd, J = 4.7, 1.5 Hz, 2H), 4.62 (s, 2H), 4.30-4.10 (m, 1H), 3.60-3.40 (m, 4H), 2.30-2.10 (m, 1H), 1.80-1.60 (m, 2H), 1.11 (t, J = 7.1 Hz, 3H), 1.0 (d, J = 6.9 Hz , 3H).
    Example 49 (83)
    N-hydroxy-2 (S) -methyl-5- (2-methoxyethoxy) methoxy-4 (S)-[N- (4-cyanophenylcarbonyl) amino] pentanamide

    TLC: Rf 0.26 (CHCl 3: MeOH = 9: 1);
    NMR (d 6 -DMSO): δ 10.37 (s, 1H), 8.65 (s, 1H), 8.36 (d, J = 8.7Hz, 1H), 8.00-7.93 (m, 4H), 4.61 (s, 2H) , 4.20-4.06 (m, 1H), 3.56-3.52 (m, 2H), 3.49 (d, J = 6.0 Hz, 2H), 3.42-3.39 (m, 2H), 3.20 (s, 3H), 2.20-2.12 (m, 1H), 1.75-1.58 (m, 2H), 1.01 (t, J = 6.9 Hz, 3H).
    Example 49 (84)
    N-hydroxy-2 (S) -methyl-5-methoxymethoxy-4 (S)-[N- (4-chlorophenylcarbonyl) amino] pentanamide

    TLC: Rf 0.50 (methylene chloride: methanol = 9: 1);
    NMR (d 6 -DMSO): δ 10.36 (d, J = 1.8 Hz.1H), 8.64 (d, J = 1.8 Hz, 1H), 8.17 (d, J = 8.4 Hz, 1H), 7.85 (d, J = 8.4 Hz, 2H), 7.51 (d, J = 8.4 Hz, 2H), 4.53 (s, 2H), 4.11 (m, 1H), 3.46 (m, 2H), 3.20 (s, 3H), 2.16 (m , 1H), 1.65 (m, 2H), 1.00 (d, J = 6.6 Hz, 3H).
    Example 49 (85)
    N-hydroxy-2 (S) -methyl-5-benzyloxymethoxy-4 (S)-[N- (4-chlorophenylcarbonyl) amino] pentanamide

    TLC: Rf 0.50 (methylene chloride: methanol = 9: 1);
    NMR (d 6 -DMSO): δ 10.36 (s, 1H), 8.64 (s, 1H), 8.19 (d, J = 8.4Hz, 1H), 7.86 (d, J = 9.0Hz, 2H), 7.51 (d , J = 9.0 Hz, 2H), 7.28 (m, 5H), 4.69 (s, 2H), 4.49 (s, 2H), 4.15 (m, 1H), 3.54 (d, J = 6.0 Hz, 2H), 2.17 (m, 1H), 1.68 (m, 2H), 1.00 (d, J = 6.9 Hz, 3H).
    Example 49 (86)
    N-hydroxy-2 (S) -methyl-5- (2-methoxyethoxy) methoxy-4 (S)-[N- (4-chlorophenylcarbonyl) amino] pentanamide

    TLC: Rf 0.45 (methylene chloride: methanol = 9: 1);
    NMR (d 6 -DMSO): δ 10.36 (s, 1H), 8.64 (s, 1H), 8.16 (d, J = 8.4Hz, 1H), 7.85 (d, J = 9.0Hz, 2H), 7.51 (d , J = 9.0 Hz, 2H), 4.60 (s, 2H), 4.13 (m, 1H), 3.55-3.38 (m, 6H), 3.19 (s, 3H), 2.14 (m, 1H), 1.65 (m, 2H), 1.00 (d, J = 6.9 Hz, 3H).
    Example 49 (87)
    N-hydroxy-2 (S) -methyl-5-ethoxymethoxy-4 (S)-[N- (2-nitrophenylcarbonyl) amino] pentanamide

    TLC: Rf 0.22 (CHCl 3: MeOH = 9: 1);
    NMR (d 6 -DMSO): δ 10.39 (d, J = 1.2 Hz, 1H), 8.70 (d, J = 1.2 Hz, 1H), 8.45 (d, J = 8.4 Hz, 1H), 8.01 (dd, J = 7.8 Hz, 1.2 Hz, 1H), 7.80-7.60 (m, 3H), 4.62 (s, 2H), 4.08-3.95 (m, 1H), 3.55-3.36 (m, 4H), 2.31-2.19 (m, 1H), 1.65 (t, J = 7.2 Hz, 2H), 1.12 (t, J = 7.2 Hz, 3H), 1.03 (d, J = 7.2 Hz, 3H).
    Example 49 (88)
    N-hydroxy-2 (S) -methyl-5-ethoxymethoxy-4 (S)-[N- (3-nitrophenylcarbonyl) amino] pentanamide

    TLC: Rf 0.31 (CHCl 3: MeOH = 9: 1);
    NMR (d 6 -DMSO): δ 10.38 (s, 1H), 8.69-8.68 (m, 1H), 8.64 (brs, 1H), 8.52 (d, J = 8.7 Hz, 1H), 8.39-8.35 (m, 1H), 8.30-8.27 (m, 1H), 7.77 (t, J = 8.1 Hz, 1H), 4.60 (s, 2H), 4.24-4.11 (m, 1H), 3.52-3.44 (m, 4H), 2.22 -2.11 (m, 1H), 1.78-1.60 (m, 2H), 1.08 (t, J = 7.2 Hz, 3H), 1.02 (d, J = 6.9 Hz, 3H).
    Example 49 (89)
    N-hydroxy-2 (S) -methyl-5-ethoxymethoxy-4 (S)-[N- (2-methoxy-4-nitrophenylcarbonyl) amino] pentanamide

    TLC: Rf 0.26 (CHCl 3: MeOH = 9: 1);
    NMR (d 6 -DMSO): δ 10.38 (s, 1H), 8.66 (brs, 1H), 8.09 (d, J = 8.4Hz, 1H), 7.87-7.77 (m, 3H), 4.61, (s, 2H ), 4.14-4.02 (m, 1H), 3.95 (s, 3H), 3.53-3.43 (m, 4H), 2.25-2.13 (m, 1H), 1.75-1.55 (m, 2H), 1.09 (t, J) = 6.9 Hz, 3H), 1.02 (d, J = 6.9 Hz, 3H).
    Example 49 (90)
    N-hydroxy-2 (S) -methyl-5-ethoxymethoxy-4 (S)-[N- (3-methoxy-4-nitrophenylcarbonyl) amino] pentanamide

    TLC: Rf 0.26 (CHCl 3: MeOH = 9: 1);
    NMR (d 6 -DMSO): δ 10.39 (s, 1H), 8.67 (s, 1H), 8.34 (d, J = 8.4Hz.1H), 7.94 (d, J = 8.7Hz, 1H), 7.70 (d , J = 1.2Hz, 1H), 7.53 (dd, J = 8.7Hz, 1.2Hz, 1H), 4.60 (s, 2H), 4.21-4.09 (m, 1H), 3.99 (s, 3H), 3.54-3.45 (m, 4H), 2.22-2.10 (m, 1H), 1.78-1.62 (m, 2H), 1.08 (t, J = 6.9 Hz, 3H), 1.02 (d, J = 6.9 Hz, 3H).
    Example 49 (91)
    N-hydroxy-2 (S) -methyl-5-ethoxymethoxy-4 (S)-[N- (3-hydroxy-4-nitrophenylcarbonyl) amino] pentanamide

    TLC: Rf 0.22 (CHCl 3: MeOH = 9: 1):
    NMR (d 6 -DMSO): δ 11.08 (s, 1H), 10.28 (s, 1H), 8.56 (s, 1H), 8.21 (d, J = 8.7Hz, 1H), 7.84 (d, J = 8.4Hz , 1H), 7.43 (d, J = 1.8 Hz, 1H), 7.28 (dd, J = 8.4 Hz, 1.8 Hz, 1H), 4.49 (s, 2H), 4.08-3.95 (m, 1H), 3.41-3.34 (m, 4H), 2.12-2.01 (m, 1H), 1.58-1.53 (m, 2H), 0.99 (t, J = 6.9 Hz, 3H), 0.91 (d, J = 6.9 Hz, 3H).
    Example 49 (92)
    N-hydroxy-2 (S) -methyl-5-ethoxymethoxy-4 (S)-[N- (4-dihydroxyboroylphenylcarbonyl) amino] pentanamide

    TLC: Rf 0.19 (methylene chloride: methanol: acetic acid = 18: 1: 1);
    NMR (d 6 -DMSO): δ 10.37 (s, 1H), 8.65 (s, 1H), 8.16 (s, 2H), 8.05 (d, J = 8.4Hz, 1H), 7.83 (d, J = 8.4Hz , 2H), 7.77 (d, J = 8.4 Hz, 2H), 4.58 (s, 2H), 4.14 (m, 1H), 3.47 (m, 4H), 2.16 (m, 1H), 1.66 (m, 2H) , 1.07 (t, J = 6.9 Hz, 3H), 1.01 (d, J = 6.9 Hz, 3H).
    Examples 49 (93) to 49 (111)
    Instead of compounds prepared in Examples 44 (7), 44 (12), 44 (13), 44 (15), 44 (16), 44 (22), 44 (23), 44 (27) or Reference Example Reference Example 37 → Reference Example 39 → Reference Example 41 (In some cases, a compound corresponding to methoxymethyl chloride may be used) → Reference Example 43 (using compound corresponding to benzyl bromide) → The compound obtained by the operation in the same manner as in Example 44 was operated in the same manner as the method shown in Example 49, to obtain a compound shown below.
    Example 49 (93)
    N-hydroxy-2 (S) -isobutyl-5-methoxymethoxy-4 (S)-[N- (4-phenoxyphenylcarbonyl) amino] pentanamide

    TLC: Rf 0.36 (CHCl 3: MeOH = l 9: 1);
    NMR (d 6 -DMSO): δ 10.46 (1H, s), 8.72 (1H, s), 8.00 (1H, d, J = 8.4 Hz), 7.88 (2H, d, J = 8.8 Hz), 7.48-7.38 (2H, m), 7.23-7.16 (1H, m), 7.10-7.03 (2H, m), 7.01 (2H, d, J = 8.8 Hz), 4.56 (2H, s), 4.22-4.01 (1H, m ), 3.60-3.40 (2H, m), 3.24 (3H, s), 2.25-2.08 (1H, m), 1.78-1.60 (2H, m), 1.58-1.32 (2H, m), 1.28-1.07 (1H) m), 0.82 (3H, d, J = 6.0 Hz), 0.80 (3H, d, J = 6.0 Hz).
    Example 49 (94)
    N-hydroxy-2 (S) -ethyl-5-methoxymethoxy-4 (S)-[N- (4-phenoxyphenylcarbonyl) amino] pentanamide

    TLC: Rf 0.60 (CHCl 3: MeOH: Acetic Acid: Water = 100: 10: 1: 1);
    NMR (d 6 -DMSO): δ 10.40 (1H, s), 8.71 (1H, s). 8.04 (1H, d, J = 8.1 Hz), 7.87 (2H, d, J = 9.0 Hz), 7.45-7.40 (2H, m), 7.22-7.17 (1H, m), 7.08-7.00 (4H, m) , 4.55 (2H, s), 4.04-4.18 (1H, m), 3.52-3.23 (2H, m), 3.22 (3H, s), 2.04-1.92 (1H, m), 1.78-1.57 (2H, m) , 1.52-1.34 (2H, m), 0.77 (3H, t, J = 7.2 Hz).
    Example 49 (95)
    N-hydroxy-2 (S) -propyl-5-methoxymethoxy-4 (S)-[N- (4-phenoxyphenylcarbonyl) amino] pentanamide

    TLC: Rf 0.60 (CHCl 3: MeOH: Acetic Acid: Water = 100: 10: 1: 1);
    NMR (d 6 -DMSO): δ 10.40 (1H, s), 8.69 (1H, s), 8.02 (1H, d, J = 8.4 Hz), 7.86 (2H, d, J = 8.8 Hz, 7.46-7.37 ( 2H, m), 7.23-7.15 (1H, m), 7.08-6.98 (4H, m), 4.54 (2H, s), 4.16-4.00 (1H, m), 3.48-3.4 (2H, m), 3.21 ( 3H, s), 2.14-1.99 (1H, m), 1.78-1.58 (2H, m), 1.45-1.28 (2H, m), 1.27-1.07 (2H, m), 0.80 (3H, t, J = 7.2 Hz).
    Example 49 (96)
    N-hydroxy-2 (R) -t-butoxycarbonylmethyl-5-methoxymethoxy-4 (S)-[N- (4-phenoxyphenylcarbonyl) amino] pentanamide

    TLC: Rf 0.54 (CHCl 3: MeOH = 9: 1);
    NMR (d 6 -DMSO): δ 10.47 (1H, s), 8.75 (1H, s), 8.05 (1H, d, J = 8.4 Hz), 7.88 (2H, d, J = 8.7 Hz), 7.47-7.40 (2H, m), 7.23-7.17 (1H, m), 7.10-7.04 (2H, m), 7.03 (2H, d, J = 8.7 Hz), 4.55 (2H, s), 4.20-4.03 (1H, m) ), 3.57-3.43 (2H, m), 3.23 (3H, s), 2.55-2.34 (3H, m), 1.74-1.66 (2H, m), 1.36 (9H, s).
    Example 49 (97)
    N-hydroxy-2 (S) -allyl-5-methoxymethoxy-4 (S)-[N- (4-phenoxyphenylcarbonyl) amino] pentanamide

    TLC: Rf 0.62 (CHCl 3: MeOH: Acetic Acid = 100: 5: 1);
    NMR (d 6 -DMSO): δ 10.43 (1H, s), 8.66 (1H, brs), 8.06 (1H, d, J = 8.4 Hz), 7.89-7.85 (2H, m), 7.47-7.38 (2H, m), 7.23-7.15 (1H, m), 7.09-6.99 (4H, m), 5.73-5.60 (1H, m), 5.05-4.92 (2H, m), 4.54 (2H, s), 4.19-4.05 ( 1H, m), 3.52 (1H, dd, J = 10.1 Hz, 5.2 Hz), 3.44 (1H, dd, J = 10.1 Hz, 5.2 Hz), 3.22 (3H, s), 2.20-2.17 (3H, m) , 1.82-1.59 (2H, m).
    Example 49 (98)
    N-hydroxy-2 (S) -ethyl-5-ethoxymethoxy-4 (S)-[N- (4-phenoxyphenylcarbonyl) amino] pentanamide

    TLC: Rf 0.33 (CHCl 3: MeOH: Acetic Acid = 100: 5: 1);
    NMR (d 6 -DMSO): δ 10.40 (1H, s), 8.70 (1H, s), 8.02 (1H, d, J = 8.4 Hz), 7.86 (2H, d, J = 8.8 Hz), 7.46-7.38 (2H, m), 7.23-7.15 (1H, m), 7.08-6.99 (4H, m), 4.59 (2H, s), 4.19-4.01 (1H, m), 3.52-3.42 (2H, m), 3.47 (2H, q, J = 7.0 Hz), 2.05-1.92 (1H, m), 1.79-1.32 (4H, m), 1.07 (3H, t, J = 7.2 Hz), 0.76 (3H, t, J = 7.0 Hz).
    Example 49 (99)
    N-hydroxy-2 (S) -ethyl-5- (2-methoxyethoxy) methoxy-4 (S)-[N- (4-phenoxyphenylcarbonyl) amino] pentanamide

    TLC: Rf 0.31 (CHCl 3: MeOH = 9: 1);
    NMR (d 6 -DMSO): δ 10.40 (1H, s), 8.71 (1H, s), 8.02 (1H, d, J = 8.4 Hz), 7.88 (2H, d, J = 8.8 Hz), 7.48-7.38 (2H, m), 7.23-7.15 (1H, m), 7.10-7.05 (2H, m), 7.02 (2H, d, J = 8.8 Hz), 4.62 (2H, m), 4.22-4.00 (1H, m) ), 3.61-3.38 (6H, m), 3.22 (3H, s), 2.09-1.91 (1H, m), 1.82-1.60 (2H, m), 1.58-1.35 (2H, m), 0.78 (3H, t , J = 7.0 Hz).
    Example 49 (100)
    N-hydroxy-2 (S) -ethyl-5-t-butylcarbonyloxy-4 (S)-[N- (4-phenoxyphenylcarbonyl) amino] pentanamide

    TLC: Rf 0.69 (CHCl 3: MeOH = 9: 1);
    NMR (d 6 -DMSO): δ 10.41 (1H, s), 8.71 (1H, s), 8.07 (1H, d, J = 8.7 Hz), 7.81 (2H, d, J = 8.6 Hz), 7.41 (2H , t, J = 7.6 Hz, 7.17 (1H, t, J = 7.6 Hz), 7.04 (2H, d, J = 7.6 Hz), 7.00 (2H, d, J = 8.6 Hz), 4.25-4.13 (1H , m), 4.08-3.94 (2H, m), 2.03-1.91 (1H, m), 1.63 (2H, t, J = 6.9 Hz), 1.48-1.36 (2H, m), 1.06 (9H, s), 0.75 (3H, t, J = 7.5 Hz).
    Example 49 (101)
    N-hydroxy-2 (S) -allyl-5-ethoxymethoxy-4 (S)-[N- (4-methylphenylcarbonyl) amino] pentanamide

    TLC: Rf 0.49 (CHCl 3: MeOH = 9: 1);
    NMR (d 6 -DMSO): δ 10.42 (s, 1H), 8.71 (s, 1H), 7.99 (d, J = 8.8Hz, 1H), 7.73 (d, J = 8.0Hz, 2H), 7.24 (d , J = 8.0 Hz, 2H), 5.72-5.55 (m, 1H), 5.02-4.91 (m, 2H), 4.58 (s, 2H), 4.19-4.01 (m, 1H), 3.52-3.41 (m, 4H ), 2.33 (s, 3H), 2.12 (m, 3H), 1.79-1.58 (m, 2H), 1.07 (t, J = 7.0 Hz, 3H).
    Example 49 (102)
    N-hydroxy-2 (S) -allyl-5-ethoxymethoxy-4 (S)-[N- (4-nitrophenylcarbonyl) amino] pentanamide

    TLC: Rf 0.32 (CHCl 3: MeOH = 9: 1);
    NMR (d 6 -DMSO): δ 10.43 (d, J = 1.5 Hz, 1H), 8.71 (d, J = 1.5 Hz, 1H), 8.47 (d, J = 8.4 Hz, 1H), 8.30-8.27 (m , 2H), 8.07-8.03 (m, 2H), 5.75-5.59 (m, 1H), 5.03-4.93 (m, 2H), 4.59 (s, 2H), 4.19-4.08 (m, 1H), 3.50 (d , J = 5.1 Hz, 2H), 3.47 (q, J = 7.2 Hz, 2H), 2.23-2.12 (m, 3H), 1.80-1.60 (m, 2H), 1.07 (t, J = 7.2 Hz, 3H) .
    Example 49 (103)
    N-hydroxy-2-methylidene-5-ethoxymethoxy-4 (S)-[N- (4-nitrophenylcarbonyl) amino] pentanamide

    TLC: Rf 0.50 (CHCl 3: MeOH = 9: 1);
    NMR (d 6 -DMSO): δ 10.77 (s, 1 H), 8.84 (s, 1 H), 8.61 (d, J = 8.4 Hz, 1 H), 8.32-8.27 (m, 2H), 8.05-8.02 (m, 2H), 5.57 (s, 1H), 5.36 (s, 1H), 4.60 (s, 2H), 4.30-4.18 (m, 1H), 3.53-3.45 (m, 4H), 2.61 (dd, J = 14.1 Hz , 4.5 Hz, 1H), 2.47-2.40 (m, 1H), 1.07 (t, J = 6.9 Hz, 3H).
    Example 49 (104)
    N-hydroxy-2 (S)-(2-propynyl) -5-ethoxymethoxy-4 (S)-[N- (4-nitrophenylcarbonyl) amino] pentanamide

    TLC: Rf 0.39 (CHCl 3: MeOH = 9: 1);
    NMR (d 6 -DMSO): δ 10.54 (s, 1H), 8.81 (s, 1H), 8.49 (d, J = 8.4Hz, 1H), 8.29 (d, J = 8.7Hz.2H), 8.07 (d , J = 8.7 Hz, 2H), 4.59 (s.2H), 4.20-4.03 (m, 1H), 3.60-3.40 (m, 4H), 2.78 (s, 1H), 2.40-2.20 (m, 3H), 1.95-1.80 (m, 1H), 1.80-1.60 (m, 1H), 1.08 (t, J = 7.1 Hz, 3H).
    Example 49 (105)
    N-hydroxy-2 (S) -allyl-5- (2-methoxyethoxy) methoxy-4 (S)-[N- (4-cyanophenylcarbonyl) amino] pentanamide

    TLC: Rf 0.22 (CHCl 3: MeOH = 9: 1);
    NMR (d 6 -DMSO): δ 10.42 (s, 1H), 8.71 (s, 1H), 8.36 (d, J = 8.7Hz, 1H), 7.98 (d, J = 8.4Hz, 2H), 7.94 (d , J = 8.4 Hz, 2H), 5.74-5.58 (m, 1H), 5.05-4.92 (m, 2H), 4.61 (s, 2H), 4.20-4.04 (m, 1H), 3.58-3.43 (m, 4H ), 3.44-3.37 (m, 2H), 3.19 (s, 3H), 2.22-2.10 (m, 3H), 1.81-1.58 (m, 2H).
    Example 49 (106)
    N-hydroxy-2 (S)-(2-propynyl) -5-ethoxymethoxy-4 (S)-[N- (4-bromophenylcarbonyl) amino] pentanamide

    TLC: Rf 0.36 (CHCl 3: MeOH = 9: 1);
    NMR (d 6 -DMSO): δ 10.52 (s, 1H), 8.80 (s, 1H), 8.20 (d, J = 8.7Hz, 1H), 7.79 (d, J = 8.4Hz, 2H), 7.64 (d , J = 8.4 Hz, 2H), 4.58 (s, 2H), 4.18-4.02 (m, 1H), 3.58-3.42 (m, 4H), 2.78-2.73 (brs, 1H), 2.38-2.20 (m, 3H ), 1.95-1.75 (m, 1H), 1.75-1.60 (m, 1H), 1.08 (t, J = 6.9 Hz, 3H).
    Example 49 (107)
    N-hydroxy-2 (S)-(2-propynyl) -5-ethoxymethoxy-4 (S)-[N- (4-chlorophenylcarbonyl) amino] pentanamide

    TLC: Rf 0.35 (CHCl 3: MeOH = 9: 1);
    NMR (d 6 -DMSO): δ 10.52 (s, 1H), 8.80 (s, 1H), 8.20 (d, J = 8.7Hz, 1H), 7.86 (d, J = 8.6Hz, 2H), 7.51 (d , J = 8.6 Hz, 2H), 4.58 (s, 2H), 4.20-4.02 (m, 1H), 3.60-3.40 (m, 4H), 2.80-2.75 (brs, 1H), 2.40-2.20 (m, 3H ), 1.95-1.78 (m, 1H), 1.78-1.60 (m, 1H), 1.08 (t, J = 6.9 Hz, 3H).
    Example 49 (108)
    N-hydroxy-2 (S) -allyl-5-ethoxymethoxy-4 (S)-[N- (4-bromophenylcarbonyl) amino] pentanamide

    TLC: Rf 0.35 (CHCl 3: MeOH = 9: 1);
    NMR (d 6 -DMSO): δ 10.42 (s, 1H), 8.71 (s, 1H), 8.19 (d, J = 8.7Hz, 1H), 7.78 (d, J = 8.6Hz, 2H), 7.65 (d , J = 8.6 Hz, 2H), 5.75-5.58 (m, 1H), 5.05-4.90 (m, 2H), 4.58 (s, 2H), 4.20-4.05 (m, 1H), 3.58-3.40 (m, 4H ), 2.25-2.08 (m, 3H), 1.80-1.60 (m, 2H), 1.07 (t, J = 7.1 Hz, 3H).
    Example 49 (109)
    N-hydroxy-2 (S) -allyl-5-ethoxymethoxy-4 (S)-[N- (4-chlorophenylcarbonyl) amino] pentanamide

    TLC: Rf 0.36 (CHCl 3: MeOH = 9: 1):
    NMR (d 6 -DMSO): δ 10.42 (s, 1H), 8.70 (s, 1H), 8.18 (d, J = 8.7Hz, 1H), 7.85 (d, J = 8.6Hz, 2H), 7.52 (d , J = 8.6 Hz, 2H), 5.75-5.58 (m, 1H), 5.05-4.90 (m, 2H), 4.58 (s, 2H), 4.20-4.05 (m, 1H), 3.58-3.40 (m, 4H ), 2.25-2.08 (m, 3H), 1.80-1.60 (m, 2H), 1.07 (t, J = 7.1 Hz, 3H).
    Example 49 (110)
    N-hydroxy-2 (R) -dimethylaminomethyl-5-ethoxymethoxy-4 (S)-[N- (4-nitrophenylcarbonyl) amino] pentanamide

    TLC: Rf 0.30 (CHCl 3: MeOH: Acetic Acid = 10: 2: 1);
    NMR (d 6 -DMSO): δ 10.44 (brs, 1 H), 8.73 (brs, 1 H), 8.48 (d, J = 8.4 Hz, 1H), 8.29 (d, J = 8.9 Hz, 2H), 8.05 (d , J = 8.9 Hz, 2H), 4.59 (s, 2H), 4.20-4.05 (m, 1H), 3.60-3.40 (m, 4H), 2.55-2.38 (m, 1H), 2.38-2.20 (m, 1H ), 2.20-2.00 (m, 7H), 1.85-1.70 (m, 1H), 1.70-1.58 (m, 1H), 1.08 (t, J = 6.9 Hz, 3H).
    Example 49 (111)
    N-hydroxy-2 (S)-(2-propynyl) -5- (2-methoxyethoxy) methoxy-4 (S)-[N- (4-cyanophenylcarbonyl) amino] pentane amides

    TLC: Rf 0.35 (CHCl 3: MeOH = 9: 1);
    NMR (d 6 -DMSO): δ 10.53 (s, 1H), 8.81 (s, 1H), 8.41 (d, J = 8.7Hz, 1H), 7.99 (d, J = 8.7Hz, 2H), 7.94 (d , J = 8.7 Hz, 2H), 4.61 (s, 2H), 4.20-4.05 (m, 1H), 3.60-3.45 (m, 4H), 3.45-3.35 (m, 2H), 3.20 (s, 3H), 2.79 (s, 1 H), 2.35-2.00 (m, 3 H), 1.92-1.75 (m, 1 H), 1.75-1.60 (m, 1 H).
    Examples 49 (112) -49 (116)
    Instead of 4 (S) -carboxy-4-aminobutanoic acid methyl ester, Reference Example 37 using the compound corresponding to 4 (R) -carboxy-4-aminobutanoic acid methyl ester and the compound prepared in Reference Example 4 Reference Example 39 → Example 41 (Sometimes a compound corresponding to methoxymethyl chloride may be used) → Reference Example 43 (The compound used instead of benzyl bromide) → Example 44 → Method shown in Example 49 The same procedure was followed to obtain the compound shown below.
    Example 49 (112)
    N-hydroxy-2 (R) -benzyl-5-methoxymethoxy-4 (R)-[N- (4-phenoxyphenylcarbonyl) amino] pentanamide

    TLC: Rf 0.39 (CHCl 3: MeOH: Acetic Acid: Water = 100: 10: 1: 1);
    NMR (d 6 -DMSO): δ 10.34 (1H, s), 8.66 (1H, s), 8.08 (1H, d, J = 8.8 Hz), 7.89 (2H, d, J = 8.4 Hz), 7.43 (2H , t, J = 8.0 Hz), 7.00-7.46 (10H, m), 4.53 (2H, s), 4.13-4.32 (1H, m), 3.48 (2H, d, J = 5.6 Hz), 3.19 (3H, s), 2.76 (2H, d, J = 7.0 Hz), 2.29-2.44 (1H, m), 1.58-1.84 (2H, m).
    Example 49 (113)
    N-hydroxy-2 (R) -benzyl-5-methoxymethoxy-4 (R)-[N- [4- (3-phenoxy-1-propynyl) phenylcarbonyl] amino] pentanamide

    TLC: Rf 0.39 (CHCl 3: MeOH: Acetic Acid: Water = 100: 10: 1: 1);
    NMR (d 6 -DMSO): δ 10.33 (1H, s), 8.65 (1H, s), 8.22 (1H, d, J = 8.7 Hz), 7.84 (2H, d, J = 8.4 Hz), 7.51 (2H , d, J = 8.4 Hz, 7.32 (2H, t, J = 7.8 Hz), 7.20 (2H, t, J = 6.9 Hz), 6.97-7.14 (6H, m), 5.05 (2H, s), 4.50 (2H, s), 4.14-4.28 (1H, m), 3.46 (2H, d, J = 5.7 Hz), 3.17 (3H, s), 2.74 (2H, d, J = 7.2 Hz), 2.29-2.39 ( 1 H, m), 1.60-1.79 (2 H, m).
    Example 49 (114)
    N-hydroxy-2 (R) -methyl-5-ethoxymethoxy-4 (R)-[N- [4- (4-cyanophenyl) phenylcarbonyl] amino] pentanamide

    TLC: Rf 0.35 (CHCl 3: MeOH = 9: 1);
    NMR (d 6 -DMSO): δ 10.37 (s, 1H), 8.65 (s, 1H), 8.18 (d, J = 8.4Hz, 1H), 7.95 (d, J = 8.6Hz, 2H), 7.83 (d , J = 8.6 Hz, 2H), 4.59 (s, 2H), 4.16 (m, 1H), 3.60-3.40 (m, 4H), 2.17 (m, 1H), 1.67 (t, J = 6.9 Hz, 2H) , 1.07 (t, J = 7.1 Hz, 3H), 1.01 (d, J = 6.9 Hz, 3H).
    Example 49 (115)
    N-hydroxy-2 (R) -allyl-5-ethoxymethoxy-4 (R)-[N- (4-phenoxyphenylcarbonyl) amino] pentanamide

    TLC: Rf 0.34 (CHCl 3: MeOH = 9: 1);
    NMR (d 6 -DMSO): δ 10.41 (s, 1H), 8.70 (s, 1H), 8.02 (d, J = 8.4Hz, 1H), 7.85 (d, J = 9.0Hz, 2H), 7.41 (t , J = 7.9 Hz, 2H), 7.17 (t, J = 7.9 Hz, 1H), 7.04 (d, J = 7.9 Hz, 2H), 6.99 (d, J = 9.0 Hz, 2H), 5.74-5.55 (m , 1H), 5.03-4.88 (m, 2H), 4.56 (s, 2H), 4.17-4.03 (m, 1H), 3.53-3.40 (m, 4H), 2.24-2.10 (m, 3H), 1.79-1.58 (m, 2H), 1.06 (t, J = 7.0 Hz, 3H).
    Example 49 (116)
    N-hydroxy-2 (R) -methyl-5-ethoxymethoxy-4 (R)-[N- (4-phenoxyphenylcarbonyl) amino] pentanamide

    TLC: Rf 0.38 (CHCl 3: MeOH = 9: 1);
    NMR (d 6 -DMSO): δ 10.36 (s, 1H), 8.64 (s, 1H), 8.01 (d, J = 8.7Hz, 1H), 7.85 (d, J = 8.7Hz, 2H), 7.41 (t , J = 7.6Hz, 2H), 7.17 (t, J = 7.6Hz, 1H), 7.04 (d, J = 7.6Hz, 2H), 7.00 (d, J = 8.7Hz, 2H), 4.57 (s, 2H ), 4.18-4.06 (m, 1H), 3.51-3.42 (m, 4H), 2.15 (m, 1H), 1.64 (t, J = 7.1 Hz, 2H), 1.06 (t, J = 7.2 Hz, 3H) , 0.99 (d, J = 7.1 Hz, 3H).
    Examples 49 (117) -49 (124)
    Reference Example 37 → Reference Example 39 → Reference Example 41 → Reference Example 43 (The equivalent compound was used instead of benzyl bromide) → Example 44 → Example 49, using the compound corresponding to the compound prepared in Reference Example 4. It operated in the same manner as the method shown, and obtained the compound shown below.
    Example 49 (117)
    N-hydroxy-2 (S) -benzyl-5-methoxymethoxy-4 (S)-[N- [4- [2E- (4-chlorophenyl) ethenyl] phenylcarbonyl] amino] pentanamide

    TLC: Rf 0.21 (CHCl 3: MeOH = 19: 1);
    NMR (d 6 -DMSO): δ 10.37 (1H, s), 8.15 (1H, d, J = 8.4 Hz), 7.89 (2H, d, J = 8.4 Hz), 7.68 (2H, d, J = 8.4 Hz ), 7.66 (2H, d, J = 8.8 Hz), 7.45 (2H, d, J = 8.8 Hz), 7.40-7.30 (2H, m), 7.29-7.08 (5H, m), 4.54 (2H, s) , 4.38-4.18 (1H, m), 3.60-3.40 (2H, m), 3.21 (3H, s), 2.78 (2H, d, J = 6.6 Hz), 2.55-2.30 (1H, m), 1.92-1.60 (2H, m).
    Example 49 (118)
    N-hydroxy-2 (S)-(indol-3-yl) -5-methoxymethoxy-4 (S)-[N- [4- (benzofuran-2-yl) phenylcarbonyl] amino] Pentanamide

    TLC: Rf 0.28 (CHCl 3: MeOH = 19: 1);
    NMR (d 6 -DMSO): δ 10.73 (1H, s), 10.37 (1H, s), 8.67 (1H, d, J = 8.6 Hz), 8.01 (4H, s), 7.78-7.48 (4H, m) , 7.44-7.20 (3H, m), 7.10-6.80 (3H, m), 4.53 (2H, s), 4.42-4.22 (1H, m), 3.62-3.40 (2H, m), 3.18 (3H, s) , 3.00-2.78 (2H, m), 2.62-2.38 (1H, m), 2.00-1.65 (2H, m).
    Example 49 (119)
    N-hydroxy-2 (S) -benzyl-5-methoxymethoxy-4 (S)-[N- [4- [3- (4-chlorophenoxy-1-propynyl) phenylcarbonyl] amino ] Pentanamide

    TLC: Rf 0.26 (CHCl 3: MeOH = 19: 1);
    NMR (d 6 -DMSO): δ 10.35 (1H, s), 8.67 (1H, s), 8.24 (1H, d, J = 8.4 Hz), 7.87 (2H, d, J = 8.4 Hz), 7.53 (2H , d, J = 8.4 Hz), 7.38 (2H, d, J = 9.2 Hz), 7.30-7.00 (7H, m), 5.08 (2H, s), 4.53 (2H, s), 4.25 (1H, m) , 3.49 (2H, d, J = 5.4 Hz), 3.20 (3H, s), 2.77 (2H, d, J = 7.0 Hz), 2.38 (1H, m), 1.90-1.60 (2H, m).
    Example 49 (120)
    N-hydroxy-2 (S) -benzyl-5-methoxymethoxy-4 (S)-[N- (4-phenoxyphenylcarbonyl) amino] pentanamide

    TLC: Rf 0.39 (CHCl 3: MeOH = 19: 1);
    NMR (d 6 -DMSO): δ 10.36 (1H, s), 8.09 (1H, d, J = 8.6 Hz), 7.91 (2H, d, J = 8.8 Hz), 7.50-7.38 (2H, m), 7.30 -7.08 (8H, m), 7.03 (2H, d, J = 8.8 Hz), 4.54 (2H, s), 4.36-4.18 (1H, m), 3.58-3.40 (2H, m), 3.20 (3H, s ), 2.84-2.65 (2H, m), 2.45-2.30 (1H, m), 1.88-1.58 (2H, m).
    Example 49 (121)
    N-hydroxy-2 (S) -benzyl-5-methoxymethoxy-4 (S)-[N- [4- (4-phenylpiperidin-1-yl) phenylcarbonyl] amino] pentanamide

    TLC: Rf 0.26 (CHCl 3: MeOH = 19: 1);
    NMR (d 6 -DMSO): δ 10.33 (1H, s), 8.66 (1H, s), 7.82 (1H, d, J = 8.8 Hz), 7.77 (2H, d, J = 8.8 Hz), 7.38-7.06 (10H, m), 6.99 (2H, d, J = 8.8 Hz), 4.54 (2H, s), 4.38-4.16 (1H, m), 4.04-3.90 (2H, m), 3.58-3.40 (2H, m ), 3.21 (3H, s), 2.96-2.60 (5H, m), 2.44-2.28 (1H, m), 1.95-1.60 (6H, m).
    Example 49 (122)
    N-hydroxy-2 (S) -benzyl-5-methoxymethoxy-4 (S)-[N- [4- (6-imidazolyl-1-hexynyl) phenylcarbonyl] amino] pentanamide

    TLC: Rf 0.46 (CHCl 3: MeOH = 9: 1);
    NMR (d 6 -DMSO): δ 10.35 (1H, s), 8.67 (1H, s), 8.18 (1H, d, J = 8.4 Hz), 7.83 (2H, d, J = 8.4 Hz), 7.63 (1H , t, J = 1.2 Hz, 7.44 (2H, d, J = 8.4 Hz), 7.28-7.07 (6H, m), 6.89 (1H, t, J = 1.2 Hz), 4.53 (2H, s), 4.36 -4.17 (1H, m), 4.01 (2H, t, J = 7.0 Hz), 3.60-3.40 (2H, m), 3.20 (3H, s), 2.84-2.70 (2H, m), 2.47 (2H, t , J = 7.0 Hz), 2.46-2.30 (1H, m), 1.96-1.62 (4H, m), 1.58-1.40 (2H, m).
    Example 49 (123)
    N-hydroxy-2 (S)-(naphthalen-1-yl) -5-methoxymethoxy-4 (S)-[N- (4-phenoxyphenylcarbonyl) amino] pentanamide

    TLC: Rf 0.36 (CHCl 3: MeOH = 19: 1);
    NMR (d 6 -DMSO): δ 10.26 (1H, s), 8.63 (1H, s), 8.16 (1H, d, J = 8.4 Hz), 8.04-7.82 (4H, m), 7.80-7.70 (1H, m), 7.52-7.16 (7H, M), 7.14-6.96 (4H, m), 4.52 (2H, s), 4.50-4.28 (1H, m), 3.61-3.40 (2H, m), 3.25-3.02 ( 5H, m), 2.69-2.52 (1H, m), 2.00-1.78 (2H, m).
    Example 49 (124)
    N-hydroxy-2 (S)-[4- (benzofuran-2-yl) benzyl] -5-methoxymethoxy-4 (S)-[N- (4-iodinephenylcarbonyl) amino] pentane amides

    TLC: Rf 0.49 (CHCl 3: MeOH = 9: 1);
    NMR (d 6 -DMSO): δ 10.38 (1H, s), 8.70 (1H, S), 8.25 (1H, d, J = 8.7 Hz), 7.85 (2H, d, J = 8.4 Hz), 7.79 (2H , d, J = 8.1 Hz), 7.70-7.56 (4H, m), 7.36 (1H, s), 7.34-7.20 (4H, m), 4.55 (2H, s), 4.35-4.20 (1H, m), 3.60-3.45 (2H, m), 3.21 (3H, s), 2.83 (2H, d, J = 6.9 Hz), 2.45-2.30 (1H, m), 1.90-1.60 (2H, m).
    Examples 49 (125) to 49 (233)
    Reference Example 37 → Reference Example 39 → Reference Example 41 (using the equivalent compound instead of methoxymethylchloride) → Reference Example 43 (the equivalent instead of the compound prepared in Reference Example 4) Using a compound) → Example 44 → Example 49 and operating in the same manner as described in the following to obtain the compound shown below.
    Example 49 (125)
    N-hydroxy-2 (S) -benzyl-5-ethoxymethoxy-4 (S)-[N- (trans-4-methylcyclohexylcarbonyl) amino] pentanamide

    TLC: Rf 0.36 (CHCl 3: MeOH = 9: 1);
    NMR (d 6 -DMSO): δ 10.32 (s, 1H), 8.80-8.60 (brs, 1H), 7.43 (d, J = 8.7 Hz, 1H), 7.28-7.19 (m, 2H), 7.19-7.07 ( m, 3H), 4.54 (s, 2H), 4.05-3.85 (m, 1H), 3.60-3.20 (m, 4H), 2.80-2.60 (m, 2H), 2.38-2.20 (m, 1H), 2.10- 1.90 (m, 1H), 1.80-1.60 (m, 5H), 1.60-1.45 (m, 1H), 1.45-1.20 (m, 3H), 1.11 (t, J = 6.9 Hz, 3H), 1.00-0.80 ( m, 5H).
    Example 49 (126)
    N-hydroxy-2 (S)-(4-nitrobenzyl) -5-ethoxymethoxy-4 (S)-[N- (trans-4-methylcyclohexylcarbonyl) amino] pentanamide

    TLC: Rf 0.40 (CHCl 3: MeOH = 9: 1);
    NMR (d 6 -DMSO): δ 10.34 (s, 1H), 8.80-8.60 (brs, 1H), 8.12 (d, J = 8.7 Hz, 2H), 7.48 (d, J = 8.7 Hz, 1H), 7.37 (d, J = 8.7 Hz, 2H), 4.57 (s, 2H), 4.10-3.90 (m, 1H), 3.55-3.25 (m, 4H), 3.00-2.70 (m, 2H), 2.40-2.25 (m , 1H), 2.10-1.95 (m, 1H), 1.85-1.60 (m, 5H), 1.60-1.20 (m, 4H), 1.11 (t, J = 7.2 Hz, 3H), 1.00-0.80 (m, 5H ).
    Example 49 (127)
    N-hydroxy-2 (S)-(indol-3-yl) -5-ethoxymethoxy-4 (S)-[N- (trans-4-methylcyclohexylcarbonyl) amino] pentanamide

    TLC: Rf 0.32 (CHCl 3: MeOH = 10: 1);
    NMR (d 6 -DMSO): δ 10.73 (brs, 1H), 10.32 (brs, 1H), 8.66 (d, J = 1.5 Hz, 1H), 7.49 (d, J = 7.8 Hz, 1H), 7.41 (d , J = 8.7 Hz, 1H), 7.28 (d, J = 8.1 Hz, 1H), 7.05-6.99 (m, 2H), 6.94-6.88 (m, 1H), 4.50 (d, J = 6.9 Hz, 1H) , 4.47 (d, J = 6.9 Hz, 1H), 4.02-3.902 (m, 1H), 3.40 (q, J = 7.2 Hz, 2H), 3.37-3.28 (m, 2H), 2.89-2.71 (m, 2H ), 2.48-2.34 (m, 1H), 2.05-1.93 (m, 1H), 1.77-1.50 (m, 6H), 1.45-1.20 (m, 3H), 1.06 (t, J = 7.2 Hz, 3H), 0.95-0.80 (m, 2H), 0.84 (d, J = 6.6 Hz, 3H).
    Example 49 (128)
    N-hydroxy-2 (S) -benzyl-5-ethoxymethoxy-4 (S)-[N-[(pyridin-4-yl) carbonyl] amino] pentanamide

    TLC: Rf 0.30 (CHCl 3: MeOH = 9: 1);
    NMR (d 6 -DMSO): δ 10.37 (s.1H), 8.76-8.63 (m, 3H), 8.43 (d, J = 8.6 Hz, 1H), 7.80-7.72 (m, 2H), 7.29-7.08 ( m, 5H), 4.58 (s, 2H), 4.34-4.14 (m, 1H), 3.60-3.39 (m, 4H), 2.83-2.65 (m, 2H), 2.42-2.28 (m, 1H), 1.88- 1.59 (m, 2H), 1.09 (t, J = 7.0 Hz, 3H).
    Example 49 (129)
    N-hydroxy-2 (S) -benzyl-5-ethoxymethoxy-4 (S)-[N- (4-hydroxyphenylcarbonyl) amino] pentanamide

    TLC: Rf 0.57 (CHCl 3: MeOH = 9: 1);
    NMR (d 6 -DMSO): δ 10.34 (s, 1H), 9.96-9.80 (br, 1H), 7.83 (d, J = 8.4Hz, 1H), 7.74 (d, J = 9.0Hz, 2H), 7.26 -7.08 (m, 5H), 6.79 (d, J = 9.0 Hz.2H), 4.57 (s, 2H), 4.30-4.17 (m, 1H), 3.58-3.40 (m, 4H), 2.76 (d, J = 6.6 Hz, 2H), 2.42-2.32 (m, 1H), 1.82-1.60 (m, 2H), 1.09 (t, J = 7.2 Hz, 3H).
    Example 49 (130)
    N-hydroxy-2 (S)-(2-nitrobenzyl) -5-ethoxymethoxy-4 (S)-[N- (trans-4-methylcyclohexylcarbonyl) amino] pentanamide

    TLC: Rf 0.23 (CHCl 3: MeOH = 9: 1);
    NMR (d 6 -DMSO): δ 10.35 (s, 1H), 8.71 (s, 1H), 7.92 (dd, J = 8.4, 1.2Hz, 1H), 7.61 (td, J = 7.4, 1.2Hz, 1H) , 7.50-7.40 (m, 2H), 7.36 (d, J = 7.4 Hz, 1H), 4.55 (s, 2H), 3.90-3.75 (m, 1H), 3.55-3.25 (m, 4H, overlap with H2O in DMSO), 3.10-2.90 (m, 2H), 2.55-2.40 (m, 1H, overlap with DMSO), 2.10-1.90 (m, 1H), 1.80-1.55 (m, 6H), 1.50-1.20 (m, 3H ), 1.10 (t, J = 7.1 Hz, 3H), 1.00-0.75 (m, 5H).
    Example 49 (131)
    N-hydroxy-2 (S)-(3-nitrobenzyl) -5-ethoxymethoxy-4 (S)-[N- (trans-4-methylcyclohexylcarbonyl) amino] pentanamide

    TLC: Rf 0.38 (CHCl 3: MeOH = 9: 1);
    NMR (d 6 -DMSO): δ 10.30 (s, 1H), 8.67 (s, 1H), 8.10-8.00 (m, 1H), 7.98 (s, 1H), 7.60-7.46 (m, 3H), 4.56 ( s, 2H), 4.10-3.95 (m, 1H), 3.55-3.30 (m, 4H, overlap with H2O in DMS0), 2.94 (dd, J = 13.0, 4.7 Hz, 1H), 2.80 (dd, J = 13.0 , 9.9 Hz, 1H), 2.30-2.20 (m, 1H), 2.10-1.95 (m, 1H), 1.85-1.60 (m, 5H), 1.60-1.20 (m, 4H), 1.11 (t, J = 7.1 Hz, 3H), 1.00-0.80 (m, 5H).
    Example 49 (132)
    N-hydroxy-2 (S) -benzyl-5-ethoxymethoxy-4 (S)-[N-[(1-methylpyrrole-2-yl) carbonyl] amino] pentanamide

    TLC: Rf 0.31 (CHCl 3: MeOH = 19: 1);
    NMR (d 6 -DMSO): δ 10.31 (s, 1H), 8.65 (d, J = 1.2Hz, 1H), 7.59 (d, J = 8.8Hz, 1H), 7.25-7.10 (m, 5H), 6.85 -6.90 (m, 1H), 6.78-6.76 (m, 1H), 5.98 (t, J = 3.2 Hz, 1H), 4.57 (s, 2H), 4.25-4.08 (m, 1H), 3.83 (s, 3H ), 3.50-3.39 (m, 4H), 2.75 (d, J = 7.0 Hz, 2H), 2.45-2.29 (m, 1H), 1.82-1.52 (m, 2H), 1.08 (t, J = 7.0 Hz, 3H).
    Example 49 (133)
    N-hydroxy-2 (S) -benzyl-5-ethoxymethoxy-4 (S)-[N- (phenylcarbonyl) amino] pentanamide

    TLC: Rf 0.34 (CHCl 3: MeOH = 9: 1);
    NMR (d 6 -DMSO): δ 10.34 (s, 1H), 8.60 (d, J = 1.6Hz, 1H), 8.12 (d, J = 8Hz, 1H), 7.85 (dd, J = 8.0Hz, 1.8 Hz, 2H), 7.52-7.40 (m, 3H), 7.26-7.09 (m, 5H), 4.57 (s, 2H), 4.33-4.15 (m, 1H), 3.49 (d, J = 5.4 Hz, 2H) , 3.45 (q, J = 7.0 Hz, 2H), 2.76 (d, J = 7.0 Hz, 2H), 2.44-2.28 (m, 1H), 1.85-1.59 (m, 2H), 1.07 (t, J = 7.0 Hz, 3H).
    Example 49 (134)
    N-hydroxy-2 (S) -benzyl-5-ethoxymethoxy-4 (S)-[N- (4-ethylphenylcarbonyl) amino] pentanamide

    TLC: Rf 0.50 (CHCl 3: MeOH = 9: 1);
    NMR (d 6 -DMSO): δ 10.33 (d, J = 1.2 Hz, 1H), 8.65 (s, 1H), 8.02 (d, J = 8.4 Hz, 1H), 7.78 (d, J = 8.2 Hz, 2H ), 7.30-7.09 (m, 7H), 4.57 (s, 2H), 4.15-4.32 (m, 1H), 3.50-3.39 (m, 4H), 2.76 (d, J = 7.4 Hz, 2H), 2.64 ( q, J = 7.4 Hz, 2H), 2.42-2.25 (m, 1H), 1.58-1.82 (m, 2H), 1.17 (t, J = 7.6 Hz, 3H), 1.07 (t, J = 7.4 Hz, 3H ).
    Example 49 (135)
    N-hydroxy-2 (S) -benzyl-5-ethoxymethoxy-4 (S)-[N- (4-methylphenylcarbonyl) amino] pentanamide

    TLC: Rf 0.56 (CHCl 3: MeOH = 9: 1);
    NMR (d 6 -DMSO): δ 10.32 (s, 1H), 8.64 (s, 1H), 8.00 (d, J = 8.7Hz, 1H), 7.73 (d, J = 8.1Hz, 2H), 7.26-7.05 (m, 7H), 4.54 (s, 2H), 4.26-4.15 (m, 1H), 3.51-3.37 (m, 4H), 2.73 (d, J = 7.2 Hz, 2H), 2.32 (s, 3H), 2.39-2.25 (m, 1H), 1.80-1.58 (m, 2H), 1.05 (t, J = 7.1 Hz, 3H).
    Example 49 (136)
    N-hydroxy-2 (S) -benzyl-5-ethoxymethoxy-4 (S)-[N- (4-nitrophenylcarbonyl) amino] pentanamide

    TLC: Rf 0.25 (methylene chloride: methanol = 19: 1);
    NMR (d 6 -DMSO): δ 10.36 (d, J = 1.5 Hz, 1H), 8.67 (d, J = 1.5 Hz, 1H), 8.50 (d, J = 8.4 Hz, 1H), 8.30 (d, J = 9.0 Hz, 2H), 8.08 (d, J = 9.0 Hz, 2H), 7.25-7.11 (m, 5H), 4.56 (s, 2H), 4.23 (m, 1H), 3.50 (d, J = 5.7 Hz , 2H), 3.43 (q, J = 7.2 Hz, 2H), 2.75 (m, 2H), 2.36 (m, 1H), 1.72 (m, 2H), 1.07 (t, J = 7.2 Hz, 3H).
    Example 49 (137)
    N-hydroxy-2 (S) -benzyl-5-ethoxymethoxy-4 (S)-[N- (2,2,3,3-tetramethylcyclopropylcarbonyl) amino] pentanamide

    TLC: Rf 0.53 (chloroform: methanol = 9: 1);
    NMR (d 6 -DMSO): δ 10.32 (d, J = 1.2 Hz, 1H), 8.69 (d, J = 1.2 Hz, 1H), 7.49 (d, J = 8.4 Hz, 1H), 7.24-7.09 (m , 5H), 4.53 (s, 2H), 3.98-3.88 (m, 1H), 3.45 (q, J = 7.2 Hz, 2H), 3.37-3.35 (m, 2H), 2.73-2.66 (m, 3H), 2.35-2.25 (m, 1H), 1.70-1.43 (m, 2H), 1.18-1.04 (m, 15H).
    Example 49 (138)
    N-hydroxy-2 (S)-(3-methoxybenzyl) -5-ethoxymethoxy-4 (S)-[N- (4-methylphenylcarbonyl) amino] pentanamide

    TLC: Rf 0.53 (chloroform: methanol = 9: 1);
    NMR (d 6 -DMSO): δ 10.33 (d, J = 1.8 Hz, 1H), 8.67 (d, J = 1.8 Hz, 1H), 8.06 (d, J = 9.0 Hz, 1H), 7.76 (d, J = 8.4 Hz, 2H), 7.24 (d, J = 8.4 Hz, 2H), 7.13-7.08 (m, 1H), 6.71-6.66 (m, 3H), 4.56 (s, 2H), 4.17-4.30 (m, 1H), 3.65 (s, 3H), 3.53-3.41 (m, 4H), 2.72 (d, J = 7.2 Hz, 2H), 2.40-2.30 (m, 1H), 2.34 (s, 3H), 1.81-1.59 (m, 2H), 1.07 (t, J = 7.2 Hz, 3H).
    Example 49 (139)
    N-hydroxy-2 (S) -benzyl-5-ethoxymethoxy-4 (S)-[N- (1-cyclohexenylcarbonyl) amino] pentanamide

    TLC: Rf 0.25 (methylene chloride: methanol = 19: 1);
    NMR (d 6 -DMSO): δ 10.31 (brs, 1H), 8.65 (brs, 1H), 7.28-7.08 (m, 6H), 6.49 (bs, 1H), 4.53 (s, 2H), 4.05 (m, 1H), 3.43 (q, J = 7.2 Hz, 2H), 3.47-3.35 (m, 2H), 2.69 (m, 2H), 2.28 (m, 1H), 2.20-2.04 (m, 4H), 1.74-1.46 (m, 6H), 1.09 (t, J = 7.2 Hz, 3H).
    Example 49 (140)
    N-hydroxy-2 (S) -benzyl-5-ethoxymethoxy-4 (S)-[N [(1-cyclohexen-4-yl) carbonyl] amino] pentanamide

    TLC: Rf 0.25 (methylene chloride: methanol = 19: 1);
    NMR (d 6 -DMSO): δ 10.31 (brs, 1H), 8.67 (brs, 1 H), 7.54 (d, J = 8.4 Hz, 1H), 7.24-7.08 (m, 5H), 5.64 (m.2H) , 4.53 (s, 2H), 3.95 (m, 1H), 3.43 (q, J = 7.2 Hz, 2H), 3.47-3.28 (m, 2H), 2.75-2.63 (m, 2H), 2.33-1.44 (m , 10H), 1.09 (t, J = 7.2 Hz. 3 H).
    Example 49 (141)
    N-hydroxy-2 (S) -benzyl-5-ethoxymethoxy-4 (S)-[N- (4-dimethylaminophenylcarbonyl) amino] pentanamide

    TLC: Rf 0.63 (CHCl 3: MeOH = 9: 1);
    NMR (d 6 -DMSO): δ 10.33 (s, 1H), 8.65 (s, 1H), 7.78-7.69 (m, 3H), 7.25-7.08 (m, 5H), 6.69 (d, J = 9.0Hz, 2H), 4.58 (s, 2H), 4.29-4.18 (m, 1H), 3.56-3.41 (m, 4H), 2.97 (s, 6H), 2.77 (d, J = 7.2 Hz, 2H), 2.42-2.32 (m, 1H), 1.82-1.62 (m, 2H), 1.10 (t, J = 6.9 Hz, 3H).
    Example 49 (142)
    N-hydroxy-2 (S) -benzyl-5-ethoxymethoxy-4 (S)-[N- (4-carbamoylphenylcarbonyl) amino] pentanamide

    TLC: Rf 0.37 (CHCl 3: MeOH = 9: 1);
    NMR (d 6 -DMSO): δ 10.37 (s, 1H), 8.68 (s, 1H), 8.24 (d, J = 8.7Hz, 1H), 8.08 (s, 1H), 7.98-7.87 (m, 4H) , 7.48 (s, 1H), 7.28-7.10 (m, 5H), 4.58 (s, 2H), 4.32-4.19 (m, 1H), 3.58-3.40 (m, 4H), 2.77 (d, J = 6.9Hz , 2H), 2.42-2.32 (m, 1H), 1.83-1.61 (m, 2H), 1.09 (t, J = 7.2 Hz, 3H).
    Example 49 (143)
    N-hydroxy-2 (S) -benzyl-5-ethoxymethoxy-4 (S)-[N- (4-methoxycarbonylphenylcarbonyl) amino] pentanamide

    TLC: Rf 0.31 (CHCl 3: MeOH = 19: 1);
    NMR (d 6 -DMSO): δ 10.38 (s, 1H), 8.69 (s, 1H), 8.35 (d, J = 8.4Hz, 1H), 8.04 (d, J = 8.8Hz, 2H), 7.98 (d , J = 8.8 Hz, 2H), 7.28-7.06 (m, 5H), 4.58 (s, 2H), 4.35-4.18 (m, 1H), 3.89 (s, 3H), 3.60-3.39 (m, 4H), 2.77 (d, J = 7.0 Hz, 2H), 2.42-2.28 (m, 1H), 1.88-1.59 (m, 2H), 1.09 (t, J = 7.0 Hz, 3H).
    Example 49 (144)
    N-hydroxy-2 (S) -benzyl-5-ethoxymethoxy-4 (S)-[N- (cyclopentylcarbonyl) amino] pentanamide

    TLC: Rf 0.51 (methylene chloride: methanol = 9: 1);
    NMR (d 6 -DMSO): δ 10.32 (brs, 1H), 8.68 (brs, 1 H), 7.49 (d, J = 8.7 Hz, 1H), 7.25-7.08 (m, 5H), 4.53 (s, 2H) , 3.92 (m, 1H), 3.43 (q, J = 7.2 Hz, 2H), 3.40-3.35 (m, 2H), 2.72 (dd, J = 13.5, 8.7 Hz, 1H), 2.65 (dd, J = 13.5 , 5.6 Hz, 1H), 2.49 (m, 1H), 2.29 (m, 1H), 1.80-1.40 (m, 10H), 1.09 (t, J = 7.2 Hz, 3H).
    Example 49 (145)
    N-hydroxy-2 (S)-(naphthalen-2-yl) -5-ethoxymethoxy-4 (S)-[N- (trans-4-methylcyclohexylcarbonyl) amino] pentanamide

    TLC: Rf 0.31 (CHCl 3: MeOH = 19: 1);
    NMR (d 6 -DMSO): δ 10.33 (s, 1H), 7.90-7.73 (m, 3H), 7.60 (s, 1H), 7.54-7.37 (m, 3H), 7.34-7.22 (m, 1H), 4.60-4.46 (m, 2H), 4.12-3.90 (m, 1H), 3.52-3.22 (m, 4H), 2.87 (d, J = 6.6 Hz, 2H), 2.45-2.28 (m, 1H), 2.17- 1.94 (m, 1 H), 1.88-1.18 (m, 10 H), 1.09 (t, J = 7.0 Hz, 3H), 1.00-0.72 (m, 4H).
    Example 49 (146)
    N-hydroxy-2 (S) -benzyl-5-ethoxymethoxy-4 (S)-[N- (4-trifluoromethylphenylcarbonyl) amino] pentanamide

    TLC: Rf 0.58 (CHCl 3: MeOH = 9: 1);
    NMR (d 6 -DMSO): δ 10.34 (s, 1H), 8.67 (d, J = 2.1Hz, 1H), 8.38 (d, J = 8.7Hz, 1H), 8.04 (d, J = 8.4Hz, 2H ), 7.83 (d, J = 8.4 Hz, 2H), 7.25-7.10 (m, 5H), 4.56 (s, 2H), 4.30-4.18 (m, 1H), 3.50-3.36 (m, 4H), 2.76- 2.74 (m, 2H), 2.41-2.30 (m, 1H), 1.81-1.62 (m, 2H), 1.07 (t, J = 7.2 Hz, 3H).
    Example 49 (147)
    N-hydroxy-2 (S) -benzyl-5-ethoxymethoxy-4 (S)-[N- (4-iodinephenylcarbonyl) amino] pentanamide

    TLC: Rf 0.45 (CHCl 3: MeOH = 9: 1);
    NMR (d 6 -DMSO): δ 10.33 (s, 1H), 8.65 (brs, 1H), 8.19 (d, J = 8.4Hz, 1H), 7.83 (d, J = 8.4Hz, 2H), 7.63 (d , J = 8.4 Hz, 2H), 7.24-7.09 (m, 5H), 4.55 (s, 2H), 4.28-4.15 (m, 1H), 3.48-3.39 (m, 4H), 2.74 (d, J = 7.2 Hz, 2H), 2.38-2.29 (m, 1H), 1.79-1.59 (m, 2H), 1.06 (t, J = 7.2 Hz, 3H).
    Example 49 (148)
    N-hydroxy-2 (S) -benzyl-5-ethoxymethoxy-4 (S)-[N- [4- (2-iodoethynyl) phenylcarbonyl] amino] pentanamide

    TLC: Rf 0.37 (CHCl 3: MeOH = 9: 1);
    NMR (d 6 -DMSO): δ 10.35 (s, 1H), 8.66 (d, J = 1.5Hz, 1H), 8.28 (d, J = 8.4Hz, 1H), 7.90 (d, J = 8.4Hz, 2H ), 7.71 (d, J = 8.4 Hz.2H), 7.24-7.10 (m, 5H), 4.56 (s, 2H), 4.29-4.18 (m, 1H), 3.50-3.35 (m, 4H), 2.75 ( d, J = 6.9 Hz, 2H), 2.40-2.31 (m, 1H), 1.81-1.61 (m, 2H), 1.07 (t, J = 6.9 Hz, 3H).
    Example 49 (149)
    N-hydroxy-2 (S) -benzyl-5-ethoxymethoxy-4 (S)-[N- (cycloheptylcarbonyl) amino] pentanamide

    TLC: Rf 0.26 (methylene chloride: methanol = 19: 1);
    NMR (d 6 -DMSO): δ 10.32 (brs, 1H), 8.68 (brs, 1 H), 7.41 (d, J = 8.7 Hz, 1H), 7.25-7.08 (m, 5H), 4.53 (s, 2H) , 3.90 (m, 1H), 3.43 (q, J = 7.2 Hz, 2H), 3.40-3.30 (m, 2H), 2.68 (m, 2H), 2.33-2.20 (m, 2H), 1.80-1.30 (m , 14H), 1.09 (t, J = 7.2 Hz, 3H).
    Example 49 (150)
    N-hydroxy-2 (S) -benzyl-5-ethoxymethoxy-4 (S)-[N- (2-thienylcarbonyl) amino] pentanamide

    TLC: Rf 0.48 (CHCl 3: MeOH = 9: 1);
    NMR (d 6 -DMSO): δ 10.35 (s, 1H), 8.17 (d, J = 9.0 Hz, 1H), 7.79-7.76 (m, 1H), 7.72-7.69 (m, 1H), 7.23-7.06 ( m, 6H), 4.54 (s, 2H), 4.19-4.08 (m, 1H), 3.50-3.38 (m, 4H), 2.76-2.67 (m, 2H), 2.40-2.30 (m, 1H), 1.79- 1.57 (m, 2H), 1.05 (t, J = 7.2 Hz, 3H).
    Example 49 (151)
    N-hydroxy-2 (R)-(3,4,4-trimethyl-2,5-dioxoimidazolidin-1-yl) methyl-5-ethoxymethoxy-4 (S)-[N -(4-methylphenylcarbonyl) amino] pentanamide

    TLC: Rf 0.41 (CHCl 3: MeOH = 9: 1);
    NMR (d 6 -DMSO): δ 10.63 (s, 1H), 8.78 (s, 1H), 7.99 (d, J = 7.8Hz, 1H), 7.73 (d, J = 8.1Hz, 2H), 7.24 (d , J = 8.1 Hz, 2H), 4.57 (s, 2H), 4.10-3.95 (m, 1H), 3.60-3.30 (m, 6H, overlapping with H 2 O in DMSO), 2.78 (s, 3H), 2.70 -2.50 (m, 1H), 2.35 (s, 3H), 1.72 (t, J = 6.9 Hz, 2H), 1.30 (s, 3H), 1.28 (s, 3H), 1.08 (t, J = 6.9 Hz, 3H).
    Example 49 (152)
    N-hydroxy-2 (S) -benzyl-5-ethoxymethoxy-4 (S)-[N-[(2-bromo-5-thienyl) carbonyl] amino] pentanamide

    TLC: Rf 0.38 (CHCl 3: MeOH = 9: 1):
    NMR (d 6 -DMSO): δ 10.35 (s, 1H), 8.27 (d, J = 8.7 Hz, 1H), 7.60 (d, J = 3.9 Hz, 1H), 7.27-7.17 (m, 3H), 7.17 -7.06 (m, 3H), 4.53 (s, 2H), 4.14-4.03 (m, 1H), 3.49-3.36 (m, 4H), 2.78-2.63 (m, 2H), 2.38-2.27 (m, 1H) , 1.77-1.56 (m, 2H), 1.05 (t, J = 6.9 Hz, 3H).
    Example 49 (153)
    N-hydroxy-2 (S) -benzyl-5-ethoxymethoxy-4 (S)-[N- (4-bromophenylcarbonyl) amino] pentanamide

    TLC: Rf 0.46 (CHCl 3: MeOH = 9: 1);
    NMR (d 6 -DMSO): δ 10.32 (s, 1H), 8.19 (d, J = 8.4 Hz, 1H), 7.78 (d, J = 8.5 Hz, 2H), 7.64 (d, J = 8.5H 42H) , 7.23-7.06 (m, 5H), 4.54 (s, 2H), 4.24-4.13 (m, 1H), 3.50-3.36 (m, 4H), 2.76-2.69 (m, 2H), 2.38-2.27 (m, 1H), 1.79-1.58 (m, 2H), 1.05 (t, J = 7.0 Hz, 3H).
    Example 49 (154)
    N-hydroxy-2 (S) -benzyl-5-ethoxymethoxy-4 (S)-[N- (4-hydroxymethylphenylcarbonyl) amino] pentanamide

    TLC: Rf 0.25 (chloroform: methanol = 9: 1);
    NMR (d 6 -DMSO): δ 10.32 (s, 1H), 8.65 (s, 1H), 8.04 (d, J = 8.4Hz, 1H), 7.79 (d, J = 7.8Hz, 2H), 7.35 (d , J = 7.8 Hz, 2H), 7.23-7.06 (m, 5H), 5.26 (t, J = 5.7 Hz, 1H), 4.55 (s, 2H), 4.52 (d, J = 5.7 Hz, 2H), 4.27 -4.15 (m, 1H), 3.55-3.37 (m, 4H), 2.76-2.70 (m, 2H), 2.34 (m, 1H), 1.81-1.59 (m.2H), 1.06 (t, J = 7.2 Hz .3H).
    Example 49 (155)
    N-hydroxy-2 (S)-(benzothiophen-3-yl) -5-ethoxymethoxy-4 (S)-[N- (trans-4-methylcyclohexylcarbonyl) amino] pentanamide

    TLC: Rf 0.37 (CHCl 3: MeOH = 19: 1);
    NMR (d 6 -DMSO): δ 10.39 (s, 1H), 8.72 (s, 1H), 7.95-7.90 (m, 1H), 7.83-7.76 (m, 1H), 7.48 (d, J = 8.7 Hz, 1H), 7.40-7.30 (m, 2H), 7.29 (s, 1H), 4.56-4.48 (m, 2H), 4.12-3.97 (m, 1H), 3.47-3.28 (m, 4H), 3.01 (dd, J = 14.4, 9.3 Hz, 1H), 2.93 (dd, J = 14.4, 5.1 Hz, 1H), 2.56-2.41 (m, 1H), 2.09-1.96 (m, 1H), 1.82-1.53 (m, 6H) , 1.48-1.20 (m, 3H), 1.09 (t, J = 6.9 Hz, 3H), 0.98-0.78 (m, 5H).
    Example 49 (156)
    N-hydroxy-2 (S) -benzyl-5-ethoxymethoxy-4 (S)-[N- (4-cyanophenylcarbonyl) amino] pentanamide

    TLC: Rf 0.32 (CHCl 3: MeOH = 19: 1);
    NMR (d 6 -DMSO): δ 10.38 (s, 1H), 8.69 (s, 1H), 8.42 (d, J = 8.7Hz, 1H), 8.02 (d, J = 8.4Hz, 2H), 7.94 (d , J = 8.4 Hz, 2H), 7.30-7.09 (m, 5H), 4.58 (s, 2H), 4.31-3.97 (m, 1H), 3.57-3.39 (m, 4H), 2.83-2.68 (m, 2H ), 2.42-2.30 (m, 1H), 1.83-1.61 (m, 2H), 1.09 (t, J = 7.2 Hz, 3H).
    Example 49 (157)
    N-hydroxy-2 (S) -benzyl-5-ethoxymethoxy-4 (S)-[N-[(1-acetylpiperidin-4-yl) carbonyl] amino] pentanamide

    TLC: Rf 0.64 (CHCl 3: MeOH = 5: 1);
    NMR (d 6 -DMSO): δ 10.32 (brs, 1H), 7.58 (brd, J = 9.0 Hz, 1H), 7.25-7.08 (m, 5H), 4.53 (s, 2H), 4.32 (brd, J = 9.6 Hz, 1H), 3.93 (m, 1H), 3.79 (brd, J = 12.6 Hz, 1H), 3.43 (q, J = 6.9 Hz, 2H), 3.35 (m, 2H), 2.98 (brt, J = 12.0 Hz, 1H), 2.68 (m, 2H), 2.49 (m, 1H), 2.40-2.20 (m, 2H), 1.98 (s, 3H), 1.75-1.30 (m, 6H), 1.09 (t, J = 6.9 Hz, 3H).
    Example 49 (158)
    N-hydroxy-2 (S) -benzyl-5-ethoxymethoxy-4 (S)-[N-[(1-methylpiperidin-4-yl) carbonyl] amino] pentanamide

    TLC: Rf 0.39 (CHCl 3: MeOH: Acetic Acid = 7: 2: 1);
    NMR (d 6 -DMSO): δ 10.30 (brs, 1H), 8.67 (brs, 1H), 7.48 (brd, J = 9.0 Hz, 1H), 7.24-7.07 (m, 5H), 4.52 (s, 2H) , 3.93 (m, 1H), 3.42 (q, J = 7.2 Hz, 2H), 3.34 (m, 2H), 2.70 (m, 4H), 2.26 (m, 1H), 2.00 (m, 1H), 2.10 ( s, 3H), 1.81-1.45 (m, 8H), 1.08 (t, J = 7.2 Hz, 3H).
    Example 49 (159)
    N-hydroxy-2 (S) -benzyl-5-ethoxymethoxy-4 (S)-[N- (4-formylphenylcarbonyl) amino] pentanamide

    TLC: Rf 0.36 (CHCl 3: MeOH = 9: 1);
    NMR (d 6 -DMSO): δ 10.38 (s, 1H), 10.09 (s, 1H), 8.69 (s, 1H), 8.38 (d, J = 8.4Hz, 1H), 8.05 (d, J = 8.4Hz , 2H), 7.99 (d, J = 8.4 Hz, 2H), 7.30-7.20 (m, 2H), 7.20-7.10 (m, 3H), 4.58 (s, 2H), 4.32-4.20 (m, 1H), 3.60-3.40 (m, 4H), 2.83-2.70 (m, 2H), 2.45-2.32 (m, 1H), 1.85-1.62 (m, 2H), 1.09 (t, J = 6.9 Hz, 3H).
    Example 49 (160)
    N-hydroxy-2 (S)-(3-methoxybenzyl) -5-ethoxymethoxy-4 (S)-[N- (4-nitrophenylcarbonyl) amino] pentanamide

    TLC: Rf 0.40 (CHCl 3: MeOH = 9: 1);
    NMR (d 6 -DMSO): δ 10.38 (d, J = 1.8Hz, 1H), 8.70 (d, J = 1.8Hz, 1H), 8.51 (d, J = 8.4Hz, 1H), 8.31 (d, J = 8.9 Hz, 2H), 8.09 (d, J = 8.9 Hz, 2H), 7.18-7.10 (m, 1H), 6.75-6.65 (m, 3H), 4.58 (s, 2H), 4.30-4.20 (m, 1H), 3.69 (s, 3H), 3.60-3.40 (m, 4H), 2.80-2.65 (m, 2H), 2.45-2.30 (m, 1H), 1.85-1.60 (m, 2H), 1.09 (t, J = 7.1 Hz, 3H).
    Example 49 (161)
    N-hydroxy-2 (S)-(3-methoxybenzyl) -5-ethoxymethoxy-4 (S)-[N- (4-chlorophenylcarbonyl) amino] pentanamide

    TLC: Rf 0.47 (CHCl 3: MeOH = 9: 1);
    NMR (d 6 -DMSO): δ 10.36 (s, 1H), 8.23 (d, J = 8.4Hz, 1H), 7.89 (d, J = 8.6Hz, 2H), 7.53 (d, J = 8.6Hz, 2H ), 7.17-7.08 (m, 1H), 6.80-6.65 (m, 3H), 4.58 (s, 2H), 4.30-4.18 (m, 1H), 3.68 (s, 3H), 3.60-3.35 (m, 4H) , overlap with H 2 O in DMSO), 2.80-2.65 (m, 2H), 2.42-2.30 (m, 1H), 1.85-1.60 (m, 2H), 1.09 (t, J = 6.9 Hz, 3H).
    Example 49 (162)
    N-hydroxy-2 (S)-(4-methoxybenzyl) -5-ethoxymethoxy-4 (S)-[N- (4-methylphenylcarbonyl) amino] pentanamide

    TLC: Rf 0.49 (CHCl 3: MeOH = 9: 1);
    NMR (d 6 -DMSO): δ 10.30 (s, 1H), 8.64 (s, 1H), 8.02 (d, J = 8.8Hz, 1H), 7.75 (d, J = 8.4Hz, 2H), 7.24 (d , J = 8.4 Hz, 2H), 7.02 (d, J = 8.4 Hz, 2H), 6.76 (d, J = 8.4 Hz, 2H), 4.56 (s, 2H), 4.12-4.30 (m, 1H), 3.68 (s, 3H), 3.49-3.38 (m, 4H), 2.68 (d, J = 7.4 Hz, 2H), 2.39-2.22 (m, 1H), 2.34 (s, 3H), 1.82-1.58 (m, 2H ), 1.07 (t, J = 7.2 Hz, 3H).
    Example 49 (163)
    N-hydroxy-2 (S)-(2-methoxybenzyl) -5-ethoxymethoxy-4 (S)-[N- (4-methylphenylcarbonyl) amino] pentanamide

    TLC: Rf 0.51 (CHCl 3: MeOH = 9: 1);
    NMR (d 6 -DMSO): δ 10.30 (s, 1H), 8.63 (d, J = 1.5Hz, 1H), 7.93 (d, J = 8.4Hz, 1H), 7.74 (d, J = 8.4Hz, 2H ), 7.23 (d, J = 8.4 Hz, 2H), 7.16-6.76 (m, 4H), 4.55 (s, 2H), 4.19-4.08 (m, 1H), 3.62 (s, 3H), 3.48-3.38 ( m, 4H), 2.71-2.62 (m, 2H), 2.51-2.40 (m, 1H), 2.33 (s, 3H), 1.75-1.70 (m, 2H), 1.06 (t, J = 7.2 Hz, 3H) .
    Example 49 (164)
    N-hydroxy-2 (S)-(naphthalen-1-yl) -5-ethoxymethoxy-4 (S)-[N- (4-methylphenylcarbonyl) amino] pentanamide

    TLC: Rf 0.44 (CHCl 3: MeOH = 9: 1);
    NMR (d 6 -DMSO): δ 10.24 (s, 1H), 8.61 (s, 1H), 8.11 (d, J = 8.4Hz, 1H), 7.98 (d, J = 8.4Hz, 1H), 7.86-7.79 (m, 4H), 7.74-7.71 (d, J = 8.4 Hz, 1H), 7.44-7.23 (m, 5H), 4.54 (s, 2H), 4.30-4.20 (m, 1H), 3.50-3.47 (m , 2H), 3.95 (q, J = 7.2 Hz, 2H), 3.29-3.10 (m, 2H), 2.62-2.51 (m, 1H), 1.95-1.75 (m, 2H), 1.04 (t, J = 7.2 Hz, 3H).
    Example 49 (165)
    N-hydroxy-2 (S)-(3-methoxybenzyl) -5-ethoxymethoxy-4 (S)-[N- (trans-4-methylcyclohexylcarbonyl) amino] pentanamide

    TLC: Rf 0.56 (CHCl 3: MeOH = 9: 1);
    NMR (d 6 -DMSO): δ 10.31 (s, 1H), 9.00-8.30 (brs, 1H), 7.44 (d, J = 8.7 Hz, 1H), 7.13 (t, J = 8.0 Hz, 1H), 6.80 -6.65 (m, 3H), 4.55 (d, J = 6.6 Hz, 1H), 4.51 (d, J = 6.6 Hz, 1H), 4.00-3.85 (m, 1H), 3.70 (s, 3H), 3.44 ( q, J = 7.1 Hz, 2H), 3.50-3.20 (m, 2H), 2.75-2.50 (m, 2H), 2.30-2.20 (m, 1H), 2.10-1.90 (m, 1H), 1.80-1.20 ( m, 9H), 1.09 (t, J = 7.1 Hz, 3H), 0.84 (d, J = 6.6 Hz, 3H), 1.00-0.80 (m, 2H).
    Example 49 (166)
    N-hydroxy-2 (S) -benzyl-5-ethoxymethoxy-4 (S)-[N- (4-methoxycyclohexylcarbonyl) amino] pentanamide

    TLC: Rf 0.40 (methylene chloride: methanol = 9: 1);
    NMR (d 6 -DMSO): δ 10.30 (brs, 1H), 8.67 (brs, 1 H), 7.48 (brd, J = 8.4 Hz, 0.4H), 7.41 (brd, J = 8.4 Hz, 0.6H), 7.24 -7.08 (m, 5H), 4.53 (s, 2H), 3.93 (m, 1H), 3.43 (q, J = 7.2 Hz, 2H), 3.34 (m, 3H), 3.21 (s, 1.2H), 3.18 (s, 1.8H), 2.67 (m, 2H), 2.30-1.30 (m, 12H), 1.09 (t, J = 7.2 Hz, 3H).
    Example 49 (167)
    N-hydroxy-2 (S)-(benzothiophen-3-yl) -5-ethoxymethoxy-4 (S)-[N- (4-bromophenylcarbonyl) amino] pentanamide

    TLC: Rf 0.43 (CHCl 3: MeOH = 9: 1);
    NMR (d 6 -DMSO): δ 10.38 (d, J = 1.2 Hz, 1H), 8.68 (d, J = 1.2 Hz, 1H, 8.27 (d, J = 8.4 Hz, 1H), 7.91 (d, J = 7.5 Hz, 1H), 7.83-7.76 (m, 3H), 7.69-7.66 (m, 2H), 7.34-7.22 (m, 3H), 4.55 (s, 2H), 4.38-4.25 (m, 1H), 3.49 (d, J = 5.1 Hz, 2H), 3.41 (q, J = 7.2 Hz, 2H), 3.02-2.98 (m, 2H), 2.56-2.48 (m, 1H), 1.91-1.70 (m, 2H), 1.04 (t, J = 7.2 Hz, 3H).
    Example 49 (168)
    N-hydroxy-2 (S)-(benzothiophen-3-yl) -5-ethoxymethoxy-4 (S)-[N- (4-chlorophenylcarbonyl) amino] pentanamide

    TLC: Rf 0.44 (CHCl 3: MeOH = 9: 1);
    NMR (d 6 -DMSO): δ 10.38 (d, J = 1.5 Hz, 1H), 8.68 (d, J = 1.5 Hz, 1H), 8.27 (d, J = 8.4 Hz, 1H), 7.93-7.87 (m , 3H), 7.78 (d, J = 7.5 Hz, 1H), 7.55-7.52 (m, 2H), 7.34-7.22 (m, 3H), 4.55 (s, 2H), 4.38-4.24 (m, 1H), 3.49 (d, J = 5.4 Hz. 2H), 3.41 (q, J = 7.2 Hz, 2H), 3.04-2.92 (m, 2H), 2.58-2.42 (m, 1H), 1.90-1.70 (m, 2H) , 1.05 (t, J = 7.2 Hz, 3H).
    Example 49 (169)
    N-hydroxy-2 (S) -benzyl-5-ethoxymethoxy-4 (S)-[N-[(2-chloropyridin-5-yl) carbonyl] amino] pentanamide

    TLC: Rf 0.36 (CHCl 3: MeOH = 9: 1);
    NMR (d 6 -DMSO): δ 10.35 (s, 1H), 8.81 (d, J = 2.4Hz, 1H), 8.65 (s, 1H), 8.43 (d, J = 9.0Hz, 1H), 8.21 (dd , J = 2.4 Hz, 8.5 Hz, 1H), 7.61 (d, J = 8.5 Hz, 1H), 7.24-7.07 (m, 5H), 4.54 (s, 2H), 4.24-4.14 (m, 1H), 3.50 -3.37 (m, 4H), 2.79-2.66 (m, 2H), 2.39-2.28 (m, 1H), 1.79-1.60 (m, 2H), 1.05 (t, J = 7.1 Hz, 3H).
    Example 49 (170)
    N-hydroxy-2 (S)-(3,5-dimethoxybenzyl) -5-ethoxymethoxy-4 (S)-[N- (4-methylphenylcarbonyl) amino] pentanamide

    TLC: Rf 0.33 (CHCl 3: MeOH = 9: 1);
    NMR (d 6 -DMSO): δ 10.33 (brs, 1H), 8.67 (brs, 1 H), 8.02 (brd, J = 8.7 Hz, 1H), 7.76 (d, J = 8.1 Hz, 2H), 7.25 (d , J = 8.1 Hz, 2H), 6.26 (s, 3H), 4.57 (s, 2H), 4.24 (m, 1H), 3.63 (s, 6H), 3.49 (m, 2H), 3.45 (q, J = 7.2 Hz, 2H), 2.68 (brd, J = 7.2 Hz, 2H), 2.34 (s, 3H), 2.34 (m, 1H), 1.80-1.59 (m, 2H), 1.07 (t, J = 7.2 Hz, 3H).
    Example 49 (171)
    N-hydroxy-2 (S) -benzyl-5-ethoxymethoxy-4 (S)-[N- (4-methylcyclohexylcarbonyl) amino] pentanamide

    TLC: Rf 0.38 (CHCl 3: MeOH = 9: 1);
    NMR (d 6 -DMSO): δ 10.29 (d, J = 1.5 Hz, 1H), 8.65 (d, J = 1.5 Hz, 1H), 7.42 (brd, J = 8.4 Hz, 0.16H), 7.34 (brd, J = 8.4 Hz, 0.84H), 7.23-7.08 (m, 5H), 4.52 (s, 2H), 3.95 (m, 1H), 3.43 (q, J = 7.2 Hz, 2H), 3.35 (m, 2H) , 2.68 (m, 2H), 2.30-2.10 (m, 2H), 1.80-1.30 (m, 11H), 1.08 (t, J = 7.2 Hz, 3H), 0.88 (d, J = 6.6 Hz, 2.5H) , 0.83 (d, J = 6.6 Hz, 0.5H).
    Example 49 (172)
    N-hydroxy-2 (S)-(3-methoxybenzyl) -5-ethoxymethoxy-4 (S)-[N- (4-cyanophenylcarbonyl) amino] pentanamide

    TLC: Rf 0.32 (CHCl 3: MeOH = 19: 1);
    NMR (d 6 -DMSO): δ 10.37 (s, 1H), 8.68 (s, 1H), 8.42 (d, J = 8.4Hz, 1H), 8.02 (d, J = 8.4Hz, 2H), 7.95 (d , J = 8.4 Hz, 2H), 7.20-7.08 (m, 1H), 6.76-6.65 (m, 3H), 4.58 (s, 2H), 4.33-4.15 (m, 1H), 3.68 (s, 3H), 3.55-3.39 (m, 4H), 2.80-2.56 (m, 2H), 2.43-2.28 (m, 1H), 1.88-1.58 (m, 2H), 1.09 (t, J = 7.2 Hz, 3H).
    Example 49 (173)
    N-hydroxy-2 (R)-(3,4,4-trimethyl-2,5-dioxoimidazolidin-1-yl) methyl-5-ethoxymethoxy-4 (S)-[N -(Trans-4-methylcyclohexylcarbonyl) amino] pentanamide

    TLC: Rf 0.47 (CHCl 3: MeOH = 19: 1);
    NMR (d 6 -DMSO): δ 10.59 (s, 1H), 8.78 (s, 1H), 7.43 (d, J = 8.4Hz, 1H), 4.52 (d, J = 6.9Hz, 1H), 4.50 (d , J = 6.9 Hz, 1H), 3.77-3.65 (m, 1H), 3.48-3.33 (m, 4H), 2.76 (s, 3H), 2.52-2.41 (m, 1H), 2.03-1.92 (m, 1H ), 1.45-1.71 (m, 6H), 1.37-1.20 (m, 1H), 1.27 (s, 3H), 1.26 (s, 3H), 1.08 (t, J = 7.2 Hz, 3H), 0.89-0.78 ( m, 2H), 0.83 (d, J = 6.3 Hz, 3H).
    Example 49 (174)
    N-hydroxy-2 (R)-(benzofuran-2-yl) -5-ethoxymethoxy-4 (S)-[N- (trans-4-methylcyclohexylcarbonyl) amino] pentanamide

    TLC: Rf 0.42 (CHCl 3: MeOH = 19: 1);
    NMR (d 6 -DMSO): δ 10.52 (s, 1H), 8.78 (s, 1H), 7.52-7.42 (m, 3H), 7.23-7.13 (m, 2H), 6.53 (s, 1H), 4.54 ( d, J = 6.6 Hz, 1H), 4.51 (d, J = 6.6 Hz, 1H), 3.95-3.82 (m, 1H), 3.46-3.33 (m, 4H), 2.97-2.81 (m, 2H), 2.55 -2.42 (m, 1H), 2.04-1.95 (m, 1H), 1.74-1.56 (m, 7H), 1.39-1.26 (m, 4H), 1.07 (t, J = 7.2 Hz, 3H), 0.84 (d , J = 6.6 Hz, 3H).
    Example 49 (175)
    N-hydroxy-2 (S)-(benzothiophen-3-yl) -5-ethoxymethoxy-4 (S)-[N- (4-nitrophenylcarbonyl) amino] pentanamide

    TLC: Rf 0.36 (CHCl 3: MeOH = 19: 1);
    NMR (d 6 -DMSO): δ 10.42 (s, 1H), 8.70 (brs, 1H), 8.55 (d, J = 8.4 Hz, 1H), 8.32-8.29 (m, 2H), 8.11-8.08 (m, 2H), 7.93-7.90 (m, 1H), 7.81-7.78 (m, 1H), 7.34-7.25 (m, 3H), 4.55 (s, 2H), 4.38-4.25 (m, 1H), 3.51 (d, J = 5.7 Hz, 2H), 3.41 (q, J = 7.2 Hz, 2H), 3.05-2.94 (m, 2H), 2.57-2.53 (m, 1H), 1.91-1.72 (m, 2H), 1.04 (t , J = 7.2 Hz, 3H).
    Example 49 (176)
    N-hydroxy-2 (S) -benzyl-5-ethoxymethoxy-4 (S)-[N- (4-cyanophenylcarbonyl) amino] pentanamide

    TLC: Rf 0.47 (CHCl 3: MeOH = 9: 1);
    NMR (d 6 -DMSO): δ 10.34 (s, 1H), 8.66 (s, 1H), 8.22 (d, J = 8.4Hz, 1H), 7.85 (d, J = 8.4Hz, 2H), 7.55 (d , J = 8.4 Hz, 2H), 7.24-7.09 (m, 5H), 4.56 (s, 2H), 4.35 (s, 1H), 4.28-4.16 (m, 1H), 3.48 (d, J = 6.0 Hz, 2H), 3.43 (q, J = 6.9 Hz, 2H), 2.75 (d, J = 7.2 Hz, 2H), 2.40-2.29 (m, 1H), 1.81-1.61 (m, 2H), 1.07 (t, J = 6.9 Hz, 3H).
    Example 49 (177)
    N-hydroxy-2 (S) -benzyl-5-ethoxymethoxy-4 (S)-[N- (4-methylidenecyclohexylcarbonyl) amino] pentanamide

    TLC: Rf 0.40 (methylene chloride: methanol = 9: 1);
    NMR (d 6 -DMSO): δ 10.31 (s, 1H), 8.67 (s, 1H), 7.50 (brd, J = 8.7Hz, 1H), 7.25-7.08 (m, 5H), 4.61 (s, 2H) , 4.53 (s, 2H), 3.93 (m, 1H), 3.43 (q, J = 6.9 Hz, 2H), 3.35 (m, 2H), 2.68 (m, 2H), 2.25 (m, 4H), 2.05- 1.30 (m, 8 H), 1.09 (t, J = 6.9 Hz, 3H).
    Example 49 (178)
    N-hydroxy-2 (S) -benzyl-5-ethoxymethoxy-4 (S)-[N-[(1-formylpiperidin-4-yl) carbonyl] amino] pentanamide

    TLC: Rf 0.38 (methylene chloride: methanol = 9: 1);
    NMR (d 6 -DMSO): δ 10.32 (s, 1H), 8.68 (s, 1H), 7.96 (s, 1H), 7.58 (brd, J = 8.7 Hz, 1H), 7.25-7.08 (m, 5H) , 4.53 (s, 2H), 4.13 (brd, J = 12.3 Hz, 1H), 3.93 (m, 1H), 3.67 (brd, J = 10.5 Hz, 1H), 3.43 (q, J = 6.9 Hz, 2H) , 3.35 (m, 2H), 3.00 (brt, J = 12.3 Hz, 1H), 2.75-2.20 (m, 5H), 1.80-1.30 (m, 6H), 1.09 (t, J = 6.9 Hz, 3H).
    Example 49 (179)
    N-hydroxy-2 (S) -benzyl-5-ethoxymethoxy-4 (S)-[N-[(1-methyl-1-cyclohexen-4-yl) carbonyl] amino] pentanamide

    TLC: Rf 0.30 (CHCl 3: MeOH = 10: 1);
    NMR (d 6 -DMSO): δ 10.33 (brs, 1H), 7.53 (d, J = 8.4 Hz, 1H), 7.30-7.05 (m, 5H), 5.35 (brs, 1H), 4.54 (s, 2H) , 4.00-3.85 (m, 1H), 3.60-3.20 (m, 4H), 2.80-2.60 (m, 2H), 2.40-1.40 (m, 10H), 1.60 (s, 3H), 1.10 (t, J = 7.2 Hz, 3H).
    Example 49 (180)
    N-hydroxy-2 (S) -benzyl-5-ethoxymethoxy-4 (S)-[N-[(4-methyl-1-cyclohexenyl) carbonyl] amino] pentanamide

    TLC: Rf 0.35 (CHCl 3: MeOH = 10: 1);
    NMR (d 6 -DMSO): δ 10.32 (s, 1H), 8.65 (s, 1H), 7.35-7.00 (m, 6H), 6.46 (brs, 1H), 4.54 (s, 2H), 4.20-3.90 ( m, 1H), 3.50-3.20 (m, 4H), 2.80-2.60 (m, 2H), 2.40-2.20 (m, 4H), 1.80-1.50 (m, 5H), 1.20-1.00 (m, 1H), 1.09 (t, J = 7.1 Hz, 3H), 0.93 (d, J = 6.3 Hz, 3H).
    Example 49 (181)
    N-hydroxy-2 (S) -benzyl-5-ethoxymethoxy-4 (S)-[N- (4-fluorophenylcarbonyl) amino] pentanamide

    TLC: Rf 0.45 (CHCl 3: MeOH = 9: 1);
    NMR (d 6 -DMSO): δ 10.36 (s, 1H), 8.60-8.55 (br, 1H), 8.16 (d, J = 8.7Hz, 1H), 7.94 (dd, J = 9.0, 5.4Hz, 2H) , 7.35-7.20 (m, 4H), 7.20-7.08 (m, 3H), 4.58 (s.2H), 4.30-4.18 (m, 1H), 3.60-3.40 (m, 4H), 2.82-2.70 (m, 2H), 2.42-2.30 (m, 1H), 1.82-1.60 (m, 2H), 1.09 (t, J = 6.9 Hz, 3H).
    Example 49 (182)
    N-hydroxy-2 (S) -benzyl-5-ethoxymethoxy-4 (S)-[N- (4-chlorophenylcarbonyl) amino] pentanamide

    TLC: Rf 0.38 (CHCl 3: MeOH = 9: 1);
    NMR (d 6 -DMSO): δ 10.36 (s, 1H), 8.80-8.55 (br, 1H), 8.22 (d, J = 8.4Hz, 1H), 7.89 (d, J = 8.7Hz.2H), 7.53 (d, J = 8.7 Hz, 2H), 7.30-7.10 (m, 5H), 4.57 (s, 2H), 4.30-4.15 (m, 1H), 3.60-3.40 (m, 4H), 2.82-2.70 (m , 2H), 2.42-2.30 (m, 1H), 1.82-1.60 (m, 2H), 1.09 (t, J = 7.1 Hz, 3H).
    Example 49 (183)
    N-hydroxy-2 (S) -benzyl-5-ethoxymethoxy-4 (S)-[N- (4-hydroxycyclohexylcarbonyl) amino] pentanamide

    TLC: Rf 0.38 (CHCl 3: MeOH: Acetic Acid = 9: 1: 0.5);
    NMR (d 6 -DMSO): δ 10.29 (s, 1H), 7.44 (d, J = 8.8 Hz, 0.4H), 7.35 (d, J = 8.8 Hz, 0.6H), 7.26-7.03 (m, 5H) , 4.51 (s, 2H), 4.02-3.82 (m, 1H), 3.76-3.67 (m, 1H), 3.41 (q, J = 7.1 Hz, 2H), 3.39-3.26 (m, 2H), 2.72-2.62 (m, 2H), 2.33-2.19 (m, 1H), 2.15-1.90 (m, 1H), 1.87-1.24 (m, 10H), 1.07 (t, J = 7.1 Hz, 3H).
    Example 49 (184)
    N-hydroxy-2 (S)-(benzofuran-3-yl) -5-ethoxymethoxy-4 (S)-[N- (trans-4-methylcyclohexylcarbonyl) amino] pentanamide

    TLC: Rf 0.33 (CHCl 3: MeOH = 19: 1);
    NMR (d 6 -DMSO): δ 10.41 (s, 1H), 8.74 (s, 1H), 7.76-7.56 (m, 2H), 7.55-7.38 (m, 2H), 7.37-7.15 (m, 2H), 4.58-4.46 (m, 2H), 4.13-3.90 (m, 1H), 3.58-3.30 (m, 4H), 2.92-2.62 (m, 2H), 2.50-2.34 (m, 1H), 2.12-1.92 (m , 1H), 1.82-1.50 (m, 6H), 1.48-1.18 (m, 3H), 1.09 (t, J = 7.0 Hz, 3H), 1.00-0.70 (m.5H).
    Example 49 (185)
    N-hydroxy-2 (S)-(3-methoxybenzyl) -5-ethoxymethoxy-4 (S)-[N- (4-trifluoromethylphenylcarbonyl) amino] pentanamide

    TLC: Rf 0.41 (CHCl 3: MeOH = 9: 1);
    NMR (d 6 -DMSO): δ 10.34 (s, 1H), 8.67 (s, 1H), 8.39 (d, J = 8.7Hz, 1H), 8.05 (d, J = 8.0Hz, 2H), 7.83 (d , J = 8.0H 42H), 7.12 (t, J = 8.4 Hz, 1H), 6.72-6.68 (m, 3H), 4.57 (s, 2H), 4.32-4.15 (m, 1H), 3.66 (s, 3H ), 3.51-3.39 (m, 4H), 2.73 (d, J = 7.0 Hz, 2H), 2.41-2.27 (m, 1H), 1.82-1.59 (m, 2H), 1.0 (t, J = 7.0 Hz, 3H).
    Example 49 (186)
    N-hydroxy-2 (S)-(1-methylindol-3-yl) -5- (2-methoxyethoxy) methoxy-4 (S)-[N- (trans-4-methylcyclohexyl Carbonyl) amino] pentanamide

    TLC: Rf 0.33 (CHCl 3: MeOH = 19: 1);
    NMR (d 6 -DMSO): δ 10.30 (s, 1H), 8.64 (s, 1H), 7.52 (d, J = 7.8Hz, 1H), 7.42 (d, J = 8.4Hz. 1H), 7.32 (d , J = 7.8Hz, 1H), 7.11 (t, J = 7.8Hz, 1H), 6.98 (s, 1H), 6.96 (t, J = 7.8Hz, 1H), 4.58-4.48 (m, 2H), 4.03 -3.92 (m, 1H), 3.70 (s, 3H), 3.51-3.25 (m, 6H), 3.23 (s, 3H), 2.89-2.70 (m, 2H), 2.43-2.34 (m, 1H), 2.08 -1.95 (m, 1H), 1.80-1.48 (m, 6H), 1.47-1.20 (m, 3H), 0.96-0.78 (m, 5H).
    Example 49 (187)
    N-hydroxy-2 (S) -benzyl-5-ethoxymethoxy-4 (S)-[N-[(1,3-dithia-2--2-) carbonyl] amino] pentanamide

    TLC: Rf 0.39 (CHCl 3: MeOH = 9: 1);
    NMR (d 6 -DMSO): δ 10.33 (s, 1H), 8.71 (brs, 1H), 7.81 (d, J = 8.1Hz, 1H), 7.25-7.08 (m, 5H), 4.51 (s.2H) , 4.41 (s, 1H), 3.47-3.17 (m, 6H), 2.78-2.56 (m, 4H), 2.38-2.27 (m, 1H), 1.98-1.82 (m, 2H), 1.67-1.49 (m, 2H), 1.08 (t, J = 7.0 Hz, 3H).
    Example 49 (188)
    N-hydroxy-2 (S)-(3-methoxybenzyl) -5-ethoxymethoxy-4 (S)-[N- (4-bromophenylcarbonyl) amino] pentanamide

    TLC: Rf 0.47 (CHCl 3: MeOH = 9: 1);
    NMR (d 6 -DMSO): δ 10.34 (s, 1 H), 8.68 (brs, 1 H), 8.22 (d, J = 8.7 Hz, 1 H), 7.81-7.68 (m, 2H), 7.68-7.64 (m, 2H), 7.12 (t, J = 8.1 Hz, 1H), 6.71-6.66 (m, 3H), 4.56 (s, 2H), 4.16-4.27 (m, 1H), 3.66 (s, 3H), 3.48 (d , J = 5.7 Hz, 2H), 3.43 (q, J = 6.9 Hz, 2H), 2.71 (d, J = 6.0 Hz, 2H), 2.39-2.28 (m, 1H), 1.79-1.59 (m, 2H) , 1.07 (t, J = 6.9 Hz, 3H).
    Example 49 (189)
    N-hydroxy-2 (S)-(3-methoxybenzyl) -5-ethoxymethoxy-4 (S)-[N-[(2-bromothiophen-5-yl) carbonyl] amino] Pentanamide

    TLC: Rf 0.46 (CHCl 3: MeOH = 9: 1);
    NMR (d 6 -DMSO): δ 10.35 (s, 1H), 8.68 (s, 1H), 8.28 (d, J = 8.7Hz, 1H), 7.62 (d, J = 4.2Hz, 1H), 7.26 (d , J = 4.2 Hz, 1H, 7.12 (t, J = 7.8 Hz, 1H), 6.72-6.66 (m, 3H), 4.55 (s, 2H), 4.18-4.05 (m, 1H), 3.68 (s, 3H), 3.49-3.38 (m, 4H), 2.75-2.62 (m, 2H), 2.38-2.26 (m, 1H), 1.78-1.58 (m, 2H), 1.07 (t, J = 7.2 Hz, 1H) .
    Example 49 (190)
    N-hydroxy-2 (S)-(2-methoxybenzyl) -5-ethoxymethoxy-4 (S)-[N- (trans-4-methylcyclohexylcarbonyl) amino] pentanamide

    TLC: Rf 0.30 (CHCl 3: MeOH = 19: 1);
    NMR (d 6 -DMSO): δ 10.31 (s, 1H), 8.67 (s, 1H), 7.36 (d, J = 8.0Hz, 1H), 7.21-7.09 (m, 1H), 7.08-7.00 (m, 1H), 6.89 (d, J = 7.4 Hz, 1H), 6.81 (t, J = 7.4 Hz, 1H), 4.56-4.48 (m, 2H), 3.90-3.75 (m, 1H), 3.74 (s, 3H ), 3.43 (q, J = 7.0 Hz, 2H), 3.40-3.24 (m, 2H), 2.80-2.56 (m, 2H), 2.44-2.28 (m, 1H), 2.09-1.89 (m, 1H), 1.78-1.48 (m, 6H), 1.44-1.17 (m, 3H), 1.10 (t, J = 7.0 Hz, 3H), 1.00-0.70 (m, 5H).
    Example 49 (191)
    N-hydroxy-2 (S) -benzyl-5-ethoxymethoxy-4 (S)-[N-[(2-methylpyridin-5-yl) carbonyl] amino] pentanamide

    TLC: Rf 0.22 (CHCl 3: MeOH = 9: 1);
    NMR (d 6 -DMSO): δ 10.33 (s, 1H), 8.86 (d, J = 2.0Hz, 1H), 8.64 (s, 1H), 8.24 (d, J = 8.8Hz, 1H), 8.06 (dd , J = 8.0Hz, 2.0Hz, 1H), 7.31 (d, J = 8.0Hz, 1H), 7.26-7.06 (m, 5H), 4.55 (s, 2H), 4.30-4.12 (m, 1H), 3.50 -3.43 (m, 2H), 3.42 (q, J = 7.0 Hz, 2H), 2.78-2.66 (m, 2H), 2.49 (s, 3H), 2.44-2.27 (m, 1H), 1.83-1.56 (m , 2H), 1.05 (t, J = 7.0 Hz, 3H).
    Example 49 (192)
    N-hydroxy-2 (S)-(benzofuran-3-yl) -5-ethoxymethoxy-4 (S)-[N- (4-nitrophenylcarbonyl) amino] pentanamide

    TLC: Rf 0.45 (CHCl 3: MeOH = 9: 1);
    NMR (d 6 -DMSO): δ 10.43 (s, 1H), 8.71 (brs, 1H), 8.54 (d, J = 8.4Hz, 1H), 8.31 (d, J = 8.8Hz, 2H), 8.09 (d , J = 8.8 Hz, 2H), 7.63-7.60 (m, 1H), 7.49 (d, J = 7.6 Hz, 1H), 7.29-7.13 (m, 2H), 4.55 (s, 2H), 4.38-4.21 ( m, 1H), 3.51 (d, J = 5.6 Hz, 2H), 3.42 (q, J = 7.0 Hz, 2H), 2.84 (d, J = 7.4 Hz, 2H), 2.40-2.20 (m, 1H), 1.91-1.63 (m, 2H), 1.05 (t, J = 7.0 Hz, 3H).
    Example 49 (193)
    N-hydroxy-2 (S) -benzyl-5-ethoxymethoxy-4 (S)-[N- (trans-4-hydroxycyclohexylcarbonyl) amino] pentanamide

    TLC: Rf 0.41 (CHCl 3: MeOH: Acetic Acid = 9: 1: 0.5);
    NMR (d 6 -DMSO): δ 10.29 (s, 1H). 8.62 (brs, 1 H). 7.42 (d, J = 8.7 Hz, 1H), 7.24-7.05 (m, 5H), 4.51 (s, 2H), 3.96-3.85 (m, 1H). 3.51-3.25 (m, 5H), 2.73-2.50 (m, 2H), 2.30-2.19 (m, 1H), 2.03-1.91 (m, 1H), 1.85-1.56 (m, 5H), 1.53-1.24 (m , 3H), 1.13-1.03 (m, 5H).
    Example 49 (194)
    N-hydroxy-2 (S)-(3-chlorobenzyl) -5-ethoxymethoxy-4 (S)-[N- (4-methylphenylcarbonyl) amino] pentanamide

    TLC: Rf 0.50 (methylene chloride: methanol = 9: 1);
    NMR (d 6 -DMSO): δ 10.34 (s, 1H), 8.06 (brd, J = 8.8Hz, 1H), 7.77 (d, J = 8.4Hz, 2H), 7.27-7.03 (m, 6H), 4.57 (s, 2H), 4.23 (m, 1H), 3.50 (m, 2H), 3.4 (q, J = 7.0 Hz, 2H), 2.90 (m, 2H), 2.34 (s, 3H), 2.34 (m, 1H), 1.80-1.60 (m, 2H), 1.08 (t, J = 7.0 Hz, 3H).
    Example 49 (195)
    N-hydroxy-2 (S) -benzyl-5-ethoxymethoxy-4 (S)-[N-[(2-hydroxypyridin-5-yl) carbonyl] amino] pentanamide

    TLC: Rf 0.42 (CHCl 3: MeOH: Acetic Acid = 9: 1: 0.5);
    NMR (d 6 -DMSO): δ 11.93 (brs, 1H), 10.32 (s, 1H), 7.98 (d, J = 2.4 Hz, 1H), 7.90 (d, J = 8.4 Hz, 1H), 7.84 (dd) , J = 2.4 Hz, 8.4 Hz, 1H), 7.24-7.06 (m, 5H), 6.31 (d, J = 9.6 Hz, 1H), 4.53 (s, 2H), 4.18-4.02 (m, 1H), 3.45 -3.33 (m, 4H), 2.75-2.64 (m, 2H), 2.36-2.25 (m, 1H), 1.73-1.53 (m, 2H), 1.06 (t, J = 7.0 Hz, 3H).
    Example 49 (196)
    N-hydroxy-2 (R)-(3,4,4-trimethyl-2,5-dioxoimidazolidin-1-yl) methyl-5-ethoxymethoxy-4 (S)-[N -(4-bromophenylcarbonyl) amino] pentanamide

    TLC: Rf 0.53 (chloroform: methanol = 9: 1);
    NMR (d 6 -DMSO): δ 10.60 (s, 1H), 8.75 (bs, 1H), 8.19 (d, J = 7.8Hz, 1H), 7.77-7.74 (m, 2H), 7.66-7.62 (m, 2H), 4.54 (s, 2H), 4.06-3.96 (m, 1H), 3.50-3.37 (m, 6H), 2.75 (s, 3H), 2.64-2.51 (m, 1H), 1.69 (t, J = 7.2 Hz. 2H), 1.27 (s, 3H), 1.26 (s, 3H), 1.05 (t, J = 6.9 Hz, 3H).
    Example 49 (197)
    N-hydroxy-2 (S)-(3-methoxybenzyl) -5-ethoxymethoxy-4 (S)-[N- (4-dimethoxymethylphenylcarbonyl) amino] pentanamide

    TLC: Rf 0.50 (CHCl 3: MeOH = 9: 1);
    NMR (d 6 -DMSO): δ 10.36 (s, 1H), 8.68 (s, 1H), 8.16 (d, J = 8.4Hz, 1H), 7.89 (d, J = 8.2Hz, 2H), 7.46 (d , J = 8.2 Hz, 2H), 7.13 (t, J = 8.0 Hz, 1H), 6.80-6.65 (m, 3H), 5.44 (s, 1H), 4.58 (s, 2H), 4.35-4.20 (m, 1H), 3.66 (s, 3H), 3.60-3.35 (m, 4H), 3.25 (s, 6H), 2.74 (d, J = 6.9 Hz, 2H), 2.45-2.30 (m, 1H), 1.85-1.60 (m, 2H), 1.09 (t, J = 6.9 Hz, 3H).
    Example 49 (198)
    N-hydroxy-2 (S)-(3-trifluoromethyloxybenzyl) -5-ethoxymethoxy-4 (S)-[N- (4-chlorophenylcarbonyl) amino] pentanamide

    TLC: Rf 0.38 (CHCl 3: MeOH = 9: 1);
    NMR (d 6 -DMSO): δ 10.38 (s, 1H), 8.70 (s, 1H), 8.24 (d, J = 8.7Hz, 1H), 7.89 (d, J = 8.7Hz, 2H), 7.53 (d , J = 8.7 Hz, 2H), 7.36 (t, J = 7.8 Hz, 1H), 7.20-7.06 (m, 3H), 4.58 (s, 2H), 4.32-4.18 (m, 1H), 3.60-3.40 ( m, 4H), 2.90-2.75 (m, 2H), 2.42-2.30 (m, 1H), 1.85-1.60 (m, 2H), 1.09 (t, J = 7.1 Hz, 3H).
    Example 49 (199)
    N-hydroxy-2 (S)-(3-methoxybenzyl) -5-ethoxymethoxy-4 (S)-[N- [2-nitrothiophen-5-yl) carbonyl] amino] pentane amides

    TLC: Rf 0.46 (CHCl 3: MeOH = 9: 1);
    NMR (d 6 -DMSO): δ 10.38 (s, 1H), 8.73-8.69 (m, 2H), 8.13 (d, J = 4.5Hz, 1H), 7.83 (d, J = 4.5Hz, 1H), 7.16 -7.11 (m, 1H), 6.73-6.67 (m, 3H), 4.56 (s, 2H), 4.18-4.09 (m, 1H), 3.69 (s, 3H), 3.49 (d, J = 8.1 Hz, 2H ), 3.43 (q, J = 7.2 Hz, 2H), 2.79-2.63 (m, 2H), 2.29-2.40 (m, 1H), 1.80-1.59 (m, 2H), 1.07 (t, J = 7.2 Hz, 3H).
    Example 49 (200)
    N-hydroxy-2 (R)-(benzotriazol-1-yl) methyl-5-ethoxymethoxy-4 (S)-[N- (4-nitrophenylcarbonyl) amino] pentanamide

    TLC: Rf 0.29 (CHCl 3: MeOH = 9: 1);
    NMR (d 6 -DMSO): δ 10.52 (s, 1H), 8.62 (d, J = 8.4Hz, 1H), 8.32 (d, J = 9.0Hz, 2H), 8.08 (d, J = 9.0Hz, 2H ), 8.00 (d, J = 8.1 Hz, 1H), 7.80 (d, J = 8.1 Hz, 1H), 7.51 (t, J = 8.1 Hz, 1H), 7.34 (t, J = 8.1 Hz, 1H), 4.88 (dd, J = 14.1 Hz, 9.0 Hz, 1H), 4.75 (dd, J = 14.1 Hz, 5.7 Hz, 1H), 4.54 (s, 2H), 4.35-4.24 (m, 1H), 3.51 (d, J = 5.1 Hz, 2H), 3.41 (q, J = 7.2 Hz, 2H), 2.95-2.86 (m, 1H), 1.86-1.81 (m, 2H), 1.05 (t, J = 7.2 Hz, 3H).
    Example 49 (201)
    N-hydroxy-2 (R)-(3,4,4-trimethyl-2,5-dioxoimidazolidin-1-yl) methyl-5-ethoxymethoxy-4 (S)-[N -(4-nitrophenylcarbonyl) amino] pentanamide

    TLC: Rf 0.40 (CHCl 3: MeOH = 9: 1);
    NMR (d 6 -DMSO): δ 10.63 (s, 1H), 8.76 (s, 1H), 8.47 (d, J = 8.1Hz, 1H), 8.28 (d, J = 8.9Hz, 2H), 8.03 (d , J = 8.9 Hz, 2H), 4.56 (s, 2H), 4.10-3.98 (m, 1H), 3.60-3.32 (m, 6H), 2.76 (s, 3H), 2.65-2.50 (m, 1H), 1.80-1.65 (m.2H), 1.28 (s, 3H), 1.27 (s, 3H), 1.06 (t, J = 7.2 Hz, 3H).
    Example 49 (202)
    N-hydroxy-2 (R)-(3,4,4-trimethyl-2,5-dioxoimidazolidin-1-yl) methyl-5-ethoxymethoxy-4 (S)-[N -(4-chlorophenylcarbonyl) amino] pentanamide

    TLC: Rf 0.40 (CHCl 3: MeOH = 9: 1);
    NMR (d 6 -DMSO): δ 10.61 (s, 1H), 8.75 (s, 1H), 8.18 (d, J = 8.1Hz, 1H), 7.82 (d, J = 8.6Hz, 2H), 7.50 (d , J = 8.6 Hz, 2H), 4.55 (s, 2H), 4.10-3.95 (m, 1H), 3.60-3.35 (m, 6H), 2.76 (s, 3H), 2.65-2.45 (m, 1H), 1.80-1.62 (m, 2H), 1.28 (s, 3H), 1.26 (s, 3H), 1.06 (t, J = 6.9 Hz, 3H).
    Example 49 (203)
    N-hydroxy-2 (S)-(3-phenylpropyl) -5-methoxymethoxy-4 (S)-[N- (4-phenoxyphenylcarbonyl) amino] pentanamide

    TLC: Rf 0.57 (CHCl 3: MeOH = 10: 1);
    NMR (d 6 -DMSO): δ 10.44 (1H, brs), 8.72 (1H, brs), 8.04 (1H, d, J = 8.1 Hz), 7.87 (2H, d, J = 8.8 Hz), 7.45-7.40 (2H, m), 7.27-7.12 (6H, m), 7.08-7.04 (2H, m), 7.01 (2H, d, J = 8.8 Hz), 4.54 (2H, s), 4.14-4.03 (1H, m) ), 3.53-3.42 (2H, m), 3.21 (3H, s), 2.60-2.40 (2H, m), 2.16-2.06 (1H, m), 1.78-1.60 (2H, m), 1.52-1.38 (4H , m).
    Example 49 (204)
    N-hydroxy-2 (S)-(3-phenylpropyl) -5-methoxymethoxy-4 (S)-[N- [4- [2E- (4-chlorophenyl) ethenyl] phenylcarbonyl ] Amino] pentanamide

    TLC: Rf 0.58 (CHCl 3: MeOH = 10: 1);
    NMR (d 6 -DMSO): δ 10.46 (1H, brs), 8.74 (1H, brs), 8.10 (1H, d, J = 8.7 Hz), 7.86 (2H, d, J = 8.3 Hz), 7.67 (2H , d, J = 8.3 Hz), 7.65 (2H, d, J = 8.8 Hz), 7.44 (2H, d, J = 8.8 Hz), 7.38 (1H, d, J = 16.5 Hz), 7.32 (1H, d , J = 16.5 Hz), 7.27-7.22 (2H, m), 7.16-7.12 (3H, m), 4.55 (2H, s), 4.16-4.05 (1H, m), 3.55-3.46 (2H, m), 3.22 (3H, s), 2.59-2.42 (2H, m), 2.17-2.07 (1H, m), 1.79-1.62 (2H, m), 1.53-1.41 (4H, m).
    Example 49 (205)
    N-hydroxy-2 (S)-(3-phenylpropyl) -5-methoxymethoxy-4 (S)-[N- [4- (4-phenyl-1,2,5,6-tetrahydro Pyridin-1-yl) phenylcarbonyl] amino] pentanamide

    TLC: Rf 0.31 (CHCl 3: MeOH = 20: 1);
    NMR (d 6 -DMSO): δ 10.45 (1H, brs), 8.73 (1H, brs), 7.80 (1H, d, J = 8.3 Hz), 7.77 (2H, d, J = 9.0 Hz), 7.48 (2H , d, J = 7.2 Hz), 7.36 (2H, t, J = 7.2 Hz), 7.28-7.22 (3H, m), 7.16-7.12 (3H, m), 6.98 (2H, d, J = 9.0 Hz) , 6.29 (1H, brs), 4.54 (2H, s), 4.13-4.02 (1H, m), 3.94 (2H, s), 3.58 (2H, t, J = 5.7 Hz), 3.53-3.42 (2H, m ), 3.21 (3H, s), 2.66-2.58 (2H, m), 2.58-2.43 (2H, m), 2.18-2.07 (1H, m), 1.78-1.60 (2H, m), 1.52-1.40 (4H , m).
    Example 49 (206)
    N-hydroxy-2 (S)-(3-phenyl-2-propenyl) -5-ethoxymethoxy-4 (S)-[N- (trans-4-methylcyclohexylcarbonyl) amino] pentane amides

    TLC: Rf 0.41 (CHCl 3: MeOH = 9: 1);
    NMR (d 6 -MSO): δ 10.43 (s, 1H), 8.73 (brs, 1H), 7.43 (d, J = 8.4 Hz, 1H), 7.33-7.24 (m, 4H), 7.20-7.14 (m, 1H), 6.33 (d, J = 15.9 Hz, 1H), 6.08 (dt, J = 15.9, 6.9 Hz, 1H), 4.53 (s, 2H), 3.90-3.78 (m, 1H), 3.44 (q, J = 7.1 Hz, 2H), 3.40-3.31 (m, 2H), 2.31-2.22 (m, 2H), 2.19-2.08 (m, 1H), 2.03-1.92 (m, 1H), 1.74-1.58 (m, 5H ), 1.56-1.43 (m, 1H), 1.40-1.18 (m, 3H), 1.06 (t, J = 7.1 Hz, 3H), 0.91-0.81 (m, 5H).
    Example 49 (207)
    N-hydroxy-2 (S)-(3-phenylpropyl) -5-ethoxymethoxy-4 (S)-[N- (trans-4-methylcyclohexylcarbonyl) amino] pentanamide

    TLC: Rf 0.51 (CHCl 3: MeOH = 9: 1);
    NMR (d 6 -DMSO): δ 10.40 (s, 1H), 8.65 (brs, 1H), 7.38 (d, J = 8.4 Hz, 1H), 7.26-7.20 (m, 2H), 7.16-7.08 (m, 3H), 4.53 (s, 2H), 3.83-3.72 (m, 1H), 3.49-3.27 (m, 4H), 2.58-2.38 (m, 2H), 2.04-1.89 (m, 2H), 1.77-1.52 ( m, 5H), 1.50-1.21 (m, 8H), 1.07 (t, J = 6.9 Hz, 3H), 0.91-0.77 (m, 5H).
    Example 49 (208)
    N-hydroxy-2 (S)-(2-phenylethyl) -5- (2-methoxyethoxy) methoxy-4 (S)-[N- (trans-4-methylcyclohexylcarbonyl) amino ] Pentanamide

    TLC: Rf 0.34 (CHCl 3: MeOH = 10: 1);
    NMR (d 6 -DMSO): δ 10.45 (s, 1H), 9.20-8.40 (brs, 1H), 7.39 (d, J = 8.4 Hz, 1H), 7.28-7.23 (m, 2H), 7.20-7.10 ( m, 3H), 4.57 (s, 2H), 3.90-3.80 (m, 1H), 3.60-3.20 (m, 6H), 3.22 (s, 3H), 2.60-2.30 (m, 2H), 2.10-2.00 ( m, 1H), 2.05-1.90 (m, 1H), 1.80-1.40 (m, 9H), 1.40-1.20 (m, 2H), 0.95-0.75 (m, 2H), 0.84 (d, J = 6.6 Hz, 3H).
    Example 49 (209)
    N-hydroxy-2 (S)-(4-phenylbutyl) -5- (2-methoxyethoxy) methoxy-4 (S)-[N- (trans-4-methylcyclohexylcarbonyl) amino ] Pentanamide

    TLC: Rf 0.36 (CHCl 3: MeOH = 9: 1);
    NMR (d 6 -DMSO): δ 10.38 (s, 1H), 7.39 (d, J = 8.4 Hz, 1H), 7.30-7.20 (m, 2H), 7.20-7.10 (m, 3H), 4.57 (s, 2H), 3.90-3.75 (m, 1H), 3.65-3.15 (m, 6H), 3.22 (s, 3H), 2.60-2.40 (m, 2H), 2.05-1.90 (m, 2H), 1.85-1.05 ( m, 15H), 0.95-0.75 (m, 2H), 0.84 (d, J = 6.3 Hz, 3H).
    Example 49 (210)
    N-hydroxy-2 (S)-(3-phenylpropyl) -5-ethoxymethoxy-4 (S)-[N- (4-bromophenylcarbonyl) amino] pentanamide

    TLC: Rf 0.33 (CHCl 3: MeOH = 19: 1);
    NMR (d 6 -DMSO): δ 10.44 (s, 1H), 8.72 (s, 1H), 8.16 (d, J = 8.2Hz, 1H), 7.79 (d, J = 8.4Hz, 2H), 7.65 (d , J = 8.4 Hz, 2H), 7.32-7.08 (m, 5H), 4.59 (s, 2H), 4.20-3.98 (m, 1H), 3.63-3.40 (m, 4H), 2.68-2.38 (m, 2H ), 2.20-2.01 (m, 1H), 1.82-1.61 (m, 2H), 1.60-1.30 (m, 4H), 1.08 (t, J = 7.0 Hz, 3H).
    Example 49 (211)
    N-hydroxy-2 (S)-(3-phenylpropyl) -5-ethoxymethoxy-4 (S)-[N- (4-nitrophenylcarbonyl) amino] pentanamide

    TLC: Rf 0.29 (CHCl 3: MeOH = 19: 1);
    NMR (d 6 -DMSO): δ 10.45 (s, 1H), 8.72 (s, 1H), 8.45 (d, J = 8.4Hz, 1H), 8.29 (d, J = 9.0Hz.2H), 8.06 (d , J = 9.0 Hz, 2H), 7.29-7.20 (m, 2H), 7.19-7.09 (m, 3H), 4.59 (s, 2H), 4.17-4.01 (m, 1H), 3.56-3.40 (m, 4H ), 2.61-2.40 (m, 2H), 2.16-2.03 (m, 1H), 1.80-1.60 (m, 2H), 1.58-1.32 (m, 4H), 1.07 (t, J = 7.2 Hz, 3H).
    Example 49 (212)
    N-hydroxy-2 (R)-(2-phenoxyethyl) -5-ethoxymethoxy-4 (S)-[N- (4-nitrophenylcarbonyl) amino] pentanamide

    TLC: Rf 0.35 (CHCl 3: MeOH = 9: 1);
    NMR (d 6 -DMSO): δ 10.51 (s, 1H), 8.76 (s, 1H), 8.47 (d, J = 8.4Hz, 1H), 8.29 (d, J = 8.9Hz, 2H), 8.07 (d , J = 8.9 Hz, 2H), 7.30-7.20 (m, 2H), 6.95-6.80 (m, 3H), 4.59 (s, 2H), 4.25-4.12 (m, 1H), 3.95-3.78 (m, 2H ), 3.60-3.40 (m, 4H), 2.40-2.25 (m, 1H), 2.00-1.65 (m, 4H), 1.07 (t, J = 7.1 Hz, 3H).
    Example 49 (213)
    N-hydroxy-2 (R)-(2-pyridyl) methyl-5-methoxymethoxy-4 (S)-[N- (4-phenoxyphenylcarbonyl) amino] pentanamide

    TLC: Rf 0.20 (CHCl 3: MeOH = 19: 1);
    NMR (d 6 -DMSO): δ 10.44 (1H, s), 8.69 (1H, s), 8.48-8.40 (1H, m), 8.06 (1H, d, J = 8.4 Hz), 7.88 (2H, d, J = 8.8 Hz), 7.65 (1H, d, J = 7.8, 1.8 Hz), 7.50-7.38 (2H, m), 7.24-7.12 (3H, m), 7.11-7.04 (2H, m), 7.02 (2H , d, J = 8.8 Hz), 4.52 (2H, s), 4.23-4.02 (1H, m), 3.49 (2H, d, J = 5.6 Hz), 3.19 (3H, s), 2.96 (1H, dd, J = 13.8, 8.4 Hz), 2.85 (1H, dd, J = 13.8, 6.6 Hz). 2.75-2.60 (1H, m), 1.77 (2H, t, J = 7.0 Hz).
    Example 49 (214)
    N-hydroxy-2 (R)-(2-pyridyl) methyl-5-methoxymethoxy-4 (S)-[N- [4- (benzofuran-2-yl) phenylcarbonyl] amino] Pentanamide

    TLC: Rf 0.45 (CHCl 3: MeOH = 9: 1);
    NMR (d 6 -DMSO): δ 10.70-10.40 (1H, brs), 9.00-8.60 (1H, brs), 8.50-8.25 (2H, m), 7.99 (4H, s), 7.80-7.44 (4H, m ), 7.41-7.06 (4H, m), 4.52 (2H, s), 4.31-4.10 (1H, m), 3.64-3.46 (2H, m), 3.19 (3H, s), 3.06-2.82 (2H, m) ), 2.80-2.63 (1H, m), 2.00-1.70 (2H, m).
    Example 49 (215)
    N-hydroxy-2 (S)-(3-pyridyl) methyl-5-methoxymethoxy-4 (S)-[N- (4-phenoxyphenylcarbonyl) amino] pentanamide

    TLC: Rf 0.43 (CHCl 3: MeOH = 9: 1);
    NMR (d 6 -DMSO): δ 10.36 (1H, s), 8.69 (1H, s), 8.40-8.32 (2H, m), 8.12 (1H, d, J = 9.4 Hz), 7.91 (2H, d, J = 8.8 Hz), 7.54-7.38 (3H, m), 7.29-7.17 (2H, m), 7.12-7.06 (2H, m), 7.03 (2H, d, J = 8.8 Hz), 4.56 (2H, s ), 4.40-4.20 (1H, m), 3.60-3.42 (2H, m), 3.22 (3H, s), 2.87 (1H, dd, J = 13.6, 4.8 Hz), 2.75 (1H, dd, J = 13.6 , 9.6 Hz), 2.43-2.28 (1H, m), 1.90-1.59 (2H, m).
    Example 49 (216)
    N-hydroxy-2 (S)-(3-pyridyl) methyl-5-methoxymethoxy-4 (S)-[N- [4- [2- (4-methylphenyl) ethynyl] phenylcarbonyl ] Amino] pentanamide

    TLC: Rf 0.40 (CHCl 3: MeOH = 9: 1);
    NMR (d 6 -DMSO): δ 10.37 (1H, s), 8.70 (1H, s), 8.40-8.33 (2H, m), 8.29 (1H, d, J = 8.0 Hz), 7.92 (2H, d, J = 8.4 Hz), 7.63 (2H, d, J = 8.4 Hz), 7.57-7.42 (3H, m), 7.31-7.20 (3H, m), 4.56 (2H, s), 4.40-4.20 (1H, m ), 3.62-3.44 (2H, m), 3.22 (3H, s), 2.87 (1H, dd, J = 13.6, 4.8 Hz), 2.76 (1H, dd, J = 13.6, 9.2 Hz), 2.42-2.26 ( 4H, m), 1.91-1.59 (2H, m).
    Example 49 (217)
    N-hydroxy-2 (S)-(3-pyridyl) methyl-5-methoxymethoxy-4 (S)-[N- [4- (1-heptinyl) phenylcarbonyl] amino] pentanamide

    TLC: Rf 0.34 (CHCl 3: MeOH: Acetic Acid: Water = 100: 10: 1: 1);
    NMR (d 6 -DMSO): δ 10.35 (1H, brs), 8.69 (1H, brs), 8.37-8.33 (2H, m), 8.23 (1H, d, J = 8.4 Hz), 7.83 (2H, d, J = 8.0 Hz), 7.51-7.43 (3H, m), 7.25 (1H, dd, J = 7.8 Hz, 4.8 Hz), 4.54 (2H, s), 4.38-4.15 (1H, m), 3.50 (2H, d, J = 5.4 Hz), 3.20 (3H, s), 2.92-2.68 (2H, m), 2.49-2.39 (1H, m), 1.91-1.20 (10H, m), 0.88 (3H, t, J = 7.0 Hz).
    Example 49 (218)
    N-hydroxy-2 (S)-(3-pyridyl) methyl-5-methoxymethoxy-4 (S)-[N- [4- [2E- (4-chlorophenyl) ethenyl] phenylcart Carbonyl] amino] pentanamide

    TLC: Rf 0.26 (CHCl 3: MeOH: Acetic Acid: Water = 100: 10: 1: 1);
    NMR (d 6 -DMSO): δ 10.40 (1H, brs), 8.72 (1H, brs), 8.35 (2H, s), 8.21 (1H, d, J = 8.7 Hz), 7.89 (2H, d, J = 8.4 Hz), 7.68 (2H, d, 8.4 Hz), 7.65 (2H, d, J = 8.7 Hz), 7.51 (1H, d, J = 7.2 Hz), 7.44 (2H, d, J = 8.7 Hz), 7.39 (1H, d, J = 16.8 Hz), 7.32 (1H, d, J = 16.8 Hz), 7.27-7.23 (1H, m), 4.55 (2H, s), 4.39-4.21 (1H, m), 3.61 -3.42 (2H, m), 3.21 (3H, s), 2.91-2.69 (2H, m), 2.45-2.31 (1H, m), 1.91-1.60 (2H, m).
    Example 49 (219)
    N-hydroxy-2 (S)-(3-pyridyl) methyl-5-methoxymethoxy-4 (S)-[N- (trans-4-methylcyclohexylcarbonyl) amino] pentanamide

    TLC: Rf 0.34 (CHCl 3: MeOH = 9: 1);
    NMR (d 6 -DMSO): δ 10.34 (1H, brs), 8.72 (1H, brs), 8.36 (1H, doublet of doublets, J = 4.8, 1.5 Hz), 8.32-8.30 (1H, m), 7.52-7.45 ( 2H, m), 7.29-7.22 (1H, m), 4.51 (2H, s), 4.05-3.93 (1H, m), 3.44-3.35 (2H, m), 3.22 (3H, s), 2.77 (1H, dd, J = 13.2, 4.8 Hz), 2.69 (1H, dd, J = 13.2, 9.6 Hz), 2.35-2.22 (1H, m), 2.10-1.97 (1H, m), 1.82-1.61 (5H, m) , 1.60-1.44 (1H, m), 1.43-1.20 (3H, m), 0.97-0.79 (5H, m).
    Example 49 (220)
    N-hydroxy-2 (S)-(4-pyridyl) methyl-5-methoxymethoxy-4 (S)-[N- (4-phenoxyphenylcarbonyl) amino] pentanamide

    TLC: Rf 0.27 (CHCl 3: MeOH = 9: 1);
    NMR (d 6 -DMSO): δ 10.44-10.30 (1H, brs), 8.75-8.62 (1H, brs), 8.40 (2H, d, J = 6.0 Hz), 8.13 (1H, d, J = 8.4 Hz) , 7.91 (2H, d, J = 8.7 Hz), 7.48-7.38 (2H, m), 7.22-7.18 (1H, m), 7.13 (2H, d, J = 6.0 Hz), 7.06 (2H, d, J = 7.8 Hz), 7.02 (2H, d, J = 8.7 Hz), 4.55 (2H, s), 4.34-4.21 (1H, m), 3.58-3.42 (2H, m), 3.22 (3H, s), 2.91 -2.71 (2H, m), 2.46-2.32 (1H, m), 1.85-1.61 (2H, m).
    Example 49 (221)
    N-hydroxy-2 (R)-(2-pyridyl) methyl-5- (2-methoxyethoxy) methoxy-4 (S)-[N- (4-phenoxyphenylcarbonyl) amino] Pentanamide

    TLC: Rf 0.38 (CHCl 3: MeOH: Acetic Acid: Water = 100: 10: 1: 1);
    NMR (d 6 -DMSO): δ 10.43 (1H, s), 8.69 (1H, s), 8.45 (1H, d, J = 4.5 Hz), 8.60 (1H, d, J = 8.4 Hz), 7.87 (2H , d, J = 8.4 Hz), 7.65 (1H, t, J = 7.5 Hz), 7.42 (2H, t, J = 8.1 Hz), 7.21-7.15 (3H, m), 7.08-7.00 (4H, m) , 4.58 (2H, s), 4.06-4.22 (1H, m), 3.43-3.60 (4H, m), 3.42-3.38 (2H, m), 3.20 (3H, s), 2.98-2.81 (2H, m) , 2.61-2.78 (1H, m), 1.75 (2H, t, J = 7.2 Hz).
    Example 49 (222)
    N-hydroxy-2 (S)-(3-pyridyl) methyl-5-ethoxymethoxy-4 (S)-[N- (2-methylphenylcarbonyl) amino] pentanamide

    TLC: Rf 0.38 (CHCl 3: MeOH = 9: 1);
    NMR (d 6 -DMSO + CD 3 OD (5 drops)): δ 8.36-8.32 (m, 2H), 7.50 (d, J = 7.5 Hz, 1H), 7.34 (d, J = 7.5 Hz, 1H), 7.31-7.14 (m, 4H), 4.59 (2H, s), 4.26-4.16 (m, 1H), 3.52-3.43 (m, 4H), 2.87-2.69 (m, 2H), 2.43-2.34 (m, 1H ), 2.31 (s, 3H), 1.77-1.57 (m, 2H), 1.09 (t, J = 6.9 Hz, 3H).
    Example 49 (223)
    N-hydroxy-2 (S)-(3-pyridyl) methyl-5-ethoxymethoxy-4 (S)-[N- (3-methylphenylcarbonyl) amino] pentanamide

    TLC: Rf 0.38 (CHCl 3: MeOH = 9: 1);
    NMR (CD 3 OD): δ 8.44-8.37 (m, 2H), 7.75-7.66 (m, 3H), 7.42-7.34 (m, 3H), 4.73 (s, 2H), 4.52-4.41 (m, 1H) , 3.71-3.57 (m, 4H), 3.13-2.88 (m, 2H), 2.55-2.42 (m, 4H), 2.06-1.90 (m, 2H), 1.21 (t, J = 7.2 Hz, 3H).
    Example 49 (224)
    N-hydroxy-2 (S)-(3-pyridyl) methyl-5-ethoxymethoxy-4 (S)-[N- (4-methylphenylcarbonyl) amino] pentanamide

    TLC: Rf 0.38 (CHCl 3: MeOH = 9: 1);
    NMR (CD 3 OD + d 6 -DMSO (5 drops)): δ 8.46-8.42 (m, 2H), 7.84 (d, J = 8.4 Hz, 2H), 7.72 (d, J = 7.8 Hz, 1H), 7.42-7.33 (m, 3H), 4.75 (s, 2H), 4.53-4.4 (m, 1H), 3.71-3.59 (m, 4H), 3.13-2.88 (m, 2H), 2.57-2.45 (m, 4H ), 2.09-1.88 (m, 2H), 1.23 (t, J = 7.2 Hz, 3H).
    Example 49 (225)
    N-hydroxy-2 (S)-(3-pyridyl) methyl-5-ethoxymethoxy-4 (S)-[N- (4-methoxyphenylcarbonyl) amino] pentanamide

    TLC: Rf 0.30 (CHCl 3: MeOH = 9: 1);
    NMR (d 6 -DMSO): δ 10.35 (s, 1H), 8.68 (s, 1H), 8.40-8.30 (m, 2H), 8.00 (d, J = 8.8Hz, 1H), 7.86 (d, J = 8.8 Hz, 2H), 7.53-7.44 (m, 1H), 7.28-7.20 (m, 1H), 6.99 (d, J = 8.8 Hz, 2H), 4.59 (s, 2H), 4.38-4.17 (m, 1H) ), 3.81 (s, 3H), 3.60-3.40 (m, 4H), 2.86 (dd, J = 13.2, 5.2 Hz, 1H), 2.74 (dd, J = 13.2, 9.2 Hz, 1H), 2.44-2.28 ( m, 1H), 1.90-1.58 (m, 2H), 1.09 (t, J = 6.8 Hz, 3H).
    Example 49 (226)
    N-hydroxy-2 (S)-(3-pyridyl) methyl-5-ethoxymethoxy-4 (S)-(N-cyclohexylcarbonylamino) pentanamide

    TLC: Rf 0.21 (CHCl 3: MeOH = 10: 1);
    NMR (d 6 -DMSO): δ 10.33 (brs, 1H), 8.70 (brs, 1H), 8.36 (dd, J = 1.8, 4.5 Hz, 1H), 8.30 (d, J = 1.8 Hz, 1H), 7.48 -7.45 (m, 2H), 7.26 (dd, J = 4.5, 7.6 Hz, 1H), 4.55 (s, 2H), 4.40-3.51 (m, 1H), 3.45 (q, J = 7.2 Hz, 2H), 3.83-3.32 (m, 2H), 2.80-2.63 (m, 2H), 2.32-2.21 (m, 1H), 2.14-2.03 (m, 1H), 1.78-1.45 (m, 7H), 1.40-1.06 (m , 5H), 1.10 (t, J = 6.9 Hz, 3H).
    Example 49 (227)
    N-hydroxy-2 (S)-(3-pyridyl) methyl-5-ethoxymethoxy-4 (S)-[N- (4-nitrophenylcarbonyl) amino] pentanamide

    TLC: Rf 0.22 (CHCl 3: MeOH = 9: 1):
    NMR (d 6 -DMSO): δ 10.36 (s, 1H), 8.69 (s, 1H), 8.53 (d, J = 8.7Hz, 1H), 8.37-8.29 (m, 3H), 8.10-8.06 (m, 2H), 7.52-7.48 (m, 1H), 7.28-7.23 (m, 1H), 4.58 (s, 2H), 4.21-4.32, (m, 1H), 3.52 (d, J = 5.7 Hz, 2H), 3.45 (q, J = 7.2 Hz, 2H), 2.86-2.69 (m, 2H), 2.42-2.23 (m, 1H), 1.85-1.62 (m 2H), 1.08 (t, J = 7.2 Hz, 3H).
    Example 49 (228)
    N-hydroxy-2 (S)-(3-pyridyl) methyl-5-ethoxymethoxy-4 (S)-[N- (4-bromophenylcarbonyl) amino] pentanamide

    TLC: Rf 0.32 (CHCl 3: MeOH: Acetic Acid = 90: 10: 1);
    NMR (d 6 -DMSO): δ 10.34 (s, 1H), 8.68 (s, 1H), 8.37-8.24 (m, 3H), 7.80 (d, J = 8.7Hz, 2H), 7.67 (d, J = 8.7 Hz, 2H), 7.49 (dt, J = 8.1 Hz, 1.8 Hz, 1H), 4.57 (s, 2H), 4.31-4.18 (m, 1H), 3.50 (d, J = 6.0 Hz, 2H), 3.45 (q, J = 7.2 Hz, 2H), 2.87-2.68 (m, 2H), 2.40-2.24 (m, 1H), 1.82-1.59 (m.2H), 1.07 (t, J = 7.2 Hz, 3H).
    Example 49 (229)
    N-hydroxy-2 (S)-(3-quinolyl) -5-ethoxymethoxy-4 (S)-[N- (trans-4-methylcyclohexylcarbonyl) amino] pentanamide

    TLC: Rf 0.37 (CHCl 3: MeOH = 9: 1);
    NMR (d 6 -DMSO): δ 10.31 (s, 1H), 8.67-8.65 (m, 2H), 7.98-7.83 (m, 3H), 7.73-7.49 (m, 3H), 4.55 (s, 2H), 4.13-3.97 (m, 1H), 3.43 (q, J = 7.0 Hz, 2H), 3.42-3.36 (m, 2H), 3.06-2.80 (m, 2H), 2.48-2.30 (m, 1H), 2.15- 1.98 (m, 1H), 1.81-1.26 (m9H), 1.08 (t, J = 7.0 Hz, 3H), 0.99-0.79 (m, 2H), 0.85 (d, J = 7.0 Hz, 3H).
    Example 49 (230)
    N-hydroxy-2 (S) -phenylthio-5-methoxymethoxy-4 (S)-[N- (4-phenoxyphenylcarbonyl) amino] pentanamide

    TLC: Rf 0.27 (CHCl 3: MeOH: Acetic Acid = 100: 5: 1):
    NMR (d 6 -DMSO): δ 10.69 (1H, s), 8.97 (1H, s), 8.17 (1H, d, J = 8.0 Hz), 7.86 (2H, d, J = 8.8 Hz), 7.47-7.39 (4H, m), 7.34-7.16 (4H, m), 7.08-6.99 (4H, m), 4.53 (2H, s), 4.38-4.25 (1H, m), 3.62-3.35 (3H, m), 3.19 (3H, s), 2.02 (2H, t, J = 6.8 Hz).
    Example 49 (231)
    N-hydroxy-2 (S) -phenylthio-5-ethoxymethoxy-4 (S)-[N- (trans-4-methylcyclohexylcarbonyl) amino] pentanamide

    TLC: Rf 0.37 (CHCl 3: MeOH = 9: 1);
    NMR (d 6 -DMSO): δ 10.67 (s, 1H), 8.94 (bs, 1H), 7.52 (d, J = 8.1Hz, 1H), 7.38-7.22 (m, 5H), 4.52 (s, 2H) , 4.04-3.93 (m, 1H), 3.52-3.24 (m, 5H), 2.01-1.78 (m, 3H), 1.69-1.55 (m, 4H), 1.36-1.19 (m, 3H), 1.07 (t, J = 7.0 Hz, 3H), 0.91-0.75 (m, 5H).
    Example 49 (232)
    N-hydroxy-2 (S) -methylthio-5-ethoxymethoxy-4 (S)-[N- (trans-4-methylcyclohexylcarbonyl) amino] pentanamide

    TLC: Rf 0.38 (CHCl 3: MeOH = 9: 1);
    NMR (d 6 -DMSO): δ 10.56 (s, 1H), 8.88 (s, 1H), 7.48 (d, J = 8.4Hz, 1H), 4.55 (s, 2H), 4.04-3.90 (m, 1H) , 3.46 (q, J = 7.1 Hz, 2H), 3.39-3.25 (m, 2H), 2.96-2.87 (m, 1H), 2.04-1.91 (m, 4H), 1.90-1.77 (m, 1H), 1.76 -1.55 (m, 5H), 1.40-1.18 (m, 3H), 1.08 (t, J = 7.1 Hz, 3H), 0.92-0.74 (m, 5H).
    Example 49 (233)
    N-hydroxy-2 (S)-(4-pyridyl) thio-5-ethoxymethoxy-4 (S)-[N- (trans-4-methylcyclohexylcarbonyl) amino] pentanamide

    TLC: Rf 0.29 (CHCl 3: MeOH = 9: 1);
    NMR (d 6 -DMSO): δ 10.87 (s, 1H), 9.08 (s, 1H), 8.35 (d, J = 6.0Hz, 2H), 7.58 (d, J = 8.1Hz.1H), 7.27 (d , J = 6.0 Hz, 2H), 4.56 (s, 2H), 3.99-3.88 (m, 1H), 3.78 (t, J = 7.4 Hz, 1H), 3.45 (q, J = 7.2 Hz, 2H), 3.42 -3.31 (m, 2H), 2.02-1.87 (m, 3H), 1.71-1.56 (m, 4H), 1.35-1.17 (m, 3H), 1.07 (t, J = 7.2 Hz, 3H), 0.91-0.76 (m, 5 H).
    Examples 49 (234) -49 (253)
    Examples 44 (8), 44 (9), 44 (11), 44 (14), 44 (l7) -44 (21), compounds prepared in 44 (24) -44 (26), or Reference Example 4 Example 37 → Example 39 → Example 41 → Example 43 (using the equivalent compound instead of benzyl bromide) → Example 44, using the equivalent compound instead of the compound prepared in The compound obtained by operation in the same manner as in the method shown in Example 49 was operated to obtain a compound shown below.
    Example 49 (234)
    N-hydroxy-2 (S) -hydroxy-5-methoxymethoxy-4 (S)-[N- (4-phenoxyphenylcarbonyl) amino] pentanamide

    TLC: Rf 0.57 (CHCl 3: MeOH: Acetic Acid = 85:15: 1);
    NMR (d 6 -DMSO): δ 10.44 (1H, s), 8.69 (1H, brs), 8.19 (1H, d, J = 8.4 Hz), 8.89 (2H, d, J = 8.8 Hz), 7.48-7.38 (2H, m), 7.22-7.16 (1H, m), 7.09-7.01 (4H, m), 5.36 (1H, brs), 4.55 (2H, s), 4.41-4.24 (1H, m), 3.87 (1H , dd, J = 9.8 Hz, 2.6 Hz), 3.56-3.42 (2H, m), 3.22 (3H, s), 1.96-1.66 (2H, m).
    Example 49 (235)
    N-hydroxy-2 (R) -hydroxymethyl-5-ethoxymethoxy-4 (S)-[N- (4-chlorophenylcarbonyl) amino] pentanamide

    TLC: Rf 0.23 (chloroform: methanol: acetic acid = 90: 10: 1);
    NMR (d 6 -DMSO): δ 10.55-10.10 (brs, 1H), 8.90-8.50 (brs, 1H), 8.21 (d, J = 8.4 Hz, 1H), 7.86 (d, J = 8.7 Hz, 2H) , 7.52 (d, J = 8.7 Hz, 2H), 4.59 (s, 2H), 4.20-4.00 (m, 1H), 3.60-3.38 (m, 6H), 2.30-2.18 (m, 1H), 1.85-1.70 (m, 1H), 1.70-1.55 (m, 1H), 1.09 (t, J = 7.1 Hz, 3H).
    Example 49 (236)
    N-hydroxy-2 (R) -methoxymethyl-5-ethoxymethoxy-4 (S)-[N- (4-nitrophenylcarbonyl) amino] pentanamide

    TLC: Rf 0.22 (CHCl 3: MeOH = 19: 1):
    NMR (d 6 -DMSO): δ 10.46 (s, 1H), 8.75 (s, 1H), 8.48 (d, J = 8.4Hz, 1H), 8.29 (d, J = 8.8Hz, 2H), 8.06 (d , J = 8.8 Hz, 2H), 4.59 (s, 2H), 4.22-4.00 (m, 1H), 3.58-3.25 (m, 6H), 3.18 (s, 3H), 2.43-2.31 (m, 1H), 1.83-1.54 (m, 2H), 1.08 (t, J = 7.0 Hz, 3H).
    Example 49 (237)
    N-hydroxy-2 (R) -benzyloxymethyl-5-ethoxymethoxy-4 (S)-[N- (4-nitrophenylcarbonyl) amino] pentanamide

    TLC: Rf 0.35 (CHCl 3: MeOH = 19: 1);
    NMR (d 6 -DMSO): δ 10.52 (s, 1H), 8.79 (s, 1H), 8.50 (d, J = 8.7Hz, 1H), 8.30 (d, J = 8.7Hz, 2H), 8.07 (d , J = 8.7 Hz, 2H), 7.40-7.22 (m, 5H), 4.60 (s, 2H), 4.47 (d, J = 12.0 Hz, 1H), 4.41 (d, J = 12.0 Hz, 1H), 4.20 -4.07 (m, 1H), 3.61-3.42 (m, 6H), 2.53-2.40 (m, 1H), 1.89-1.78 (m, 1H), 1.77-1.62 (m, 1H), 1.08 (t, J = 7.2 Hz, 3H).
    Example 49 (238)
    N-hydroxy-2 (R)-(2-methoxyethoxy) methyl-5-ethoxymethoxy-4 (S)-[N- (4-nitrophenylcarbonyl) amino] pentanamide

    TLC: Rf 0.24 (CHCl 3: MeOH = 19: 1);
    NMR (d 6 -DMSO): δ 10.47 (s, 1H), 8.77 (s, 1H), 8.49 (d, J = 8.1Hz, 1H), 8.30 (d, J = 8.7Hz, 2H), 8.08 (d , J = 8.7 Hz, 2H), 4.61 (s, 2H), 4.20-4.07 (m, 1H), 3.58-3.38 (m, 10H), 3.23 (s, 3H), 2.47-2.36 (m, 1H), 1.83-1.58 (m, 2H), 1.10 (t, J = 7.2 Hz, 3H).
    Example 49 (239)
    N-hydroxy-2 (R) -methoxymethyl-5- (2-methoxyethoxy) methoxy-4 (S)-[N- (4-cyanophenylcarbonyl) amino] pentanamide

    TLC: Rf 0.26 (CHCl 3: MeOH = 19: 1);
    NMR (d 6 -DMSO): δ 10.45 (s, 1H), 8.74 (s, 1H), 8.40 (d, J = 8.4Hz, 1H), 7.98 (d, J = 8.8Hz, 2H), 7.93 (d , J = 8.8 Hz, 2H), 4.61 (s, 2H), 4.20-4.00 (m, 1H), 3.60-3.24 (m, 8H), 3.20 (s, 3H), 3.17 (s, 3H), 2.43- 2.29 (m, 1 H), 1.82-1.50 (m, 2 H).
    Example 49 (240)
    N-hydroxy-2 (R) -methoxymethyl-5-ethoxymethoxy-4 (S)-[N- (trans-4-methylcyclohexylcarbonyl) amino] pentanamide

    TLC: Rf 0.27 (CHCl 3: MeOH = 19: 1);
    NMR (d 6 -DMSO): δ 10.41 (s, 1H), 8.75 (s, 1H), 7.43 (d, J = 8.7Hz, 1H), 4.56 (s, 2H), 3.86-3.72 (m.1H) , 3.47 (q, J = 7.2 Hz, 2H), 3.41-3.20 (m, 4H), 3.15 (s, 3H), 2.36-2.24 (m, 1H), 2.05-1.93 (m, 1H), 1.77-1.56 (m, 5H), 1.49-1.18 (m, 4H), 1.10 (t, J = 7.2 Hz, 3H), 0.95-0.77 (m, 5H).
    Example 49 (241)
    N-hydroxy-2 (R) -methoxymethyl-5-ethoxymethoxy-4 (S)-[N- (4-bromophenylcarbonyl) amino] pentanamide

    TLC: Rf 0.31 (CHCl 3: MeOH = 9: 1);
    NMR (d 6 -DMSO): δ 10.43 (s, 1H), 8.74 (brs, 1H), 8.21 (d, J = 8.4Hz, 1H), 7.78 (d, J = 8.7Hz, 2H), 7.66 (d , J = 8.7 Hz, 2H), 4.58 (s, 2H), 4.13-4.01 (m, 1H), 3.50-3.31 (m, 6H), 3.16 (s, 3H), 2.42-2.12 (m, 1H), 1.79-1.53 (m, 2H), 1.07 (t, J = 7.2 Hz, 3H).
    Example 49 (242)
    N-hydroxy-2 (R) -methoxymethyl-5-ethoxymethoxy-4 (S)-[N- (4-chlorophenylcarbonyl) amino] pentanamide

    TLC: Rf 0.31 (CHCl 3: MeOH = 9: 1);
    NMR (d 6 -DMSO): δ 10.44 (s, 1H), 8.74 (s.1H), 8.21 (d, J = 8.4Hz.1H), 7.76 (d, J = 8.7Hz, 2H), 7.52 (d , J = 8.7 Hz, 2H), 4.58 (s, 2H), 4.16-4.02 (m, 1H), 3.50-3.33 (m, 6H), 3.16 (s, 3H), 2.42-2.32 (m, 1H), 1.79-1.55 (m, 2H), 1.07 (t, J = 7.2 Hz, 3H).
    Example 49 (243)
    N-hydroxy-2 (R) -benzyloxymethyl-5- (2-methoxyethoxy) methoxy-4 (S)-[N-4-cyanophenylcarbonyl) amino] pentanamide

    TLC: Rf 0.30 (methylene chloride: methanol = 19: 1);
    NMR (d 6 -DMSO): δ 10.49 (d, J = 1.5 Hz, 1H), 8.77 (d, J = 1.5 Hz, 1H), 8.41 (d, J = 8.4 Hz, 1H), 7.98 (d, J = 8.7 Hz, 2H), 7.94 (d, J = 8.7 Hz, 2H), 7.29 (m, 5H), 4.60 (s, 2H), 4.45 (d, J = 12.0 Hz, 1H), 4.39 (d, J = 12.0 Hz, 1H), 4.10 (m, 1H), 3.60-3.36 (m, 8H), 3.18 (s, 3H), 2.45 (m, 1H), 1.78 (m, 1H), 1.63 (m, 1H) .
    Example 49 (244)
    N-hydroxy-2 (R) -benzyloxymethyl-5-ethoxymethoxy-4 (S)-[N- (4-chlorophenylcarbonyl) amino] pentanamide

    TLC: Rf 0.32 (methylene chloride: methanol = 19: 1);
    NMR (d 6 -DMSO): δ 10.48 (s, 1H), 8.76 (s, 1H), 8.22 (d, J = 8.4Hz, 1H), 7.85 (d, J = 8.7Hz, 2H), 7.52 (d , J = 8.7 Hz, 2H), 7.29 (m, 5H), 4.57 (s, 2H), 4.44 (d, J = 12.0 Hz, 1H), 4.39 (d, J = 12.0 Hz, 1H), 4.08 (m , 1H), 3.55-3.40 (m, 6H), 2.45 (m, 1H), 1.78 (m, 1H), 1.62 (m, 1H), 1.05 (t, J = 7.2 Hz, 3H).
    Example 49 (245)
    N-hydroxy-2 (R) -benzyloxymethyl-5-ethoxymethoxy-4 (S)-[N- (4-bromophenylcarbonyl) amino] pentanamide

    TLC: Rf 0.32 (methylene chloride: methanol = 19: 1);
    NMR (d 6 -DMSO): δ 10.49 (d, J = 1.8 Hz, 1H), 8.77 (d, J = 1.8 Hz, 1H), 8.22 (d, J = 8.4 Hz.1H), 7.78 (d, J = 8.7 Hz, 2H), 7.66 (d, J = 8.7 Hz, 2H), 7.29 (m, 5H), 4.57 (s, 2H), 4.44 (d, J = l2.0 Hz, 1H), 4.39 (d, J = 12.0 Hz, 1H), 4.08 (m, 1H), 3.55-3.40 (m, 6H), 2.45 (m, 1H), 1.78 (m, 1H), 1.62 (m, 1H), 1.05 (t.J = 7.2 Hz, 3H).
    Example 49 (246)
    N-hydroxy-2 (R)-[2- (3-methoxyphenoxy) ethyl] -5-ethoxymethoxy-4 (S)-[N- (4-nitrophenylcarbonyl) amino] pentane amides

    TLC: Rf 0.40 (CHCl 3: MeOH = 9: 1);
    NMR (d 6 -DMSO): δ 10.50 (s, 1H), 8.76 (s, 1H), 8.48 (d, J = 8.4Hz, 1H), 8.30 (d, J = 8.6Hz, 2H), 8.06 (d , J = 8.6 Hz, 2H), 7.13 (t, J = 8.3 Hz, 1H), 6.52-6.35 (m, 3H), 4.59 (s, 2H), 4.25-4.12 (m, 1H), 3.95-3.75 ( m, 2H), 3.68 (s, 3H), 3.60-3.40 (m, 4H), 2.40-2.25 (m, 1H), 2.00-165 (m, 4H), 1.07 (t, J = 7.1 Hz, 3H) .
    Example 49 (247)
    N-hydroxy-2 (R) -methoxymethyl-5-ethoxymethoxy-4 (S)-[N-[(2-nitrothiophen-5-yl) carbonyl] amino] pentanamide

    TLC: Rf 0.37 (CHCl 3: MeOH = 9: 1);
    NMR (d 6 -DMSO): δ 10.46 (s, 1H), 8.75 (brs, 1H), 8.71 (d, J = 8.4Hz, 1H), 8.13 (d, J = 4.2Hz, 1H), 7.82 (d , J = 4.2 Hz, 1H), 4.58 (s, 2H), 3.97-4.09 (m, 1H), 3.50-3.38 (m, 6H), 3.17 (s, 3H), 2.41-2.32 (m, 1H), 1.79-1.55 (m, 2H), 1.07 (t, J = 7.2 Hz, 3H).
    Example 49 (248)
    N-hydroxy-2 (R) -methoxymethyl-5-ethoxymethoxy-4 (S)-[N-[(2-bromothiophen-5-yl) carbonyl] amino] pentanamide

    TLC: Rf 0.34 (CHCl 3: MeOH = 9: 1);
    NMR (d 6 -DMSO): δ 10.44 (s, 1H), 8.75 (s.1H), 8.27 (d, J = 8.1Hz, 1H), 7.61 (d, J = 4.2Hz, 1H), 7.27 (d , J = 4.2 Hz, 1H), 4.57 (s, 2H), 4.05-3.91 (m, 1H), 3.50-3.37 (m, 6H), 3.16 (s, 3H), 2.41-2.31 (m, 1H), 1.78-1.51 (m, 2H), 1.07 (t, J = 7.2 Hz, 3H).
    Example 49 (249)
    N-hydroxy-2 (R)-(2-methoxyethoxy) methyl-5-ethoxymethoxy-4 (S)-[N- (4-bromophenylcarbonyl) amino] pentanamide

    TLC: Rf 0.31 (CHCl 3: MeOH = 9: 1);
    NMR (d 6 -DMSO): δ 10.43 (s, 1H), 8.74 (s, 1H), 8.20 (d, J = 8.6Hz, 1H), 7.78 (d, J = 8.6Hz, 2H), 7.65 (d , J = 8.6 Hz, 2H), 4.58 (s, 2H), 4.18-4.01 (m, 1H), 3.50-3.36 (m, 10H), 3.20 (s, 3H), 2.44-2.39 (m, 1H), 1.81-1.52 (m, 2H), 1.07 (t, J = 7.0 Hz, 3H).
    Example 49 (250)
    N-hydroxy-2 (R)-(2-methoxyethoxy) methyl-5- (2-methoxyethoxy) methoxy-4 (S)-[N- (4-cyanophenylcarbonyl) Amino] pentanamide

    TLC: Rf 0.24 (CHCl 3: MeOH = 19: 1);
    NMR (d 6 -DMSO): δ 10.45 (brs, 1 H), 8.78 (brs, 1 H), 8.43 (d, J = 8.1 Hz, 1H), 7.99 (d, J = 8.4 Hz, 2H), 7.94 (d , J = 8.4 Hz, 2H), 4.61 (s, 2H), 4.16-4.02 (m, 1H), 3.57-3.35 (m, 12H), 3.21 (s, 3H), 3.20 (s, 3H), 2.42- 2.32 (m, 1 H), 1.80-1.56 (m, 2 H).
    Example 49 (251)
    N-hydroxy-2 (R)-(2-methoxyethoxy) methyl-5-ethoxymethoxy-4 (S)-[N- (4-chlorophenylcarbonyl) amino] pentanamide

    TLC: Rf 0.34 (CHCl 3: MeOH = 9: 1);
    NMR (d 6 -DMSO): δ 10.43 (s, 1H), 8.74 (brs, 1H), 8.20 (d, J = 8.4 Hz, 1H), 7.87-7.83 (m, 2H), 7.54-7.49 (m, 2H), 4.58 (s, 2H), 4.18-4.10 (m, 1H), 3.52-3.36 (m, 10H), 3.20 (s, 3H), 2.42-2.29 (m, 1H), 1.81-1.53 (m, 2H), 1.07 (t, J = 7.0 Hz, 3H).
    Example 49 (252)
    N-hydroxy-2 (R) -benzyloxymethyl-5-ethoxymethoxy-4 (S)-[N- (trans-4-methylcyclohexylcarbonyl) amino] pentanamide

    TLC: Rf 0.34 (CHCl 3: MeOH = 19: 1);
    NMR (d 6 -DMSO): δ 10.46 (s, 1H), 8.78 (s, 1H), 7.44 (d, J = 8.4 Hz, 1H), 7.38-7.21 (m, 5H), 4.59-4.52 (m, 2H), 4.43 (d, J = 12.0 Hz, 1H), 4.37 (d, J = 12.0 Hz, 1H), 3.85-3.72 (m, 1H), 3.54-3.28 (m, 6H), 2.43-2.30 (m , 1H), 2.06-1.92 (m, 1H), 1.76-1.59 (m, 5H), 1.52-1.20 (m, 4H), 1.09 (t, J = 6.9 Hz, 3H), 0.93-0.75 (m, 5H ).
    Example 49 (253)
    N-hydroxy-2 (R)-(3-thienyl) methoxymethyl-5-ethoxymethoxy-4 (S)-[N- (4-nitrophenylcarbonyl) amino] pentanamide

    TLC: Rf 0.34 (CHCl 3: MeOH = 19: 1);
    NMR (d 6 -DMSO): δ 10.49 (s, 1H), 8.76 (s, 1H), 8.49 (d, J = 8.4Hz, 1H), 8.30 (d, J = 8.8Hz, 2H), 8.06 (d , J = 8.8 Hz, 2H), 7.49 (dd, J = 5.2, 2.8 Hz, 1H), 7.40-7.36 (m, 1H), 7.03 (dd, J = 5.2, 1.6 Hz, 1H), 4.59 (s, 2H), 4.50-4.36 (m, 2H), 4.21-4.00 (m, 1H), 3.60-3.36 (m, 6H), 2.52-2.38 (m, 1H), 1.88-1.56 (m, 2H), 1.07 ( t, J = 7.0 Hz, 3H).
    Examples 49 (254) -49 (263)
    Example 37-Example 39-Example 45-Example 46 (Using the equivalent compound instead of benzyl bromide)-Example 47-Example 48 → The compound shown below was obtained in the same manner as the method shown in Example 49.
    Example 49 (254)
    N-hydroxy-2 (R)-(2-pyridinyl) methyl-5-hydroxy-4 (S)-[N- (4-phenoxyphenylcarbonyl) amino] pentanamide

    TLC: Rf 0.17 (CHCl 3: MeOH: Acetic Acid: Water = 100: 10: 1: 1);
    NMR (d 6 -DMSO): δ 10.35 (1H, brs), 8.63 (1H, bs), 8.42-8.40 (1H, m), 7.91-7.86 (3H, m), 7.64 (1H, dt, J = 7.8 Hz, 1.8 Hz), 7.45-7.39 (2H, m), 7.25-7.14 (3H, m), 7.07-7.00 (4H, m), 4.67 (1H, brs), 4.15-3.94 (1H, m), 3.50 -3.34 (2H, m), 2.97-2.81 (2H, m), 2.71-2.62 (1H, m), 1.82-1.65 (2H, m).
    Example 49 (255)
    N-hydroxy-2 (S) -methyl-5-hydroxy-4 (S)-[N- (4-phenoxyphenylcarbonyl) amino] pentanamide

    TLC: Rf 0.14 (CHCl 3: MeOH = 9: 1);
    NMR (d 6 -DMSO): δ 10.33 (1H, s), 8.62 (1H, s), 7.89-7.83 (3H, m), 7.41 (2H, t, J = 7.6 Hz), 7.17 (1H, t, J = 7.6 Hz), 7.04 (2H, d, J = 7.6 Hz), 7.00 (2H, d, J = 8.7 Hz), 4.68 (1H, t, J = 5.7 Hz), 4.02-3.91 (1H, m) , 3.45-3.28 (2H, m), 2.21-2.08 (1H, m), 1.72-1.55 (2H, m), 0.98 (3H, d, J = 6.6 Hz).
    Example 49 (256)
    N-hydroxy-2 (S) -methyl-5-hydroxy-4 (S)-[N- (4-bromophenylcarbonyl) amino] pentanamide

    TLC: Rf 0.25 (chloroform: methanol = 9: 1);
    NMR (d 6 -DMSO): δ 10.37 (s, 1H), 8.64 (s, 1H), 8.02 (d, J = 8.6Hz, 1H), 7.81 (d, J = 8.4Hz, 2H), 7.65 (d , J = 8.4 Hz, 2H), 4.80-4.64 (m, 1H), 4.10-3.88 (m, 1H), 3.60-3.10 (m, 2H), 2.26-2.06 (m, 1H), 1.80-1.56 (m , 2H), 1.02 (d, J = 6.8 Hz, 3H).
    Example 49 (257)
    N-hydroxy-2 (S)-(3-methoxybenzyl) -5-hydroxy-4 (S)-[N- (4-bromophenylcarbonyl) amino] pentanamide

    TLC: Rf 0.45 (methylene chloride: methanol = 9: 1);
    NMR (d 6 -DMSO): δ 10.28 (s, 1H), 8.63 (s, 1H), 8.04 (brd, J = 8.4Hz, 1H), 7.82 (d, J = 8.4Hz, 2H), 7.66 (d , J = 8.4 Hz, 2H), 7.11 (t, J = 8.0 Hz, 1H), 6.67 (m, 3H), 4.69 (brt, J = 5.8 Hz, 1H), 4.09 (m, 1H), 3.65 (s , 3H), 3.44 (m, 2H), 2.75 (brd, J = 7.2 Hz, 2H), 2.33 (m, 1H), 1.85-1.50 (m, 2H).
    Example 49 (258)
    N-hydroxy-2 (S)-(3-methoxybenzyl) -5-hydroxy-4 (S)-[N- (4-nitrophenylcarbonyl) amino] pentanamide

    TLC: Rf 0.52 (methylene chloride: methanol = 9: 1);
    NMR (d 6 -DMSO): δ 10.31 (s, 1H), 8.64 (s.1H), 8.34 (brd, J = 8.4Hz, 1H), 8.30 (d, J = 9.2Hz, 2H), 8.09 (d , J = 9.2 Hz, 2H), 7.11 (t, J = 8.8 Hz, 1H), 6.70 (m, 3H), 4.73 (brt, J = 5.8 Hz, 1H), 4.10 (m, 1H), 3.67 (s , 3H), 3.43 (m, 2H), 2.73 (brd, J = 7.0 Hz, 2H), 2.35 (m, 1H), 1.85-1.55 (m, 2H).
    Example 49 (259)
    N-hydroxy-2 (S)-(3-methoxybenzyl) -5-hydroxy-4 (S)-[N- (4-chlorophenylcarbonyl) amino] pentanamide

    TLC: Rf 0.52 (methylene chloride: methanol = 9: 1);
    NMR (d 6 -DMSO): δ 10.28 (s, 1H), 8.63 (s, 1H), 8.06 (brd, J = 8.4Hz, 1H), 7.89 (d, J = 8.7Hz, 2H), 7.52 (d , J = 8.7 Hz, 2H), 7.11 (t, J = 8.4 Hz, 1H), 6.67 (m, 3H), 4.70 (brt, J = 5.7 Hz, 1H), 4.10 (m, 1H), 3.65 (s , 3H), 3.41 (m, 2H), 2.72 (brd, J = 7.2 Hz, 2H), 2.33 (m, 1H), 1.82-1.55 (m, 2H).
    Example 49 (260)
    N-hydroxy-2 (S)-(3-methoxybenzyl) -5-hydroxy-4 (S)-[N-[(2-bromothiophen-5-yl) carbonyl] amino] pentanamide

    TLC: Rf 0.52 (methylene chloride: methanol = 9: 1);
    NMR (d 6 -DMSO): δ 10.30 (s, 1H), 8.64 (s, 1H), 8.13 (brd, J = 8.8Hz, 1H), 7.63 (d, J = 4.0Hz, 1H), 7.27 (d , J = 4.0 Hz.1H), 7.12 (t, J = 8.4 Hz, 1H), 6.69 (m, 3H), 4.72 (brs, 1H), 4.00 (m, 1H), 3.68 (s, 3H), 3.39 (m, 2H), 2.71 (brd, J = 7.2 Hz, 2H), 2.32 (m, 1H), 1.83-1.49 (m, 2H).
    Example 49 (261)
    N-hydroxy-2 (S)-(3-methoxybenzyl) -5-hydroxy-4 (S)-[N-[(2-nitrothiophen-5-yl) carbonyl] amino] pentanamide

    TLC: Rf 0.47 (methylene chloride: methanol = 9: 1);
    NMR (d 6 -DMSO): δ 10.32 (s, 1H), 8.65 (s, 1H), 8.57 (brd, J = 9.0Hz, 1H), 8.14 (d, J = 4.5Hz, 1H), 7.84 (d , J = 4.5 Hz, 1H), 7.12 (t, J = 8.4 Hz, 1H), 6.69 (m, 3H), 4.78 (brs, 1H), 4.01 (m, 1H), 3.69 (s, 3H), 3.42 (m, 2H), 2.71 (m. 2H), 2.33 (m, 1H), 1.81-1.54 (m, 2H).
    Example 49 (262)
    N-hydroxy-2 (S)-(3-methoxybenzyl) -5-hydroxy-4 (S)-[N- (4-cyanophenylcarbonyl) amino] pentanamide

    TLC: Rf 0.39 (CHCl 3: MeOH = 9: 1);
    NMR (d 6 -DMSO): δ 10.31 (s, 1H), 8.64 (s, 1H), 8.23 (d, J = 8.8Hz, 1H), 8.03 (d, J = 8.4Hz, 2H), 7.93 (d , J = 8.4 Hz, 2H), 7.18-7.06 (m, 1H), 6.75-6.64 (m, 3H), 4.71 (t, J = 5.8 Hz, 1H), 4.21-4.00 (m, 1H), 3.67 ( s, 3H), 3.57-3.37 (m, 2H), 2.74 (d, J = 7.0 Hz, 2H), 2.42-2.25 (m, 1H), 1.90-1.52 (m, 2H).
    Example 49 (263)
    N-hydroxy-2 (R) -benzyloxymethyl-5-hydroxy-4 (S)-[N- (4-nitrophenylcarbonyl) amino] pentanamide

    TLC: Rf 0.62 (methylene chloride: methanol = 9: 1);
    NMR (d 6 -DMSO): δ 10.47 (s, 1H), 8.74 (s, 1H), 8.33 (d, J = 8.8Hz, 1H), 8.29 (d, J = 8.6Hz, 2H), 8.06 (d , J = 8.6 Hz, 2H), 7.29 (m, 5H), 4.72 (t, J = 5.6 Hz, 1H), 4.45 (d, J = 12.4 Hz, 1H), 4.38 (d, J = 12.0 Hz, 1H ), 3.95 (m, 1H), 3.60-3.35 (m, 4H), 2.45 (m, 1H), 1.78 (m, 1H), 1.62 (m, 1H).
    Examples 49 (264) -49 (269)
    Example 37 → Example 39 → Example 41 (Sometimes the equivalent compound may be used in place of methoxymethylchloride) → Example 43 (The equivalent compound instead of benzyl bromide) → The compound shown below was obtained in the same manner as the method shown in Example 5-Example 44-Example 49.
    Example 49 (264)
    N-hydroxy-5-methoxymethoxy-4 (S)-[N-methyl-N- [4- (4-chlorophenyl) phenylcarbonyl] amino] pentanamide

    TLC: Rf 0.22 (CHCl 3: MeOH = 9: 1);
    NMR (d 6 -DMSO): δ 10.36 (1H, s), 7.75-7.65 (4H, m), 7.54-7.37 (4H, m), 4.66-3.68 (3H, m), 3.64-3.35 (2H, m ), 3.25, 3.21 (3H, s), 2.81, 2.74 (3H, s), 2.07-1.55 (4H, m).
    Example 49 (265)
    N-hydroxy-2 (S)-(3-pyridyl) methyl-5-methoxymethoxy-4 (S)-[N-methyl-N- [4- (4-chlorophenyl) phenylcarbonyl] Amino] pentanamide

    TLC: Rf 0.42 (CHCl 3: MeOH: Acetic Acid = 9: 1: 0.5);
    NMR (d 6 -DMSO): δ 10.43 (1H, s), 8.72 (1H, s), 8.45-8.29 (2H, m), 7.78-7.60 (5H, m), 7.58-7.40 (4H, m), 7.33-7.22 (1H, m), 4.97-4.84 (0.6H, m), 4.56-4.44 (2H, m), 3.94-3.84 (0.4H, m), 3.64-3.30 (2H, m), 3.25, 3.20 (3H, s), 2.82, 2.73 (3H, s), 2.85-2.21 (3H, m), 1.88-1.49 (2H, m).
    Example 49 (266)
    N-hydroxy-2 (S) -methyl-5-ethoxymethoxy-4 (S)-[N-methyl-N- (4-bromophenylcarbonyl) amino] pentanamide

    TLC: Rf 0.36 (CHCl 3: MeOH = 9: 1);
    NMR (d 6 -DMSO): δ 10.47 & 10.45 (s, 1H), 8.72 & 8.69 (s, 1H), 7.63 & 7.60 (d, J = 8.4 Hz, 2H), 7.32 & 7.30 (d , J = 8.4 Hz, 2H), 4.79-4.67 & 3.77-3.64 (m, 1H), 4.61 & 4.56 (s.2H), 3.60-3.36 (m, 4H), 2.78 & 2.65 (s, 3H ), 2.18-2.06 & 2.03-1.92 (m, 1H), 1.85-1.67 (m, 1H), 1.54-1.43 & 1.38-1.27 (m, 1H), 1.10 (q, J = 6.6 Hz, 3H) , 1.03 & 0.73 (d, J = 6.9 Hz, 3H).
    Example 49 (267)
    N-hydroxy-2 (S)-(3-methoxybenzyl) -5-ethoxymethoxy-4 (S)-[N-methyl-N- (4-bromophenylcarbonyl) amino] pentanamide

    TLC: Rf 0.47 (CHCl 3: MeOH = 9: 1);
    NMR (d 6 -DMSO): δ 10.44 & 10.42 (s, 1H), 8.71 (s, 1H). 7.66 & 7.53 (d, J = 8.1 Hz, 2H), 7.36 & 7.29 (d, J = 8.1 Hz, 2H), 7.14 (t, J = 8.0 Hz, 1H), 6.80-6.58 (m, 3H) , 4.89-4.79 & 3.75-3.63 (m, 1H), 4.60 & 4.52 (s, 2H), 3.71 & 3.67 (s, 3H), 3.58-3.36 (m, 4H), 2.78 & 2.68 (s , 3H), 2.77-2.56 (m, 2H), 2.33-2.15 (m, 1H), 1.85-1.72 (m, 1H), 1.66-1.57 & 1.54-1.43 (m, 1H), 1.15-1.04 (m , 3H).
    Example 49 (268)
    N-hydroxy-2 (S) -methyl-5-ethoxymethoxy-4 (S)-[N-methyl-N- (4-nitrophenylcarbonyl) amino] pentanamide

    TLC: Rf 0.27 (CHCl 3: MeOH = 19: 1);
    NMR (d 6 -DMSO): δ 10.51 and 10.45 (s, 1H), 8.76 and 8.70 (s, 1H), 8.29 and 8.26 (d, J = 8.8Hz, 2H), 7.64 and 7.60 (d, J = 8.8 Hz, 2H), 4.86-4.51 (m, 3H), 3.70-3.36 (m, 4H), 2.84 and 2.65 (s, 3H), 2.22-1.65 (m, 2H), 1.60-1.20 (m, 1H), 1.15 and 1.12 (t, J = 7.0 Hz, 3H), 1.07 and 0.79 (d, J = 7.0 Hz, 3H).
    Example 49 (269)
    N-hydroxy-2 (S) -methyl-5-benzyloxymethoxy-4 (S)-[N-methyl-N- (4-nitrophenylcarbonyl) amino] pentanamide

    TLC: Rf 0.43 (CHCl 3: MeOH = 9: 1);
    NMR (d 6 -DMSO): δ 10.50 & 10.43 (s, 1H), 8.75 & 8.69 (d, J = 1.5 Hz, 1H), 8.27 & 8.25 (d, J = 8.9 Hz, 2H), 7.63 & 7.60 (d, J = 8.9 Hz, 2H), 7.37-7.26 (m, 5H), 4.83-4.67 (m, 2.5H), 4.58-4.46 (m, 2H), 3.69-3.56 & 3.48-3.37 (m, 2.5H), 2.83 & 2.63 (s, 3H), 2.20-2.10 & 2.06-1.95 (m, 1H), 1.90-1.72 (m, 1H), 1.55-1.44 & 1.39-1.29 (m , 1H), 1.05 & 0.76 (d, J = 6.8 Hz, 3H).
    Examples 49 (270) -49 (277)
    Example 37-Example 39-Example 45-Example 46 (using equivalent compound instead of benzyl bromide)-Example 5-Example 47-Example 48 instead of the reference compound 4 → The compound shown below was obtained in the same manner as the method shown in Example 49.
    Example 49 (270)
    N-hydroxy-2 (S)-(3-methoxybenzyl) -5-hydroxy-4 (S)-[N-methyl-N- (4-chlorophenylcarbonyl) amino] pentanamide

    TLC: Rf 0.51 (methylene chloride: methanol = 9: 1);
    NMR (d 6 -DMSO): δ 10.40 (s, 0.45H), 10.38 (s, 0.55H), 8.67 (s, 1H), 7.53-7.35 (m, 3.45H), 7.24-7.10 (m, 1.55H ), 6.73-6.56 (m, 3H), 4.94 (brt, J = 5.2 Hz, 0.45H), 4.79 (brt, J = 5.2 Hz, 0.55H), 4.72 (m, 0.55H), 3.70 (s, 1.65 H), 3.67 (s, 1.35H), 3.70-3.30 (m, 2.45H), 2.78 (s, 1.35H), 2.66 (s, 1.65H), 2.80-2.10 (m, 4H), 1.80-1.35 ( m, 2H).
    Example 49 (271)
    N-hydroxy-2 (S)-(3-methoxybenzyl) -5-hydroxy-4 (S)-[N-methyl-N- (4-nitrophenylcarbonyl) amino] pentanamide

    TLC: Rf 0.56 (methylene chloride: methanol = 9: 1);
    NMR (d 6 -DMSO): δ 10.39 (s, 0.5H), 10.37 (s, 0.5H), 8.69 (s, 0.5H), 8.64 (s, 0.5H), 8.28 (d, J = 8.8Hz, 1H), 8.17 (d, J = 8.8 Hz, 1H), 7.68 (d, J = 8.8 Hz, 1H), 7.59 (d, J = 8 Hz, 1H), 7.11 (m, 1H), 6.72 (m, 2H), 6.57 (m, 1H), 4.95 (brt, J = 5.2 Hz, 0.5H), 4.82 (brt, J = 5.2 Hz, 0.5H), 4.69 (m, 0.5H), 3.68 (s, 3H) , 3.60-3.30 (m, 2.5H), 3.55-3.25 (m, 2H), 2.80 (s, 1.5H), 2.63 (s, 1.5H), 2.80-2.10 (m, 4H), 1.80-1.35 (m , 2H).
    Example 49 (272)
    N-hydroxy-2 (S)-(3-methoxybenzyl) -5-hydroxy-4 (S)-[N-methyl-N- (4-bromophenylcarbonyl) amino] pentanamide

    TLC: Rf 0.45 (methylene chloride: methanol = 9: 1);
    NMR (d 6 -DMSO): δ 10.41 (s, 0.45H), 10.38 (s, 0.55H), 8.67 (s, 1H), 7.64 (d, J = 8Hz, 1.1H), 7.53 (d, J = 8.4 Hz, 0.9H), 7.39 (d, J = 8.4 Hz, 1.1H), 7.35 (d, J = 8.4 Hz, 0.9H), 7.13 (t, J = 7.8 Hz, 1H), 6.70 (m, 2.1H), 6.57 (m, 0.9H), 4.94 (brt, J = 5.1 Hz, 0.45H), 4.79 (brt, J = 5.7 Hz, 0.55H), 4.70 (m, 0.55H), 3.70 (s, 1.65H), 3.67 (s, 1.35H), 3.70-3.60 (m, 0.45H), 3.55-3.25 (m, 2H), 2.78 (s, 1.35H), 2.66 (s, 1.65H), 2.80-2.10 (m, 4H), 1.80-1.35 (m, 2H).
    Example 49 (273)
    N-hydroxy-2 (S) -methyl-5-hydroxy-4 (S)-[N-methyl-N- (4-nitrophenylcarbonyl) amino] pentanamide

    TLC: Rf 0.16 (CHCl 3: MeOH = 9: 1);
    NMR (d 6 -DMSO): δ 10.49 & 10.42 (s, 1 H), 8.72 & 8.67 (d, J = 1.5 Hz, 1 H), 8.27 & 8.25 (d, J = 8.8 Hz, 2H), 7.65 & 7.62 (d, J = 8.8 Hz, 2H), 5.01 & 4.83 (t, J = 5.4 Hz, 1H), 4.65-4.54 & 3.51-3.40 (m, 1H), 3.53-3.27 (m, 2H ), 2.81 & 2.62 (s, 3H), 2.17-2.09 & 2.03-1.91 (m, 1H), 1.80-1.63 (m, 1H), 1.52-1.42 & 1.33-1.22 (m, 1H), 1.05 & 0.72 (d, J = 6.9 Hz, 3H).
    Example 49 (274)
    N-hydroxy-2 (S) -benzyl-5-hydroxy-4 (S)-[N-methyl-N- (4-nitrophenylcarbonyl) amino] pentanamide

    TLC: Rf 0.25 (chloroform: methanol: water = 9: 1: 0.1);
    NMR (d 6 -DMSO): δ 10.40 and 10.37 (s, 1 H), 8.70 and 8.65 (brs, 1 H), 8.29 and 8.19 (d, J = 8.7 Hz, 2H), 7.69 and 7.60 (d, J = 8.7 Hz, 2H), 7.30-7.01 (m, 5H), 4.91 and 4.84 (t, J = 5.4 Hz, 1H), 4.75-4.64 and 3.54-3.44 (m, 1H), 3.49-3.25 (m, 2H), 2.81 and 2.65 (s, 3H), 2.84-2.51 (m, 2H), 2.35-2.12 (m, 1H), 1.84-1.56 and 1.47-1.36 (m, 2H).
    Example 49 (275)
    N-hydroxy-2 (S) -methyl-5-hydroxy-4 (S)-[N-methyl-N- (4-bromophenylcarbonyl) amino] pentanamide

    TLC: Rf 0.17 (CHCl 3: MeOH: Water = 9: 1: 0.1);
    NMR (d 6 -DMSO): δ 10.43 (s, 1H), 8.66 (s, 1H), 7.62 and 7.59 (d, J = 8.1Hz, 2H), 7.35 (d, J = 8.1Hz, 2H), 4.98 -4.92 and 4.81-4.73 (m, 1H), 4.63-4.52 and 3.64-3.52 (m, 1H), 3.52-3.39 (m, 2H), 2.77 and 2.64 (s, 3H), 2.15-2.05 and 2.00-1.89 (m, 1 H), 1.77-1.58 and 1.53-1.43 and 1.32-1.21 (m, 2H), 1.04 and 0.68 (d, J = 6.7 Hz, 3H).
    Example 49 (276)
    N-hydroxy-2 (S) -benzyl-5-hydroxy-4 (S)-[N-methyl-N- (4-bromophenylcarbonyl) amino] pentanamide

    TLC: Rf 0.25 (chloroform: methanol: water = 9: 1: 0.1);
    NMR (d 6 -DMSO): δ 10.40 and 10.37 (s, 1 H), 8.66 (s, 1 H), 7.64 and 7.54 (d, J = 8 Hz, 2H), 7.39 and 7.36 (d, J = 8.6 Hz, 2H), 7.28-6.97 (m, 5H), 4.95 and 4.79 (t, J = 5.4 Hz, 1H), 4.75-4.65 and 3.69-3.60 (m, 1H), 3.52-3.26 (m, 2H), 2.78 and 2.66 (s, 3H), 2.82-2.55 (m, 2H), 2.31-2.12 (m, 1H), 1.80-1.56 and 1.67-1.35 (m, 2H).
    Example 49 (277)
    N-hydroxy-2 (S) -methyl-5-hydroxy-4 (S)-[N-methyl-N- (4-chlorophenylcarbonyl) amino] pentanamide

    TLC: Rf 0.17 (CHCl 3: MeOH: Water = 9: 1: 0.1);
    NMR (d 6 -DMSO): δ 10.45 and 10.43 (s, 1H), 8.69 and 8.66 (s, 1H), 7.53-7.38 (m, 4H), 4.96 and 4.77 (t, J = 5.3 Hz, 1H), 4.63-4.52 and 3.65-3.51 (m, 1H), 3.51-3.40 (m, 2H), 2.78 and 2.64 (s, 3H), 2.15-2.05 and 1.98-1.88 (m, 1H), 1.77-1.54 (m, 1H), 1.54-1.43 and 1.32-1.21 (m, 1H), 1.03 and 0.67 (d, J = 6.8 Hz, 3H).
    Example 50
    2 (S) -benzyloxy-3 (S) -hydroxy-4- (N- (4- (3-methoxy-1-propynyl) phenylcarbonyl) amino) butanoic acid ethyl ester

    The method described in 2 (S) -benzyloxy-3 (S) -hydroxy-4-aminobutanoic acid ethyl ester (Bioorg. Med. Chem. Leet, 2, 515 (1992) instead of 4-aminobutanoic acid ethyl ester. Was prepared in the same manner as in the above), and instead of the compound prepared in Reference Example 4, using the corresponding acid halide in the same manner as in the method shown in Example 1 to obtain the title compound having the following physical properties.
    TLC: Rf 0.20 (n-hexane: ethyl acetate = 3: 2).
    Example 51
    2 (S) -benzyloxy-3 (S) -hydroxy-4- (N- (4- (3-methoxy-1-propynyl) phenylcarbonyl) amino) butanoic acid

    The title compound was obtained in the same manner as the method shown in Example 2, using the compound prepared in Example 50 instead of the compound prepared in Example 1.
    TLC: Rf 0.22 (CHCl 3: MeOH = 9: 1).
    Example 52
    2 (S) -benzyloxy-3 (S) -t-butylcarbonyloxy-4- (N- (4- (3-methoxy-1-propynyl) phenylcarbonyl) amino) butanoic acid ethyl ester

    Using the compound prepared in Example 50 instead of 4-aminobutanoic acid ethyl ester, the procedure was the same as that described in Example 1 (using pivaloyl chloride instead of the compound prepared in Reference Example 4). , The title compound having the following physical properties was obtained.
    TLC: Rf 0.44 (n-hexane: ethyl acetate = 7: 3);
    NMR (CDCl 3 ): δ 7.49 (2H, d, J = 8.8 Hz), 7.43-7.30 (7H, m), 6.80-6.68 (1H, m), 5.36 (1H, td, J = 5.6, 3.8 Hz) , 4.87 (1H, d, J = 11.4 Hz), 4.43 (1H, d, J = 11.4 Hz), 4.34 (2H, s), 4.25 (1H, d, J = 3.8 Hz), 4.22 (2H, q, J = 7.0 Hz), 3.90 (1H, dt, J = 14.2, 5.6 Hz), 3.66 (1H, dt, J = 14.2, 5.6 Hz), 3.46 (3H, s), 1.29 (3H, t, J = 7.0 Hz), 1.14 (9H, S).
    Example 53
    2-benzyloxy-4- (N- (4- (3-methoxy-1-propynyl) phenylcarbonyl) amino) -2-butenoic acid

    Using the compound prepared in Example 52 instead of the compound prepared in Example 1, the title compound was obtained in the same manner as the method shown in Example 2 to obtain the following physical property value.
    TLC: Rf 0.36 (CHCl 3: MeOH = 9: 1).
    Example 54
    N-hydroxy-2 (S) -benzyloxy-3 (S) -hydroxy-4- (N- (4- (3-methoxy-1-propynyl) phenylcarbonyl) amino) butylamide

    Using the compound prepared in Example 51 instead of the compound prepared in Example 2, the title compound was obtained in the same manner as the method shown in Example 3-Example 4, to obtain the title compound having the following physical properties.
    TLC: Rf 0.25 (chloroform: methanol = 9: 1);
    NMR (CD 3 OD): δ 7.74 (2H, d, J = 8.4 Hz), 7.49 (2H, d, J = 8.4 Hz), 7.45-7.20 (5H, m), 4.73 (1H, d, J = 11.4 Hz), 4.49 (1H, d, J = 11.4 Hz), 4.34 (2H, s), 4.14-3.95 (1H, m), 3.91 (1H, d, J = 3.4 Hz), 3.60 (1H, dd, J = 13.6, 5.4 Hz), 3.44 (3H, s), 3.42 (1H, dd, J = 13.6, 7.2 Hz).
    Example 54 (1)
    N-hydroxy-2-benzyloxy-4- (N- (4- (3-methoxy-1-propynyl) phenylcarbonyl) amino) -2-butylamide

    Using the compound prepared in Example 53 instead of the compound prepared in Example 51, the same procedure as described in Example 54 was carried out to obtain the title compound having the following physical properties.
    TLC: Rf 0.37 (CHCl 3: MeOH = 9: 1);
    NMR (CD 3 OD): δ 8.52-8.40 (1H, m), 7.74 (2H, d, J = 8.4 Hz), 7.49 (2H, d, J = 8.4 Hz), 7.45-7.20 (5H, m), 5.89 (1H, t, J = 6.6 Hz), 4.88 (2H, s), 4.33 (2H, s), 4.02-3.90 (2H, m), 3.43 (3H, s).
    Example 55
    Cis-1-carboxymetal-2- (N- (4- (3-methoxy-1-propynyl) phenylcarbonyl) amino) cyclopentane

    Reference Example 4 using cis-1-carboxymetal-2-aminocyclopentane (compound described in J. Chem. Soc., Perkin Trans. 1, 11, 2553 (1982)) instead of 4-aminobutanoic acid ethyl ester The title compound having the following physical properties was obtained in the same manner as the method shown in Example 1 using an acid halide corresponding to the compound prepared in the above.
    TLC: Rf 0.80 (CHCl 3: MeOH: Acetic Acid = 18: 2: 1).
    Examples 55 (1) to 55 (4)
    Trans-1-carboxymetal-2-aminocyclopentane, cis-3-aminocyclopentanoic acid, trans-3-aminocyclopentanoic acid instead of cis-1-carboxymetal-2-aminocyclopentane (Chem.Bcr., 101, 1525 (1968)) and 2-aminomethylcyclopentanoic acid were used to operate in the same manner as the method shown in Example 55 to obtain the compound shown below.
    Example 55 (1)
    Trans-1-carboxymethyl-2- (N- (4- (3-methoxy-1-propynyl) phenylcarbonyl) amino) cyclopentane

    TLC: Rf 0.36 (CHCl 3: MeOH = 10: 1);
    NMR (CDCl 3 ): δ 7.72 (2H, d, J = 8.4 Hz), 7.49 (2H, d, J = 8.4 Hz), 6.49 (1H, d, J = 7.4 Hz), 4.34 (2H, s), 4.04 (1H, m), 3.46 (3H, s), 2.56 (2H, m), 2.25 (2H, m), 1.99 (1H, m), 1.75 (2H, m), 1.50 (2H, m).
    Example 55 (2)
    Trans-3- (N- (4- (3-methoxy-1-propynyl) phenylcarbonyl) amino) cyclopentanoic acid

    TLC: Rf 0.21 (CHCl 3: MeOH = 9: 1);
    NMR (d 6 -DMSO): δ 12.09 (1H, s), 8.40 (1H, d, J = 6.8 Hz), 7.85 (2H, d, J = 8.4 HI), 7.53 (2H, d, J = 8.4 Hz ), 4.42-4.22 (3H, m), 3.34 (3H, s), 3.30-2.82 (1H, m), 2.20-1.48 (6H, m).
    Example 55 (3)
    Cis-3- (N- (4- (3-methoxy-1-propynyl) phenylcarbonyl) amino) cyclopentanoic acid

    TLC: Rf 0.32 (CHCl 3: MeOH = 9: 1);
    NMR (d 6 -DMSO): δ 12.11 (1H, s), 8.45 (1H, d, J = 7.4 Hz), 7.85 (2H, d, J = 8.8 Hz), 7.52 (2H, d, J = 8.8 Hz ), 4.34 (2H, s), 4.33-4.18 (1H, m), 3.34 (3H, s), 2.84-2.66 (1H, m), 2.18 (1H, m), 2.00-1.50 (5H, m).
    Example 55 (4)
    Trans-2- (N- (4- (3-methoxy-1-propynyl) phenylcarbonyl) aminomethyl) cyclopentanoic acid

    TLC: Rf 0.26 (CHCl 3: MeOH = 19: 1);
    NMR (CDCl 3 ): δ 7.72 (2H, d, J = 8.2 Hz), 7.46 (2H, d, J = 8.2 Hz), 7.08-6.98 (1H, m), 4.33 (2H, s), 3.69 (1H , dt, J = 13.8, 5.4 Hz), 3.45 (3H, s), 3.34 (1H, ddd, J = 13.8, 8.8, 5.4 Hz), 2.62-2.30 (2H, m), 2.06-1.84 (3H, m ), 1.80-1.62 (2H, m), 1.52-1.32 (1H, m).
    Example 56
    Cis-1- (N-hydroxyaminocarbonylmethyl) -2- (N- (4- (3-methoxy-1-propynyl) phenylcarbonyl) amino) cyclopentane

    Using the compound prepared in Example 55 instead of the compound prepared in Example 2, the title compound was obtained in the same manner as the method shown in Example 3-Example 4, to obtain the title compound having the following physical properties.
    TLC: Rf 0.33 (CHCl 3: MeOH = 10: 1);
    NMR (d 6 -DMSO): δ 10.40 (1H, s), 8.37 (1H, d, J = 7.8 Hz), 7.86 (2H, d, J = 8.4 Hz), 7.54 (2H, d, J = 8.4 Hz ), 4.38 (1H, m), 4.35 (2H, s), 3.35 (3H, s), 2.35 (1H, m), 2.09 (1H, dd, J = 14.6, 4.6 Hz), 1.91 (1H, m) , 1.83 (1 H, m), 1.80-1.50 (4 H, m), 1.44 (1 H, m).
    Examples 56 (1) to 56 (4)
    Using the compound prepared in Examples 55 (1) to (4) instead of the compound prepared in Example 55, it was operated in the same manner as the method shown in Example 56 to obtain a compound shown below.
    Example 56 (1)
    Trans-1- (N-hydroxyaminocarbonylmethyl) -2- (N- (4- (3-methoxy-1-propynyl) phenylcarbonyl) amino) cyclopentane

    TLC: Rf 0.43 (CHCl 3: MeOH = 10: 1);
    NMR (d 6 -DMSO): δ 10.37 (1H, s), 8.41 (1H, d, J = 8.0Hz), 7.87 (2H, d, J = 8.4Hz), 7.53 (2H, d, J = 8.4Hz ), 4.35 (2H, s), 3.90 (1H, m), 3.35 (3H, s), 2.19 (2H, m), 1.87 (3H, m), 1.58 (3H, m), 1.24 (1H, m) .
    Example 56 (2)
    Trans-1- (N-hydroxyaminocarbonyl) -3- (N- (4- (3-methoxy-1-propynyl) phenylcarbonyl) amino) cyclopentane

    TLC: Rf 0.26 (CHCl 3: MeOH = 9: 1);
    NMR (d 6 -DMSO): δ 10.42 (1H, s), 8.80-8.60 (1H, br), 8.37 (1H, d, J = 7.0 Hz), 7.85 (2H, d, J = 8.4 Hz), 7.53 (2H, d, J = 8.4 Hz), 4.44-4.24 (3H, m), 3.35 (3H, s), 2.78-2.68 (1H, m), 2.10-1.50 (6H, m).
    Example 56 (3)
    Cis-1- (N-hydroxyaminocarbonyl) -3- (N- (4- (3-methoxy-1-propynyl) phenylcarbonyl) amino) cyclopentane

    TLC: Rf 0.38 (CHCl 3: MeOH = 9: 1);
    NMR (d 6 -DMSO): δ 10.62 (1H, s), 8.94-8.76 (1H, br), 8.82 (1H, d, J = 7.8 Hz), 7.87 (2H, d, J = 8.4 Hz), 7.53 (2H, d, J = 8.4 Hz), 4.34 (2H, s), 4.42-4.22 (1H, m), 3.35 (3H, s), 2.70-2.55 (1H, m), 2.14-1.95 (1H, m ), 1.92-1.62 (5H, m).
    Example 56 (4)
    Trans-1- (N-hydroxyaminocarbonyl) -2- (N- (4- (3-methoxy-1-propynyl) phenylcarbonyl) aminomethyl) cyclopentane

    TLC: Rf 0.31 (CHCl 3: MeOH = 9: 1);
    NMR (d 6 -DMSO): δ 10.39 (1H, s), 8.50 (1H, t, J = 5.6 Hz), 7.83 (2H, d, J = 8.2 Hz), 7.52 (2H, d, J = 8.2 Hz ), 4.34 (2H, s), 3.35 (3H, s), 3.32-3.14 (2H, m), 2.40-2.22 (1H, m), 2.20-2.04 (1H, m), 1.90-1.50 (5H, m) ), 1.48-1.24 (1 H, m).
    Example 57
    2 (R) -allyl-5-ethoxymethoxy-4 (S)-[N- (4-phenoxyphenylcarbonyl) amino] pentanoic acid

    Example 37 → Example 39 → Examples, in a tetrahydrofuran (20 ml) solution of lithium diisopropylamide (3.6 ml) at −20 ° C., using the corresponding compounds instead of the compounds prepared in Reference Example 4 Example 41 (using ethoxymethylchloride instead of methoxymethylchloride) → 2 (S) -2-propenyl, obtained by operation in the same manner as shown in Example 43 (using allyl bromide instead of benzyl bromide). A tetrahydrofuran (4 ml) solution of -4 (S) -ethoxymethoxymethyl-4- (N- (4-phenoxyphenylcarbonyl) aminobutanoic acid methyl ester (1.06 g) was added dropwise. The mixture was stirred for 30 minutes at −5 ° C. To the reaction mixture, saturated ammonium chloride solution and water were added, followed by extraction with ethyl acetate The extract was washed with saturated aqueous sodium chloride solution, dried over anhydrous sodium sulfate, and concentrated. Silica gel column chromatography (toluene: acetic acid Ethyl = 87:13) The same procedure as in Example 2 was carried out using the purified compound (200 mg) to obtain the title compound (193 mg) having the following physical properties.
    TLC: 0.19 (chloroform: methanol = 9: 1).
    Example 58
    N-hydroxy-2 (R) -allyl-5-ethoxymethoxy-4 (S)-[N- (4-phenoxyphenylcarbonyl) amino] pentanamide

    Using the compound prepared in Example 57, the same procedure as in Example 3-Example 4 was carried out to obtain the title compound having the following physical properties.
    TLC: Rf 0.23 (CHCl 3: MeOH = 10: 1);
    NMR (d 6 -DMSO): δ 10.37 (s, 1H), 8.74 (brs, 1H), 8.13 (d, J = 8.1Hz, 1H), 7.90-7.85 (m, 2H), 7.45-7.39 (m, 2H), 7.19 (t, J = 7.2 Hz.1H), 7.07-6.99 (m, 4H), 5.69-5.60 (m, 1H), 5.02-4.93 (m, 2H), 4.56 (s, 2H), 3.99 -3.89 (m, 1H), 3.80-3.39 (m, 4H), 2.26-2.01 (m, 3H), 1.85-1.79 (m, 1H), 1.61-1.54 (m, 1H), 1.07 (t, J = 7.2 Hz, 3H).
    Examples 58 (1) to 58 (3)
    Using the corresponding compound, it operated in the same manner as the method shown in Example 57-Example 58, to obtain a compound shown below.
    Example 58 (1)
    N-hydroxy-2 (R) -benzyl-5-methoxymethoxy-4 (S)-[N- [4- (benzofuran-2-yl) phenylcarbonyl] amino] pentanamide

    TLC: Rf 0.35 (CHCl 3: MeOH = 19: 1);
    NMR (d 6 -DMSO): δ 10.37 (1H, s), 8.72 (1H, s), 8.28 (1H, d, J = 7.2 Hz), 8.02 (2H, d, J = 8.8 Hz), 7.97 (2H , d, J = 8.8 Hz), 7.74-7.62 (2H, m), 7.57 (1H, d, J = 0.6 Hz), 7.41-7.10 (7H, m), 4.56 (2H, s), 4.18-3.98 ( 1H, m), 3.57-3.39 (2H, m), 3.23 (3H, s), 2.85 (1H, dd, J = 13.6, 8.4 Hz), 2.64 (1H, dd, J = 13.6, 6.0 Hz), 2.54 -2.40 (1H, m), 2.03-1.80 (1H, m), 1.72-1.52 (1H, m).
    Example 58 (2)
    N-hydroxy-2 (R) -methyl-5-ethoxymethoxy-4 (S)-[N- (4-phenoxyphenylcarbonyl) amino] pentanamide

    TLC: Rf 0.29 (CHCl 3: MeOH: Acetic Acid = 100: 10: 1);
    NMR (d 6 -DMSO): δ 10.35 (s, 1H), 8.70 (s, 1H), 8.13 (d, J = 8.1Hz, 1H), 7.88 (d, J = 8.4Hz, 2H), 7.45-7.39 (m, 2H), 7.19 (t, J = 7.2 Hz, 1H), 7.07-7.01 (m, 4H), 4.57 (s, 2H), 4.01-3.88 (m, 1H), 3.47 (q, J = 7.2 Hz, 2H), 3.44-3.38 (m, 2H), 2.30-2.18 (m, 1H), 1.91-1.82 (m, 1H), 1.55-1.46 (m, 1H), 1.07 (t, J = 7.2 Hz, 3H), 0.99 (d, J = 6.9 Hz, 3H).
    Example 58 (3)
    N-hydroxy-2 (R) -methyl-5-ethoxymethoxy-4 (S)-[N- [4- (4-cyanophenyl) phenylcarbonyl] amino] pentanamide

    TLC: Rf 0.49 (CHCl 3: MeOH = 9: 1);
    NMR (d 6 -DMSO): δ 10.36 (s, 1H), 8.69 (s, 1H), 8.28 (d, J = 8.2Hz, 1H), 8.00-7.94 (m, 6H), 7.84 (d, J = 8.4 Hz, 2H), 4.57 (s, 2H), 4.06-3.88 (m, 1H), 3.52-3.42 (m, 4H), 2.34-2.18 (m, 1H), 1.95-1.81 (m, 1H), 1.60 -1.45 (m, 1H), 1.07 (t, J = 7.2 Hz, 3H), 1.00 (d, J = 6.6 Hz).
    Example 59 (1)-59 (2)
    Reference example 37 using 4 (R) -carboxy-4-aminobutanoic acid methyl ester instead of 4 (S) -carboxy-4-aminobutanoic acid methyl ester and the corresponding compound instead of the compound prepared in Reference Example 4 → Reference Example 39 → Reference Example 41 (in some cases, a compound corresponding to methoxymethyl chloride may be used) → Compound obtained by operation in the same manner as described in Reference Example 43 (using equivalent compound instead of benzyl bromide) In the same manner as in Example 57-Example 2-Example 3-Example 4 using-, the compound shown below was obtained.
    Example 59 (1)
    N-hydroxy-2 (S) -benzyl-5-methoxymethoxy-4 (R)-[N- (4-phenoxyphenylcarbonyl) amino] pentanamide

    TLC: Rf 0.41 (CHCl 3: MeOH: Acetic Acid: Water = 100: 10: 1: 1);
    NMR (d 6 -DMSO): δ 10.33 (1H, s), 8.69 (1H, s), 8.12 (1H, d, J = 8.0 Hz), 7.85 (2H, d, J = 8.8 Hz), 7.37-7.46 (2H, m), 6.99-7.27 (10H, m), 4.52 (2H, s), 3.90-4.13 (1H, m), 3.38-3.44 (2H, m), 3.20 (3H, s), 2.81 (1H , dd, J = 13.2 Hz, 6.2 Hz), 2.59 (1H, dd, J = 13.2 Hz, 6.2 Hz), 2.38-2.52 (1H, m), 1.79-1.93 (1H, m), 1.50-1.63 (1H , m).
    Example 59 (2)
    N-hydroxy-2 (S) -benzyl-5-methoxymethoxy-4 (R)-[N- [4- (3-phenoxy-1-propynyl) phenylcarbonyl] amino] pentanamide

    TLC: Rf 0.41 (CHCl 3: MeOH: Acetic Acid: Water = 100: 10: 1: 1);
    NMR (d 6 -DMSO): δ 10.31 (1H, s), 8.68 (1H, s), 8.24 (1H, d, J = 8.1 Hz), 7.81 (2H, d, J = 7.8 Hz), 7.51 (2H , d, J = 7.8 Hz), 7.32 (2H, t, J = 7.8 Hz), 6.95-7.24 (8H, m), 5.05 (2H, s), 4.50 (2H, s), 3.90-4.07 (1H, m), 3.37-3.42 (2H, m), 3.18 (3H, s), 2.79 (1H, dd, J = 13.5 Hz, 6.2 Hz), 2.58 (1H, dd, J = 13.5 Hz, 6.2 Hz), 2.43 -2.52 (1H, m), 1.82-1.89 (1H, m), 1.54-1.62 (1H, m).
    Example 60 (1) -60 (5)
    Example 37-Example 39-Example 41 (using the equivalent compound instead of methoxymethylchloride)-Example 43 (corresponding instead of the benzyl bromide, using compound equivalent to the compound prepared in Reference Example 4). To obtain the title compound having the following physical properties in the same manner as the method shown in Example 2 → Example 3 → Example 3 → Example 4 → Example 27.
    Example 60 (1)
    N-hydroxy-2 (S)-(3-aminobenzyl) -5-ethoxymethoxy-4 (S)-[N- (trans-4-methylcyclohexylcarbonyl) amino] pentanamide

    TLC: Rf 0.27 (CHCl 3: MeOH = 9: 1);
    NMR (d 6 -DMSO): δ 10.45-10.10 (brs, 1H), 8.80-8.45 (brs, 1H), 7.40 (d, J = 8.1 Hz, 1H), 6.86 (t, J = 7.7 Hz, 1H) , 6.35 (d, J = 7.7 Hz, 1H), 6.32 (s, 1H), 6.28 (d, J = 7.7 Hz, 1H), 4.85 (s, 2H), 4.54 (s, 2H), 3.95-3.80 ( m, 1H), 3.55-3.20 (m, 4H, overlapping with H 2 O in DMSO), 2.59 (dd, J = 13.2, 8.4 Hz, 1H), 2.45 (dd, J = 13.2, 5.7 Hz, 1H), 2.32-2.20 (m, 1H), 2.08-1.92 (m, 1H), 1.80-1.57 (m, 5H), 1.57-1.44 (m, 1H), 1.44-1.20 (m, 3H), 1.11 (t, J = 7.1 Hz, 3H), 0.96-0.76 (m, 5H).
    Example 60 (2)
    N-hydroxy-2 (S) -benzyl-5-ethoxymethoxy-4 (S)-[N- (4-carboxyphenylcarbonyl) amino] pentanamide

    TLC: Rf 0.22 (CHCl 3: MeOH: Acetic Acid = 90: 10: 1);
    NMR (d 6 -DMSO): δ 13.50-12.70 (br, 1H), 10.37 (s, 1H), 8.82-8.58 (br, 1H), 8.31 (d, J = 8.7Hz, 1H), 8.01 (d, J = 8.7 Hz, 2H), 7.95 (d, J = 8.7 Hz, 2H), 7.27-7.08 (m, 5H), 4.58 (s, 2H), 4.34-4.19 (m, 1H), 3.60-3.40 (m , 4H), 2.77 (d, J = 7.2, 2H), 2.42-2.32 (m, 1H), 1.85-1.62 (m, 2H), 1.09 (t, J = 6.9 Hz, 3H).
    Example 60 (3)
    N-hydroxy-2 (S) -benzyl-5-ethoxymethoxy-4 (S)-[N- (4-aminophenylcarbonyl) amino] pentanamide

    TLC: Rf 0.36 (methylene chloride: methanol = 19: 1);
    NMR (d 6 -DMSO): δ 10.34 (brs, 1 H), 8.65 (brs, 1 H), 7.61 (brd, J = 9.0 Hz, 1H), 7.58 (d, J = 8.4 Hz, 2H), 7.22-7.08 (m, 5H), 6.52 (d, J = 8.4 Hz, 2H), 5.57 (brs, 2H), 4.55 (s, 2H), 4.20 (m, 1H), 3.50-3.40 (m, 4H), 2.74 ( d, J = 7.2 Hz, 2H), 2.35 (m, 1H), 1.80-1.59 (m, 2H), 1.07 (t, J = 7.2 Hz, 3H).
    Example 60 (4)
    N-hydroxy-2 (S) -benzyl-5-ethoxymethoxy-4 (S)-[N- (4-piperidylcarbonyl) amino] pentanamide

    TLC: Rf 0.50 (CHCl 3: MeOH: Acetic Acid = 7: 2: 1):
    NMR (d 6 -DMSO): δ 10.30 (brs, 1H), 7.47 (brd, J = 9.0 Hz, 1H), 7.25-7.08 (m, 5H), 4.53 (s, 2H), 3.93 (m, 1H) , 3.43 (q, J = 6.9 Hz, 2H), 3.35 (m, 2H), 2.94 (brd, J = 12.0 Hz, 2H), 2.68 (m, 2H), 2.49 (m, 2H), 2.35-2.10 ( m, 2H), 1.70-1.40 (m, 6H), 1.09 (t, J = 6.9 Hz, 3H).
    Example 60 (5)
    N-hydroxy-2 (S)-(3-hydroxybenzyl) -5-ethoxymethoxy-4 (S)-[N- (4-methylphenylcarbonyl) amino] pentanamide

    TLC: Rf 0.45 (methylene chloride: methanol = 9: 1);
    NMR (d 6 -DMSO): δ 10.33 (s, 1H), 9.16 (s, 1H), 8.64 (s, 1H), 7.99 (brd, J = 8.4Hz, 1H), 7.75 (d, J = 8.4Hz , 2H), 7.23 (d, J = 8.4 Hz, 2H), 6.97 (t, J = 7.2 Hz, 1H), 6.51 (m, 3H), 4.55 (s, 2H), 4.17 (m, 1H), 3.50 (m, 2H), 3.44 (q, J = 7.2 Hz, 2H), 2.62 (m, 2H), 2.33 (s, 3H), 2.33 (m, 1H), 1.80-1.60 (m, 2H), 1.06 ( t, J = 7.2 Hz, 3H).
    Examples 61 (1) to 61 (13)
    Example 43-Example 2-Example using the compound prepared in Example 1, or the compound obtained by operation in the same manner as the example shown in Example 1 using the corresponding compound, and benzyl bromide or an equivalent compound 3 → The same procedure as described in Example 4 was carried out to obtain the title compound having the following physical properties.
    Example 61 (1)
    N-hydroxy-2-benzyl-4- [N- [4- (benzofuran-2-yl) phenylcarbonyl] amino] butylamide

    TLC: Rf 0.39 (CHCl 3: MeOH = 10: 1);
    NMR (d 6 -DMSO): δ 10.43 (1H, s), 8.52 (1H, t, J = 5.6 Hz), 8.00 (2H, d, J = 8.8 Hz), 7.94 (2H, d, J = 8.8 Hz ), 7.71-7.63 (2H, m), 7.57 (1H, s), 7.39-7.16 (7H, m), 3.30-3.15 (2H, m), 2.83 (1H, dd, J = 8.6, 13.6 Hz), 2.66 (1H, doublet of doublets, J = 6.2, 13.6 Hz), 2.44-2.31 (1H, m), 1.88-1.53 (2H, m).
    Example 61 (2)
    N-hydroxy-2- (3-phenylpropyl) -4- [N- [4- (benzofuran-2-yl) phenylcarbonyl] amino] butylamide

    TLC: Rf 0.41 (CHCl 3: MeOH = 10: 1);
    NMR (d 6 -DMSO): δ 10.48 (1H, s), 8.50 (1H, t, J = 5.6 Hz), 8.01 (2H, d, J = 8.8 Hz), 7.95 (2H, d, J = 8.8 Hz ), 7.71-7.63 (2H, m), 7.57 (1H, s), 7.39-7.11 (7H, m), 3.25-3.15 (2H, m), 2.59-2.47 (2H, m), 2.18-2.02 (1H) m), 1.82-1.36 (6H, m).
    Example 61 (3)
    N-hydroxy-2- (2-phenylethyl) -4- [N- [4- (benzofuran-2-yl) phenylcarbonyl] amino] butylamide

    TLC: Rf 0.47 (CHCl 3: MeOH = 10: 1);
    NMR (CD 3 OD): δ 7.98 (2H, d, J = 8.4 Hz), 7.89 (2H, d, J = 8.4 Hz), 7.64-7.60 (1H, m), 7.56-7.52 (1H, m), 7.36-7.09 (7H, m), 7.32 (1H, brs), 3.51-3.24 (2H, m), 2.68-2.50 (2H, m), 2.28-2.14 (1H, m), 2.04-1.69 (4H, m ).
    Example 61 (4)
    N-hydroxy-2-benzyl-4- [N- [4- [2E- (4-chlorophenyl) ethenyl] phenylcarbonyl] amino] butylamide

    TLC: Rf 0.46 (CHCl 3: MeOH = 10: 1);
    NMR (d 6 -DMSO): 10.41 (1H, brs), 8.76 (1H, brs), 8.41 (1H, t, J = 5.4 Hz), 7.83 (2H, d, J = 8.4 Hz), 7.66 (2H, d, J = 8.4 Hz), 7.65 (2H, d, J = 8.8 Hz), 7.44 (2H, d, J = 8.8 Hz), 7.35-7.12 (7H, m), 3.28-3.15 (2H, m), 2.83 (1H, dd, J = 8.4, 13.2 Hz), 2.65 (1H, dd, J = 5.8, 13.2 Hz), 2.46-2.30 (1H, m), 1.86-1.51 (2H, m).
    Example 61 (5)
    N-hydroxy-2-benzyl-4- [N- (4-phenoxyphenylcarbonyl) amino] butylamide

    TLC: Rf 0.45 (CHCl 3: MeOH = 10: 1);
    NMR (d 6 -DMSO): δ 10.40 (1H, s), 8.75 (1H, brs), 8.35 (1H, t, J = 5.6 Hz), 7.84 (2H, d, J = 8.8 Hz), 7.47-7.38 (2H, m), 7.30-6.99 (10H, m), 3.26-3.14 (2H, m), 2.82 (1H, dd, J = 8.4, 13.6 Hz), 2.64 (1H, dd, J = 6.2, 13.6 Hz ), 2.43-2.28 (1H, m), 1.84-1.49 (2H, m).
    Example 61 (6)
    N-hydroxy-2- (naphthalen-1-yl) methyl-4- [N- (4-phenoxyphenylcarbonyl) amino] butylamide

    TLC: Rf 0.45 (CHCl 3: MeOH = 10: 1);
    NMR (d 6 -DMSO): δ 10.39 (1H, brs), 8.74 (1H, brs), 8.33 (1H, t, J = 5.4 Hz), 8.08-8.03 (1H, m), 7.92-7.75 (2H, m), 7.81 (2H, d. J = 8.8 Hz), 7.54-7.40 (9H, m), 7.00 (2H, d, J = 8.8 Hz), 3.33-3.07 (4H, m), 2.63-2.45 (1H m), 1.96-1.56 (2H, m).
    Example 61 (7)
    N-hydroxy-2-isopropyl-4- [N- (4-phenoxyphenylcarbonyl) amino] butylamide

    TLC: Rf 0.35 (CHCl 3: MeOH = l 0: 1);
    NMR (d 6 -DMSO): δ 10.39 (1H, brs), 8.34 (1H, t, J = 5.6 Hz), 7.90 (2H, d, J = 8.8 Hz), 7.43 (2H, t, J = 7.4 Hz ), 7.19 (1H, t, J = 7.4 Hz), 7.09-7.04 (2H, m), 7.01 (2H, d, J = 8.8 Hz), 3.22-3.06 (2H, m), 1.78-1.61 (4H, m), 0.87 (3H, d, J = 6.8 Hz), 0.83 (3H, d, J = 6.0 Hz).
    Example 61 (8)
    N-hydroxy-2- (quinolin-4-yl) methyl-4- [N- (4-phenoxyphenylcarbonyl) amino] butylamide

    TLC: Rf 0.38 (CHCl 3: MeOH = 10: 1);
    NMR (d 6 -DMSO): δ 10.41 (1H, brs), 8.76 (1H, bs), 8.76 (1H, d, J = 4.4 Hz), 8.37 (1H, t, J = 5.6 Hz), 8.15 (1H , br.d, 7.6 Hz), 8.00 (1H, d, J = 7.4 Hz), 7.83 (2H, d, J = 8.8 Hz), 7.77-7.69 (1H, m), 7.62-7.54 (1H, m) , 7.47-7.38 (2H, m), 7.30 (1H, d, J = 4.4 Hz), 7.23-7.16 (1H, m), 7.08-7.05 (2H, m), 7.01 (2H, d, J = 8.8 Hz ), 3.33-3.14 (4H, m), 2.64-2.50 (1H, m), 1.98-1.58 (2H, M).
    Example 61 (9)
    N-hydroxy-2- (2-pyridyl) methyl-4- [N- (4-phenoxyphenylcarbonyl) amino] butylamide

    TLC: Rf 0.34 (CHCl 3: MeOH = 10: 1);
    NMR (d 6 -DMSO): δ 10.47 (1H, brs), 8.76 (1H, s), 8.47-8.43 (1H, m), 8.34 (1H, t, J = 5.6 Hz), 7.83 (2H, d, J = 8.8 Hz), 7.66 (1H, dt, J = 1.8, 7.6 Hz), 7.46-7.39 (2H, m), 7.23-7.15 (3H, m), 7.09-7.03 (2H, m), 7.01 (2H , d, J = 8.8 Hz), 3.25-3.12 (2H, m), 2.97 (1H, dd, J = 7.6, 13.6 Hz), 2.78 (1H, dd, J = 6.6, 13.6 Hz), 2.76-2.56 ( 1 H, m), 1.85-1.46 (2 H, m).
    Example 61 (10)
    N-hydroxy-2- (3-pyridyl) methyl-4- [N- (4-phenoxyphenylcarbonyl) amino] butylamide

    TLC: Rf 0.20 (CHCl 3: MeOH = 10: 1);
    NMR (d 6 -DMSO): δ 10.41 (1H, brs), 8.76 (1H, s), 8.40-8.37 (3H, m), 7.85 (2H, d, J = 8.8 Hz), 7.56 (1H, dt, J = 7.6, 2.2 Hz), 7.47-7.38 (2H, m), 7.30-7.16 (2H, m), 7.10-7.04 (2H, m), 7.02 (2H, d, J = 8.8 Hz), 3.30-3.13 (2H, m), 2.87-2.66 (2H, m), 2.44-2.30 (1H, m), 1.86-1.52 (2H, m).
    Example 61 (11)
    N-hydroxy-2- (naphthalen-2-yl) methyl-4- [N- (4-phenoxyphenylcarbonyl) amino] butylamide

    TLC: Rf 0.45 (CHCl 3: MeOH = 10: 1);
    NMR (d 6 -DMSO): δ 10.40 (1H, d, J = 1.4 Hz), 8.74 (1H, d, J = 1.4 Hz), 8.36 (1H, t, J = 5.6 Hz), 7.84 (2H, d , J = 8.8 Hz), 7.83-7.79 (3H, m), 7.65 (1H, brs), 7.50-7.33 (5H, m), 7.19 (1H, tt, J = 1.8, 7.4 Hz), 7.09-7.04 ( 2H, m), 7.01 (2H, d, J = 8.8 Hz), 3.30-3.12 (2H, m), 2.98 (1H, dd, J = 8.8.13.6 Hz), 2.83 (1H, dd, J = 6.0, 13.6 Hz), 2.50-2.40 (1H, m), 1.90-1.54 (2H, m).
    Example 61 (12)
    N-hydroxy-2- (4-pyridyl) methyl-4- [N- (4-phenoxyphenylcarbonyl) amino] butylamide

    TLC: Rf 0.17 (CHCl 3: MeOH = 10: 1);
    NMR (d 6 -DMSO): δ 10.44 (1H, brs), 8.78 (1H, brs), 8.42 (2H, doublet, J = 5.8 Hz), 8.38 (1H, t, J = 5.6 Hz), 7.85 (2H , d, J = 8.8 Hz), 7.47-7.38 (2H, m), 7.23-7.15 (3H, m), 7.10-7.05 (2H, m), 7.02 (2H, d, J = 8.8 Hz), 3.30- 3.13 (2H, m), 2.87-2.66 (2H, m), 2.48-2.33 (1H, m), 1.85-1.52 (2H, m).
    Example 61 (13)
    N-hydroxy-2- (3-methoxybenzyl) -4- [N- (4-phenoxyphenylcarbonyl) amino] butylamide

    TLC: Rf 0.41 (CHCl 3: MeOH = 10: 1);
    NMR (d 6 -DMSO): δ 10.40 (1H, s), 8.76 (1H, brs), 8.35 (1H, t, J = 5.6 Hz), 7.84 (2H, d, J = 8.8 Hz), 7.47-7.39 (2H, m), 7.24-7.04 (4H, m), 7.01 (2H, d, J = 8.8 Hz), 6.75-6.70 (3H, m), 3.70 (3H, s), 3.30-3.10 (2H, m ), 2.79 (1H, dd, J = 8.8, 13.4 Hz), 2.61 (1H, dd, J = 6.2, 13.4 Hz), 2.43-2.29 (1H, m), 1.83-1.48 (2H, m).
    Example 62
    N-hydroxy-2-isobutyl-4- [N- (4-phenoxyphenylcarbonyl) amino] butylamide

    Example 43-Example 27-Example 2-Example 3 using the compound obtained by operation in the same manner as the method shown in Example 1 using the corresponding compound, and 3-bromo-2-methylpropene. → The title compound having the following physical properties was obtained in the same manner as the method shown in Example 4.
    TLC: Rf 0.33 (CHCl 3: MeOH = 10: 1);
    NMR (d 6 -DMSO): δ 10.47 (1H, s), 9.10-8.41 (1H, brs), 8.33 (1H, t, J = 5.2 Hz), 7.85 (2H, d, J = 8.8 Hz), 7.23 (2H, t, J = 7.4 Hz), 7.19 (1H, t, J = 7.4 Hz), 7.09-7.04 (2H, m), 7.01 (2H, d, J = 8.8 Hz), 3.21-3.11 (2H, m), 2.22-2.04 (1H, m), 1.76-1.34 (4H, m), 1.16-1.02 (1H, m), 0.84 (3H, d, J = 5.4 Hz), 0.81 (3H, d, J = 5.8 Hz).
    Example 63
    5-methoxy-4 (S)-[N- [4- (4-chlorophenyl) phenylcarbonyl] amino] pentanoic acid

    5-hydroxy-4 (S)-[N- (4'-chlorobiphenyl-4-yl) obtained by operation in the same manner as in Example 37-> Example 38 using the corresponding compound. To a tetrahydrofuran (5 ml) solution of carbonyl] aminopentanoic acid methyl ester (1.7 g) was added a solution of silica gel (500 mg) and ether (4 ml) of diazomethane. The mixture was stirred at rt for 10 min. The reaction solution was concentrated. To the tetrahydrofuran (5 ml) solution of the residue, an ether (4 ml) solution of diazomethane was added and stirred for 10 minutes. This operation was repeated 10 times. The residue was purified by silica gel column chromatography (hexane: ethyl acetate = 9: 1-&gt; 3: 1) to obtain a methyl ester of the title compound (1.42 g). Using the methyl ester body (1.4 g), it operated in the same manner as the method shown in Example 2 to obtain the title compound (1.2 g) having the following physical property values.
    TLC: Rf 0.50 (methylene chloride: methanol = 9: 1).
    Example 64
    N-hydroxy-5-methoxy-4 (S)-[N- [4- (4-chlorophenyl) phenylcarbonyl] amino] pentanamide

    Using the compound prepared in Example 63, the title compound was obtained in the same manner as the method shown in Example 3-Example 4, to obtain the title compound having the following physical properties.
    TLC: Rf 0.38 (CHCl 3: MeOH = 10: 1);
    NMR (d 6 -DMSO): δ 10.35 (1H, brs), 8.27 (1H, d, J = 8.4 Hz), 7.95 (2H, d, J = 8.4 Hz), 7.77 (2H, d, J = 8.4 Hz ), 7.76 (2H, d, J = 8.8 Hz), 7.54 (2H, d, J = 8.8 Hz), 4.20-4.03 (1H, m), 3.42 (1H, dd, J = 6.2, 9.6 Hz), 3.33 (1H, doublet of doublets, J = 6.2, 9.6 Hz), 3.26 (3H, s), 2.08-1.95 (2H, m), 1.94-1.58 (2H, m).
    Reference Example 7
    2 (S) -Methyl-5-hydroxy-4 (S)-(N-benzyloxycarbonyl) aminopentanoic acid t-butylester

    Example 39 → Example 45 → Example 46 using 4 (S) -carboxy-4- (N-benzyloxycarbonylamino) butanoic acid t-butylester (instead of benzyl bromide, use methyl iodide) → The title compound was obtained in the same manner as the method shown in Example 48 and having the following physical properties.
    TLC: Rf 0.36 (hexane: AcOEt = 3: 1).
    Example 65
    2 (S) -Methyl-5-succinimide-4 (S)-[N- (4-chlorophenylcarbonyl) amino] pentanoic acid

    Compound (1.42 g), succinimide (521 mg) and triphenylphosphine (1.38 g) prepared in Reference Example 7 were dissolved in anhydrous tetrahydrofuran (20 ml) and cooled to 0 ° C. Diethyl azodicarboxylic acid (2.3 ml; 40% toluene solution) was dripped at the mixture, and it stirred at 0 degreeC for 2 hours. The reaction mixture was concentrated. The residue was purified twice by silica gel column chromatography (hexane: acetone = 9: 1, hexane: ethyl acetate = 3: 1 → 2: 1) to give a mixture of the target compound and triphenylphosphine oxide (2.09 g). . 10% palladium carbon (400 mg) was added to the methanol (20 ml) solution of this mixture, and the mixture was stirred at room temperature under hydrogen atmosphere for 1 hour. The reaction mixture was filtered through Celite (trade name), and the filtrate was concentrated. The residue was dissolved in dichloromethane (20 ml) and cooled to 0 ° C. Triethylamine (2 ml) and p-chlorobenzoyl chloride (1.10 g) were added to this solution, and the mixture was stirred at 0 ° C for 2 hours. The reaction mixture was diluted with ethyl acetate, washed sequentially with 1N hydrochloric acid, water, saturated aqueous sodium carbonate solution, water and saturated brine, dried over anhydrous sodium sulfate, and concentrated. The residue was purified by silica gel column chromatography (hexane: ethyl acetate = 3: 1-&gt; 2: 1-&gt; 3: 3: 2) to obtain t-butyl ester of the title compound (1.29 g). The title compound (845 mg) having the following physical properties was obtained in the same manner as the method shown in Example 29 using t-butyl ester (1.07 g).
    TLC: Rf 0.40 (methylene chloride: methanol = 9: 1);
    NMR (CDCl 3 ): δ 7.64 (d, J = 9.0 Hz, 2H), 7.35 (d, J = 9.0 Hz, 2H), 6.55 (d, J = 8.7 Hz, 1H), 4.51 (m, 1H), 3.69 (dd, J = 13.8, 9.3 Hz, 1H), 3.62 (dd, J = 13.8, 4.2 Hz, 1H), 2.75-2.51 (m, 5H), 1.97 (ddd, J = 14.4, 10.8, 7.2 Hz, 1H), 1.65 (ddd, J = 14.4, 6.3, 4.2 Hz, 1H), 1.26 (d, J = 7.2 Hz, 3H).
    Example 66
    N-hydroxy-2 (S) -methyl-5-succinimide-4 (S)-[N- (4-chlorophenylcarbonyl) amino] pentanamide

    Using the compound prepared in Example 65, the same procedure as in Example 3-Example 4 was carried out to obtain the title compound having the following physical properties.
    TLC: Rf 0.42 (methylene chloride: methanol = 9: 1);
    NMR (d 6 -DMSO): δ 10.35 (d, J = 1.5 Hz, 1H), 8.65 (d, J = 1.5 Hz, 1H), 8.12 (d, J = 9.0 Hz, 1H), 7.75 (d, J = 8.4 Hz, 2H), 7.51 (d, J = 8.4 Hz, 2H), 4.22 (m, 1H), 3.49 (m, 2H), 2.53 (m, 4H), 2.17 (m, 1H), 1.70 (ddd) , J = 13.8, 10.5, 5.4 Hz, 1H), 1.50 (ddd, J = 13.8, 9.0, 4.5 Hz, 1H), 0.96 (d, J = 6.9 Hz, 3H).
    Example 66 (1)
    N-hydroxy-2 (S) -methyl-5-succinimideoxy-4 (S)-[N-methyl-N- (4-nitrophenylcarbonyl) amino] pentanamide

    Example 65 (using N-hydroxysuccinimide instead of succinimide and p-nitrobenzoylchloride instead of p-chlorobenzoyl chloride, using the compound prepared in Reference Example 7 , t-butyl ester was used for the following reaction), and the title compound having the following physical properties was obtained in the same manner as the method shown in Example 5-> Example 29- Example 66.
    TLC: Rf 0.45 (methylene chloride: methanol = 9: 1);
    NMR (d 6 -DMSO): δ 10.50 (s.0.7H), 10.45 (s, 0.3H), 8.28 (d, J = 9.0 Hz, 1.4H), 8.24 (d, J = 9.0 Hz, 0.6H) , 7.69 (d, J = 9.0 Hz, 1.4H), 7.61 (d, J = 9.0 Hz, 0.6H), 4.86 (m, 0.7H), 4.20-4.00 (m, 2H), 3.72 (m, 0.3H ), 2.89 (s, 0.9H), 2.71 (s, 2.1H), 2.60 (m, 4H), 2.20-1.70 (m, 2H), 1.60-1.30 (m, 1H), 1.05 (d, J = 6.9 Hz, 2.1H), 0.74 (d, J = 6.9 Hz, 0.9H).
    Reference Example 8
    5-ethoxymethoxy-4 (S)-[N- (4-phenoxyphenylcarbonyl) amino] pentanol

    5-Ethoxymethoxy-4 (S)-(obtained by operating in the same manner as in Example 37-39-Example 41-Example 42 using a compound corresponding to Reference Example 4. After cooling a tetrahydrofuran (100 ml) solution of N- (4-phenoxyphenylcarbonyl) aminopentanoic acid (3.62 g) to 0 ° C., triethylamine (1.69 ml) and ethylchloroformate (1.2 ml) The mixture was stirred for 1.5 hours at 0 ° C. Sodium borohydride (0.5 equivalent) was added to the reaction mixture, which was stirred for 30 minutes, and then acetic acid (5 ml) was added dropwise and stirred for 30 minutes. The organic layer was separated by adding ethyl acetate and water to the residue, and the organic layer was washed with water and saturated aqueous sodium chloride solution, dried over anhydrous sodium sulfate, and then concentrated. Ethyl: hexane = 2: 1 (containing 1% triethylamine) → 4: 1) W, to give the title compound (1.84 g) having the following physical properties of the.
    TLC: Rf 0.52 (ethyl acetate: hexane = 4: 1).
    Reference Example 9
    1-bromo-5-ethoxymethoxy-4 (S)-[N- (4-phenoxyphenylcarbonyl) amino] pentane

    Triphenylphosphine (409 mg) and sodium hydrogencarbonate (328 mg) were added to the methylene chloride (10 ml) solution of the compound (490 mg) prepared in the reference example 8, and it cooled to 0 degreeC. The methylene chloride (5 ml) solution of carbon tetrabromide (647 mg) was dripped at the mixture, and it stirred at 0 degreeC for 15 minutes. The reaction mixture was poured into water and extracted with ethyl acetate. The extract was washed with water and saturated sodium chloride, dried over anhydrous sodium sulfate, and concentrated. The residue was purified by silica gel column chromatography (hexane: ethyl acetate = 3: 1) to obtain the title compound (293 g) having the following physical properties.
    TLC: Rf 0.41 (hexane: ethyl acetate = 2: 1).
    Example 67
    1-acetylthio-5-ethoxymethoxy-4 (S)-[N- (4-phenoxyphenylcarbonyl) amino] pentane

    Potassium thioacetate (113 mg) was added to the acetone (8 ml) solution of the compound (290 mg) prepared in Reference Example 9, and the mixture was refluxed for 2 hours. After cooling, the reaction solution was poured into water and extracted with ethyl acetate. The extract was washed with water and saturated aqueous sodium chloride solution, dried over anhydrous sodium sulfate, and concentrated. The residue was purified by silica gel column chromatography (hexane: ethyl acetate = 3: 1) to obtain the title compound (268 mg) having the following physical properties.
    TLC: Rf 0.28 (hexane: AcOEt = 2: 1).
    NMR (CDCl 3 ): δ 7.77 (d, J = 8.7 Hz, 2H), 7.38 (t, J = 7.5 Hz, 2H), 7.17 (t, J = 7.5 Hz, 1H), 7.05 (d, J = 7.5 Hz) and 7.01 (d, J = 8.7 Hz) total 4H, 6.54 (d, J = 8.7 Hz, 1H), 4.72 (d, J = 6.9 Hz, 1H), 4.68 (d, J = 6.9 Hz, 1H) , 4.35-4.25 (m, 1H), 3.74 (dd, J = 10, 3 Hz, 1H), 3.63-3.58 (m, 3H), 2.92 (t, J = 6.9 Hz, 2H), 2.32 (s, 3H) , 1.80-1.65 (m, 4H), 1.21 (t, J = 7.2 Hz, 3H).
    Example 68
    5-ethoxymethoxy-4 (S)-[N- (4-phenoxyphenylcarbonyl) amino] pentanethiol

    Potassium carbonate (l46 mg) was added to a methanol (5 ml) solution of the compound (230 mg) prepared in Example 67 at room temperature, followed by stirring for 2 hours. The reaction solution was poured into ice / 1N hydrochloric acid and extracted with ethyl acetate. The extract was washed with water and saturated aqueous sodium chloride solution, dried over anhydrous sodium sulfate, and concentrated. The residue was purified by silica gel column chromatography (hexane: ethyl acetate = 3: 1) to obtain the title compound (170 mg) having the following physical properties.
    TLC: Rf 0.27 (hexane: ethyl acetate = 2: 1),
    NMR (CDCl 3 ): δ 7.77 (d, J = 9HZ, 2H), 7.40-7.34 (m, 2H), 7.17 (t, J = 7.5 Hz, 1H), 7.08-6.96 (m, 4H), 6.54 ( d, J = 9 Hz, 1H), 4.73 (d, J = 6.9 Hz, 1H), 4.69 (d, J = 6.9 Hz, 1H), 4.34-4.24 (m, 1H), 3.77 (dd, J = 10.2, 3 Hz, 1H), 3.66-3.56 (m, 3H), 2.63-2.53 (m.2H), 1.83-1.65 (m, 4H), 1.37 (t, J = 7.5 Hz, 1H), 1.22 (t, J = 7.2 Hz, 3H).
    Example 69
    5-Ethoxymethoxy-4 (S)-[N- (4-phenoxyphenylcarbonyl) amino] pentanoic acid methyl ester

    4 (S) -carboxy-4- (N-benzyloxycarbonylamino) butanoic acid methyl ester and the method shown in Example 39-&gt; Example 41 (using ethoxymethylchloride instead of methoxymethylchloride) To a methanol (150 ml) solution of 5 (S) -ethoxymethoxy-4 (S)-(benzyloxycarbonyl) aminopentanoic acid methyl ester (10 g) obtained by operation in the same manner, 10% palladium carbon ( 1 g) was added and it heated and refluxed for 2 hours in hydrogen atmosphere. The reaction mixture was cooled, the insolubles were filtered through Celite, and the filtrate was concentrated. To the solution of dimethylformamide (DMF) (150 ml) of the residue, 1-hydroxybenzotriazole monohydrate (4.8 g) and 4-phenoxycyanic acid (6 g) were added, and the mixture was ice-cooled and 1- Ethyl-3- (3-dimethylaminopropyl) carbodiimide hydrochloride (6.5 g) was added, and then triethylamine (4.7 ml) was added dropwise, followed by stirring at room temperature overnight. Water was added to the reaction mixture, which was then extracted with ethyl acetate. The extract was washed with 1N hydrochloric acid, saturated aqueous sodium carbonate solution and saturated aqueous sodium chloride solution, dried over anhydrous sodium sulfate, and concentrated. The residue was washed with n-hexane to give the title compound (8.1 g) having the following physical properties.
    TLC: Rf 0.22 (n-hexane: ethyl acetate = 1: 1).
    Example 70
    2 (S) -Methyl-5-ethoxymethoxy-4 (S)-[N- (4-phenoxyphenylcarbonyl) amino] pentanoic acid

    Using the compound prepared in Example 68, the title compound having the following physical properties was obtained in the same manner as the method shown in Example 43 (Using methyl iodide instead of benzyl bromide) → Example 2.
    TLC: Rf 0.45 (CHCl 3: MeOH: Acetic Acid: Water = 100: 10: 1: 1),
    NMR (DMSO-d 6 ): δ 7.75 (2H, dJ = 8.8 Hz), 7.37 (2H, m), 7.17 (1H, t, J = 7.4 Hz), 7.03 (2H, m), 6.97 (2H, d , J = 8.8 Hz), 6.58 (1H, d, J = 9.1 Hz), 4.71 (1H, d, J = 6.9 Hz), 4.68 (1H, d, J = 6.9 Hz), 4.43 (1H, m), 3.74 (1H, dd, J = 3.0, 10.2 Hz), 3.65-3.55 (3H, m), 2.56 (1H, m), 2.16 (1H, m), 1.68 (1H, m), 1.27 (3H, d, J = 6.9 Hz), 1.18 (3H, t, J = 7.1 Hz).
    Example 70 (1) -70 (2)
    Using the corresponding compound, it was operated in the same manner as the method shown in Example 69-Example 70 to obtain a compound shown below.
    Example 70 (1)
    2 (S) -allyl-5-ethoxymethoxy-4 (S)-[N- (4-phenoxyphenylcarbonyl) amino] pentanoic acid
    TLC: Rf 0.49 (CHCl 3: MeOH: Acetic Acid = 100: 10: 1).

    Example 70 (2)
    2 (S) -Methyl-5-ethoxymethoxy-4 (S)-[N- [4- (4-cyanophenyl) phenylcarbonyl] amino] pentanoic acid

    NMR (DMSO-d6): δ 12.7 (1H, s), 8.29-8.25 (2H, m), 7.97-7.92 (6H, m), 7.83 (2H, d, J = 8.4 Hz), 4.59 (2H, s ), 4.28-4.16 (1H, m), 3.53-3.42 (4H, m), 2.39-2.30 (1H, m), 1.95-1.84 (1H, m), 1.64-1.54 (1H, m), 1.12-1.04 (6H, m).
    Example 71
    N-hydroxy-2 (S) -methyl-5-ethoxymethoxy-4 (S)-[N- (4-phenoxyphenylcarbonyl) amino] pentanamide

    Using the compound prepared in Example 70, the title compound having the following physical properties was obtained in the same manner as the method shown in Example 3-Example 4.
    TLC: Rf 0.40 (CHCl 3: MeOH: Acetic Acid: Water = 100: 10: 1: 1);
    NMR (DMSO-d 6 ): δ 10.37 (1H, brs), 8.66 (1H, brs), 8.03 (1H, d, J = 8.8 Hz), 7.87 (2H, d, J = 8.8 Hz), 7.43 (2H , dd, J = 7.4, 8.5 Hz, 7.20 (1H, t, J = 7.4 Hz), 7.06 (2H, d, J = 8.5 Hz), 7.02 (2H, d, J = 8.8 Hz), 4.59 (2H , s), 4.14 (1H, m), 3.50-3.45 (4H, m), 2.17 (1H, m), 1.66 (2H, m), 1.09 (3H, t, J = 7.1 Hz), 1.01 (3H, d, J = 6.9 Hz).
    Example 71 (1)-71 (2)
    Using the compound prepared in Example 70 (1) or 70 (2), the same procedure as in Example 71 was performed to obtain a compound shown below.
    Example 71 (1)
    N-hydroxy-2 (S) -allyl-5-ethoxymethoxy-4 (S)-[N- (4-phenoxyphenylcarbonyl) amino] pentanamide

    TLC: Rf 0.26 (CHCl 3: MeOH: Acetic Acid = 100: 10: 1);
    NMR (d 6 -DMSO): δ 10.42 (1H, s), 8.70 (1H, s), 8.03 (1H, d, J = 8.8 Hz), 7.89-7.85 (2H, m), 7.47-7.37 (2H, m), 7.23-7.15 (1H, m), 7.09-6.99 (4H, m), 5.77-5.55 (1H, m), 5.03-4.92 (2H, m), 4.58 (2H, s), 4.19-4.05 ( 1H, m), 3.53-3.42 (2H, m), 3.47 (2H, q, J = 7.0 Hz), 2.19-2.17 (3H, m), 1.38-1.82 (2H, m), 1.08 (3H, t, J = 7.0 Hz).
    Example 71 (2)
    N-hydroxy-2 (S) -methyl-5-ethoxymethoxy-4 (S)-[N- [4- (4-cyanophenyl) phenylcarbonyl] amino] pentanamide

    TLC: Rf 0.48 (CHCl 3: MeOH = 9: 1);
    NMR (d 6 -DMSO): δ 10.37 (1H, s), 8.18 (1H, d, J = 8.4 Hz), 7.99-7.91 (6H, m), 7.83 (2H, d, J = 8.2 Hz), 4.58 (2H, s), 4.24-4.07 (1H, m), 3.54-3.41 (4H, m), 2.26-2.10 (1H, m), 1.74-1.62 (2H, m), 1.12-0.97 (6H, m) .
    [Example]
    Formulation Example 1
    Each of the following components were mixed by a conventional method and then compressed into tablets to obtain 100 tablets containing 50 mg of the active ingredient in one tablet.
    5.0 g of N-hydroxy-2 (S) -methyl-5-ethoxymethoxy-4 (S)-[N- (4-phenoxyphenylcarbonyl) amino] pentanamide
    0.2 g of carboxymethyl cellulose calcium (disintegrant)
    0.1 g magnesium stearate (lubricant)
    4.7 g of microcrystalline cellulose
    Formulation Example 2
    After mixing each of the following components by a conventional method, the solution is sterilized by a conventional method, 5 ml each is filled in ampoules, and lyophilized by a conventional method to obtain 20 mg of the active ingredient in 1 ampoule 100 ampoules were obtained.
    2.0 g of N-hydroxy-2 (S) -methyl-5-ethoxymethoxy-4 (S)-[N- (4-phenoxyphenylcarbonyl) amino] pentanamide
    20 g of mannitol
    500 ml of distilled water
    权利要求:
    Claims (15)
    [1" claim-type="Currently amended] Aminobutanoic acid derivatives represented by the formula (I) or nontoxic salts thereof.

    [Wherein, R 1 represents -COOR 10 , -CONHOR 10 , -CONHNHR 10 ,-(CH 2 ) n SR 50 or -Y-PO (OR 51 ) 2 ,
    R 10 is (i) a hydrogen atom, (ii) a C1-8 alkyl group, (iii) a phenyl group, (iv) a C1-8 alkyl group substituted with a phenyl group or a C1-8 alkoxy group, or (v) a phenyl group, benzyl group or C1-8 An oxycarbonyl group substituted with an 8 alkyl group,
    n represents an integer of 0 to 3,
    R 50 represents (i) a hydrogen atom, (ii) a C 1-8 alkyl group, (iii) -COR 52 (wherein R 52 represents a C 1-8 alkyl group or a phenyl group), (iv) -SR 53 (in the group, R 53 represents a hydrogen atom, a C1-8 alkyl group or a phenyl group),
    R 51 represents a hydrogen atom, a C1-8 alkyl group or a phenyl group,
    Y represents a single bond, -CH 2 -or -O-,
    R 2 , R 3 , R 4 , R 5 , R 6 , and R 7 are each independently
    1) hydrogen atom,
    2) a C1-8 alkyl group,
    3) a C2-8 alkenyl group,
    4) -OR 11 ,
    5) -SR 11 ,
    6) -NR 12 R 13 ,
    7) -COR 14 ,
    8) Cyc1,
    9) a C1-8 alkyl group substituted with a group selected from -OR 11 , -SR 11 , -NR 12 R 13 , -COR 14 , guanidino group or Cyc1, or
    10) -OR 11 , -SR 11 , -NR 12 R 13 , -COR 14 , represent a C2-8 alkenyl group substituted with a group selected from a guanidino group or Cyc1, or R 3 and R 4 groups are integrally C1-8 alkylene group, R 5 group and R 6 group are integrated, C1-8 alkylene group, R 3 group and R 6 group are integrated, C1-8 alkylene group, R 2 group and R 3 group are integrated, C2-8 alkyl group, R 4 group and R 5 groups are integrally C2~8 alkylene group, or R 6 group and R 7 groups are integrally or represents a group C2~8 alkylene, or
    R 2 represents a 2-propynyl group, and R 3 , R 4 , R 5 , R 6 , and R 7 each independently
    1) hydrogen atom,
    2) a C1-8 alkyl group,
    3) a C2-8 alkenyl group,
    4) -OR 11 ,
    5) -SR 11 ,
    6) -NR 12 R 13 ,
    7) -COR 14 ,
    8) Cyc1,
    9) a C1-8 alkyl group substituted with a group selected from -OR 11 , -SR 11 , -NR 12 R 13 , -COR 14 , guanidino group or Cyc1, or
    10) -OR 11 , -SR 11 , -NR 12 R 13 , -COR 14 , represent a C2-8 alkenyl group substituted with a group selected from a guanidino group or Cyc1, or R 3 and R 4 groups are integrally C1-8 alkylene group, R 5 group and R 6 group are integrated, C1-8 alkylene group, R 3 group and R 6 group are integrated, C1-8 alkylene group, R 4 group and R 5 group are integrated, C2-8 alkyl A rene group or an R 6 group and an R 7 group are integrated to represent a C2-8 alkylene group,
    In the group, Cyc1 represents a carbocyclic ring or a heterocyclic ring, and these carbocyclic or heterocycles represent one or more (i) C1-8 alkyl groups, (ii) C1-8 alkoxy groups, (iii) nitro groups, (iv ) Guanidino group, (v) amidino group, (vi) halogen atom, (vii) nitrile group, (viii) hydroxyl group, (ix) benzyloxy group, (x) -NR 101 R 102 (R 101 and R 102 each independently represent a hydrogen atom or a C1-8 alkyl group), (xi) -COOR 103 (R 103 represents a hydrogen atom or a C1-8 alkyl group), (xii) trifluoromethyl group, (xiii) trifluoro Phenyl group, (xvi) phenyloxy group, (xvii) phenylsulfonyl group, (xviii) phenyl group or nitrile group, substituted by a romoxyoxy group, (xiv) phenyl group, (xv) C1-8 alkyl group or C1-8 alkoxy group the C1~8 alkyl group, (xix) heterocyclic, or (xx) keto group, (xxi) -CONR 104 R 105 the C1~8 alkoxy group substituted with a (group of, R 104 and R 105 are each independently hydrogen, optionally substituted Atom, C1-8 alkyl group or phenyl group) may be substituted.
    R 11 is
    (i) a hydrogen atom,
    (ii) a C1-8 alkyl group,
    (iii) a Cyc 1 group,
    (iv) -COR 18 groups,
    (v) a C1-8 alkyl group substituted with a group selected from -OR 15 , -SR 15 , -NR 16 R 17 , -COR 18 , guanidino group or Cyc1,
    R 15 represents a hydrogen atom, a C 1-8 alkyl group, Cyc 1, or a C 1-8 alkyl group substituted with a Cyc 1 or C 1-8 alkoxy group,
    R 16 represents a hydrogen atom or a C1-8 alkyl group,
    R 17 represents a hydrogen atom, a C 1-8 alkyl group or —COR 19 (wherein R 19 represents a C 1-8 alkyl group, a C 1-8 alkyl group substituted with Cyc 1 or Cyc 1),
    R 18 represents a hydroxyl group, a C 1-8 alkyl group, a C 1-8 alkoxy group, or —NR 20 R 21 (wherein R 20 and R 21 each independently represent a hydrogen atom, a C 1-8 alkyl group, Cyc 1 or Cyc 1 substituted with C 1-); 8 alkyl group).
    R 12 represents a hydrogen atom, a C1-8 alkyl group, a Cyc1 or a C1-8 alkyl group substituted with Cyc1,
    R 13 represents a hydrogen atom, a C 1-8 alkyl group, a C 1-8 alkyl group substituted with Cyc 1, Cyc 1 or -COR 22 (wherein R 22 represents a C 1-8 alkyl group, a C 1-8 alkyl group substituted with Cyc 1 or Cyc 1) Indicates
    R 14 is a hydroxyl group, a C 1-8 alkyl group, a C 1-8 alkoxy group, a C 1-8 alkyl group substituted with Cyc 1, Cyc 1 or —NR 23 R 24 (wherein R 23 and R 24 are each independently (i) a hydrogen atom , (ii) a C1-8 alkyl group, (iii) Cyc1 or (iv) a Cyc1 or a C1-8 alkyl group substituted with a hydroxyl group).
    (1) R 8
    1) hydrogen atom,
    2) a C1-8 alkyl group,
    3) a C1-8 alkoxycarbonyl group,
    4) a C1-8 alkyl group substituted with a group selected from -OR 26 , -SR 26 , -NR 27 R 28 or -COR 29 , or
    5) when a C1-8 alkoxycarbonyl group is substituted with Cyc2,
    R 9 is Represents a group,
    (2) R 8 is
    Flag or When representing a flag,
    R 9 is
    1) a C1-8 alkyl group,
    2) a C1-8 alkoxy group,
    3) a C1-8 alkoxy group substituted with Cyc2,
    4) a C1-8 alkyl group substituted with a group selected from -OR 26 , -SR 26 , -NR 27 R 28 , -COR 29 or Cyc2, or
    5) Represents a group,
    In the group, Cyc2 represents a carbocyclic ring or a heterocycle, and these carbocyclic rings or heterocycles may include one or more (1) C1-8 alkyl groups, (ii) C1-8 alkoxy groups, (iii) nitro groups, (iv ) Guanidino group, (v) amidino group, (vi) halogen atom, (vii) nitrile group, (viii) hydroxyl group, (ix) benzyloxy group, (x) -NR 201 R 202 (R 201 and R 202 each independently represents a hydrogen atom or a C1-8 alkyl group), (xi) -COOR 203 (R 203 represents a hydrogen atom or a C1-8 alkyl group), (xii) trifluoromethyl group, (xiii) trifluoro Phenyl group, (xvi) phenyloxy group, (xvii) phenylsulfonyl group, (xviii) phenyl group or nitrile group, substituted by a romoxyoxy group, (xiv) phenyl group, (xv) C1-8 alkyl group or C1-8 alkoxy group A C1-8 alkoxy group substituted with a C1-8 alkyl group, a (xix) heterocycle or a (xx) keto group, or a (xxi) -CONR 204 R 205 group, wherein R 204 and R 205 are each independently hydrogen Atom, C1-8 alkyl group or phenyl group) may be substituted.
    R 26 represents a hydrogen atom, a C 1-8 alkyl group, Cyc 2 or a C 1-8 alkyl group substituted with Cyc 2,
    R 27 represents a hydrogen atom, a C1-8 alkyl group, a Cyc2 or a C1-8 alkyl group substituted with Cyc2,
    R 28 represents a hydrogen atom, a C 1-8 alkyl group, a C 1-8 alkyl group substituted with Cyc 2, Cyc 2 or -COR 30 (R 30 represents a C 1-8 alkyl group, a C 1-8 alkyl group substituted with Cyc 2 or Cyc 2),
    R 29 is a hydroxyl group, a C 1-8 alkyl group, a C 1-8 alkyl group substituted with Cyc 2, Cyc 2 or —NR 31 R 32 (R 31 and R 32 are each independently a hydrogen atom, a C 1-8 alkyl group, Cyc 2 or Cyc 2 substituted with C1-8 alkyl group);
    Represents a carbon or heterocycle,
    R 25 represents -EG,
    E is
    1) single bond,
    2) -CONR 33 -,
    3) -NR 33 CO-,
    4) -CO-O-,
    5) -O-CO-,
    6) -NR 33 -CO-NR 34- ,
    7) -CO-CH 2- ,
    8) -CO-,
    9) -O-CO-NR 33- ,
    10) -NR 33 -CO-O-,
    11) -0-CO-0-,
    12) -CS-NR 33 -,
    13) -NR 33 -CS-,
    14) -CS-O-,
    15) -O-CS-,
    16) -NR 33 -CS-R 34- ,
    17) -CS-CH 2- ,
    18) -CS-,
    19) -O-CS-NR 33- ,
    20) -NR 33 -CS-O-,
    21) -O-CS-O-,
    22) -CH 2 -CH 2- ,
    23) -HC = CH-,
    24) -C≡C-,
    25) -SO 2 -NR 33 -,
    26) -NR 33 -SO 2- ,
    27) -SO 2 -CH 2- , or
    28) -CH 2 -SO 2- ;
    In the group, R 33 and R 34 each independently represent a hydrogen atom, a C1-8 alkyl group, a Cyc3 or a C1-8 alkyl group substituted with Cyc3,
    Cyc3 represents a carbocyclic ring or a heterocyclic ring, and these carbocyclic rings or heterocycles include one or more (i) C1-8 alkyl groups, (ii) C1-8 alkoxy groups, (iii) nitro groups, (iv) guanies Dino group, (v) amidino group, (vi) halogen atom, (vii) nitrile group, (viii) hydroxyl group, (ix) benzyloxy group, (x) -NR 301 R 302 (R 301 and R 302 are respectively Independently a hydrogen atom or a C1-8 alkyl group), (xi) -COOR 303 (R 303 represents a hydrogen atom or a C1-8 alkyl group), (xii) trifluoromethyl group, (xiii) trifluoromethyljade Or (xiv) a phenyl group, (xv) a phenyl group substituted by a C1-8 alkyl group or a C1-8 alkoxy group, (xvi) a phenyloxy group, (xvii) a phenylsulfonyl group, (xviii) a phenyl group or a nitrile group A C1-8 alkoxy group substituted with a C1-8 alkyl group, (xix) heterocycle or (xx) keto group, (xxi) -CONR 304 R 305 group (wherein R 304 and R 305 are each independently a hydrogen atom, C1 ～ 8 It may even be substituted by a phenyl group or represents an kilgi).
    G is
    1) hydrogen atom,
    2) a C1-8 alkyl group,
    3) Cyc4,
    4) -OR 35 ,
    5) -SR 35 ,
    6) halogen atom,
    7) nitro groups,
    8) nitrile group,
    9) -NR 36 R 37 ,
    10) -COR 38 ,
    11) a C1-8 alkyl group substituted with a group selected from Cyc4, -OR 35 , -SR 35 , a halogen atom, -NR 36 R 37 or -COR 38 ,
    In the group, Cyc4 represents a carbocyclic ring or heterocyclic ring, and these carbocyclic rings or heterocycles may include one or more of (i) C1-8 alkyl group, (ii) C1-8 alkoxy group, (iii) nitro group, (iv ) Guanidino group, (v) amidino group, (vi) halogen atom, (vii) nitrile group, (viii) hydroxyl group, (ix) benzyloxy group, (x) -NR 401 R 402 (R 401 and R 402 each independently represents a hydrogen atom or a C1-8 alkyl group), (xi) -COOR 403 (R 403 represents a hydrogen atom or a C1-8 alkyl group), (xii) trifluoromethyl group, (xiii) trifluoro Phenyl group, (xvi) phenyloxy group, (xvii) phenylsulfonyl group, (xviii) phenyl group or nitrile group, substituted by a romoxyoxy group, (xiv) phenyl group, (xv) C1-8 alkyl group or C1-8 alkoxy group A C 1-8 alkoxy group substituted with a C 1-8 alkyl group, a (xix) heterocycle, a (xx) keto group, or a (xxi) -CONR 404 R 405 group, wherein R 404 and R 405 are each independently Hydrogen atom, C1-8 alkyl group or phenyl group) may be substituted.
    R 35 represents a hydrogen atom, a C 1-8 alkyl group, a C 1-8 alkoxy group, a C 1-8 alkyl group substituted with Cyc 4 or Cyc 4,
    R 36 represents a hydrogen atom, a C 1-8 alkyl group, a C 1-8 alkyl group substituted with Cyc 4 or Cyc 4,
    R 37 represents a hydrogen atom, a C1-8 alkyl group, a C1-8 alkyl group substituted with Cyc4, Cyc4 or -COR 39 (R 39 represents a C1-8 alkyl group, a C1-8 alkyl group substituted with Cyc4 or Cyc4),
    R 38 is a hydroxyl group, a C 1-8 alkyl group, a C 1-8 alkyl group substituted with Cyc 4, Cyc 4 , -NR 40 R 41 (R 40 and R 41 are each independently a hydrogen atom, a C 1-8 alkyl group, Cyc 4 or Cyc 4 substituted with C1-8 alkyl group) or integrally with -EG to represent a C1-4 alkylidene group,
    p represents an integer of 1 to 5,
    M represents a C1-8 alkylene group,
    J represents a single bond, an oxygen atom, a sulfur atom or -NR 42- (R 42 represents a hydrogen atom or a C1-8 alkyl group),
    Is a single bond or R 2 , R 3 , R 4 , R 5 , R 6 , or R 7 when adjacent two groups which are not bonded to the same carbon is hydrogen, leaving a double bond (wherein R 3 When group and R 4 group are integrated, C1-8 alkylene group, R 5 group and R 6 group are integral, C1-8 alkylene group, R 3 group and R 6 group are integral and represent C1-8 alkylene group. Not)].
    [2" claim-type="Currently amended] According to claim 1, R 2 , R 3 , R 4 , R 5 , R 6 , R 7 are each independently
    1) hydrogen atom,
    2) a C1-8 alkyl group,
    3) a C2-8 alkenyl group,
    4) -OR 11 ,
    5) -SR 11 ,
    6) -NR 12 R 13 ,
    7) -COR 14 ,
    8) Cyc1,
    9) a C1-8 alkyl group substituted with a group selected from -OR 11 , -SR 11 , -NR 12 R 13 , -COR 14 , guanidino group or Cyc1, or
    10) -OR 11 , -SR 11 , -NR 12 R 13 , -COR 14 , represent a C2-8 alkenyl group substituted with a group selected from a guanidino group or Cyc1, or R 3 and R 4 groups are integrally C1-8 alkylene group, R 5 group and R 6 group are integrated, C1-8 alkylene group, R 3 group and R 6 group are integrated, C1-8 alkylene group, R 2 group and R 3 group are integrated, C2-8 alkyl group, R 4 group and R 5 groups are integrally C2~8 alkylene group, or R 6 group and R 7 groups are integrally compound, characterized in that represents a C2~8 alkylene.
    [3" claim-type="Currently amended] The compound of claim 1, wherein R 2 represents a 2-propynyl group, and R 3 , R 4 , R 5 , R 6 , and R 7 are each independently
    1) hydrogen atom,
    2) a C1-8 alkyl group,
    3) a C2-8 alkenyl group,
    4) -OR 11 ,
    5) -SR 11 ,
    6) -NR 12 R 13 ,
    7) -COR 14 ,
    8) Cyc1,
    9) a C1-8 alkyl group substituted with a group selected from -OR 11 , -SR 11 , -NR 12 R 13 , -COR 14 , guanidino group or Cyc1, or
    10) -OR 11 , -SR 11 , -NR 12 R 13 , -COR 14 , represent a C2-8 alkenyl group substituted with a group selected from a guanidino group or Cyc1, or R 3 and R 4 groups are integrally C1-8 alkylene group, R 5 group and R 6 group are integrated, C1-8 alkylene group, R 3 group and R 6 group are integrated, C1-8 alkylene group, R 4 group and R 5 group are integrated, C2-8 alkyl A lene group or a R 6 group and an R 7 group are integrated to represent a C2-8 alkylene group.
    [4" claim-type="Currently amended] The compound of claim 1, wherein R 1 is a —COOR 10 group.
    [5" claim-type="Currently amended] The compound of claim 1, wherein R 1 is a -CONHOR 10 group.
    [6" claim-type="Currently amended] The compound of claim 1, wherein R 1 is a -CONHNHR 10 group.
    [7" claim-type="Currently amended] The compound of claim 1, wherein R 1 is a — (CH 2 ) n SR 50 group.
    [8" claim-type="Currently amended] The compound of claim 1, wherein R 1 is a -Y-PO (OR 51 ) 2 group.
    [9" claim-type="Currently amended] The compound of claim 2 wherein the compound is
    (1) 4- (N- (4- (benzofuran-2-yl) phenylcarbonyl) amino) butanoic acid,
    (2) 4- (N- (4-methylphenylcarbonyl) amino) butanoic acid,
    (3) 4- (N- (4-butyloxyphenylcarbonyl) amino) butanoic acid,
    (4) 4- (N- (3-butyloxyphenylcarbonyl) amino) butanoic acid,
    (5) 4- [N- [4- (2- (4-methylphenyl) ethynyl) furan-2-ylcarbonyl] amino] butanoic acid,
    (6) 4- (N- (4- (pyrrole-1-yl) phenylcarbonyl) amino) butanoic acid,
    (7) 4- (N- (trans-4-methylcyclohexylcarbonyl) amino) butanoic acid,
    (8) 4- (N- (4- (3-methoxy-1-propynyl) phenylcarbonyl) amino) butanoic acid,
    (9) 4- (N- (4-butylphenylcarbonyl) amino) butanoic acid,
    (10) 4- (N- (benzofuran-2-ylcarbonyl) amino) butanoic acid,
    (11) 4- [N- [4- (2- (4-chlorophenyl) ethenyl) phenylcarbonyl] amino] butanoic acid,
    (12) 4- [N- [4- (2- (4- (imidazol-1-yl) phenyl) ethynyl) phenylcarbonyl] amino] butanoic acid,
    (13) 4- (N- (trans-4-propylcyclohexylcarbonyl) amino) butanoic acid,
    (14) 4- [N- [4- (2- (4-methylphenyl) ethynyl) phenylcarbonyl] amino] butanoic acid,
    (15) 4- [N- [4-((4-bromophenyl) aminosulfonyl) phenylcarbonyl] amino] butanoic acid,
    (16) 4- [N- (4-cyclohexylphenylcarbonyl) amino] butanoic acid,
    (17) 4- [N- [4- (4-propylphenyl) phenylcarbonyl] amino] butanoic acid,
    (18) 4- [N- [4- (4-hydroxyphenyl) phenylcarbonyl] amino] butanoic acid,
    (19) 4- [N- [4- (4-chlorophenyl) furan-2-ylcarbonyl] amino] butanoic acid,
    (20) 4- [N- [4- (4-heptylphenyl) phenylcarbonyl] amino] butanoic acid,
    (21) 4- [N- [4- (4-methoxyphenyl) phenylcarbonyl] amino] butanoic acid,
    (22) 4- [N- [4- (4-chlorophenyl) phenylcarbonyl] amino] butanoic acid,
    (23) 4- [N- (5-benzyloxyindol-2-ylcarbonyl) amino] butanoic acid,
    (24) 4- [N- [5- (2- (4-chlorophenyl) ethenyl) furan-2-ylcarbonyl] amino] butanoic acid,
    (25) 4- [N- [4- (4-phenyloxyphenyl) phenylcarbonyl] amino] butanoic acid,
    (26) 4- (N-methyl-N- (4- (benzofuran-2-yl) phenylcarbonyl) amino) butanoic acid,
    (27) 4- (N- (4- (benzofuran-2-yl) phenylcarbonyl) amino) -2 (S) -hydroxybutanoic acid,
    (28) 4- (N- (4- (benzofuran-2-yl) phenylcarbonyl) amino) -2 (R) -hydroxybutanoic acid,
    (29) 4- (N- (4- (benzofuran-2-yl) phenylcarbonyl) amino) -2 (S) -benzyloxymethoxybutanoic acid,
    (30) 4- (N- (4- (benzofuran-2-yl) phenylcarbonyl) amino) -2 (R) -benzyloxymethoxybutanoic acid,
    (31) 4- (N- (4- (2- (4-chlorophenyl) ethenyl) phenylcarbonyl) amino) -2 (S) -benzyloxymethoxybutanoic acid,
    (32) 4- (N- (4-chlorophenylcarbonyl) amino) -2-benzyloxymethoxybutanoic acid,
    (33) 4- (N- (4-chlorophenylcarbonyl) amino) -2-((N-benzyl-N-methylamino) carbonylmethoxy) butanoic acid,
    (34) 4- (N- (4-chlorophenylcarbonyl) amino) -2-((N-phenyl-N-methylamino) carbonylmethoxy) butanoic acid,
    (35) 4- (N- (4-chlorophenylcarbonyl) amino) -2-((N-phenylethyl-N-methylamino) carbonylmethoxy) butanoic acid,
    (36) 3 (S) -hydroxy-4- (N- (4- (benzofuran-2-yl) phenylcarbonyl) amino) butanoic acid,
    (37) 3 (R) -hydroxy-4- (N- (4- (benzofuran-2-yl) phenylcarbonyl) amino) butanoic acid,
    (38) 3 (S) -methoxymethyloxy-4- (N- (4- (benzofuran-2-yl) phenylcarbonyl) amino) butanoic acid,
    (39) 4- (N- (4- (benzofuran-2-yl) phenylcarbonyl) amino) -2-butenoic acid,
    (40) 3 (R) -methoxymethyloxy-4- (N- (4- (benzofuran-2-yl) phenylcarbonyl) amino) butanoic acid,
    (41) 4- (N- (4- (benzofuran-2-yl) phenylcarbonyl) amino) -3-butenoic acid,
    (42) 2-benzyloxymethyl-4- (N- (4-methylphenylcarbonyl) amino) butanoic acid,
    (43) 4 (S) -methylaminocarbonyl-4- (N- (4-methylphenylcarbonyl) amino) butanoic acid,
    (44) 4 (R) -methylaminocarbonyl-4- (N- (4-methylphenylcarbonyl) amino) butanoic acid,
    (45) 4 (S) -benzylaminocarbonyl-4- (N- (4-methylphenylcarbonyl) amino) butanoic acid,
    (46) 4 (S)-(4-hydroxybutyl) aminocarbonyl-4- (N- (4-methylphenylcarbonyl) amino) butanoic acid,
    (47) 4 (S) -methoxycarbonyl-4- [N- [4- (4-hydroxy-1-butynyl) phenylcarbonyl] amino] butanoic acid,
    (48) 4 (S) -t-butoxycarbonyl-4- (N- (4-methylphenylcarbonyl) amino) butanoic acid,
    (49) 4 (S)-(morpholin-1-yl) carbonyl-4- (N- (4- (benzofuran-2-yl) phenylcarbonyl) amino) butanoic acid,
    (50) 4 (S) -hydroxymethyl-4- (N- (4- (benzofuran-2-yl) phenylcarbonyl) amino) butanoic acid,
    (51) 4 (S) -methoxymethyloxymethyl-4- (N- (4- (benzofuran-2-yl) phenylcarbonyl) amino) butanoic acid,
    (52) 2 (S) -benzyl-4 (S) -methoxymethyloxymethyl-4- (N- (4- (benzofuran-2-yl) phenylcarbonyl) amino) butanoic acid,
    (53) 2 (S) -methyl-4 (S) -methoxymethyloxymethyl-4- (N- (4- (benzofuran-2-yl) phenylcarbonyl) amino) butanoic acid,
    (54) 2 (S)-(3-phenyl-2-propenyl) -4 (S) -methoxymethyloxymethyl-4- (N- (4- (benzofuran-2-yl) phenylcarbonyl) Amino) butanoic acid,
    (55) 2 (S)-(3-phenylpropyl) -4 (S) -methoxymethyloxymethyl-4- (N- (4- (benzofuran-2-yl) phenylcarbonyl) amino) butanoic acid ,
    (56) 2 (S) -methyl-5-ethoxymethoxy-4 (S)-[N- (4-chlorophenylcarbonyl) amino] pentanoic acid,
    (57) 2 (S) -methyl-5-ethoxymethoxy-4 (S)-[N- (4-nitrophenylcarbonyl) amino] pentanoic acid,
    (58) 2 (S) -methyl-5-ethoxymethoxy-4 (S)-[N- (4-bromophenylcarbonyl) amino] pentanoic acid,
    (59) 2 (S) -allyl-5-ethoxymethoxy-4 (S)-[N- (4-nitrophenylcarbonyl) amino] pentanoic acid,
    (60) 2 (R) -methoxymethyl-5-ethoxymethoxy-4 (S)-[N- (4-nitrophenylcarbonyl) amino] pentanoic acid,
    (61) 2 (R) -benzyloxymethyl-5-ethoxymethoxy-4 (S)-[N- (4-nitrophenylcarbonyl) amino] pentanoic acid,
    (62) 2 (S) -methyl-5- (2-methoxyethoxy) methoxy-4 (S)-[N- (4-cyanophenylcarbonyl) amino] pentanoic acid,
    (63) 2 (R)-(2-methoxyethoxy) methyl-5-ethoxymethoxy-4 (S)-[N- (4-nitrophenylcarbonyl) amino] pentanoic acid,
    (65) 2 (S) -allyl-5- (2-methoxyethoxy) methoxy-4 (S)-[N- (4-cyanophenylcarbonyl) amino] pentanoic acid,
    (66) 2 (S) -methoxymethyl-5- (2-methoxyethoxy) methoxy-4 (S)-[N- (4-cyanophenylcarbonyl) amino] pentanoic acid,
    (69) 2 (R) -methoxymethyl-5-ethoxymethoxy-4 (S)-[N- (4-bromophenylcarbonyl) amino] pentanoic acid,
    (70) 2 (R) -methoxymethyl-5-ethoxymethoxy-4 (S)-[N- (4-chlorophenylcarbonyl) amino] pentanoic acid,
    (71) 2 (R) -benzyloxymethyl-5- (2-methoxyethoxy) methoxy-4 (S)-[N- (4-cyanophenylcarbonyl) amino] pentanoic acid,
    (72) 2 (R) -benzyloxymethyl-5-ethoxymethoxy-4 (S)-[N- (4-chlorophenylcarbonyl) amino] pentanoic acid,
    (73) 2 (R) -benzyloxymethyl-5-ethoxymethoxy-4 (S)-[N- (4-bromophenylcarbonyl) amino] pentanoic acid,
    (74) 2 (S) -allyl-5-ethoxymethoxy-4 (S)-[N- (4-bromophenylcarbonyl) amino] pentanoic acid,
    (75) 2 (S) -allyl-5-ethoxymethoxy-4 (S)-[N- (4-chlorophenylcarbonyl) amino] pentanoic acid,
    (76) 2 (R)-(2-methoxyethoxy) methyl-5-ethoxymethoxy-4 (S)-[N- (4-bromophenylcarbonyl) amino] pentanoic acid,
    (77) 2 (R)-(2-methoxyethoxy) methyl-5- (2-methoxyethoxy) methoxy-4 (S)-[N- (4-cyanophenylcarbonyl) amino] Pentanic Acid,
    (78) 2 (R)-(2-methoxyethoxy) methyl-5-ethoxymethoxy-4 (S)-[N- (4-chlorophenylcarbonyl) amino] pentanoic acid,
    (80) 2 (S) -methyl-5-ethoxymethoxy-4 (S)-[N-methyl-N- (4-bromophenylcarbonyl) amino] pentanoic acid,
    (81) 2 (S) -methyl-5-ethoxymethoxy-4 (S)-[N-methyl-N- (4-nitrophenylcarbonyl) amino] pentanoic acid,
    (82) 2 (S) -benzyl-4 (S) -t-butyldimethylsilyloxymethyl-4- (N- (4- (benzofuran-2-yl) phenylcarbonyl) amino) butanoic acid,
    (83) 2 (R) -benzyl-4 (S) -hydroxymethyl-4- (N- (4- (benzofuran-2-yl) phenylcarbonyl) amino) butanoic acid,
    (84) 2 (S) -benzyl-4 (S) -hydroxymethyl-4- (N- (4- (3-methoxy-1-propynyl) phenylcarbonyl) amino) butanoic acid,
    (85) 2 (S) -benzyloxy-3 (S) -hydroxy-4- (N- (4- (3-methoxy-1-propynyl) phenylcarbonyl) amino) butanoic acid,
    (86) 2-benzyloxy-4- (N- (4- (3-methoxy-1-propynyl) phenylcarbonyl) amino) -2-butenoic acid,
    (87) cis-1-carboxymethyl-2- (N- (4- (3-methoxy-1-propynyl) phenylcarbonyl) amino) cyclopentane,
    (88) trans-1-carboxymethyl-2- (N- (4- (3-methoxy-1-propynyl) phenylcarbonyl) amino) cyclopentane,
    (89) trans-3- (N- (4- (3-methoxy-1-propynyl) phenylcarbonyl) amino) cyclopentanoic acid,
    (90) cis-3- (N- (4- (3-methoxy-1-propynyl) phenylcarbonyl) amino) cyclopentanoic acid,
    (91) trans-2- (N- (4- (3-methoxy-1-propynyl) phenylcarbonyl) aminomethyl) cyclopentanoic acid,
    (92) 2 (R) -allyl-5-ethoxymethoxy-4 (S)-[N- (4-phenoxyphenylcarbonyl) amino] pentanoic acid,
    (93) 5-methoxy-4 (S)-[N- [4- (4-chlorophenyl) phenylcarbonyl] amino] pentanoic acid,
    (94) 2 (S) -methyl-5-succinimide-4 (S)-[N- (4-chlorophenylcarbonyl) amino] pentanoic acid,
    (95) 2 (S) -methyl-5-ethoxymethoxy-4 (S)-[N- (4-phenoxyphenylcarbonyl) amino] pentanoic acid,
    (96) 2 (S) -allyl-5-ethoxymethoxy-4 (S)-[N- (4-phenoxyphenylcarbonyl) amino] pentanoic acid,
    (97) 2 (S) -methyl-5-ethoxymethoxy-4 (S)-[N- [4- (4-cyanophenyl) phenylcarbonyl] amino] pentanoic acid,
    Methyl ester, ethyl ester, t-butyl ester, or a nontoxic salt thereof.
    [10" claim-type="Currently amended] The compound of claim 2 wherein the compound is
    (1) N-hydroxy-4- (N- (4- (benzofuran-2-yl) phenylcarbonyl) amino) butylamide,
    (2) N-hydroxy-4- (N- (4-methylphenylcarbonyl) amino) butylamide,
    (3) N-hydroxy-4- (N- (4-butyloxyphenylcarbonyl) amino) butylamide,
    (4) N-hydroxy-4- (N- (3-butyloxyphenylcarbonyl) amino) butylamide,
    (5) N-hydroxy-4- [N- [4-((4-methylphenyl) ethynyl) furan-2-ylcarbonyl] amino] butylamide,
    (6) N-hydroxy-4- (N- (4- (pyrrole-1-yl) phenylcarbonyl) amino) butylamide,
    (7) N-hydroxy-4- (N- (trans-4-methylcyclohexylcarbonyl) amino) butylamide,
    (8) N-hydroxy-4- (N- (4- (3-methoxy-1-propynyl) phenylcarbonyl) amino) butylamide,
    (9) N-hydroxy-4- (N- (4-butylphenylcarbonyl) amino) butylamide,
    (10) N-hydroxy-4- (N- (benzofuran-2-ylcarbonyl) amino) butylamide,
    (11) N-hydroxy-4- [N- [4- (2- (4-chlorophenyl) ethenyl) phenylcarbonyl] amino] butylamide,
    (12) N-hydroxy-4- [N- [4-((4- (imidazol-1-yl) phenyl) ethynyl) phenylcarbonyl] amino] butylamide,
    (13) N-hydroxy-4- (N- (trans-4-propylcyclohexylcarbonyl) amino) butylamide,
    (14) N-hydroxy-4- [N- [4-((4-methylphenyl) ethynyl) phenylcarbonyl] amino] butylamide,
    (15) N-hydroxy-4- [N- [4-((4-bromophenyl) aminosulfonyl) phenylcarbonyl] amino] butylamide,
    (16) N-hydroxy-4- [N- (4-cyclohexylphenylcarbonyl) amino] butylamide,
    (17) N-hydroxy-4- [N- [4- (4-propylphenyl) phenylcarbonyl] amino] butylamide,
    (18) N-hydroxy-4- [N- [4- (4-hydroxyphenyl) phenylcarbonyl] amino] butylamide,
    (19) N-hydroxy-4- [N- [4- (4-chlorophenyl) furan-2-ylcarbonyl] amino] butylamide,
    (20) N-hydroxy-4- [N- [4- (4-heptylphenyl) phenylcarbonyl] amino] butylamide,
    (21) N-hydroxy-4- [N- [4- (4-methoxyphenyl) phenylcarbonyl] amino] butylamide,
    (22) N-hydroxy-4- [N- [4- (4-chlorophenyl) phenylcarbonyl] amino] butylamide,
    (23) N-hydroxy-4- [N- (5-benzyloxyindol-2-ylcarbonyl) amino] butylamide,
    (24) N-hydroxy-4- [N- [5- (2- (4-chlorophenyl) ethenyl) furan-2-ylcarbonyl] amino] butylamide,
    (25) N-hydroxy-4- [N- [4- (4-phenyloxyphenyl) phenylcarbonyl] amino] butylamide,
    (26) N-hydroxy-5- [N- [4- (benzofuran-2-yl) phenylcarbonyl] amino] pentylamide,
    (27) N-hydroxy-6- [N- [4- (benzofuran-2-yl) phenylcarbonyl] amino] hexylamide,
    (28) N-hydroxy-4- [N-[[(4'-carbamoylmethoxy) biphenyl-4-yl] carbonyl] amino] butylamide,
    (29) N-hydroxy-4- [N- [4- (4-phenylbiridin-1-yl) phenylcarbonyl] amino] butylamide,
    (30) N-hydroxy-4- [N- [4- [3- (4-chlorophenoxy) -1-propynyl] phenylcarbonyl] amino] butylamide,
    (31) N-hydroxy-4- [N- [4- (3-phenoxy-1-propynyl) phenylcarbonyl] amino] butylamide,
    (32) N-hydroxy-4- [N- [4- (4-methoxyphenoxy) phenylcarbonyl] amino] butylamide,
    (33) N-hydroxy-4- [N- [4- (4-hydroxyphenoxy) phenylcarbonyl] amino] butylamide,
    (34) N-hydroxy-4- [N- [4- (4-phenoxypiperazin-1-yl) phenylcarbonyl] amino] butylamide,
    (35) N-hydroxy-4- [N- [4- (4-phenyl-1,2,5,6-tetrahydropyridin-1-yl) phenylcarbonyl] amino] butylamide,
    (36) N-hydroxy-4- [N- [4- (1-heptinyl) phenylcarbonyl] amino] butylamide,
    (37) N-hydroxy-4- [N- (4-benzyloxyphenylcarbonyl) amino] butylamide,
    (38) N-hydroxy-4- (N-methyl-N- (4- (benzofuran-2-yl) phenylcarbonyl) amino) butylamide,
    (39) N-hydroxy-4- (N- (4- (benzofuran-2-yl) phenylcarbonyl) amino) -2 (S) -hydroxybutylamide,
    (40) N-hydroxy-4- (N- (4- (benzofuran-2-yl) phenylcarbonyl) amino) -2 (R) -hydroxybutylamide,
    (41) N-hydroxy-4- (N- (4- (benzofuran-2-yl) phenylcarbonyl) amino) -2 (S) -benzyloxymethoxybutylamide,
    (42) N-hydroxy-4- (N- (4- (benzofuran-2-yl) phenylcarbonyl) amino) -2 (R) -benzyloxymethoxybutylamide,
    (43) N-hydroxy-4- (N- (4- (2- (4-chlorophenyl) ethenyl) phenylcarbonyl) amino) -2 (S) -benzyloxymethoxybutylamide,
    (44) N-hydroxy-4- (N- (4-chlorophenylcarbonyl) amino) -2-benzyloxymethoxybutylamide,
    (45) N-hydroxy-4- (N- (4-chlorophenylcarbonyl) amino) -2-((N-benzyl-N-methylamino) carbonylmethoxy) butylamide,
    (46) N-hydroxy-4- (N- (4-chlorophenylcarbonyl) amino) -2-((N-phenyl-N-methylamino) carbonylmethoxy) butylamide,
    (47) N-hydroxy-4- (N- (4-chlorophenylcarbonyl) amino) -2-((N-phenylethyl-N-methylamino) carbonylmethoxy) butylamide,
    (48) N-hydroxy-3 (S) -hydroxy-4- (N- (4- (benzofuran-2-yl) phenylcarbonyl) amino) butylamide,
    (49) N-hydroxy-3 (R) -hydroxy-4- (N- (4- (benzofuran-2-yl) phenylcarbonyl) amino) butylamide,
    (50) N-hydroxy-3 (S) -methoxymethyloxy-4- (N- (4- (benzofuran-2-yl) phenylcarbonyl) amino) butylamide,
    (51) N-hydroxy-4- (N- (4- (benzofuran-2-yl) phenylcarbonyl) amino) -2-butylamide,
    (52) N-hydroxy-3 (R) -methoxymethyloxy-4- (N- (4- (benzofuran-2-yl) phenylcarbonyl) amino) butylamide,
    (53) N-hydroxy-4- (N- (4- (benzofuran-2-yl) phenylcarbonyl) amino) -3-butylamide,
    (54) N-hydroxy-4- [N- [4- (benzofuran-2-yl) phenylcarbonyl] amino] -3 (S) -benzyloxymethoxybutylamide,
    (55) N-hydroxy-2-benzyloxymethyl-4- (N- (4-methylphenylcarbonyl) amino) butylamide,
    (56) N-hydroxy-2-hydroxymethyl-4- (N- (4-methylphenylcarbonyl) amino) butylamide,
    (57) N-hydroxy-2-hydroxymethyl-4- (N- (4-methylphenylcarbonyl) amino) butylamide,
    (58) N-hydroxy-2-hydroxymethyl-4- (N- (4-methylphenylcarbonyl) amino) butylamide,
    (59) N-hydroxy-4 (S) -methylaminocarbonyl-4- (N- (4-methylphenylcarbonyl) amino) butylamide,
    (60) N-hydroxy-4 (R) -methylaminocarbonyl-4- (N- (4-methylphenylcarbonyl) amino) butylamide,
    (61) N-hydroxy-4 (S) -benzylaminocarbonyl-4- (N- (4-methylphenylcarbonyl) amino) butylamide,
    (62) N-hydroxy-4 (S)-(4-hydroxybutyl) aminocarbonyl-4- (N- (4-methylphenylcarbonyl) amino) butylamide,
    (63) N-hydroxy-4 (S) -methoxycarbonyl-4- [N- [4- (4-hydroxy-1-butynyl) phenylcarbonyl] amino] butylamide,
    (64) N-hydroxy-4 (R) -carbonyl-4- [N- [4- (3-methoxy-1-propynyl) phenylcarbonyl] amino] butylamide,
    (65) N-hydroxy-4 (S) -carboxy-4- (N- (4-methylphenylcarbonyl) amino) butylamide,
    (66) N-hydroxy-4 (S)-(morpholin-1-yl) carbonyl-4- (N- (4- (benzofuran-2-yl) phenylcarbonyl) amino) butylamide,
    (67) N-hydroxy-4 (S) -hydroxymethyl-4- (N- (4- (benzofuran-2-yl) phenylcarbonyl) amino) butylamide,
    (68) N-hydroxy-4 (S) -methoxymethyloxymethyl-4- (N- (4- (benzofuran-2-yl) phenylcarbonyl) amino) butylamide,
    (69) N-hydroxy-2 (S) -benzyl-4 (S) -methoxymethyloxymethyl-4- (N- (4- (benzofuran-2-yl) phenylcarbonyl) amino) butylamide ,
    (70) N-hydroxy-2 (S) -methyl-4 (S) -methoxymethyloxymethyl-4- (N- (4- (benzofuran-2-yl) phenylcarbonyl) amino) butylamide ,
    (71) N-hydroxy-2 (S)-(3-phenyl-2-propenyl) -4 (S) -methoxymethyloxymethyl-4- (N- (4- (benzofuran-2-yl ) Phenylcarbonyl) amino) butylamide,
    (72) N-hydroxy-2 (S)-(3-phenylpropyl) -4 (S) -methoxymethyloxymethyl-4- (N- (4- (benzofuran-2-yl) phenylcarbonyl ) Amino) butylamide,
    (73) N-hydroxy-2 (R) -benzyl-4 (S) -hydroxymethyl-4- (N- (4- (benzofuran-2-yl) phenylcarbonyl) amino) butylamide,
    (74) N-hydroxy-2 (S) -benzyl-4 (S) -hydroxymethyl-4- (N- (4- (3-methoxy-1-propynyl) phenylcarbonyl) amino) butyl amides,
    (75) N-hydroxy-5-hydroxy-4 (S)-[N- [4- (3-methoxy-1-propynyl) phenylcarbonyl] amino] pentanamide,
    (76) N-hydroxy-5-hydroxy-4 (R)-[N- [4- (3-methoxy-1-propynyl) phenylcarbonyl] amino] pentanamide,
    (77) N-hydroxy-4 (S)-(4-hydroxybutylcarbamoyl) -4- [N- [4- (3-methoxy-1-propynyl) phenylcarbonyl] amino] butyl amides,
    (78) N-hydroxy-4 (S)-(3-phenylpropylcarbamoyl) -4- [N- [4- (3-methoxy-1-propynyl) phenylcarbonyl] amino] butylamide ,
    (79) N-hydroxy-4 (S) -propylcarbamoyl-4- [N- [4- (3-methoxy-1-propynyl) phenylcarbonyl] amino] butylamide,
    (80) N-hydroxy-4 (S)-(2-hydroxyethylcarbamoyl) -4- [N- [4- (3-methoxy-1-propynyl) phenylcarbonyl] amino] butyl amides,
    (81) N-hydroxy-4 (S)-(6-hydroxyhexylcarbamoyl) -4- [N- [4- (3-methoxy-1-propynyl) phenylcarbonyl] amino] butyl amides,
    (82) N-hydroxy-4 (S)-[2- (4-methoxyphenyl) ethylcarbamoyl] -4- [N- [4- (3-methoxy-1-propynyl) phenylcar Carbonyl] amino] butylamide,
    (83) N-hydroxy-4 (S)-(2-morpholinoethylcarbamoyl) -4- [N- [4- (3-methoxy-1-propynyl) phenylcarbonyl] amino] Butylamide,
    (84) N-hydroxy-4 (S)-[2- (indol-3-yl) ethylcarbamoyl) -4- [N- [4- (3-methoxy-1-propynyl) phenylcar Carbonyl] amino] butylamide,
    (85) N-hydroxy-4 (S)-(4-phenylbutylcarbamoyl) -4- [N- [4- (3-methoxy-1-propynyl) phenylcarbonyl] amino] butylamide ,
    (86) N-hydroxy-4 (S)-(2-phenylethylcarbamoyl) -4- [N- [4- (3-methoxy-1-propynyl) phenylcarbonyl] amino] butylamide ,
    (87) N-hydroxy-4 (S)-[3- (pyrazol-1-yl) propylcarbamoyl] -4- [N- [4- (3-methoxy-1-propynyl) phenyl Carbonyl] amino] butylamide,
    (88) N-hydroxy-4 (R)-(3-phenylpropylcarbamoyl) -4- [N- [4- (3-methoxy-1-propynyl) phenylcarbonyl] amino] butylamide ,
    (89) N-hydroxy-2- (pyridin-3-yl) methyl-4- (2-phenylethylcarbamoyl) -4- [N- (4-phenoxyphenylcarbonyl) amino] butylamide,
    (90) N-hydroxy-5-methoxymethoxy-4 (S)-[N- [4- (3-methoxy-1-propynyl) phenylcarbonyl] amino] pentanamide,
    (91) N-hydroxy-5-benzyloxymethoxy-4 (S)-[N- [4- (3-methoxy-1-propynyl) phenylcarbonyl] amino] pentanamide,
    (92) N-hydroxy-5- (2-methoxyethoxy) methoxy-4 (S)-[N- [4- (3-phenoxy-1-propynyl) phenylcarbonyl] amino] pentane amides,
    (93) N-hydroxy-5-methoxymethoxy-4 (S)-[N- [4- (3-phenoxy-1-propynyl) phenylcarbonyl] amino] pentanamide,
    (94) N-hydroxy-5-benzyloxymethoxy-4 (S)-[N- [4- (3-phenoxy-1-propynyl) phenylcarbonyl] amino] pentanamide,
    (95) N-hydroxy-5-methoxymethoxy-4 (S)-[N- (4-phenoxyphenylcarbonyl) amino] pentanamide,
    (96) N-hydroxy-5-methoxymethoxy-4 (S)-[N- [4- (4-chlorophenyl) phenylcarbonyl] amino] pentanamide,
    (97) N-hydroxy-5-methoxymethoxy-4 (S)-[N- [4- [2- (4-methylphenyl) ethynyl] phenylcarbonyl] amino] pentanamide,
    (98) N-hydroxy-5-methoxymethoxy-4 (S)-[N- [4- [2E- (4-chlorophenyl) ethenyl] phenylcarbonyl] amino] pentanamide,
    (99) N-hydroxy-5-methoxymethoxy-4 (S)-[N- [4- (1-heptinyl) phenylcarbonyl] amino] pentanamide,
    (100) N-hydroxy-5-ethoxymethoxy-4 (S)-[N- (4-phenoxyphenylcarbonyl) amino] pentanamide,
    (101) N-hydroxy-5-ethoxymethoxy-4 (S)-[N- (4-methylphenylcarbonyl) amino] pentanamide,
    (102) N-hydroxy-5-methoxymethoxy-4 (R)-[N- [4- (3-methoxy-1-propynyl) phenylcarbonyl] amino] pentanamide,
    (103) N-hydroxy-2 (S) -methyl-5-methoxymethoxy-4 (S)-[N- [4- [2- (4-imidazolylphenyl) ethynyl] phenylcarbonyl ] Amino] pentanamide,
    (104) N-hydroxy-2 (S) -methyl-5-methoxymethoxy-4 (S)-[N- [4- (4-phenyl-1,2,5,6-tetrahydropyridine- 1-yl) phenylcarbonyl] amino] pentanamide,
    (105) N-hydroxy-2 (S) -methyl-5-methoxymethoxy-4 (S)-[N- (4-phenoxyphenylcarbonyl) amino] pentanamide,
    (106) N-hydroxy-2 (S) -methyl-5-methoxymethoxy-4 (S)-[N- [4- [2- (4-chlorophenyl) ethenyl] phenylcarbonyl] amino ] Pentanamide,
    (107) N-hydroxy-2 (S) -methyl-5-methoxymethoxy-4 (S)-[N- [4- (4-propylphenyl) phenylcarbonyl] amino] pentanamide,
    (108) N-hydroxy-2 (S) -methyl-5-methoxymethoxy-4 (S)-[N- [4- (benzothiophen-2-yl) phenylcarbonyl] amino] pentanamide ,
    (109) N-hydroxy-2 (S) -methyl-5-methoxymethoxy-4 (S)-[N- [4- (3-methoxyphenoxy) phenylcarbonyl] amino] pentanamide,
    (110) N-hydroxy-2 (S) -methyl-5-methoxymethoxy-4 (S)-[N- [4- (4-methoxyphenoxy) phenylcarbonyl] amino] pentanamide,
    (111) N-hydroxy-2 (S) -methyl-5-methoxymethoxy-4 (S)-[N- (4-benzoylphenylcarbonyl) amino] pentanamide,
    (112) N-hydroxy-2 (S) -methyl-5-methoxymethoxy-4 (S)-[N- [4- (naphthalen-2-yl) phenylcarbonyl] amino] pentanamide,
    (113) N-hydroxy-2 (S) -methyl-5-methoxymethoxy-4 (S)-[N- [4-[(4-methoxybiphenyl-4'-yl) oxy] phenylcar Carbonyl] amino] pentanamide,
    (114) N-hydroxy-2 (S) -methyl-5-methoxymethoxy-4 (S)-[N- [4- (4-ethoxyphenyl) phenylcarbonyl] amino] pentanamide,
    (115) N-hydroxy-2 (S) -methyl-5-methoxymethoxy-4 (S)-[N- [4- (4-phenoxyphenyl) phenylcarbonyl] amino] pentanamide,
    (116) N-hydroxy-2 (S) -methyl-5-methoxymethoxy-4 (S)-[N- [4- (3-cyanomethylphenyl) phenylcarbonyl] amino] pentanamide,
    (117) N-hydroxy-2 (S) -methyl-5-methoxymethoxy-4 (S)-[N- [4- (biphenyl-4-yl) phenylcarbonyl] amino] pentanamide,
    (118) N-hydroxy-2 (S) -methyl-5-methoxymethoxy-4 (S)-[N- [4- (3-hydroxyphenoxy) phenylcarbonyl] amino] pentanamide,
    (119) N-hydroxy-2 (S) -methyl-5-methoxymethoxy-4 (S)-[N- [4- [2- (4-methylphenyl) ethynyl] phenylcarbonyl] amino] Pentanamide,
    (120) N-hydroxy-2 (S) -methyl-5-methoxymethoxy-4 (S)-[N- [4- (4-hydroxyphenoxy) phenylcarbonyl] amino] pentanamide,
    (121) N-hydroxy-2 (S) -methyl-5-methoxymethoxy-4 (S)-[N- [4- (4-chlorophenyl) phenylcarbonyl] amino] pentanamide,
    (122) N-hydroxy-2 (S) -methyl-5-methoxymethoxy-4 (S)-[N-[[5- (4-methoxyphenyl) -2-thienyl] carbonyl] Amino] pentanamide,
    (123) N-hydroxy-2 (S) -methyl-5-methoxymethoxy-4 (S)-[N- [4-[(biphenyl-3-yl) oxy] phenylcarbonyl] amino] Pentanamide,
    (124) N-hydroxy-2 (S) -methyl-5-methoxymethoxy-4 (S)-[N- [4- (1-heptinyl) phenylcarbonyl] amino] pentanamide,
    (125) N-hydroxy-2 (S) -methyl-5-methoxymethoxy-4 (S)-[N- [4- (3-phenoxy-1-propynyl) phenylcarbonyl] amino] Pentanamide,
    (126) N-hydroxy-2 (S) -methyl-5-methoxymethoxy-4 (S)-[N- [4- (4-cyanophenyl) phenylcarbonyl] amino] pentanamide,
    (127) N-hydroxy-2 (S) -methyl-5-methoxymethoxy-4 (S)-[N- [4- (3-cyanophenyl) phenylcarbonyl] amino] pentanamide,
    (128) N-hydroxy-2 (S) -methyl-5-methoxymethoxy-4 (S)-[N- (4-benzylphenylcarbonyl) amino] pentanamide,
    (129) N-hydroxy-2 (S) -methyl-5-methoxymethoxy-4 (S)-[N- [4- [2E- (pyridin-4-yl) ethenyl] phenylcarbonyl] Amino] pentanamide,
    (130) N-hydroxy-2 (S) -methyl-5-methoxymethoxy-4 (S)-[N- [4- (benzooxazol-2-yl) phenylcarbonyl] amino] pentanamide ,
    (131) N-hydroxy-2 (S) -methyl-5-methoxymethoxy-4 (S)-[N- [4- (3-ethoxyphenyl) phenylcarbonyl] amino] pentanamide,
    (132) N-hydroxy-2 (S) -methyl-5-methoxymethoxy-4 (S)-[N- [4- (4-methylphenylcarbonylamino) phenylcarbonyl] amino] pentanamide,
    (133) N-hydroxy-2 (S) -methyl-5-methoxymethoxy-4 (S)-[N-[[5- [2- (4-methylphenyl) ethynyl] -2-thienyl ] Carbonyl] amino] pentanamide,
    (134) N-hydroxy-2 (S) -methyl-5- (2-methoxyethoxy) methoxy-4 (S)-[N- (4-phenoxyphenylcarbonyl) amino] pentanamide,
    (135) N-hydroxy-2 (S) -methyl-5-t-butylcarbonyloxy-4 (S)-[N- (4-phenoxyphenylcarbonyl) amino] pentanamide,
    (136) N-hydroxy-2 (S) -methyl-5-benzyloxymethoxy-4 (S)-[N- (4-phenoxyphenylcarbonyl) amino] pentanamide,
    (137) N-hydroxy-2 (S) -methyl-5-ethoxymethoxy-4 (S)-[N- (trans-4-methylcyclohexylcarbonyl) amino] pentanamide,
    (138) N-hydroxy-2 (S) -methyl-5-ethoxymethoxy-4 (S)-[N- (4-methylphenylcarbonyl) amino] pentanamide,
    (139) N-hydroxy-2 (S) -methyl-5-ethoxymethoxy-4 (S)-[N- (4-chlorophenylcarbonyl) amino] pentanamide,
    (140) N-hydroxy-2 (S) -methyl-5-ethoxymethoxy-4 (S)-[N- (adamantylcarbonyl) amino] pentanamide,
    (141) N-hydroxy-2 (S) -methyl-5-ethoxymethoxy-4 (S)-[N- (2-furylcarbonyl) amino] pentanamide,
    (142) N-hydroxy-2 (S) -methyl-5-ethoxymethoxy-4 (S)-[N-[(benzothiazol-6-yl) carbonyl] amino] pentanamide,
    (143) N-hydroxy-2 (S) -methyl-5-ethoxymethoxy-4 (S)-[N- (4-fluorophenylcarbonyl) amino] pentanamide,
    (144) N-hydroxy-2 (S) -methyl-5-ethoxymethoxy-4 (S)-[N-[(2-bromofuryl-5-yl) carbonyl] amino] pentanamide,
    (145) N-hydroxy-2 (S) -methyl-5-ethoxymethoxy-4 (S)-[N- (4-nitrophenylcarbonyl) amino] pentanamide,
    (146) N-hydroxy-2 (S) -methyl-5-ethoxymethoxy-4 (S)-[N- (4-bromophenylcarbonyl) amino] pentanamide,
    (147) N-hydroxy-2 (S) -methyl-5-ethoxymethoxy-4 (S)-[N- (4-cyanophenylcarbonyl) amino] pentanamide,
    (148) N-hydroxy-2 (S) -methyl-5-ethoxymethoxy-4 (S)-[N- [4- (4-pyridyloxy) phenylcarbonyl] amino] pentanamide,
    (149) N-hydroxy-2 (S) -methyl-5- (2-methoxyethoxy) methoxy-4 (S)-[N- (4-cyanophenylcarbonyl) amino] pentanamide,
    (150) N-hydroxy-2 (S) -methyl-5-methoxymethoxy-4 (S)-[N- (4-chlorophenylcarbonyl) amino] pentanamide,
    (151) N-hydroxy-2 (S) -methyl-5-benzyloxymethoxy-4 (S)-[N- (4-chlorophenylcarbonyl) amino] pentanamide,
    (152) N-hydroxy-2 (S) -methyl-5- (2-methoxyethoxy) methoxy-4 (S)-[N- (4-chlorophenylcarbonyl) amino] pentanamide,
    (153) N-hydroxy-2 (S) -methyl-5-ethoxymethoxy-4 (S)-[N- (2-nitrophenylcarbonyl) amino] pentanamide,
    (154) N-hydroxy-2 (S) -methyl-5-ethoxymethoxy-4 (S)-[N- (3-nitrophenylcarbonyl) amino] pentanamide,
    (155) N-hydroxy-2 (S) -methyl-5-ethoxymethoxy-4 (S)-[N- (2-methoxy-4-nitrophenylcarbonyl) amino] pentanamide,
    (156) N-hydroxy-2 (S) -methyl-5-ethoxymethoxy-4 (S)-[N- (3-methoxy-4-nitrophenylcarbonyl) amino] pentanamide,
    (157) N-hydroxy-2 (S) -methyl-5-ethoxymethoxy-4 (S)-[N- (3-hydroxy-4-nitrophenylcarbonyl) amino] pentanamide,
    (158) N-hydroxy-2 (S) -methyl-5-ethoxymethoxy-4 (S)-[N- (4-dihydroxyboroylphenylcarbonyl) amino] pentanamide,
    (159) N-hydroxy-2 (S) -isobutyl-5-methoxymethoxy-4 (S)-[N- (4-phenoxyphenylcarbonyl) amino] pentanamide,
    (160) N-hydroxy-2 (S) -ethyl-5-methoxymethoxy-4 (S)-[N- (4-phenoxyphenyl carbonyl) amino] pentanamide,
    (161) N-hydroxy-2 (S) -propyl-5-methoxymethoxy-4 (S)-[N- (4-phenoxyphenylcarbonyl) amino] pentanamide,
    (162) N-hydroxy-2 (R) -t-butoxycarbonylmethyl-5-methoxymethoxy-4 (S)-[N- (4-phenoxyphenylcarbonyl) amino] pentanamide,
    (163) N-hydroxy-2 (S) -allyl-5-methoxymethoxy-4 (S)-[N- (4-phenoxyphenylcarbonyl) amino] pentanamide,
    (164) N-hydroxy-2 (S) -ethyl-5-ethoxymethoxy-4 (S)-[N- (4-phenoxyphenylcarbonyl) amino] pentanamide,
    (165) N-hydroxy-2 (S) -ethyl-5- (2-methoxyethoxy) methoxy-4 (S)-[N- (4-phenoxyphenylcarbonyl) amino] pentanamide,
    (166) N-hydroxy-2 (S) -ethyl-5-t-butylcarbonyloxy-4 (S)-[N- (4-phenoxyphenylcarbonyl) amino] pentanamide,
    (167) N-hydroxy-2 (S) -allyl-5-ethoxymethoxy-4 (S)-[N- (4-methylphenylcarbonyl) amino] pentanamide,
    (168) N-hydroxy-2 (S) -allyl-5-ethoxymethoxy-4 (S)-[N- (4-nitrophenylcarbonyl) amino] pentanamide,
    (169) N-hydroxy-2-methylidene-5-ethoxymethoxy-4 (S)-[N- (4-nitrophenylcarbonyl) amino] pentanamide,
    (171) N-hydroxy-2 (S) -allyl-5- (2-methoxyethoxy) methoxy-4 (S)-[N- (4-cyanophenylcarbonyl) amino] pentanamide,
    (174) N-hydroxy-2 (S) -allyl-5-ethoxymethoxy-4 (S)-[N- (4-bromophenylcarbonyl) amino] pentanamide,
    (175) N-hydroxy-2 (S) -allyl-5-ethoxymethoxy-4 (S)-[N- (4-chlorophenylcarbonyl) amino] pentanamide,
    (176) N-hydroxy-2 (R) -dimethylaminomethyl-5-ethoxymethoxy-4 (S)-[N- (4-nitrophenylcarbonyl) amino] pentanamide,
    (178) N-hydroxy-2 (R) -benzyl-5-methoxymethoxy-4 (R)-[N- (4-phenoxyphenylcarbonyl) amino] pentanamide,
    (179) N-hydroxy-2 (R) -benzyl-5-methoxymethoxy-4 (R)-[N- [4- (3-phenoxy-1-propynyl) phenylcarbonyl] amino] Pentanamide,
    (180) N-hydroxy-2 (R) -methyl-5-ethoxymethoxy-4 (R)-[N- [4- (4-cyanophenyl) phenylcarbonyl] amino] pentanamide,
    (181) N-hydroxy-2 (R) -allyl-5-ethoxymethoxy-4 (R)-[N- (4-phenoxyphenylcarbonyl) amino] pentanamide,
    (182) N-hydroxy-2 (R) -methyl-5-ethoxymethoxy-4 (R)-[N- (4-phenoxyphenylcarbonyl) amino] pentanamide,
    (183) N-hydroxy-2 (S) -benzyl-5-methoxymethoxy-4 (S)-[N- [4- [2E- (4-chlorophenyl) ethenyl] phenylcarbonyl] amino ] Pentanamide,
    (184) N-hydroxy-2 (S)-(indol-3-yl) -5-methoxymethoxy-4 (S)-[N- [4- (benzofuran-2-yl) phenylcarbonyl ] Amino] pentanamide,
    (185) N-hydroxy-2 (S) -benzyl-5-methoxymethoxy-4 (S)-[N- [4- [3- (4-chlorophenoxy-1-propynyl) phenylcar Carbonyl] amino] pentanamide,
    (186) N-hydroxy-2 (S) -benzyl-5-methoxymethoxy-4 (S)-[N- (4-phenoxyphenylcarbonyl) amino] pentanamide,
    (187) N-hydroxy-2 (S) -benzyl-5-methoxymethoxy-4 (S)-[N- [4- (4-phenylpiperidin-1-yl) phenylcarbonyl] amino ] Pentanamide,
    (188) N-hydroxy-2 (S) -benzyl-5-methoxymethoxy-4 (S)-[N- [4- (6-imidazolyl-1-hexynyl) phenylcarbonyl] amino ] Pentanamide,
    (189) N-hydroxy-2 (S)-(naphthalen-1-yl) -5-methoxymethoxy-4 (S)-[N- (4-phenoxyphenylcarbonyl) amino] pentanamide,
    (190) N-hydroxy-2 (S)-[4- (benzofuran-2-yl) benzyl] -5-methoxymethoxy-4 (S)-[N- (4-iodinephenylcarbonyl) Amino] pentanamide,
    (191) N-hydroxy-2 (S) -benzyl-5-ethoxymethoxy-4 (S)-[N- (trans-4-methylcyclohexylcarbonyl) amino] pentanamide,
    (192) N-hydroxy-2 (S)-(4-nitrobenzyl) -5-ethoxymethoxy-4 (S)-[N- (trans-4-methylcyclohexylcarbonyl) amino] pentanamide ,
    (193) N-hydroxy-2 (S)-(indol-3-yl) -5-ethoxymethoxy-4 (S)-[N- (trans-4-methylcyclohexylcarbonyl) amino] pentane amides,
    (194) N-hydroxy-2 (S) -benzyl-5-ethoxymethoxy-4 (S)-[N-[(pyridin-4-yl) carbonyl] amino] pentanamide,
    (195) N-hydroxy-2 (S) -benzyl-5-ethoxymethoxy-4 (S)-[N- (4-hydroxyphenylcarbonyl) amino] pentanamide,
    (196) N-hydroxy-2 (S)-(2-nitrobenzyl) -5-ethoxymethoxy-4 (S)-[N- (trans-4-methylcyclohexylcarbonyl) amino] pentanamide ,
    (197) N-hydroxy-2 (S)-(3-nitrobenzyl) -5-ethoxymethoxy-4 (S)-[N- (trans-4-methylcyclohexylcarbonyl) amino] pentanamide ,
    (198) N-hydroxy-2 (S) -benzyl-5-ethoxymethoxy-4 (S)-[N-[(1-methylpyrrole-2-yl) carbonyl] amino] pentanamide,
    (199) N-hydroxy-2 (S) -benzyl-5-ethoxymethoxy-4 (S)-[N- (phenylcarbonyl) amino] pentanamide,
    (200) N-hydroxy-2 (S) -benzyl-5-ethoxymethoxy-4 (S)-[N- (4-ethylphenylcarbonyl) amino] pentanamide,
    (201) N-hydroxy-2 (S) -benzyl-5-ethoxymethoxy-4 (S)-[N- (4-methylphenylcarbonyl) amino] pentanamide,
    (202) N-hydroxy-2 (S) -benzyl-5-ethoxymethoxy-4 (S)-[N- (4-nitrophenylcarbonyl) amino] pentanamide,
    (203) N-hydroxy-2 (S) -benzyl-5-ethoxymethoxy-4 (S)-[N- (2,2,3,3-tetramethylcyclopropylcarbonyl) amino] pentanamide ,
    (204) N-hydroxy-2 (S)-(3-methoxybenzyl) -5-ethoxymethoxy-4 (S)-[N- (4-methylphenylcarbonyl) amino] pentanamide,
    (205) N-hydroxy-2 (S) -benzyl-5-ethoxymethoxy-4 (S)-[N- (1-cyclohexenylcarbonyl) amino] pentanamide,
    (206) N-hydroxy-2 (S) -benzyl-5-ethoxymethoxy-4 (S)-[N [(1-cyclohexen-4-yl) carbonyl] amino] pentanamide,
    (207) N-hydroxy-2 (S) -benzyl-5-ethoxymethoxy-4 (S)-[N- (4-dimethylaminophenylcarbonyl) amino] pentanamide,
    (208) N-hydroxy-2 (S) -benzyl-5-ethoxymethoxy-4 (S)-[N- (4-carbamoylphenylcarbonyl) amino] pentanamide,
    (209) N-hydroxy-2 (S) -benzyl-5-ethoxymethoxy-4 (S)-[N- (4-methoxycarbonylphenylcarbonyl) amino] pentanamide,
    (210) N-hydroxy-2 (S) -benzyl-5-ethoxymethoxy-4 (S)-[N- (cyclopentylcarbonyl) amino] pentanamide,
    (211) N-hydroxy-2 (S)-(naphthalen-2-yl) -5-ethoxymethoxy-4 (S)-[N- (trans-4-methylcyclohexylcarbonyl) amino] pentane amides,
    (212) N-hydroxy-2 (S) -benzyl-5-ethoxymethoxy-4 (S)-[N- (4-trifluoromethylphenylcarbonyl) amino] pentanamide,
    (213) N-hydroxy-2 (S) -benzyl-5-ethoxymethoxy-4 (S)-[N- (4-iodinephenylcarbonyl) amino] pentanamide,
    (214) N-hydroxy-2 (S) -benzyl-5-ethoxymethoxy-4 (S)-[N- [4- (2-ioethynyl) phenylcarbonyl] amino] pentanamide,
    (215) N-hydroxy-2 (S) -benzyl-5-ethoxymethoxy-4 (S)-[N- (cycloheptylcarbonyl) amino] pentanamide,
    (216) N-hydroxy-2 (S) -benzyl-5-ethoxymethoxy-4 (S)-[N- (2-thienylcarbonyl) amino] pentanamide,
    (217) N-hydroxy-2 (R)-(3,4,4-trimethyl-2,5-dioxoimidazolidin-1-yl) methyl-5-ethoxymethoxy-4 (S) -[N- (4-methylphenylcarbonyl) amino] pentanamide,
    (218) N-hydroxy-2 (S) -benzyl-5-ethoxymethoxy-4 (S)-[N-[(2-bromo-5-thienyl) carbonyl] amino] pentanamide,
    (219) N-hydroxy-2 (S) -benzyl-5-ethoxymethoxy-4 (S)-[N- (4-bromophenylcarbonyl) amino] pentanamide,
    (220) N-hydroxy-2 (S) -benzyl-5-ethoxymethoxy-4 (S)-[N- (4-hydroxymethylphenylcarbonyl) amino] pentanamide,
    (221) N-hydroxy-2 (S)-(benzothiophen-3-yl) -5-ethoxymethoxy-4 (S)-[N- (trans-4-methylcyclohexylcarbonyl) amino ] Pentanamide,
    (222) N-hydroxy-2 (S) -benzyl-5-ethoxymethoxy-4 (S)-[N- (4-cyanophenylcarbonyl) amino] pentanamide,
    (223) N-hydroxy-2 (S) -benzyl-5-ethoxymethoxy-4 (S)-[N-[(1-acetylpiperidin-4-yl) carbonyl] amino] pentanamide ,
    (224) N-hydroxy-2 (S) -benzyl-5-ethoxymethoxy-4 (S)-[N-[(1-methylpiperidin-4-yl) carbonyl] amino] pentanamide ,
    (225) N-hydroxy-2 (S) -benzyl-5-ethoxymethoxy-4 (S)-[N- (4-formylphenylcarbonyl) amino] pentanamide,
    (226) N-hydroxy-2 (S)-(3-methoxybenzyl) -5-ethoxymethoxy-4 (S)-[N- (4-nitrophenylcarbonyl) amino] pentanamide,
    (227) N-hydroxy-2 (S)-(3-methoxybenzyl) -5-ethoxymethoxy-4 (S)-[N- (4-chlorophenylcarbonyl) amino] pentanamide,
    (228) N-hydroxy-2 (S)-(4-methoxybenzyl) -5-ethoxymethoxy-4 (S)-[N- (4-methylphenylcarbonyl) amino] pentanamide,
    (229) N-hydroxy-2 (S)-(2-methoxybenzyl) -5-ethoxymethoxy-4 (S)-[N- (4-methylphenylcarbonyl) amino] pentanamide,
    (230) N-hydroxy-2 (S)-(naphthalen-1-yl) -5-ethoxymethoxy-4 (S)-[N- (4-methylphenylcarbonyl) amino] pentanamide,
    (231) N-hydroxy-2 (S)-(3-methoxybenzyl) -5-ethoxymethoxy-4 (S)-[N- (trans-4-methylcyclohexylcarbonyl) amino] pentane amides,
    (232) N-hydroxy-2 (S) -benzyl-5-ethoxymethoxy-4 (S)-[N- (4-methoxycyclohexylcarbonyl) amino] pentanamide,
    (233) N-hydroxy-2 (S)-(benzothiophen-3-yl) -5-ethoxymethoxy-4 (S)-[N- (4-bromophenylcarbonyl) amino] pentane amides,
    (234) N-hydroxy-2 (S)-(benzothiophen-3-yl) -5-ethoxymethoxy-4 (S)-[N- (4-chlorophenylcarbonyl) amino] pentanamide ,
    (235) N-hydroxy-2 (S) -benzyl-5-ethoxymethoxy-4 (S)-[N-[(2-chloropyridin-5-yl) carbonyl] amino] pentanamide,
    (236) N-hydroxy-2 (S)-(3,5-dimethoxybenzyl) -5-ethoxymethoxy-4 (S)-[N- (4-methylphenylcarbonyl) amino] pentanamide,
    (237) N-hydroxy-2 (S) -benzyl-5-ethoxymethoxy-4 (S)-[N- (4-methylcyclohexylcarbonyl) amino] pentanamide,
    (238) N-hydroxy-2 (S)-(3-methoxybenzyl) -5-ethoxymethoxy-4 (S)-[N- (4-cyanophenylcarbonyl) amino] pentanamide,
    (239) N-hydroxy-2 (R)-(3,4,4-trimethyl-2,5-dioxoimidazolidin-1-yl) methyl-5-ethoxymethoxy-4 (S) -[N- (trans-4-methylcyclohexylcarbonyl) amino] pentanamide,
    (240) N-hydroxy-2 (R)-(benzofuran-2-yl) -5-ethoxymethoxy-4 (S)-[N- (trans-4-methylcyclohexylcarbonyl) amino] Pentanamide,
    (241) N-hydroxy-2 (S)-(benzothiophen-3-yl) -5-ethoxymethoxy-4 (S)-[N- (4-nitrophenylcarbonyl) amino] pentanamide ,
    (242) N-hydroxy-2 (S) -benzyl-5-ethoxymethoxy-4 (S)-[N- (4-cyanophenylcarbonyl) amino] pentanamide,
    (243) N-hydroxy-2 (S) -benzyl-5-ethoxymethoxy-4 (S)-[N- (4-methylidenecyclohexylcarbonyl) amino] pentanamide,
    (244) N-hydroxy-2 (S) -benzyl-5-ethoxymethoxy-4 (S)-[N-[(1-formylpiperidin-4-yl) carbonyl] amino] pentanamide ,
    (245) N-hydroxy-2 (S) -benzyl-5-ethoxymethoxy-4 (S)-[N-[(1-methyl-1-cyclohexen-4-yl) carbonyl] amino] Pentanamide,
    (246) N-hydroxy-2 (S) -benzyl-5-ethoxymethoxy-4 (S)-[N-[(4-methyl-1-cyclohexenyl) carbonyl] amino] pentanamide,
    (247) N-hydroxy-2 (S) -benzyl-5-ethoxymethoxy-4 (S)-[N- (4-fluorophenylcarbonyl) amino] pentanamide,
    (248) N-hydroxy-2 (S) -benzyl-5-ethoxymethoxy-4 (S)-[N- (4-chlorophenylcarbonyl) amino] pentanamide,
    (249) N-hydroxy-2 (S) -benzyl-5-ethoxymethoxy-4 (S)-[N- (4-hydroxycyclohexylcarbonyl) amino] pentanamide,
    (250) N-hydroxy-2 (S)-(benzofuran-3-yl) -5-ethoxymethoxy-4 (S)-[N- (trans-4-methylcyclohexylcarbonyl) amino] Pentanamide,
    (251) N-hydroxy-2 (S)-(3-methoxybenzyl) -5-ethoxymethoxy-4 (S)-[N- (4-trifluoromethylphenylcarbonyl) amino] pentanamide ,
    (252) N-hydroxy-2 (S)-(1-methylindol-3-yl) -5- (2-methoxyethoxy) methoxy-4 (S)-[N- (trans-4- Methylcyclohexylcarbonyl) amino] pentanamide,
    (253) N-hydroxy-2 (S) -benzyl-5-ethoxymethoxy-4 (S)-[N-[(1,3-dithia-2--2-yl) carbonyl] amino] pentanamide
    (254) N-hydroxy-2 (S)-(3-methoxybenzyl) -5-ethoxymethoxy-4 (S)-[N- (4-bromophenylcarbonyl) amino] pentanamide,
    (255) N-hydroxy-2 (S)-(3-methoxybenzyl) -5-ethoxymethoxy-4 (S)-[N-[(2-bromothiophen-5-yl) carbonyl ] Amino] pentanamide,
    (256) N-hydroxy-2 (S)-(2-methoxybenzyl) -5-ethoxymethoxy-4 (S)-[N- (trans-4-methylcyclohexylcarbonyl) amino] pentane amides,
    (257) N-hydroxy-2 (S) -benzyl-5-ethoxymethoxy-4 (S)-[N-[(2-methylpyridin-5-yl) carbonyl] amino] pentanamide,
    (258) N-hydroxy-2 (S)-(benzofuran-3-yl) -5-ethoxymethoxy-4 (S)-[N- (4-nitrophenylcarbonyl) amino] pentanamide,
    (259) N-hydroxy-2 (S) -benzyl-5-ethoxymethoxy-4 (S)-[N- (trans-4-hydroxycyclohexylcarbonyl) amino] pentanamide,
    (260) N-hydroxy-2 (S)-(3-chlorobenzyl) -5-ethoxymethoxy-4 (S)-[N- (4-methylphenylcarbonyl) amino] pentanamide,
    (261) N-hydroxy-2 (S) -benzyl-5-ethoxymethoxy-4 (S)-[N-[(2-hydroxypyridin-5-yl) carbonyl] amino] pentanamide,
    (262) N-hydroxy-2 (R)-(3,4,4-trimethyl-2,5-dioxoimidazolidin-1-yl) methyl-5-ethoxymethoxy-4 (S) -[N- (4-bromophenylcarbonyl) amino] pentanamide,
    (263) N-hydroxy-2 (S)-(3-methoxybenzyl) -5-ethoxymethoxy-4 (S)-[N- (4-dimethoxymethylphenylcarbonyl) amino] pentanamide,
    (264) N-hydroxy-2 (S)-(3-trifluoromethyloxybenzyl) -5-ethoxymethoxy-4 (S)-[N- (4-chlorophenylcarbonyl) amino] pentane amides,
    (265) N-hydroxy-2 (S)-(3-methoxybenzyl) -5-ethoxymethoxy-4 (S)-[N- [2-nitrothiophen-5-yl) carbonyl] Amino] pentanamide,
    (266) N-hydroxy-2 (R)-(benzotriazol-1-yl) methyl-5-ethoxymethoxy-4 (S)-[N- (4-nitrophenylcarbonyl) amino] pentane amides,
    (267) N-hydroxy-2 (R)-(3,4,4-trimethyl-2,5-dioxoimidazolidin-1-yl) methyl-5-ethoxymethoxy-4 (S) -[N- (4-nitrophenylcarbonyl) amino] pentanamide,
    (268) N-hydroxy-2 (R)-(3,4,4-trimethyl-2,5-dioxoimidazolidin-1-yl) methyl-5-ethoxymethoxy-4 (S) -[N- (4-chlorophenylcarbonyl) amino] pentanamide,
    (269) N-hydroxy-2 (S)-(3-phenylpropyl) -5-methoxymethoxy-4 (S)-[N- (4-phenoxyphenylcarbonyl) amino] pentanamide,
    (270) N-hydroxy-2 (S)-(3-phenylpropyl) -5-methoxymethoxy-4 (S)-[N- [4- [2E- (4-chlorophenyl) ethenyl] Phenylcarbonyl] amino] pentanamide,
    (271) N-hydroxy-2 (S)-(3-phenylpropyl) -5-methoxymethoxy-4 (S)-[N- [4- (4-phenyl-1,2,5,6 -Tetrahydropyridin-1-yl) phenylcarbonyl] amino] pentanamide,
    (272) N-hydroxy-2 (S)-(3-phenyl-2-propenyl) -5-ethoxymethoxy-4 (S)-[N- (trans-4-methylcyclohexylcarbonyl) Amino] pentanamide,
    (273) N-hydroxy-2 (S)-(3-phenylpropyl) -5-ethoxymethoxy-4 (S)-[N- (trans-4-methylcyclohexylcarbonyl) amino] pentanamide ,
    (274) N-hydroxy-2 (S)-(2-phenylethyl) -5- (2-methoxyethoxy) methoxy-4 (S)-[N- (trans-4-methylcyclohexylcar Carbonyl) amino] pentanamide,
    (275) N-hydroxy-2 (S)-(4-phenylbutyl) -5- (2-methoxyethoxy) methoxy-4 (S)-[N- (trans-4-methylcyclohexylcar Carbonyl) amino] pentanamide,
    (276) N-hydroxy-2 (S)-(3-phenylpropyl) -5-ethoxymethoxy-4 (S)-[N- (4-bromophenylcarbonyl) amino] pentanamide,
    (277) N-hydroxy-2 (S)-(3-phenylpropyl) -5-ethoxymethoxy-4 (S)-[N- (4-nitrophenylcarbonyl) amino] pentanamide,
    (278) N-hydroxy-2 (R)-(2-phenoxyethyl) -5-ethoxymethoxy-4 (S)-[N- (4-nitrophenylcarbonyl) amino] pentanamide,
    (279) N-hydroxy-2 (R)-(2-pyridyl) methyl-5-methoxymethoxy-4 (S)-[N- (4-phenoxyphenylcarbonyl) amino] pentanamide,
    (280) N-hydroxy-2 (R)-(2-pyridyl) methyl-5-methoxymethoxy-4 (S)-[N- [4- (benzofuran-2-yl) phenylcarbonyl ] Amino] pentanamide,
    (281) N-hydroxy-2 (S)-(3-pyridyl) methyl-5-methoxymethoxy-4 (S)-[N- (4-phenoxyphenylcarbonyl) amino] pentanamide,
    (282) N-hydroxy-2 (S)-(3-pyridyl) methyl-5-methoxymethoxy-4 (S)-[N- [4- [2- (4-methylphenyl) ethynyl] Phenylcarbonyl] amino] pentanamide,
    (283) N-hydroxy-2 (S)-(3-pyridyl) methyl-5-methoxymethoxy-4 (S)-[N- [4- (1-heptinyl) phenylcarbonyl] amino ] Pentanamide,
    (284) N-hydroxy-2 (S)-(3-pyridyl) methyl-5-methoxymethoxy-4 (S)-[N- [4- [2E- (4-chlorophenyl) ethenyl ] Phenylcarbonyl] amino] pentanamide,
    (285) N-hydroxy-2 (S)-(3-pyridyl) methyl-5-methoxymethoxy-4 (S)-[N- (trans-4-methylcyclohexylcarbonyl) amino] pentane amides,
    (286) N-hydroxy-2 (S)-(4-pyridyl) methyl-5-methoxymethoxy-4 (S)-[N- (4-phenoxyphenylcarbonyl) amino] pentanamide,
    (287) N-hydroxy-2 (R)-(2-pyridyl) methyl-5- (2-methoxyethoxy) methoxy-4 (S)-[N- (4-phenoxyphenylcarbonyl ) Amino] pentanamide,
    (288) N-hydroxy-2 (S)-(3-pyridyl) methyl-5-ethoxymethoxy-4 (S)-[N- (2-methylphenylcarbonyl) amino] pentanamide,
    (289) N-hydroxy-2 (S)-(3-pyridyl) methyl-5-ethoxymethoxy-4 (S)-[N- (3-methylphenylcarbonyl) amino] pentanamide,
    (290) N-hydroxy-2 (S)-(3-pyridyl) methyl-5-ethoxymethoxy-4 (S)-[N- (4-methylphenylcarbonyl) amino] pentanamide,
    (291) N-hydroxy-2 (S)-(3-pyridyl) methyl-5-ethoxymethoxy-4 (S)-[N- (4-methoxyphenylcarbonyl) amino] pentanamide,
    (292) N-hydroxy-2 (S)-(3-pyridyl) methyl-5-ethoxymethoxy-4 (S)-(N-cyclohexylcarbonylamino) pentanamide,
    (293) N-hydroxy-2 (S)-(3-pyridyl) methyl-5-ethoxymethoxy-4 (S)-[N- (4-nitrophenylcarbonyl) amino] pentanamide,
    (294) N-hydroxy-2 (S)-(3-pyridyl) methyl-5-ethoxymethoxy-4 (S)-[N- (4-bromophenylcarbonyl) amino] pentanamide,
    (295) N-hydroxy-2 (S)-(3-quinolyl) -5-ethoxymethoxy-4 (S)-[N- (trans-4-methylcyclohexylcarbonyl) amino] pentanamide ,
    (296) N-hydroxy-2 (S) -phenylthio-5-methoxymethoxy-4 (S)-[N- (4-phenoxyphenylcarbonyl) amino] pentanamide,
    (297) N-hydroxy-2 (S) -phenylthio-5-ethoxymethoxy-4 (S)-[N- (trans-4-methylcyclohexylcarbonyl) amino] pentanamide,
    (298) N-hydroxy-2 (S) -methylthio-5-ethoxymethoxy-4 (S)-[N- (trans-4-methylcyclohexylcarbonyl) amino] pentanamide,
    (299) N-hydroxy-2 (S)-(4-pyridyl) thio-5-ethoxymethoxy-4 (S)-[N- (trans-4-methylcyclohexylcarbonyl) amino] pentane amides,
    (300) N-hydroxy-2 (S) -hydroxy-5-methoxymethoxy-4 (S)-[N- (4-phenoxyphenylcarbonyl) amino] pentanamide,
    (301) N-hydroxy-2 (R) -hydroxymethyl-5-ethoxymethoxy-4 (S)-[N- (4-chlorophenylcarbonyl) amino] pentanamide,
    (302) N-hydroxy-2 (R) -methoxymethyl-5-ethoxymethoxy-4 (S)-[N- (4-nitrophenylcarbonyl) amino] pentanamide,
    (303) N-hydroxy-2 (R) -benzyloxymethyl-5-ethoxymethoxy-4 (S)-[N- (4-nitrophenylcarbonyl) amino] pentanamide,
    (304) N-hydroxy-2 (R)-(2-methoxyethoxy) methyl-5-ethoxymethoxy-4 (S)-[N- (4-nitrophenylcarbonyl) amino] pentanamide ,
    (305) N-hydroxy-2 (R) -methoxymethyl-5- (2-methoxyethoxy) methoxy-4 (S)-[N- (4-cyanophenylcarbonyl) amino] pentane amides,
    (306) N-hydroxy-2 (R) -methoxymethyl-5-ethoxymethoxy-4 (S)-[N- (trans-4-methylcyclohexylcarbonyl) amino] pentanamide,
    (307) N-hydroxy-2 (R) -methoxymethyl-5-ethoxymethoxy-4 (S)-[N- (4-bromophenylcarbonyl) amino] pentanamide,
    (308) N-hydroxy-2 (R) -methoxymethyl-5-ethoxymethoxy-4 (S)-[N- (4-chlorophenylcarbonyl) amino] pentanamide,
    (309) N-hydroxy-2 (R) -benzyloxymethyl-5- (2-methoxyethoxy) methoxy-4 (S)-[N- (4-cyanophenylcarbonyl) amino] pentane amides,
    (310) N-hydroxy-2 (R) -benzyloxymethyl-5-ethoxymethoxy-4 (S)-[N- (4-chlorophenylcarbonyl) amino] pentanamide,
    (311) N-hydroxy-2 (R) -benzyloxymethyl-5-ethoxymethoxy-4 (S)-[N- (4-bromophenylcarbonyl) amino] pentanamide,
    (312) N-hydroxy-2 (R)-[2- (3-methoxyphenoxy) ethyl] -5-ethoxymethoxy-4 (S)-[N- (4-nitrophenylcarbonyl) Amino] pentanamide,
    (313) N-hydroxy-2 (R) -methoxymethyl-5-ethoxymethoxy-4 (S)-[N-[(2-nitrothiophen-5-yl) carbonyl] amino] pentane amides,
    (314) N-hydroxy-2 (R) -methoxymethyl-5-ethoxymethoxy-4 (S)-[N-[(2-bromothiophen-5-yl) carbonyl] amino] pentane amides,
    (315) N-hydroxy-2 (R)-(2-methoxyethoxy) methyl-5-ethoxymethoxy-4 (S)-[N- (4-bromophenylcarbonyl) amino] pentane amides,
    (316) N-hydroxy-2 (R)-(2-methoxyethoxy) methyl-5- (2-methoxyethoxy) methoxy-4 (S)-[N- (4-cyanophenyl Carbonyl) amino] pentanamide,
    (317) N-hydroxy-2 (R)-(2-methoxyethoxy) methyl-5-ethoxymethoxy-4 (S)-[N- (4-chlorophenylcarbonyl) amino] pentanamide ,
    (318) N-hydroxy-2 (R) -benzyloxymethyl-5-ethoxymethoxy-4 (S)-[N- (trans-4-methylcyclohexylcarbonyl) amino] pentanamide,
    (319) N-hydroxy-2 (R)-(3-thienyl) methoxymethyl-5-ethoxymethoxy-4 (S)-[N- (4-nitrophenylcarbonyl) amino] pentanamide ,
    (320) N-hydroxy-2 (R)-(2-pyridinyl) methyl-5-hydroxy-4 (S)-[N- (4-phenoxyphenylcarbonyl) amino] pentanamide,
    (321) N-hydroxy-2 (S) -methyl-5-hydroxy-4 (S)-[N- (4-phenoxyphenylcarbonyl) amino] pentanamide,
    (322) N-hydroxy-2 (S) -methyl-5-hydroxy-4 (S)-[N- (4-bromophenylcarbonyl) amino] pentanamide,
    (323) N-hydroxy-2 (S)-(3-methoxybenzyl) -5-hydroxy-4 (S)-[N- (4-bromophenylcarbonyl) amino] pentanamide,
    (324) N-hydroxy-2 (S)-(3-methoxybenzyl) -5-hydroxy-4 (S)-[N- (4-nitrophenylcarbonyl) amino] pentanamide,
    (325) N-hydroxy-2 (S)-(3-methoxybenzyl) -5-hydroxy-4 (S)-[N- (4-chlorophenylcarbonyl) amino] pentanamide
    (326) N-hydroxy-2 (S)-(3-methoxybenzyl) -5-hydroxy-4 (S)-[N-[(2-bromothiophen-5-yl) carbonyl] amino ] Pentanamide,
    (327) N-hydroxy-2 (S)-(3-methoxybenzyl) -5-hydroxy-4 (S)-[N-[(2-nitrothiophen-5-yl) carbonyl] amino ] Pentanamide,
    (328) N-hydroxy-2 (S)-(3-methoxybenzyl) -5-hydroxy-4 (S)-[N- (4-cyanophenylcarbonyl) amino] pentanamide,
    (329) N-hydroxy-2 (R) -benzyloxymethyl-5-hydroxy-4 (S)-[N- (4-nitrophenylcarbonyl) amino] pentanamide,
    (330) N-hydroxy-5-methoxymethoxy-4 (S)-[N-methyl-N- [4- (4-chlorophenyl) phenylcarbonyl] amino] pentanamide,
    (331) N-hydroxy-2 (S)-(3-pyridyl) methyl-5-methoxymethoxy-4 (S)-[N-methyl-N- [4- (4-chlorophenyl) phenyl Carbonyl] amino] pentanamide,
    (332) N-hydroxy-2 (S) -methyl-5-ethoxymethoxy-4 (S)-[N-methyl-N- (4-bromophenylcarbonyl) amino] pentanamide,
    (333) N-hydroxy-2 (S)-(3-methoxybenzyl) -5-ethoxymethoxy-4 (S)-[N-methyl-N- (4-bromophenylcarbonyl) amino ] Pentanamide,
    (334) N-hydroxy-2 (S) -methyl-5-ethoxymethoxy-4 (S)-[N-methyl-N- (4-nitrophenylcarbonyl) amino] pentanamide,
    (335) N-hydroxy-2 (S) -methyl-5-benzyloxymethoxy-4 (S)-[N-methyl-N- (4-nitrophenylcarbonyl) amino] pentanamide,
    (336) N-hydroxy-2 (S)-(3-methoxybenzyl) -5-hydroxy-4 (S)-[N-methyl-N- (4-chlorophenylcarbonyl) amino] pentanamide ,
    (337) N-hydroxy-2 (S)-(3-methoxybenzyl) -5-hydroxy-4 (S)-[N-methyl-N- (4-nitrophenylcarbonyl) amino] pentanamide ,
    (338) N-hydroxy-2 (S)-(3-methoxybenzyl) -5-hydroxy-4 (S)-[N-methyl-N- (4-bromophenylcarbonyl) amino] pentane amides,
    (339) N-hydroxy-2 (S) -methyl-5-hydroxy-4 (S)-[N-methyl-N- (4-nitrophenylcarbonyl) amino] pentanamide,
    (340) N-hydroxy-2 (S) -benzyl-5-hydroxy-4 (S)-[N-methyl-N- (4-nitrophenylcarbonyl) amino] pentanamide,
    (341) N-hydroxy-2 (S) -methyl-5-hydroxy-4 (S)-[N-methyl-N- (4-bromophenylcarbonyl) amino] pentanamide,
    (342) N-hydroxy-2 (S) -benzyl-5-hydroxy-4 (S)-[N-methyl-N- (4-bromophenylcarbonyl) amino] pentanamide,
    (343) N-hydroxy-2 (S) -methyl-5-hydroxy-4 (S)-[N-methyl-N- (4-chlorophenylcarbonyl) amino] pentanamide,
    (344) N-hydroxy-2 (S) -benzyloxy-3 (S) -hydroxy-4- (N- (4- (3-methoxy-1-propynyl) phenylcarbonyl) amino) butyl amides,
    (345) N-hydroxy-2-benzyloxy-4- (N- (4- (3-methoxy-1-propynyl) phenylcarbonyl) amino) -2-butylamide,
    (346) cis-1- (N-hydroxyaminocarbonylmethyl) -2- (N- (4- (3-methoxy-1-propynyl) phenylcarbonyl) amino) cyclopentane,
    (347) trans-1- (N-hydroxyaminocarbonylmethyl) -2- (N- (4- (3-methoxy-1-propynyl) phenylcarbonyl) amino) cyclopentane,
    (348) trans-1- (N-hydroxyaminocarbonyl) -3- (N- (4- (3-methoxy-1-propynyl) phenylcarbonyl) amino) cyclopentane,
    (349) cis-1- (N-hydroxyaminocarbonyl) -3- (N- (4- (3-methoxy-1-propynyl) phenylcarbonyl) amino) cyclopentane,
    (350) trans-1- (N-hydroxyaminocarbonyl) -2- (N- (4- (3-methoxy-1-propynyl) phenylcarbonyl) aminomethyl) cyclopentane,
    (351) N-hydroxy-2 (R) -allyl-5-ethoxymethoxy-4 (S)-[N- (4-phenoxyphenylcarbonyl) amino] pentanamide,
    (352) N-hydroxy-2 (R) -benzyl-5-methoxymethoxy-4 (S)-[N- [4- (benzofuran-2-yl) phenylcarbonyl] amino] pentanamide,
    (353) N-hydroxy-2 (R) -methyl-5-ethoxymethoxy-4 (S)-[N- (4-phenoxyphenylcarbonyl) amino] pentanamide,
    (354) N-hydroxy-2 (R) -methyl-5-ethoxymethoxy-4 (S)-[N- [4- (4-cyanophenyl) phenylcarbonyl] amino] pentanamide,
    (355) N-hydroxy-2 (S) -benzyl-5-methoxymethoxy-4 (R)-[N- (4-phenoxyphenylcarbonyl) amino] pentanamide,
    (356) N-hydroxy-2 (S) -benzyl-5-methoxymethoxy-4 (R)-[N- [4- (3-phenoxy-1-propynyl) phenylcarbonyl] amino] Pentanamide,
    (357) N-hydroxy-2 (S)-(3-aminobenzyl) -5-ethoxymethoxy-4 (S)-[N- (trans-4-methylcyclohexylcarbonyl) amino] pentanamide ,
    (358) N-hydroxy-2 (S) -benzyl-5-ethoxymethoxy-4 (S)-[N- (4-carboxyphenylcarbonyl) amino] pentanamide,
    (359) N-hydroxy-2 (S) -benzyl-5-ethoxymethoxy-4 (S)-[N- (4-aminophenylcarbonyl) amino] pentanamide,
    (360) N-hydroxy-2 (S) -benzyl-5-ethoxymethoxy-4 (S)-[N- (4-piperidylcarbonyl) amino] pentanamide,
    (361) N-hydroxy-2 (S)-(3-hydroxybenzyl) -5-ethoxymethoxy-4 (S)-[N- (4-methylphenylcarbonyl) amino] pentanamide,
    (362) N-hydroxy-2-benzyl-4- [N- [4- (benzofuran-2-yl) phenylcarbonyl] amino] butylamide,
    (363) N-hydroxy-2- (3-phenylpropyl) -4- [N- [4- (benzofuran-2-yl) phenylcarbonyl] amino] butylamide,
    (364) N-hydroxy-2- (2-phenylethyl) -4- [N- [4- (benzofuran-2-yl) phenylcarbonyl] amino] butylamide,
    (365) N-hydroxy-2-benzyl-4- [N- [4- [2E- (4-chlorophenyl) ethenyl] phenylcarbonyl] amino] butylamide,
    (366) N-hydroxy-2-benzyl-4- [N- (4-phenoxyphenylcarbonyl) amino] butylamide,
    (367) N-hydroxy-2- (naphthalen-1-yl) methyl-4- [N- (4-phenoxyphenylcarbonyl) amino] butylamide,
    (368) N-hydroxy-2-isopropyl-4- [N- (4-phenoxyphenylcarbonyl) amino] butylamide,
    (369) N-hydroxy-2- (quinolin-4-yl) methyl-4- [N- (4-phenoxyphenylcarbonyl) amino] butylamide,
    (370) N-hydroxy-2- (2-pyridyl) methyl-4- [N- (4-phenoxyphenylcarbonyl) amino] butylamide,
    (371) N-hydroxy-2- (3-pyridyl) methyl-4- [N- (4-phenoxyphenylcarbonyl) amino] butylamide,
    (372) N-hydroxy-2- (naphthalen-2-yl) methyl-4- [N- (4-phenoxyphenylcarbonyl) amino] butylamide,
    (373) N-hydroxy-2- (4-pyridyl) methyl-4- [N- (4-phenoxyphenylcarbonyl) amino] butylamide,
    (374) N-hydroxy-2- (3-methoxybenzyl) -4- [N- (4-phenoxyphenylcarbonyl) amino] butylamide,
    (375) N-hydroxy-2-isobutyl-4- [N- (4-phenoxyphenylcarbonyl) amino] butylamide,
    (376) N-hydroxy-5-methoxy-4 (S)-[N- [4- (4-chlorophenyl) phenylcarbonyl] amino] pentanamide,
    (377) N-hydroxy-2 (S) -methyl-5-succinimide-4 (S)-[N- (4-chlorophenylcarbonyl) amino] pentanamide,
    (378) N-hydroxy-2 (S) -methyl-5-succinimideoxy-4 (S)-[N-methyl-N- (4-nitrophenylcarbonyl) amino] pentanamide,
    (379) N-hydroxy-2 (S) -methyl-5-ethoxymethoxy-4 (S)-[N- (4-phenoxyphenylcarbonyl) amino] pentanamide,
    (380) N-hydroxy-2 (S) -allyl-5-ethoxymethoxy-4 (S)-[N- (4-phenoxyphenylcarbonyl) amino] pentanamide,
    (381) N-hydroxy-2 (S) -methyl-5-ethoxymethoxy-4 (S)-[N- [4- (4-cyanophenyl) phenylcarbonyl] amino] pentanamide, or Compounds characterized in that these are non-toxic salts.
    [11" claim-type="Currently amended] The compound of claim 2 wherein the compound is
    (1) 1-acetylthio-5-ethoxymethoxy-4- [N- (4-phenoxyphenylcarbonyl) amino] pentane,
    (2) 5-ethoxymethoxy-4- [N- (4-phenoxyphenylcarbonyl) amino] pentanethiol, or a nontoxic salt thereof.
    [12" claim-type="Currently amended] The compound of claim 3 wherein the compound is
    (64) 2 (S)-(2-propynyl) -5-ethoxymethoxy-4 (S)-[N- (4-nitrophenylcarbonyl) amino] pentanoic acid,
    (67) 2 (S)-(2-propynyl) -5-ethoxymethoxy-4 (S)-[N- (4-bromophenylcarbonyl) amino] pentanoic acid,
    (68) 2 (S)-(2-propynyl) -5-ethoxymethoxy-4 (S)-[N- (4-chlorophenylcarbonyl) amino] pentanoic acid,
    (79) 2 (S)-(2-propynyl) -5- (2-methoxyethoxy) methoxy-4 (S)-[N- (4-cyanophenylcarbonyl) amino] pentanoic acid or Compounds characterized in that these are non-toxic salts.
    [13" claim-type="Currently amended] The compound of claim 3 wherein the compound is
    (170) N-hydroxy-2 (S)-(2-propynyl) -5-ethoxymethoxy-4 (S)-[N- (4-nitrophenylcarbonyl) amino] pentanamide,
    (172) N-hydroxy-2 (S)-(2-propynyl) -5-ethoxymethoxy-4 (S)-[N- (4-bromophenylcarbonyl) amino] pentanamide,
    (173) N-hydroxy-2 (S)-(2-propynyl) -5-ethoxymethoxy-4 (S)-[N- (4-chlorophenylcarbonyl) amino] pentanamide,
    (177) N-hydroxy-2 (S)-(2-propynyl) -5- (2-methoxyethoxy) methoxy-4 (S)-[N- (4-cyanophenylcarbonyl) Amino] pentanamide or a nontoxic salt thereof.
    [14" claim-type="Currently amended] A metalloproteinase inhibitor containing as an active ingredient an aminobutanoic acid derivative represented by the formula (I) according to claim 1 or a nontoxic salt thereof.
    [15" claim-type="Currently amended] Rheumatoid arthritis, osteoarthritis, pathological bone resorption, osteoporosis, periodontal disease, interstitial containing the aminobutanoic acid derivative represented by the formula (I) according to claim 1 or a nontoxic salt thereof as an active ingredient Nephritis, Atherosclerosis, Emphysema, Liver cirrhosis, Corneal injury, Diseases of metastasis infiltration or proliferation of cancer cells, Autoimmune diseases (Clon's disease, Sjgren's disease, etc.), Vascular outflow of leukocyte cells Or prophylactic and / or therapeutic agents such as diseases caused by invasion, angiogenesis, multiple sclerosis, aortic aneurysms, endometriosis, and the like.
    类似技术:
    公开号 | 公开日 | 专利标题
    JP6399148B2|2018-10-03|Substituted pyrrolidines as factor XIa inhibitors for the treatment of thromboembolism
    CA2859604C|2019-12-17|Compounds
    CN103402996B|2015-02-11|Indole compounds or analogues thereof useful for the treatment of age-related macular degeneration |
    US9974777B2|2018-05-22|Tetrahydrocarboline derivative
    TWI631099B|2018-08-01|Amide derivatives of n-urea substituted amino acids as formyl peptide receptor like-1 | receptor modulators
    US5486513A|1996-01-23|2-substituted indane-2-mercaptoacetylamide derivatives useful as inhibitors or enkephalinase and ace
    EP0478362B1|1999-06-09|Fibrinogen receptor antagonists
    WO2014084312A1|2014-06-05|Imidazopyridine compound
    AU2010235236B2|2013-10-24|Isoxazol-3|-one analogs as therapeutic agents
    EP0757984B1|2002-10-30|Hydroxamic acid derivatives useful for inhibiting gelatinase
    JP5024039B2|2012-09-12|Indole compounds and uses thereof
    JP4547912B2|2010-09-22|8-Azaprostaglandin derivative compound and drug containing the compound as an active ingredient
    JP2552986B2|1996-11-13|Fibrinogen receptor antagonist
    KR100234927B1|2000-02-01|Pyrrolidine and thiazolidine derivatives, preparation thereof and drugs containing same
    KR101262400B1|2013-05-08|Aminocarboxylic acid derivative and medicinal use thereof
    EP2598486B1|2017-06-28|Bicyclic acetyl-coa carboxylase inhibitors
    KR100886854B1|2009-03-05|N-phenylarylsulfonamide compound, drug containing the compound as active ingredient, intermediate for the compound, and processes for producing the same
    US6677333B1|2004-01-13|2H-phthalazin-1-one derivatives and drug containing its derivatives as active ingredient
    US6515011B2|2003-02-04|Thrombin inhibitors
    HUE034919T2|2018-03-28|2,4,5,6-Substituted 3,6-dihydropyrimidine derivatives as hepatitis B virus | polymerase inhibitors for the treatment of e.g. chronic hepatitis
    EP2651957B1|2015-02-18|Phosphorous derivatives as chemokine receptor modulators
    US20020128270A1|2002-09-12|Piperazine compounds as inhibitors of MMP or TNF
    TWI680970B|2020-01-01|Heteroaryl compounds useful as inhibitors of sumo activating enzyme
    US7166590B2|2007-01-23|Amino acid derivatives
    EP0512831B1|1999-09-22|Fibrinogen receptor antagonists
    同族专利:
    公开号 | 公开日
    NO20001813L|2000-06-09|
    AU760181B2|2003-05-08|
    CA2305463C|2005-12-27|
    TR200101019T2|2002-06-21|
    WO1999019296A8|2001-03-08|
    CA2305463A1|1999-04-22|
    EP1024134A1|2000-08-02|
    JP3155536B2|2001-04-09|
    WO1999019296A1|1999-04-22|
    RU2215735C2|2003-11-10|
    NZ503789A|2002-11-26|
    TR200101020T2|2002-06-21|
    HU0100579A2|2001-05-28|
    HU0100579A3|2001-11-28|
    NO20001813D0|2000-04-07|
    CN1282319A|2001-01-31|
    TW568897B|2004-01-01|
    EP1024134A4|2003-05-14|
    AU9458098A|1999-05-03|
    US6420427B1|2002-07-16|
    BR9812807A|2000-10-17|
    TR200001732T2|2001-01-22|
    引用文献:
    公开号 | 申请日 | 公开日 | 申请人 | 专利标题
    法律状态:
    1997-10-09|Priority to JP29183497
    1997-10-09|Priority to JP97-291834
    1998-02-10|Priority to JP98-28533
    1998-02-10|Priority to JP2853398
    1998-10-07|Application filed by 우에노 도시오, 오노 야꾸힝 고교 가부시키가이샤
    1998-10-07|Priority to PCT/JP1998/004529
    2001-03-26|Publication of KR20010024456A
    优先权:
    申请号 | 申请日 | 专利标题
    JP29183497|1997-10-09|
    JP97-291834|1997-10-09|
    JP98-28533|1998-02-10|
    JP2853398|1998-02-10|
    PCT/JP1998/004529|WO1999019296A1|1997-10-09|1998-10-07|Aminobutanoic acid derivatives|
    [返回顶部]